,Unnamed: 0,Patient ID,Prompts,Outcome,Prognosis
0,0,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors related to his underlying medical conditions and laboratory results. 

1. Idiopathic dilated cardiomyopathy: This condition is characterized by the weakening of the heart muscle, leading to reduced heart function and decreased ejection fraction (LVEF of 30.0% in this case). This condition can lead to heart failure, which is a significant risk factor for pump failure.

2. NYHA Class III: This classification indicates that the patient has severe symptoms of heart failure, such as shortness of breath, fatigue, and limited physical activity. This suggests that the patient's heart is not functioning adequately to meet the body's demands, increasing the risk of pump failure.

3. High Pro-BNP levels (1100.0 ng/L): B-type natriuretic peptide (BNP) is a hormone released by the heart in response to ventricular strain. Elevated levels of BNP are associated with heart failure and are used as a biomarker to diagnose and monitor the condition. High levels, such as in this patient, indicate severe heart failure and increased risk of pump failure.

4. Reduced LVEF (30.0%): The left ventricular ejection fraction (LVEF) measures the percentage of blood pumped out of the left ventricle with each beat. A reduced LVEF indicates that the heart is not pumping efficiently, increasing the risk of pump failure.

5. High Creatinine levels (120.0 mmol/L): Elevated creatinine levels indicate impaired kidney function, which can be a consequence of heart failure. This suggests that the patient's heart is not pumping efficiently, leading to reduced blood flow and kidney function.

6. Hypotension (115/70 mmHg): Although the blood pressure is within a relatively normal range, it may be too low for a patient with severe heart failure. This can lead to inadequate perfusion of vital organs, including the kidneys, and increase the risk of pump failure.

7. Electrocardiogram (ECG) findings: The presence of ventricular extrasystoles, although polymorphic, may indicate abnormal electrical activity in the heart, which can contribute to decreased heart function and increased risk of pump failure.

Given these factors, the patient's outcome of pump failure death is a plausible consequence of his underlying medical conditions and laboratory results."
1,1,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors present in the patient's medical history and test results. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to decreased heart function. This condition is a significant risk factor for heart failure and can lead to pump failure.

The patient's LVEF (Left Ventricular Ejection Fraction) is 30%, which is significantly below the normal range of 55-70%. A low LVEF indicates that the heart is not pumping efficiently, which can lead to fluid buildup in the lungs and other parts of the body, further exacerbating heart failure.

The patient's high Pro-BNP (B-type natriuretic peptide) level of 1100.0 ng/L is also indicative of heart failure. Elevated Pro-BNP levels are often associated with increased ventricular wall stress and are used as a marker for diagnosing and monitoring heart failure.

The patient's medication regimen includes loop diuretics and spironolactone, which are commonly used to manage heart failure symptoms and slow the progression of the disease. However, the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

Additionally, the patient's diabetes and hypertension are contributing factors to the development and progression of heart failure. Diabetes can damage the blood vessels and nerves that control the heart, while hypertension can increase the workload on the heart, leading to further damage and decreased function.

The patient's laboratory results also show elevated creatinine levels (120.0 mmol/L), which can indicate kidney damage, often seen in patients with advanced heart failure. The patient's low hemoglobin level (124.0 g/L) may also be indicative of anemia, a common comorbidity in patients with heart failure.

The patient's troponin level is within normal limits (0.7 ng/mL), which suggests that there is no acute myocardial infarction. However, the presence of ventricular extrasystoles and the patient's overall clinical presentation suggest that the heart is under significant stress, which may have ultimately led to pump failure.

In conclusion, the patient's outcome of pump failure death can be attributed to a combination of idiopathic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, diabetes, hypertension, kidney damage, and anemia, which have likely contributed to the progression of heart failure and ultimately led to pump failure."
2,2,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death is likely due to a combination of factors related to his underlying cardiomyopathy and other comorbidities. 

1. Idiopathic dilated cardiomyopathy: This is a condition where the heart muscle becomes weakened, leading to reduced heart function. The patient's LVEF (Left Ventricular Ejection Fraction) of 30% indicates severely impaired heart function, which is a significant risk factor for pump failure.

2. Advanced NYHA Class III: The New York Heart Association (NYHA) classification system categorizes heart failure severity. A Class III classification indicates that the patient experiences marked limitation in physical activity due to symptoms, such as shortness of breath, fatigue, or angina, even during ordinary physical activity.

3. High Pro-BNP levels: B-type natriuretic peptide (BNP) is a hormone released by the heart in response to ventricular stretch and pressure overload. Elevated Pro-BNP levels (> 100 ng/L) are associated with heart failure and are used as a prognostic marker for mortality.

4. Significant kidney impairment: The patient's elevated creatinine level (120.0 mmol/L) and urea level (12.1 mg/dL) indicate compromised kidney function, which is common in patients with heart failure. This suggests that the patient may have had chronic kidney disease, which further compromises his overall health.

5. Diabetes and hypertension: These comorbidities contribute to cardiovascular disease and can exacerbate heart failure. The patient's high glucose level (12.4 mmol/L) and blood pressure (115/70 mmHg) indicate that these conditions are not well-controlled.

6. Reduced ejection fraction and low hemoglobin: The patient's LVEF of 30% and low hemoglobin level (124 g/L) suggest that his heart is not pumping efficiently, leading to inadequate oxygen delivery to tissues, which can result in fatigue, weakness, and ultimately, pump failure.

7. Electrocardiogram (ECG) findings: The presence of polymorphic ventricular extrasystoles may indicate arrhythmias, which can further compromise cardiac function and increase the risk of pump failure.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of his underlying cardiomyopathy, advanced heart failure, kidney impairment, uncontrolled diabetes and hypertension, and other comorbidities."
3,3,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors evident from the provided data.

1.  Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 30%, which is significantly below the normal range of 50-70%. This indicates severe left ventricular dysfunction, which is a hallmark of heart failure.

2.  Diabetes: The patient has diabetes, which is a well-established risk factor for heart failure. Diabetes can lead to diabetic cardiomyopathy, a condition where the heart muscle becomes stiff and less efficient, leading to decreased LVEF.

3.  Idiopathic Dilated Cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weak and the heart chambers enlarge, leading to decreased LVEF.

4.  High Pro-BNP Levels: The patient has a high pro-b-type natriuretic peptide (Pro-BNP) level of 1100.0 ng/L. Elevated Pro-BNP levels are indicative of heart failure and are associated with increased mortality.

5.  Medication Non-Response: Despite being on medications such as ACE inhibitors, loop diuretics, and spironolactone, the patient's condition has not improved significantly. This suggests that the patient's heart failure is refractory to medical therapy.

6.  Poor Renal Function: The patient has elevated creatinine levels of 120.0 mmol/L, indicating poor renal function. Renal dysfunction can further exacerbate heart failure by leading to fluid overload and electrolyte imbalances.

7.  Electrolyte Imbalance: The patient has a low potassium level of 3.44 mEq/L, which can contribute to arrhythmias and further compromise cardiac function.

8.  Advanced Age and NYHA Class III: The patient is 72 years old and has a New York Heart Association (NYHA) class III classification, indicating severe symptoms of heart failure that limit physical activity. Advanced age and NYHA class III classification are both associated with poor prognosis.

In summary, the combination of severe left ventricular dysfunction, diabetes, idiopathic dilated cardiomyopathy, high Pro-BNP levels, medication non-response, poor renal function, electrolyte imbalance, advanced age, and NYHA class III classification all contributed to the patient's outcome of pump failure death."
4,4,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of his underlying medical conditions and laboratory results. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to a decrease in the heart's ability to pump blood effectively. This is supported by his low left ventricular ejection fraction (LVEF) of 30%, which is a critical indicator of heart failure.

Furthermore, the patient's elevated creatinine levels (120.0 mmol/L) suggest significant kidney impairment, which is often seen in patients with advanced heart failure. This is likely due to the heart's inability to pump blood efficiently, leading to decreased perfusion of the kidneys.

The patient's high pro-BNP (brain natriuretic peptide) levels (1100.0 ng/L) are also indicative of heart failure, as BNP is a hormone released by the heart in response to increased ventricular wall stress. Elevated BNP levels are associated with worsening heart failure.

Additionally, the patient's laboratory results show a high glucose level (12.4 mmol/L), which may be contributing to his heart failure. Hyperglycemia can lead to inflammation and oxidative stress, exacerbating cardiac damage and worsening heart failure.

The patient's medication regimen, which includes a loop diuretic, spironolactone, and an ACE inhibitor, is typically used to manage heart failure symptoms and slow disease progression. However, the presence of these medications does not seem to have adequately controlled his heart failure, as indicated by his low LVEF and high pro-BNP levels.

The patient's age (72 years) and NYHA class III classification also suggest that he has advanced heart failure, with symptoms that limit his physical activity.

In summary, the patient's outcome of pump failure death can be attributed to his advanced idiopathic dilated cardiomyopathy, kidney impairment, high pro-BNP levels, high glucose levels, and inadequate management of his heart failure symptoms despite his medication regimen."
5,5,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors, primarily related to his underlying heart condition and comorbidities.

1.  Idiopathic dilated cardiomyopathy: The patient has a pre-existing condition of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged, leading to reduced heart function. This condition is a significant contributor to his poor prognosis.

2.  Reduced LVEF (Left Ventricular Ejection Fraction): The patient's LVEF of 30% is significantly below the normal range of 50-70%. This indicates that his heart is not pumping efficiently, which can lead to heart failure.

3.  High Pro-BNP levels: A Pro-BNP level of 1100 ng/L is elevated, indicating that the patient's heart is under stress, which is consistent with heart failure.

4.  Kidney function impairment: The patient's creatinine level of 120.0 umol/L indicates impaired kidney function, which can be a consequence of reduced cardiac output and decreased perfusion of the kidneys.

5.  Diabetes and hypertension: The patient's history of diabetes and hypertension are significant contributors to his cardiovascular disease. Diabetes can lead to diabetic cardiomyopathy, and hypertension can cause cardiac remodeling and fibrosis, further impairing heart function.

6.  Medication regimen: While the patient is on several medications, including ACE inhibitors, digoxin, loop diuretics, and spironolactone, which are commonly used to manage heart failure, his condition suggests that these medications may not have been sufficient to adequately manage his symptoms and improve his heart function.

7.  ECG findings: The presence of polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing arrhythmias, which can further compromise cardiac output and increase the risk of sudden cardiac death.

In summary, the patient's outcome of pump failure death is likely due to a combination of his underlying idiopathic dilated cardiomyopathy, reduced LVEF, impaired kidney function, comorbidities (diabetes and hypertension), and the severity of his cardiac symptoms, which were not adequately managed by his current medication regimen."
6,6,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to several factors contributing to the progression of his heart condition. 

1.  Idiopathic dilated cardiomyopathy: The patient has a pre-existing condition of idiopathic dilated cardiomyopathy, which is a weakening of the heart muscle that can lead to reduced cardiac output and heart failure. This condition has likely been ongoing for some time, as evidenced by the patient's NYHA Class III classification, indicating moderate to severe symptoms of heart failure.

2.  Reduced LVEF: The patient's left ventricular ejection fraction (LVEF) is severely reduced at 30.0%, indicating poor heart function and reduced ability to pump blood efficiently. This is a critical factor in the development of heart failure and increased risk of pump failure.

3.  Elevated Pro-BNP: The patient's Pro-BNP level is significantly elevated at 1100.0 ng/L, which is a biomarker of heart failure. Elevated Pro-BNP levels are associated with increased risk of heart failure and mortality.

4.  Diabetes and Hypertension: The patient has a history of diabetes and hypertension, which are both risk factors for the development of heart failure. Diabetes can damage the heart muscle and blood vessels, while hypertension can lead to left ventricular hypertrophy and increased cardiac workload.

5.  Medications: The patient is on a combination of medications, including ACE inhibitors, which are commonly used to treat heart failure. However, the patient's condition may have progressed to a point where these medications are no longer effective in managing symptoms or improving cardiac function.

6.  Electrocardiogram findings: While the ECG does not show any signs of sustained ventricular tachycardia, the presence of polymorphic ventricular extrasystoles may indicate underlying cardiac instability and increased risk of arrhythmias.

Considering these factors, the patient's outcome of pump failure death is likely due to the progression of his underlying heart condition, exacerbated by his comorbidities and reduced cardiac function."
7,7,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors evident from the provided data. 

1.  Idiopathic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition characterized by the weakening of the heart muscle, leading to a decrease in the heart's ability to pump blood effectively. This condition is a significant risk factor for heart failure and ultimately, pump failure.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 30%, which is significantly below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, making it difficult for the body to receive the necessary oxygen and nutrients.

3.  Elevated Pro-BNP Levels: The patient's Pro-BNP (Brain Natriuretic Peptide) level is 1100.0 ng/L, which is elevated. Elevated Pro-BNP levels are associated with heart failure and are used as a biomarker to diagnose and monitor the condition.

4.  Diabetes and Hypertension: The patient has a history of diabetes and hypertension, which are both significant risk factors for heart disease and can contribute to the progression of IDC and heart failure.

5.  Medication Use: Although the patient is on medications such as ACE inhibitors, loop diuretics, and spironolactone, which are commonly used to treat heart failure, the patient's condition has not improved, and the outcome suggests that these medications may not be sufficient to manage the patient's heart failure.

6.  Ventricular Extrasystole: The presence of polymorphic ventricular extrasystoles may indicate underlying electrical instability in the heart, which can contribute to the progression of heart failure and increase the risk of sudden cardiac death.

Considering these factors, the patient's outcome of pump failure death is likely a result of the combination of IDC, reduced LVEF, elevated Pro-BNP levels, comorbid conditions (diabetes and hypertension), and the ineffectiveness of current medications in managing the patient's heart failure."
8,8,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors that are evident from the provided data. 

1. Idiopathic dilated cardiomyopathy: The patient has a pre-existing condition that affects the heart's pumping ability, leading to a reduced left ventricular ejection fraction (LVEF) of 30%. This condition puts the patient at an increased risk of heart failure.

2. Reduced LVEF: The patient's LVEF of 30% indicates severe left ventricular dysfunction, which is a hallmark of heart failure. This reduction in pumping efficiency can lead to inadequate blood circulation, contributing to pump failure.

3. High Pro-BNP levels: The elevated pro-B-type natriuretic peptide (Pro-BNP) level of 1100 ng/L is indicative of heart failure. Pro-BNP is a biomarker that is released by the heart in response to increased ventricular wall stress, which is often seen in heart failure.

4. Electrocardiogram (ECG) findings: The presence of polymorphic ventricular extrasystoles may indicate abnormal heart rhythms that can further compromise cardiac function and contribute to pump failure.

5. Medication regimen: The patient is on a combination of medications, including diabetes medication, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. While these medications are intended to manage the patient's heart failure and other comorbidities, their efficacy may be limited by the severity of the underlying condition.

6. Renal impairment: The elevated creatinine level (120.0 mmol/L) and urea level (12.1 mg/dL) suggest impaired renal function, which is often seen in advanced heart failure. This can further exacerbate the condition by reducing the body's ability to eliminate waste products and electrolytes, leading to a vicious cycle of worsening heart failure.

7. Hypokalemia: The patient's low potassium level (3.44 mEq/L) may be a contributing factor to arrhythmias and decreased cardiac function, which can worsen pump failure.

8. Hyperglycemia: The patient's elevated glucose level (12.4 mmol/L) may indicate poor glycemic control, which can further stress the heart and worsen cardiac function.

In summary, the patient's outcome of pump failure death can be attributed to the combination of idiopathic dilated cardiomyopathy, reduced LVEF, high Pro-BNP levels, ECG findings, medication regimen, renal impairment, hypokalemia, and hyperglycemia."
9,9,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death is likely due to a combination of factors contributing to advanced heart failure. 

1.  Idiopathic dilated cardiomyopathy: The patient has a pre-existing condition of dilated cardiomyopathy, which is a significant contributor to heart failure. This condition leads to the heart's inability to pump blood effectively, ultimately resulting in decreased cardiac output and increased risk of heart failure.

2.  Low LVEF (30%): The left ventricular ejection fraction (LVEF) of 30% indicates severe systolic dysfunction, which is a hallmark of heart failure with reduced ejection fraction (HFrEF). This suggests that the patient's heart is not pumping efficiently, leading to decreased cardiac output and increased risk of complications.

3.  Elevated Pro-BNP (1100.0 ng/L): B-type natriuretic peptide (BNP) is a hormone released by the heart in response to increased wall stress. Elevated Pro-BNP levels indicate increased ventricular wall stress, which is often seen in heart failure. A level of 1100.0 ng/L is significantly elevated, indicating severe heart failure.

4.  Medications: The patient is on a combination of medications, including ACE inhibitors, which are typically used to treat heart failure. However, the presence of other medications such as digoxin and spironolactone suggests that the patient's heart failure is severe, and the medications are being used to manage symptoms and slow disease progression.

5.  Comorbidities: The patient has comorbid conditions such as hypertension, diabetes, and kidney dysfunction (elevated creatinine), which can contribute to the development and progression of heart failure.

6.  Electrocardiogram (ECG) findings: The presence of polymorphic ventricular extrasystoles may indicate underlying electrical instability in the heart, which can contribute to the development of life-threatening arrhythmias.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of advanced heart failure, severe systolic dysfunction, and the presence of comorbid conditions."
10,10,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors. Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a previous heart attack, leading to reduced heart function and potential heart failure. The patient's left ventricular ejection fraction (LVEF) of 36% is significantly below the normal range of 50-70%, indicating compromised heart function.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 535.0 ng/L is a strong indicator of heart failure, as it is a biomarker released by the heart in response to increased wall tension and stretch. This suggests that the heart is under strain and unable to function properly.

Additionally, the patient's past medical history of myocardial infarction and dyslipemia further increases the risk of cardiovascular events and exacerbates the progression of heart failure. The presence of ventricular extrasystoles on the ECG may also indicate underlying electrical instability in the heart, which can contribute to the development of arrhythmias and further compromise cardiac function.

The patient's medications, including beta blockers, spironolactone, statins, ACE inhibitor, and nitrovasodilator, are standard treatments for heart failure and ischemic cardiomyopathy. However, despite these treatments, the patient's condition has progressed to pump failure death, indicating that these medications may not have been sufficient to prevent or reverse the progression of heart failure.

The patient's laboratory results, including elevated creatinine and urea levels, suggest that there may be underlying kidney dysfunction, which can further exacerbate heart failure and contribute to the patient's outcome.

Overall, the combination of ischemic dilated cardiomyopathy, compromised LVEF, elevated Pro-BNP, and the presence of ventricular extrasystoles on the ECG, along with the patient's past medical history and laboratory results, all contribute to the patient's outcome of pump failure death."
11,11,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) of 36% is significantly below the normal range of 55-70%, indicating reduced cardiac function.

The patient's laboratory results also suggest chronic kidney disease, as evidenced by a high creatinine level of 98.0 mmol/L and a urea level of 7.35 mg/dL. This can be a contributing factor to the progression of heart failure, as the kidneys play a crucial role in regulating fluid balance and electrolyte levels, which are essential for maintaining cardiac function.

Additionally, the patient's high pro-BNP level of 535.0 ng/L is indicative of heart failure, as BNP is a hormone released by the heart in response to increased ventricular stretch and pressure. Elevated BNP levels are often associated with heart failure and can be used as a marker for its diagnosis and monitoring.

The patient's medication regimen includes beta blockers, spironolactone, statins, ACE inhibitors, and nitrovasodilators, which are all standard treatments for heart failure. However, despite these treatments, the patient's cardiac function has deteriorated, leading to pump failure.

The presence of ventricular extrasystoles on the ECG may also be a contributing factor, as it can indicate abnormal heart rhythms that may further compromise cardiac function.

The patient's age of 69 and NYHA class II also suggest that the patient has a higher risk of heart failure, as heart failure is more common in older adults and those with a history of cardiovascular disease.

In summary, the patient's outcome of pump failure death is likely due to a combination of factors, including ischemic dilated cardiomyopathy, chronic kidney disease, high pro-BNP levels, and the presence of ventricular extrasystoles, despite being on standard treatments for heart failure."
12,12,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data. 

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in the heart's pumping ability. This condition is a significant risk factor for heart failure and pump failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 36%, which is below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, leading to a decrease in cardiac output and increased risk of pump failure.

3.  Elevated Pro-BNP: The patient's Pro-BNP level is 535.0 ng/L, which is elevated. Pro-BNP is a biomarker that indicates heart failure and can be used to diagnose and monitor heart failure. Elevated levels are associated with increased mortality and morbidity in heart failure patients.

4.  Medications: Although the patient is on beta blockers, spironolactone, statins, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure, the patient's condition has progressed to pump failure death. This suggests that the medications may not have been sufficient to manage the patient's condition effectively.

5.  Other Factors: The patient's age (69), weight (64 kg), and height (163 cm) are within normal ranges, but the patient's overall health status and comorbidities (dyslipemia, myocardial infarction) contribute to the increased risk of pump failure.

Considering these factors, the patient's outcome of pump failure death is a likely consequence of the progression of ischemic dilated cardiomyopathy, combined with a low LVEF, elevated Pro-BNP, and inadequate management of the condition despite medication."
13,13,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors from the provided data. 

1. Ischemic dilated cardiomyopathy: This condition is a known risk factor for heart failure and pump failure. The patient's history of myocardial infarction further supports this diagnosis, as it is a common cause of dilated cardiomyopathy.

2. Reduced LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 36%, which is below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, leading to potential pump failure.

3. Elevated Pro-BNP (B-type Natriuretic Peptide): The patient's Pro-BNP level is significantly elevated at 535.0 ng/L, which is a marker of heart failure and increased ventricular wall stress. Elevated Pro-BNP levels are associated with a poor prognosis in patients with heart failure.

4. Medications not optimized: Although the patient is on beta blockers, spironolactone, statins, ACE inhibitors, and nitrovasodilators, these medications are not sufficient to manage the patient's heart failure. The patient's LVEF and Pro-BNP levels suggest that the current medication regimen may not be adequately addressing the underlying heart failure.

5. Poor lipid profile: The patient's total cholesterol and LDL levels are elevated, which can contribute to atherosclerosis and further exacerbate heart failure.

6. Reduced HDL: The patient's HDL (good cholesterol) level is low, which can also contribute to atherosclerosis and heart failure.

7. Electrocardiogram (ECG) findings: While the ECG does not show any acute arrhythmias, the presence of monomorphic ventricular extrasystoles may indicate underlying electrical instability, which can contribute to pump failure.

Considering these factors, the patient's outcome of pump failure death is likely due to the combination of ischemic dilated cardiomyopathy, reduced LVEF, elevated Pro-BNP, and inadequate medication management, as well as other contributing factors such as poor lipid profile and reduced HDL."
14,14,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy and previous myocardial infarction, it is not surprising that the patient has developed pump failure. Ischemic dilated cardiomyopathy is a condition where the heart muscle becomes weakened due to a heart attack or coronary artery disease, leading to a decrease in the heart's ability to pump blood effectively. The patient's low left ventricular ejection fraction (LVEF) of 36% further supports this diagnosis.

The patient's laboratory results, such as elevated Pro-BNP (535.0 ng/L) and low hemoglobin (138.0 g/L), are indicative of heart failure. Pro-BNP is a biomarker that is often elevated in patients with heart failure, and low hemoglobin levels can indicate a decrease in the body's ability to deliver oxygen to tissues.

The patient's medication regimen, including beta blockers, spironolactone, statins, ACE inhibitors, and nitrovasodilators, is typical for managing heart failure and reducing the risk of further cardiac events. However, the patient's outcome of pump failure death suggests that these medications may not have been sufficient to prevent progression of the disease.

The presence of ventricular extrasystoles on the ECG is also consistent with heart failure, as the heart muscle may become weakened and irregular heart rhythms can occur.

The patient's age (69) and NYHA Class II classification also indicate that the patient has some limitations in physical activity but is still able to perform daily tasks without symptoms. However, the combination of these factors, along with the patient's underlying medical conditions, likely contributed to the progression of heart failure and ultimately led to pump failure death."
15,15,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged, leading to poor heart function. This condition is a significant risk factor for heart failure.

The patient's left ventricular ejection fraction (LVEF) of 36% is significantly below the normal range of 55-70%, indicating reduced heart function. This suggests that the patient's heart is not pumping blood efficiently, which can lead to symptoms of heart failure.

The elevated Pro-BNP level of 535.0 ng/L is a marker of heart failure, as it is released by the heart in response to increased ventricular wall stress. High levels of Pro-BNP are associated with more severe heart failure.

Additionally, the patient's medications, including beta blockers, spironolactone, statins, ACE inhibitors, and nitrovasodilators, are standard treatments for heart failure. However, the presence of these medications does not necessarily indicate that the patient's heart failure is well-managed, especially given the patient's low LVEF and elevated Pro-BNP level.

The patient's past medical history of myocardial infarction (heart attack) also increases the risk of heart failure. The patient's dyslipidemia (elevated cholesterol levels) and high blood pressure may have contributed to the development of atherosclerosis, which can lead to ischemic dilated cardiomyopathy.

In conclusion, the patient's outcome of pump failure death can be attributed to a combination of their history of ischemic dilated cardiomyopathy, reduced LVEF, elevated Pro-BNP level, and past medical history of myocardial infarction, which have likely contributed to the progression of heart failure."
16,16,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy, a reduced left ventricular ejection fraction (LVEF) of 36%, and elevated Pro-BNP levels (535 ng/L), which is indicative of increased ventricular wall stress, the patient is at high risk for heart failure. The patient's medications, including beta blockers, spironolactone, statins, ACE inhibitor, and nitrovasodilator, are consistent with a treatment plan for heart failure with reduced ejection fraction (HFrEF). 

The patient's creatinine level of 98.0 mol/L suggests impaired renal function, which is a common comorbidity in patients with heart failure. The patient's total cholesterol level of 3.96 mmol/L is within a relatively normal range, and the patient is on statins, which suggests that the patient's dyslipidemia is being managed.

However, the patient's troponin level of 0.01 ng/mL is within the normal range, indicating that there is no acute myocardial infarction. The TSH level of 0.983 mIU/L is within the normal range, indicating that the patient does not have hypothyroidism.

The patient's LVEF of 36% is significantly reduced, which is a strong predictor of poor outcomes in patients with heart failure. The patient's NYHA Class II classification indicates that the patient has symptoms of heart failure, but they are manageable with medication and lifestyle modifications.

Given the patient's history, lab results, and treatment plan, the most likely reason for the patient outcome of pump failure death is the progression of the patient's ischemic dilated cardiomyopathy, which has resulted in a severe reduction in cardiac function and a high risk of sudden cardiac death. The patient's impaired renal function and elevated Pro-BNP levels also contribute to the high risk of adverse outcomes."
17,17,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death is likely due to a combination of factors related to their underlying cardiovascular disease and laboratory results. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in left ventricular ejection fraction (LVEF). The patient's LVEF of 36% indicates a severely reduced ejection fraction, which is a strong indicator of heart failure.

Additionally, the patient's high Pro-BNP (B-type natriuretic peptide) level of 535.0 ng/L suggests that the patient has elevated levels of this hormone, which is often associated with heart failure. Elevated Pro-BNP levels are a marker of increased ventricular wall stress, indicating that the heart is working harder than normal.

The patient's laboratory results also show elevated levels of creatinine (98.0 mmol/L), which suggests impaired renal function, a common comorbidity in patients with heart failure. The patient's weight of 64 kg and height of 163 cm also indicate a low body mass index (BMI), which may further contribute to the patient's vulnerability to heart failure.

Furthermore, the patient's medication regimen includes beta blockers, spironolactone, statins, ACE inhibitor, and nitrovasodilator, which are commonly used to manage heart failure symptoms and improve cardiac function. However, despite these medications, the patient's condition has progressed to pump failure death, indicating that these treatments may not have been sufficient to prevent this outcome.

The patient's ECG results show monomorphic ventricular extrasystoles, which can be a sign of underlying cardiac disease, but it is not a direct cause of pump failure death. 

In conclusion, the patient's outcome of pump failure death is likely due to the progression of their underlying ischemic dilated cardiomyopathy, combined with the patient's impaired renal function, elevated Pro-BNP levels, and potentially inadequate response to medical therapy."
18,18,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is likely due to a combination of factors related to their underlying cardiac condition and comorbidities. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart's ability to pump blood is impaired. The patient's left ventricular ejection fraction (LVEF) is 36%, which is significantly below the normal range of 55-70%, indicating a compromised cardiac function. This suggests that the patient's heart is not pumping efficiently, leading to a reduced cardiac output and increased risk of pump failure.

Additionally, the patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 535.0 ng/L is a marker of cardiac stress and strain, often associated with heart failure. The patient's high creatinine level of 98.0 mmol/L also suggests impaired renal function, which can be a consequence of chronic heart failure.

The patient's past medical history of myocardial infarction (heart attack) further increases the risk of pump failure, as it can lead to scarring and damage to the heart muscle. The patient's dyslipidemia (elevated cholesterol levels) and hypertension (elevated blood pressure) also contribute to the development and progression of cardiovascular disease.

Furthermore, the patient's low HDL (good cholesterol) level of 1.27 mmol/L and high LDL (bad cholesterol) level of 1.99 mmol/L indicate an imbalance in lipid metabolism, which can exacerbate atherosclerosis and further compromise cardiac function.

The patient's current medications, including beta blockers, spironolactone, statins, ACE inhibitor, and nitrovasodilator, are standard treatments for heart failure and hypertension, but may not be sufficient to control the patient's condition given the severity of their cardiac dysfunction.

The presence of ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing abnormal electrical activity, which can further compromise cardiac function and increase the risk of arrhythmias.

Overall, the combination of the patient's underlying cardiac condition, comorbidities, and compromised cardiac function makes pump failure death a likely outcome."
19,19,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to several factors. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to coronary artery disease, leading to impaired heart function. This condition is a significant risk factor for heart failure and increased mortality.

2.  Low LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 36%, which is significantly lower than the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, leading to decreased cardiac output and increased risk of heart failure.

3.  Elevated Pro-BNP (B-type Natriuretic Peptide): The patient's Pro-BNP level is 535.0 ng/L, which is elevated. Elevated Pro-BNP levels are associated with heart failure and are used as a biomarker to diagnose and monitor heart failure.

4.  Medication regimen: Although the patient is on beta blockers, spironolactone, statins, ACE inhibitors, and nitrovasodilators, these medications are commonly used to manage heart failure and may not have been sufficient to reverse the patient's cardiac dysfunction.

5.  Age and NYHA Class II: The patient is 69 years old and has a NYHA Class II heart failure classification, indicating that he experiences symptoms of heart failure with moderate exertion but is able to perform ordinary physical activity without discomfort.

6.  Additional factors: The patient's low HDL cholesterol, elevated LDL cholesterol, and elevated creatinine levels may also contribute to his cardiovascular risk and potentially exacerbate heart failure.

Considering these factors, the patient's outcome of pump failure death can be attributed to a combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP levels, and the patient's age and NYHA Class II classification, which may have ultimately led to cardiac decompensation and pump failure."
20,20,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's advanced age (71 years), history of ischemic dilated cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 26%, the patient is at high risk for heart failure and associated complications. The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath and fatigue, even at rest or with minimal exertion.

The patient's elevated Pro-BNP level (32552 ng/L) is indicative of severe heart failure, which is consistent with the patient's symptoms and reduced LVEF. Additionally, the patient's elevated creatinine level (102.0 mmol/L) suggests impaired renal function, which is a common complication of heart failure.

The patient's medication regimen includes Digoxin, Loop Diuretics, Statins, and ACE Inhibitor, which are standard treatments for heart failure. However, the patient's LVEF of 26% and NYHA Class III classification suggest that the patient's heart failure is severe and refractory to medical therapy.

The presence of ventricular extrasystoles on the ECG is a common finding in patients with heart failure and is not a cause for concern in this context. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG is reassuring.

The patient's laboratory results show a slightly elevated ALT and AST, which may indicate mild liver dysfunction, but this is not a significant contributor to the patient's outcome. The patient's lipid profile shows a high LDL level, which is being managed with Statins.

The patient's low T3 and T4 levels are likely due to the use of Digoxin, which can suppress thyroid function. The patient's TSH level is within the normal range.

In conclusion, the patient's advanced age, history of ischemic dilated cardiomyopathy, reduced LVEF, and severe heart failure symptoms, as well as the elevated Pro-BNP level and impaired renal function, are contributing factors to the patient's outcome of pump failure death."
21,21,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is likely due to a combination of factors related to their advanced heart failure and underlying medical conditions. 

Firstly, the patient has a low left ventricular ejection fraction (LVEF) of 26%, which is a significant indicator of heart failure. This suggests that the patient's heart is not pumping efficiently, leading to a decrease in cardiac output and potentially causing symptoms such as fatigue, shortness of breath, and swelling.

The patient's ischemic dilated cardiomyopathy, a history of myocardial infarction, and dyslipemia further contribute to the progression of heart failure. Ischemic cardiomyopathy is a condition where the heart muscle becomes weakened due to a lack of blood flow, leading to a decrease in cardiac function. The history of myocardial infarction indicates that the patient has had a previous heart attack, which can further damage the heart muscle and contribute to heart failure.

The patient's elevated Pro-BNP (brain natriuretic peptide) level of 32552.0 ng/L is a strong indicator of heart failure. BNP is a hormone produced by the heart in response to increased ventricular wall stress, and elevated levels are associated with heart failure.

Additionally, the patient's medication regimen, which includes digoxin, loop diuretics, statins, and ACE inhibitors, suggests that they have been managed for heart failure. However, the patient's outcome suggests that these medications may not have been sufficient to manage the progression of heart failure.

The patient's age and NYHA class III classification also indicate a high risk of heart failure. The NYHA classification is a system used to measure the severity of heart failure, with class III indicating a moderate level of symptoms and limitations.

In conclusion, the patient's outcome of pump failure death is likely due to a combination of advanced heart failure, ischemic dilated cardiomyopathy, history of myocardial infarction, dyslipemia, and a high NYHA class III classification."
22,22,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is likely due to a combination of factors, primarily related to his severe heart failure and underlying cardiac conditions. 

The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to coronary artery disease, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 26%, indicating that the heart is not pumping efficiently. This is a significant predictor of heart failure and increased mortality risk.

The patient's elevated Pro-BNP (brain natriuretic peptide) level of 32552 ng/L is also indicative of heart failure, as this hormone is released by the heart in response to increased ventricular stretch and wall tension. High levels are associated with increased risk of mortality and hospitalization in patients with heart failure.

The patient's medication regimen includes Digoxin, Loop Diuretics, Statins, and ACE Inhibitor, which are standard treatments for heart failure. However, despite these treatments, the patient's condition has progressed to pump failure death, suggesting that the underlying cardiac damage and disease progression have overwhelmed the treatment effects.

Additionally, the patient's laboratory results show elevated creatinine levels (102.0 mmol/L), which indicates impaired kidney function, a common complication of heart failure. The patient's low hemoglobin level (124 g/L) may also contribute to decreased oxygen delivery to tissues, further exacerbating cardiac dysfunction.

The patient's T3 and T4 levels are within normal limits, ruling out hypothyroidism as a contributing factor. The patient's TSH level is also within the normal range, indicating that the thyroid function is not a contributing factor to his cardiac condition.

In conclusion, the patient's outcome of pump failure death is likely due to the progression of his ischemic dilated cardiomyopathy, severe heart failure, and underlying cardiac conditions, despite standard treatment and management."
23,23,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy, myocardial infarction, and current NYHA Class III symptoms, it is not surprising that the patient's left ventricular ejection fraction (LVEF) is severely reduced at 26%. This indicates that the patient's heart is not pumping efficiently, which can lead to symptoms such as fatigue, shortness of breath, and swelling in the legs.

The elevated levels of Pro-BNP (32552.0 ng/L) further supports the diagnosis of heart failure, as BNP is a biomarker that is released by the heart when it is under strain. The patient's troponin level (0.05 ng/mL) is also elevated, indicating myocardial damage.

The patient's ECG findings of monomorphic ventricular extrasystoles and TPSV (paroxysmal supraventricular tachyarrhythmia) suggest that the patient's heart rhythm is unstable, which can contribute to the development of heart failure.

The patient's laboratory results show a slightly elevated creatinine level (102.0 mmol/L), which indicates impaired kidney function, which can be a complication of heart failure. The patient's low albumin level (39.7 g/L) and low HDL cholesterol (1.32 mmol/L) are also consistent with heart failure.

The patient's medications, including digoxin, loop diuretics, statins, and ACE inhibitor, are standard treatments for heart failure, but in this case, they may not be sufficient to manage the patient's symptoms and underlying condition.

Considering the patient's advanced age (71 years), severe heart failure symptoms, and reduced LVEF, the patient's outcome of pump failure death is not unexpected. The patient's condition has likely progressed to the point where the heart is no longer able to pump blood effectively, leading to organ failure and ultimately death."
24,24,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient outcome of pump failure death can be attributed to several factors. 

1. Severe Left Ventricular Dysfunction: The patient has a low Left Ventricular Ejection Fraction (LVEF) of 26%, which is a strong indicator of heart failure. This suggests that the left ventricle is not pumping efficiently, leading to a decrease in cardiac output and increased risk of pump failure.

2. High BNP Levels: The patient's Pro-BNP level is significantly elevated at 32552 ng/L, which is a strong indicator of heart failure and fluid overload. Elevated BNP levels are associated with increased morbidity and mortality in heart failure patients.

3. History of Ischemic Dilated Cardiomyopathy and Myocardial Infarction: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction suggests that the patient's heart muscle has been damaged due to a lack of blood flow, leading to scarring and decreased cardiac function.

4. Medication Non-Response: Despite being on medications such as ACE inhibitors, statins, and loop diuretics, the patient's condition has not improved, indicating a possible non-response to therapy or inadequate dosing.

5. Malnutrition and Hypoalbuminemia: The patient's low albumin level (39.7 g/L) and low protein level (79 g/L) suggest malnutrition, which can exacerbate heart failure by reducing cardiac function and increasing fluid overload.

6. Electrocardiogram (ECG) Findings: The presence of ventricular extrasystoles and TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG indicates arrhythmias, which can further compromise cardiac function and increase the risk of pump failure.

Considering these factors, the patient's outcome of pump failure death is a likely consequence of a combination of severe left ventricular dysfunction, high BNP levels, history of ischemic dilated cardiomyopathy, and medication non-response, compounded by malnutrition and arrhythmias."
25,25,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data.

Firstly, the patient's left ventricular ejection fraction (LVEF) of 26% is significantly reduced, indicating severe left ventricular dysfunction. This is a hallmark of heart failure with reduced ejection fraction (HFrEF), which is a major risk factor for pump failure.

Secondly, the patient's creatinine level of 102.0 mol/L suggests impaired renal function, which is a common complication of advanced heart failure. The patient's serum albumin level of 39.7 g/L is also low, indicating possible malnutrition and muscle wasting, which can further exacerbate cardiac dysfunction.

The patient's elevated pro-BNP (Brain Natriuretic Peptide) level of 32552.0 ng/L is indicative of increased ventricular wall stress, which is a strong predictor of heart failure hospitalization and mortality.

Additionally, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction suggests that the patient's heart muscle has been damaged due to lack of blood flow, leading to scarring and reduced cardiac function.

The patient's medications, including digoxin, loop diuretics, statins, and ACE inhibitor, are standard treatments for heart failure, but the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

The presence of ventricular extrasystoles on the ECG may also be indicative of electrical instability in the heart, which can contribute to pump failure.

Lastly, the patient's age of 71 and NYHA Class III classification indicate that the patient has severe symptoms of heart failure, which further increases the risk of pump failure.

In summary, the patient's outcome of pump failure death can be attributed to a combination of severe left ventricular dysfunction, impaired renal function, malnutrition, elevated ventricular wall stress, history of ischemic dilated cardiomyopathy and myocardial infarction, and electrical instability in the heart."
26,26,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to several factors based on the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack or reduced blood flow, leading to a decrease in the heart's ability to pump blood efficiently. This condition is further exacerbated by the patient's low left ventricular ejection fraction (LVEF) of 26%, indicating that the left ventricle is not pumping blood effectively.

The patient's NYHA Class III classification also suggests that the patient experiences symptoms of heart failure, such as shortness of breath, fatigue, and swelling, which can further compromise the heart's ability to function.

The elevated levels of N-terminal pro b-type natriuretic peptide (Pro-BNP) at 32552.0 ng/L is a strong indicator of heart failure, as it is a hormone produced by the heart in response to increased ventricular wall stress.

Additionally, the patient's elevated creatinine levels (102.0 mmol/L) and low hemoglobin levels (124.0 g/L) suggest that the patient may have kidney dysfunction, which can further contribute to the progression of heart failure.

The patient's medication regimen, including digoxin, loop diuretics, statins, and an ACE inhibitor, is aimed at managing heart failure symptoms, but the patient's condition has progressed to pump failure, likely due to the severity of the underlying heart disease and other comorbidities.

The patient's low T3 and T4 levels may also suggest hypothyroidism, which can contribute to heart failure, although this is not the primary cause of the patient's outcome.

In summary, the combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP levels, kidney dysfunction, and the progression of heart failure symptoms despite medication, ultimately led to pump failure and death."
27,27,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's clinical presentation and laboratory results, the outcome of pump failure death is likely due to the combination of severe left ventricular dysfunction (LVEF 26.0%) and elevated B-type natriuretic peptide (BNP) levels (32552.0 ng/L), which are indicative of heart failure. The patient's ischemic dilated cardiomyopathy and history of myocardial infarction are contributing factors to the development of heart failure.

The patient's low left ventricular ejection fraction (LVEF 26.0%) indicates that the heart is not pumping efficiently, which can lead to fluid buildup in the body and increase the risk of heart failure. The elevated BNP levels further support this diagnosis, as BNP is a hormone released by the heart in response to increased ventricular stretch and wall tension, which is often seen in heart failure.

Additionally, the patient's NYHA Class III classification indicates that the patient has severe symptoms of heart failure, including shortness of breath, fatigue, and swelling in the legs and feet, which further supports the diagnosis of heart failure.

The patient's laboratory results, including the elevated creatinine levels (102.0 mmol/L), suggest that the patient may have underlying kidney dysfunction, which can further exacerbate heart failure.

The patient's medications, including digoxin, loop diuretics, statins, and ACE inhibitor, are commonly used to treat heart failure, but the patient's outcome of pump failure death suggests that these medications may not have been sufficient to manage the patient's condition.

Overall, the combination of severe left ventricular dysfunction, elevated BNP levels, and NYHA Class III classification, along with the patient's underlying medical history and laboratory results, supports the outcome of pump failure death."
28,28,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors, primarily related to his underlying heart condition and laboratory results. 

1.  Ischemic dilated cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy indicates that his heart muscle has been damaged due to reduced blood flow, leading to a weakened heart pump. This condition is a significant risk factor for heart failure and is likely contributing to the patient's poor prognosis.

2.  Low LVEF (26.0%): The left ventricular ejection fraction (LVEF) measures the heart's ability to pump blood efficiently. A low LVEF of 26% indicates that the heart is not pumping blood effectively, which is consistent with heart failure. This value is well below the normal range of 50-70%, suggesting severe left ventricular dysfunction.

3.  High Pro-BNP (32552.0 ng/L): B-type natriuretic peptide (BNP) is a hormone released by the heart in response to increased wall stress. Elevated BNP levels, such as in this patient, are associated with heart failure and indicate that the heart is working harder than normal to pump blood.

4.  Elevated Creatinine (102.0 mmol/L): This suggests impaired kidney function, which is a common complication of heart failure. The kidneys rely on adequate blood flow to function properly, and decreased cardiac output can lead to reduced kidney function.

5.  Electrocardiogram (ECG) findings: The presence of ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia (PSVT) indicates abnormal heart rhythms, which can further compromise cardiac function.

6.  Medication regimen: While the patient is on medications that are commonly used to manage heart failure, such as digoxin, loop diuretics, statins, and ACE inhibitors, their effectiveness may be limited in this case due to the advanced stage of the disease.

Considering these factors, the patient's outcome of pump failure death is likely the result of a combination of his underlying heart condition, reduced cardiac function, and associated complications."
29,29,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors, primarily driven by the patient's severe left ventricular dysfunction and elevated B-type natriuretic peptide (BNP) levels. The patient has an LVEF (Left Ventricular Ejection Fraction) of 26%, indicating severe systolic heart failure, which is a strong predictor of poor prognosis. The elevated BNP level of 32552 ng/L further supports this, as BNP is a marker of heart failure and is associated with increased morbidity and mortality in patients with heart failure.

The patient's past medical history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia also contribute to the patient's poor outcome. Ischemic cardiomyopathy is a common cause of heart failure, and the patient's history of myocardial infarction suggests that the patient has had significant cardiac damage. Dyslipidemia, characterized by an elevated total cholesterol level (4.84 mmol/L) and low HDL level (1.32 mmol/L), increases the risk of cardiovascular disease and may have contributed to the patient's cardiac damage.

The patient's NYHA Class III classification indicates that the patient has severe symptoms of heart failure, including shortness of breath and fatigue, which further supports the likelihood of pump failure death. The patient's low hemoglobin level (124 g/L) may also contribute to the patient's poor outcome, as anemia is a common comorbidity in patients with heart failure and can worsen symptoms and outcomes.

The patient's medications, including digoxin, loop diuretics, statins, and ACE inhibitors, are appropriate for heart failure management, but may not have been sufficient to prevent the patient's poor outcome. The patient's ECG findings, including monomorphic ventricular extrasystoles and paroxysmal supraventricular tachycardia, may also contribute to the patient's poor outcome, as these arrhythmias can worsen cardiac function and increase the risk of cardiac arrest.

In summary, the patient's outcome of pump failure death can be attributed to a combination of severe left ventricular dysfunction, elevated BNP levels, ischemic cardiomyopathy, myocardial infarction, dyslipidemia, and anemia, which were not adequately managed by the patient's medications and may have been exacerbated by arrhythmias."
30,30,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of factors. Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or reduced blood flow, leading to a decrease in the heart's pumping efficiency. The patient's left ventricular ejection fraction (LVEF) of 35% indicates severe left ventricular dysfunction, further supporting this diagnosis.

The patient's creatinine level of 207.0 mmol/L indicates severe kidney dysfunction, which is often a consequence of chronic heart failure. This is likely due to the heart's inability to pump blood efficiently, leading to fluid buildup in the body and strain on the kidneys.

The patient's high pro-BNP level of 428.0 ng/L is indicative of heart failure, as BNP is a hormone released by the heart in response to stress and strain. Elevated levels of BNP are often associated with heart failure.

The patient's ECG findings of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles suggest arrhythmias, which can further compromise cardiac function and increase the risk of sudden cardiac death.

Additionally, the patient's NYHA Class III classification indicates that he has severe symptoms of heart failure, such as shortness of breath, fatigue, and swelling, which further support the diagnosis of pump failure.

The patient's age of 81 and the presence of multiple comorbidities, including diabetes, peripheral vascular disease, and myocardial infarction, also contribute to his increased risk of cardiac complications and mortality.

Overall, the combination of ischemic dilated cardiomyopathy, severe kidney dysfunction, high pro-BNP levels, arrhythmias, and multiple comorbidities likely contributed to the patient's outcome of pump failure death."
31,31,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death is likely due to a combination of factors related to his underlying cardiovascular disease and other comorbidities.

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, a condition where the heart muscle is weakened due to heart attacks or coronary artery disease. This condition can lead to reduced heart function, decreased left ventricular ejection fraction (LVEF), and ultimately, heart failure.

2.  Low LVEF (35%): The patient's LVEF is significantly reduced, indicating that the heart is not pumping efficiently. This is a strong indicator of heart failure.

3.  High Pro-BNP (428 ng/L): The patient's B-type natriuretic peptide (BNP) level is elevated, which is a biomarker for heart failure. High BNP levels indicate that the heart is under strain and is not pumping effectively.

4.  History of Myocardial Infarction: The patient has a history of heart attacks, which can contribute to the development of IDC and heart failure.

5.  Peripheral Vascular Disease (PVD): The patient has PVD, which can further reduce blood flow to the heart, exacerbating the effects of IDC and contributing to heart failure.

6.  Diabetes: The patient's diabetes is a significant risk factor for cardiovascular disease and can contribute to the development of IDC and heart failure.

7.  Medications: While the patient is on ACE inhibitor, which is a standard treatment for heart failure, the combination of his other comorbidities and reduced LVEF may have made it challenging to control the disease.

8.  ECG Findings: The patient's ECG shows non-sustained ventricular tachycardia, which can be a sign of underlying cardiac disease and may indicate an increased risk of sudden cardiac death.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of his underlying cardiovascular disease, comorbidities, and reduced heart function."
32,32,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's profile, the outcome of pump failure death can be attributed to a combination of factors. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a previous heart attack, leading to a reduced left ventricular ejection fraction (LVEF of 35%). This is evident from the patient's low LVEF percentage and elevated Pro-BNP levels, which is a biomarker for heart failure.

The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath, fatigue, and swelling in the legs, during everyday activities. The patient's creatinine level of 207.0 mmol/L is also elevated, indicating impaired kidney function, which is a common complication of heart failure.

The patient's diabetes and peripheral vascular disease further exacerbate the condition, as diabetes can damage blood vessels and nerves, leading to poor circulation and further strain on the heart. The patient's lipid profile shows an elevated LDL level of 2.53 mmol/L, which can contribute to the progression of atherosclerosis and worsen the patient's heart condition.

The patient's medications, including digoxin and an ACE inhibitor, are commonly used to manage heart failure symptoms and slow disease progression. However, the patient's low T3 level and normal T4 level suggest that the patient may be experiencing hypothyroidism, which can also contribute to heart failure.

The ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia indicate arrhythmias, which can further compromise cardiac function and increase the risk of sudden cardiac death.

Overall, the combination of ischemic dilated cardiomyopathy, impaired kidney function, diabetes, peripheral vascular disease, and arrhythmias, along with the patient's age and NYHA Class III classification, likely contributed to the patient's outcome of pump failure death."
33,33,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's advanced age of 81 years, the patient's history of ischemic dilated cardiomyopathy, and a left ventricular ejection fraction (LVEF) of 35%, it is clear that the patient has severe heart failure. The presence of non-sustained ventricular tachycardia (VT) on the ECG further indicates that the patient's heart is at high risk of life-threatening arrhythmias.

The patient's high levels of B-type natriuretic peptide (BNP) at 428 ng/L is indicative of severe heart failure, as elevated BNP levels are associated with increased ventricular wall stress and poor cardiac function.

The patient's low serum albumin level of 40.9 g/L may indicate malnutrition or liver disease, which can further exacerbate heart failure. The patient's total cholesterol level of 3.9 mmol/L is within the normal range, but the low HDL level of 1.03 mmol/L may indicate decreased cardiac function and increased risk of cardiovascular events.

The patient's high creatinine level of 207.0 umol/L suggests impaired kidney function, which is a common complication of heart failure. The patient's urea level of 28.28 mg/dL also indicates impaired kidney function.

The patient's medications, including diabetes medication, digoxin, and an ACE inhibitor, are appropriate for heart failure management. However, despite these treatments, the patient's condition has progressed to pump failure, leading to death.

The patient's low T4 level of 17 ng/L may indicate hypothyroidism, which can contribute to heart failure. However, the TSH level of 2.14 mIU/L is within the normal range, suggesting that hypothyroidism is unlikely.

In conclusion, the patient's advanced age, severe heart failure, impaired kidney function, and history of ischemic dilated cardiomyopathy, along with the presence of non-sustained VT, high BNP levels, and low HDL levels, all contributed to the patient's outcome of pump failure death."
34,34,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors, primarily driven by their underlying heart condition and comorbidities. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or reduced blood flow to the heart, leading to a decrease in the heart's ability to pump blood effectively. This condition is a significant contributor to their reduced left ventricular ejection fraction (LVEF) of 35%, indicating that only 35% of the heart's chambers are pumping blood efficiently.

2.  Reduced LVEF: The patient's LVEF of 35% is significantly below the normal range (50-70%), indicating that their heart is not pumping blood effectively. This can lead to a buildup of fluid in the lungs and other parts of the body, causing symptoms such as shortness of breath, fatigue, and swelling in the legs and feet, consistent with their NYHA Class III classification.

3.  High Pro-BNP levels: The patient's Pro-BNP level of 428.0 ng/L is elevated, indicating increased stress on the heart, which can be a sign of heart failure. Pro-BNP is a hormone produced by the heart in response to ventricular stretch and strain.

4.  Comorbidities: The patient's comorbidities, including diabetes, peripheral vascular disease, and a history of myocardial infarction, further increase their risk of heart failure and pump failure.

5.  Medications: Although the patient is taking medications for diabetes and heart failure (Digoxin and ACE Inhibitor), these medications may not be sufficient to manage their underlying condition effectively, especially considering their reduced LVEF and high Pro-BNP levels.

6.  ECG findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates abnormal heart rhythms, which can be a sign of underlying cardiac dysfunction.

Given these factors, the patient's outcome of pump failure death can be attributed to the progression of their underlying heart condition, exacerbated by their comorbidities and potentially inadequate management of their heart failure symptoms."
35,35,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors. 

Firstly, the patient's ischemic dilated cardiomyopathy, with an LVEF of 35%, indicates a significant impairment of the heart's pumping function. This condition is a result of previous myocardial infarctions and may have led to the development of ventricular extrasystoles and non-sustained ventricular tachycardia, as seen on the ECG. 

The patient's high creatinine level (207.0 mmol/L) suggests compromised kidney function, which is a common comorbidity in patients with heart failure. This can further exacerbate the condition by contributing to fluid overload, electrolyte imbalances, and increased levels of various neurohormonal factors that can worsen heart failure.

The patient's diabetes and peripheral vascular disease also contribute to the overall cardiovascular risk profile, increasing the likelihood of further cardiac events and complications.

The elevated Pro-BNP level (428.0 ng/L) indicates increased ventricular stretch and wall tension, consistent with heart failure. The patient's low hemoglobin level (119.0 g/L) may also contribute to decreased oxygen delivery to the tissues, further impairing cardiac function.

The combination of these factors, along with the patient's advanced age (81 years) and NYHA Class III symptoms, likely contributed to the progression of heart failure to a point where the patient's cardiac output was insufficient to meet the body's needs, ultimately leading to pump failure and death."
36,36,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death can be attributed to a combination of several factors based on the provided data. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack or lack of blood flow to the heart. This condition can lead to reduced heart function and ultimately, heart failure.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly below the normal range (50-70%). This indicates that the patient's heart is not pumping efficiently, and the left ventricle is not effectively pumping blood out to the body.

3.  High Pro-BNP levels: The patient's Pro-BNP level is 428.0 ng/L, which is elevated. BNP is a hormone produced by the heart in response to strain. Elevated BNP levels are often associated with heart failure.

4.  Presence of Non-sustained Ventricular Tachycardia (VT): The ECG shows non-sustained VT, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death.

5.  Reduced Hemoglobin levels: The patient's hemoglobin level is 119.0 g/L, which is slightly below the normal range. Anemia can contribute to reduced oxygen delivery to the heart muscle, exacerbating heart failure.

6.  Elevated Creatinine levels: The patient's creatinine level is 207.0 mmol/L, indicating impaired kidney function. Kidney disease is a common comorbidity in patients with heart failure, and it can further worsen the prognosis.

7.  Medication regimen: The patient is taking diabetes medication, digoxin, and an ACE inhibitor. While these medications are standard treatments for heart failure, their effectiveness may be limited in this patient due to the severity of their condition.

Considering these factors, the patient's outcome of pump failure death is likely due to the combination of ischemic dilated cardiomyopathy, reduced LVEF, elevated Pro-BNP levels, presence of non-sustained VT, anemia, and impaired kidney function."
37,37,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to several factors in their medical history and current clinical presentation. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate due to a previous heart attack or coronary artery disease. This condition can lead to reduced cardiac function and ultimately, heart failure.

The patient's current LVEF (Left Ventricular Ejection Fraction) is 35%, which is significantly below the normal range of 55-70%. This indicates that the patient's heart is not pumping efficiently, and this is likely contributing to their symptoms of heart failure.

Furthermore, the patient has a high Pro-BNP (B-type natriuretic peptide) level of 428.0 ng/L, which is a marker of heart failure. Elevated Pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

Additionally, the patient's medication regimen includes an ACE inhibitor, which is commonly used to treat heart failure. However, the patient's current condition suggests that the medication may not be sufficient to manage their heart failure symptoms.

The patient's other comorbidities, including diabetes, peripheral vascular disease, and myocardial infarction, also contribute to their increased risk of heart failure and poor outcomes.

The presence of non-sustained ventricular tachycardia on the ECG is a sign of arrhythmia, which can further compromise cardiac function and increase the risk of sudden cardiac death.

The patient's laboratory results, including elevated creatinine and urea levels, suggest impaired renal function, which is often seen in patients with advanced heart failure. The patient's low hemoglobin level may also indicate anemia, which can further exacerbate heart failure symptoms.

The patient's overall clinical presentation and laboratory results suggest that their heart failure is severe and advanced, leading to pump failure and ultimately, death."
38,38,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of his underlying medical conditions and laboratory results. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in the heart's pumping efficiency. The patient's left ventricular ejection fraction (LVEF) of 35% is significantly below the normal range, indicating severe left ventricular dysfunction.

The patient's laboratory results also suggest elevated levels of pro-BNP (428 ng/L), which is a biomarker for heart failure. Additionally, the patient's creatinine level of 207.0 mol/L indicates impaired renal function, which is a common complication of heart failure. The elevated creatinine level suggests that the patient's kidneys are not functioning properly, which may be due to decreased blood flow caused by the heart failure.

The patient's past medical history of myocardial infarction, diabetes, and peripheral vascular disease further increases the risk of heart failure and pump failure. The patient's diabetes medication, digoxin, and ACE inhibitor are medications commonly used to manage heart failure, but the patient's continued decline suggests that these medications may not be sufficient to manage the severity of his condition.

The patient's ECG results show non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can lead to decreased cardiac output and increased risk of pump failure. The presence of polymorphic ventricular extrasystoles also suggests that the patient's heart is experiencing abnormal electrical activity, which can further compromise cardiac function.

In conclusion, the patient's outcome of pump failure death is likely due to the combination of his underlying medical conditions, laboratory results, and ECG findings, which indicate severe left ventricular dysfunction, impaired renal function, and abnormal heart rhythms."
39,39,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's advanced age (81 years) and history of ischemic dilated cardiomyopathy, the patient's reduced left ventricular ejection fraction (LVEF) of 35% suggests severe systolic heart failure. The elevated Pro-BNP (428 ng/L) level further supports the presence of heart failure, as it is a well-established biomarker for cardiac stress.

The patient's history of myocardial infarction and peripheral vascular disease indicates a high risk of cardiovascular disease, which has likely contributed to the development of ischemic dilated cardiomyopathy. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a marker of increased risk for sudden cardiac death and arrhythmias.

The patient's low HDL cholesterol (1.03 mmol/L) and high LDL cholesterol (2.53 mmol/L) levels suggest poor lipid management, which may have contributed to the development and progression of atherosclerotic cardiovascular disease.

The patient's diabetes history is well-managed, as indicated by the normal glucose level (6.9 mmol/L), but the presence of peripheral vascular disease suggests that the diabetes has had a significant impact on the patient's cardiovascular system.

The patient's creatinine level of 207.0 mol/L indicates chronic kidney disease, which is a common comorbidity in patients with heart failure. The elevated urea level (28.28 mg/dL) further supports this diagnosis.

The patient's low T3 level (0.03 pg/dL) and normal T4 level (17 ng/L) suggest hypothyroidism, which can contribute to decreased cardiac function and worsening heart failure.

The combination of these factors, including advanced age, severe systolic heart failure, history of cardiovascular disease, poor lipid management, chronic kidney disease, and hypothyroidism, has likely contributed to the patient's outcome of pump failure death."
40,40,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of several factors.

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a previous heart attack or reduced blood flow. This condition can lead to reduced cardiac function and eventual heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly lower than the normal range of 50-70%. A low LVEF indicates that the heart is not pumping efficiently, leading to reduced cardiac output and increased risk of heart failure.

3.  Elevated Pro-BNP Levels: The patient's Pro-BNP level is 475.0 ng/L, which is elevated. BNP is a hormone released by the heart in response to increased wall tension, which is often seen in heart failure. Elevated BNP levels are a marker of heart failure and can indicate poor cardiac function.

4.  Medications: Although the patient is on several medications, including ACE inhibitors and beta-blockers, which are commonly used to manage heart failure, the patient's condition has likely progressed to a point where these medications are no longer effective in managing the condition.

5.  Comorbidities: The patient has several comorbidities, including diabetes, peripheral vascular disease, and hypertension, which can all contribute to the progression of heart failure.

6.  Age and NYHA Class III: The patient is 69 years old and has a NYHA Class III classification, indicating that she experiences symptoms of heart failure at rest or with minimal exertion. This suggests that the patient's heart failure is severe and may be difficult to manage.

Given these factors, it is likely that the patient's heart failure has progressed to a point where it is no longer manageable with medical therapy, leading to pump failure and eventual death."
41,41,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is weakened due to scarring of the heart muscle from a heart attack. This underlying condition increases the risk of heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, leading to reduced cardiac output and increased risk of heart failure.

3.  High Pro-BNP levels: The patient's Pro-BNP level is 475.0 ng/L, which is elevated. Pro-BNP is a biomarker for heart failure, and high levels indicate increased ventricular stress and stretch, suggesting that the heart is working harder to compensate for its reduced pumping ability.

4.  Medication regimen: The patient is on a combination of medications, including Calcium Channel Blockers, Beta Blockers, and Loop Diuretics, which are commonly used to manage heart failure symptoms and slow disease progression. However, the patient's outcome suggests that these medications may not have been sufficient to control the progression of the disease.

5.  Age and comorbidities: The patient is 69 years old and has multiple comorbidities, including diabetes, peripheral vascular disease, and hypertension. These conditions can further compromise cardiac function and increase the risk of heart failure.

6.  Electrocardiogram (ECG) findings: The ECG shows polymorphic ventricular extrasystoles, which can be a sign of abnormal heart rhythm and reduced cardiac function.

Considering these factors, the patient's outcome of pump failure death can be attributed to the combination of ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, and the presence of multiple comorbidities, which ultimately led to a decline in cardiac function and pump failure."
42,42,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors present in her medical history and laboratory results. 

1. Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's pumping ability is reduced due to a previous heart attack or coronary artery disease. This condition can lead to heart failure, which is a significant risk factor for pump failure death.

2. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, which can lead to heart failure and ultimately pump failure death.

3. High Pro-BNP levels: The patient's Pro-BNP levels are elevated at 475.0 ng/L, which is a marker of heart failure. Elevated Pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

4. Medications: The patient is on a combination of medications, including calcium channel blockers, beta blockers, loop diuretics, and ACE inhibitors, which are commonly used to manage heart failure symptoms and improve survival. However, these medications may not be sufficient to control the patient's heart failure in this case.

5. Other comorbidities: The patient has diabetes, peripheral vascular disease, hypertension, and a history of myocardial infarction, which are all risk factors for heart failure and pump failure.

6. Poor nutritional status: The patient's albumin level is low at 40.7 g/L, which may indicate poor nutritional status or malnutrition. Malnutrition can exacerbate heart failure symptoms and worsen outcomes.

7. Electrocardiogram (ECG) findings: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of arrhythmias or electrical instability in the heart. This can increase the risk of sudden cardiac death.

In summary, the patient's outcome of pump failure death is likely due to a combination of her ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, comorbidities, poor nutritional status, and ECG findings."
43,43,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data.

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened due to coronary artery disease, leading to impaired heart function. This condition is a significant risk factor for heart failure and can lead to pump failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is below the normal range (50-70%). A low LVEF indicates that the left ventricle is not pumping efficiently, leading to a buildup of fluid in the lungs and other parts of the body, resulting in heart failure.

3.  Elevated Pro-BNP levels: The patient's Pro-BNP level is 475 ng/L, which is significantly elevated. Pro-BNP is a biomarker for heart failure, and high levels indicate increased stress on the heart, which can lead to pump failure.

4.  Medication regimen: Although the patient is on medications such as ACE inhibitors, beta blockers, and loop diuretics, which are commonly used to manage heart failure, it appears that these medications may not be sufficient to control the patient's condition, given the patient's low LVEF and elevated Pro-BNP levels.

5.  Other comorbidities: The patient has multiple comorbidities, including diabetes, peripheral vascular disease, and hypertension, which can contribute to the development and progression of heart failure.

6.  ECG findings: Although the ECG does not show any acute arrhythmias, the presence of polymorphic ventricular extrasystoles may indicate underlying electrical instability in the heart, which can contribute to pump failure.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP levels, and inadequate control of the condition despite medication."
44,44,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors evident in the provided data.

Firstly, the patient's left ventricular ejection fraction (LVEF) is 35%, which is significantly below the normal range of 50-70%. This indicates that the patient's heart is not pumping efficiently, leading to potential pump failure.

Secondly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or reduced blood flow. This condition can lead to decreased cardiac function and increased risk of pump failure.

Thirdly, the patient's elevated Pro-BNP (brain natriuretic peptide) level of 475.0 ng/L is a marker of heart failure and increased ventricular wall stress. Elevated Pro-BNP levels are associated with a higher risk of mortality and morbidity in patients with heart failure.

Fourthly, the patient's blood pressure is within a relatively normal range (130/80 mmHg), but the patient is taking a calcium channel blocker, a beta blocker, and an ACE inhibitor, which are commonly used to manage hypertension and heart failure. However, the patient's blood pressure is not well-controlled, and the patient's heart failure symptoms are not adequately managed.

Lastly, the patient's laboratory results show elevated glucose (5.7 mmol/L) and creatinine (63.0 mmol/L) levels, which can indicate kidney dysfunction and insulin resistance, both of which can contribute to the progression of heart failure.

Considering these factors, the patient's outcome of pump failure death is a likely consequence of the cumulative effect of these underlying conditions and the inadequate management of their heart failure symptoms."
45,45,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's advanced age (69 years), the patient's outcome of pump failure death is consistent with the expected natural history of ischemic dilated cardiomyopathy, a condition that often leads to progressive left ventricular dysfunction and eventual heart failure. The patient's low left ventricular ejection fraction (LVEF) of 35% indicates severe systolic dysfunction, which is a hallmark of advanced heart failure.

The patient's past medical history, including a history of myocardial infarction, hypertension, and peripheral vascular disease, further increases the risk of developing heart failure. The presence of diabetes, as indicated by elevated glucose levels (5.7 mmol/L), is also a significant risk factor for cardiovascular disease and heart failure.

The patient's laboratory results, including elevated creatinine levels (63.0 mol/L), indicate impaired renal function, which is a common complication of heart failure. The elevated Pro-BNP (brain natriuretic peptide) level of 475.0 ng/L is a marker of heart failure, particularly heart failure with reduced ejection fraction (HFrEF).

The patient's medications, including calcium channel blockers, beta blockers, loop diuretics, and ACE inhibitors, are standard treatments for heart failure, but in this case, they may not have been sufficient to prevent the progression to pump failure.

The patient's ECG findings of polymorphic ventricular extrasystoles suggest underlying ventricular dysfunction and may indicate a high risk of arrhythmias, which can contribute to sudden cardiac death.

Given the combination of advanced age, severe systolic dysfunction, impaired renal function, and elevated BNP levels, the patient's outcome of pump failure death is a predictable consequence of the disease progression."
46,46,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors evident from the provided data.

1.  Ischemic dilated cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy suggests that the heart muscle has been damaged due to a lack of blood flow, leading to reduced heart function. This condition is a significant risk factor for heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is below the normal range (50-70%). This indicates that the heart is not pumping efficiently, leading to reduced cardiac output and increased risk of heart failure.

3.  High B-type Natriuretic Peptide (BNP): The patient's Pro-BNP level is 475.0 ng/L, which is elevated. BNP is a marker of heart failure, and high levels indicate that the heart is under strain.

4.  Medication regimen: The patient is on medications that are commonly used to manage heart failure, including a calcium channel blocker, beta blockers, loop diuretics, and an ACE inhibitor. However, the effectiveness of these medications may be limited by the patient's advanced disease state.

5.  Electrocardiogram (ECG) findings: The presence of polymorphic ventricular extrasystoles may indicate underlying electrical instability in the heart, which can contribute to the development of arrhythmias and increased risk of sudden cardiac death.

6.  Other comorbidities: The patient's history of diabetes, peripheral vascular disease, hypertension, and myocardial infarction further increases the risk of cardiovascular events and mortality.

7.  Laboratory results: The patient's elevated creatinine level (63.0 mmol/L) suggests impaired kidney function, which can contribute to the development of heart failure and increase the risk of mortality.

Considering these factors, the patient's outcome of pump failure death is a likely consequence of the cumulative effect of these conditions, which have compromised the heart's ability to function effectively, leading to a fatal outcome."
47,47,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors, primarily related to her advanced heart failure and comorbid conditions.

1.  Ischemic Dilated Cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy is a significant risk factor for heart failure. The condition leads to a weakened heart muscle, making it difficult for the heart to pump blood efficiently, ultimately resulting in heart failure.

2.  Low LVEF (Left Ventricular Ejection Fraction): The patient's LVEF of 35% indicates severely impaired heart function. A normal LVEF is typically above 55%. A low LVEF is a strong predictor of heart failure and increased mortality risk.

3.  High Pro-BNP Levels: The patient's Pro-BNP level of 475 ng/L is elevated, indicating increased stress on the heart. Elevated Pro-BNP levels are associated with heart failure and can be used as a prognostic marker for mortality.

4.  Advanced Age and Comorbidities: The patient is 69 years old and has multiple comorbid conditions, including diabetes, peripheral vascular disease, hypertension, and myocardial infarction. These conditions can contribute to the progression of heart failure and increase the risk of mortality.

5.  Suboptimal Medications: Although the patient is on various medications, including beta blockers and ACE inhibitors, which are typically used to manage heart failure, the patient's symptoms and LVEF suggest that these medications may not be adequately controlling her heart failure.

6.  Poor Nutritional Status: The patient's albumin level of 40.7 g/L is slightly below the normal range, indicating possible malnutrition or poor nutritional status, which can exacerbate heart failure.

7.  Electrocardiogram (ECG) Findings: The presence of polymorphic ventricular extrasystoles may indicate underlying electrical instability in the heart, which can increase the risk of arrhythmias and cardiac arrest.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of advanced heart failure, comorbid conditions, and suboptimal management of her heart failure."
48,48,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors evident in their medical history, laboratory results, and ECG findings.

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a previous heart attack. This condition can lead to reduced heart function and increased risk of heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, leading to decreased cardiac output and increased risk of heart failure.

3.  Elevated Pro-BNP levels: The patient's Pro-BNP level is 475 ng/L, which is significantly elevated. Pro-BNP is a marker of heart failure and is often used to diagnose and monitor the severity of heart failure. Elevated levels indicate increased stress on the heart, which can lead to pump failure.

4.  Medication regimen: Although the patient is on several medications, including ACE inhibitors, beta blockers, and loop diuretics, these medications may not be sufficient to manage the patient's underlying heart condition, leading to progression of heart failure.

5.  Ventricular extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG suggests abnormal heart rhythm, which can further strain the heart and contribute to pump failure.

6.  Other comorbidities: The patient's history of diabetes, peripheral vascular disease, and hypertension can also contribute to the development of heart failure, as these conditions can lead to atherosclerosis, inflammation, and oxidative stress, which can damage the heart muscle.

In summary, the patient's outcome of pump failure death is likely due to a combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP levels, and the presence of ventricular extrasystoles, among other comorbidities."
49,49,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's pumping ability is impaired due to scarring from previous heart attacks. The left ventricular ejection fraction (LVEF) of 35% indicates that the heart is not pumping efficiently, which is consistent with heart failure.

The patient's NYHA Class III classification indicates that she has severe symptoms of heart failure, including shortness of breath and fatigue, which further supports the diagnosis of heart failure. The elevated Pro-BNP (brain natriuretic peptide) level of 475.0 ng/L is also consistent with heart failure, as this biomarker is often elevated in patients with heart failure.

The patient's past medical history of myocardial infarction, hypertension, and peripheral vascular disease also contribute to the development of heart failure. The presence of diabetes mellitus is also a significant risk factor for heart failure, as it can lead to damage to the heart muscle and blood vessels.

The patient's current medications, including beta blockers and ACE inhibitors, are standard treatments for heart failure, but they may not be sufficient to reverse the underlying damage to the heart. The patient's low hemoglobin level (119.0 g/L) may also contribute to reduced oxygen delivery to the heart muscle, exacerbating the heart failure.

The presence of ventricular extrasystoles on the ECG may indicate that the heart is experiencing electrical instability, which can further compromise cardiac function.

In summary, the combination of ischemic dilated cardiomyopathy, heart failure symptoms, elevated Pro-BNP levels, and the patient's past medical history and current medications, along with the presence of ventricular extrasystoles, suggest that the patient's outcome of pump failure death is likely due to the progression of her underlying heart disease."
50,50,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors evident from the provided data. 

1. Idiopathic dilated cardiomyopathy: The patient has a pre-existing condition of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weak and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. This underlying condition sets the stage for potential heart failure.

2. Low LVEF (Left Ventricular Ejection Fraction) of 30%: The LVEF of 30% indicates that the patient's heart is not pumping efficiently, which is a key indicator of heart failure. A normal LVEF is typically above 55%. This low ejection fraction suggests that the patient's heart is not able to effectively pump blood to meet the body's needs, leading to potential complications.

3. High Pro-BNP (B-type natriuretic peptide) levels: The Pro-BNP level of 475 ng/L is significantly elevated, indicating that the heart is under strain and releasing more natriuretic peptides to compensate for the decreased pumping efficiency. High Pro-BNP levels are associated with heart failure.

4. Ventricular Extrasystole and Non-sustained Ventricular Tachycardia: The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates abnormal heart rhythms that can further reduce the heart's pumping efficiency and increase the risk of arrhythmias.

5. Medication regimen: The patient is on Amiodarone, Spironolactone, and an ACE Inhibitor. While these medications are used to manage heart failure and arrhythmias, the patient's outcome suggests that they may not have been effective in managing the underlying condition.

6. Electrolyte imbalance: The patient's potassium level is slightly low (4.5 mEq/L), which can contribute to arrhythmias and further compromise heart function.

7. TSH (Thyroid-stimulating hormone) level: The elevated TSH level of 78.34 mIU/L suggests hypothyroidism, which can contribute to heart failure by reducing the heart's pumping efficiency.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of these conditions, leading to a weakened heart that is unable to meet the body's needs, ultimately resulting in pump failure and death."
51,51,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of factors related to his underlying medical conditions, laboratory results, and medication regimen. 

1. Idiopathic Dilated Cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing its ability to pump blood effectively. This underlying condition increases the risk of heart failure.

2. Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is severely reduced at 30%, indicating that the left ventricle is not pumping efficiently. This is a critical factor in the development of heart failure.

3. High Pro-BNP levels: Elevated Pro-BNP levels (475 ng/L) are indicative of heart failure. Pro-BNP is a biomarker that is released by the heart when it is under strain.

4. Medication regimen: While the patient is on medications such as Amiodarone, Spironolactone, and an ACE inhibitor, these medications are primarily used to manage arrhythmias, fluid retention, and hypertension, respectively. Although they may help manage symptoms, they do not directly address the underlying cause of the heart failure.

5. ECG findings: The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG indicates arrhythmias, which can further strain the heart and contribute to heart failure.

6. Low HDL and high LDL cholesterol levels: Elevated LDL and low HDL cholesterol levels can contribute to atherosclerosis, which can lead to coronary artery disease and further compromise cardiac function.

7. Hypertension: The patient's blood pressure of 140/80 mmHg, while within a relatively normal range, may not be adequately controlled, given his history of hypertension. Uncontrolled hypertension can lead to further cardiac strain.

8. Other laboratory abnormalities: The patient's elevated creatinine level (125.0 mmol/L) suggests impaired renal function, which can be a consequence of heart failure. The slightly elevated gamma-glutamil transpeptidase (GGT) level may indicate liver dysfunction, which can be a secondary effect of heart failure.

Given these factors, the patient's reduced cardiac function, arrhythmias, and underlying medical conditions likely led to a progression of heart failure, ultimately resulting in pump failure death."
52,52,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of his underlying medical conditions and laboratory results. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced heart function. This condition is reflected in the patient's low left ventricular ejection fraction (LVEF) of 30%, which is significantly below the normal range of 55-70%.

Furthermore, the patient's blood pressure is within a relatively normal range, which may indicate that his heart is not pumping effectively to meet the body's demands. Additionally, the patient's pro-BNP (brain natriuretic peptide) level is elevated at 475.0 ng/L, which is a marker of heart failure and can indicate increased wall stress on the heart.

The patient's medications, including amiodarone and spironolactone, are commonly used to treat heart failure and arrhythmias, but may not be sufficient to manage the patient's underlying condition.

The patient's ECG shows non-sustained ventricular tachycardia (VT), which is a type of abnormal heart rhythm that can be a sign of underlying heart disease. The presence of ventricular extrasystoles (abnormal heartbeats) also suggests that the patient's heart is not functioning normally.

The patient's laboratory results also show elevated levels of creatinine, which indicates impaired kidney function, likely due to decreased blood flow to the kidneys. This can be a complication of heart failure.

Lastly, the patient's low T3 and T4 levels, as well as elevated TSH, may indicate hypothyroidism, which can contribute to heart failure.

Considering these factors, the patient's outcome of pump failure death is likely due to the progression of his underlying heart disease, which has resulted in a failure of the heart to pump blood effectively, leading to organ dysfunction and ultimately, death."
53,53,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient outcome of pump failure death can be attributed to a combination of factors indicated by the patient's data and medical history. 

1.  Severe Left Ventricular Dysfunction: The patient has an ejection fraction (LVEF) of 30%, which is significantly below the normal range (50-70%). This indicates severe left ventricular dysfunction, making the heart unable to pump blood efficiently, leading to potential pump failure.

2.  Idiopathic Dilated Cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. This condition is a significant risk factor for heart failure.

3.  Elevated Pro-BNP Levels: The patient has elevated pro-B-type natriuretic peptide (Pro-BNP) levels of 475 ng/L, which is a marker of heart failure. Elevated Pro-BNP levels are associated with increased ventricular wall stress and are indicative of heart failure.

4.  Medications: While the patient is on medications such as Amiodarone, Spironolactone, and an ACE Inhibitor, which are commonly used to manage heart failure, the presence of severe left ventricular dysfunction and idiopathic dilated cardiomyopathy suggests that these medications may not have been sufficient to manage the patient's condition effectively.

5.  ECG Findings: The patient has non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death and can be a precursor to sustained ventricular tachycardia. Additionally, the presence of polymorphic ventricular extrasystoles further increases the risk of arrhythmias.

6.  Age and Comorbidities: The patient is 71 years old and has hypertension, which is a significant risk factor for heart failure. The patient's age and comorbidities may have contributed to the progression of heart failure and reduced the effectiveness of treatments.

In conclusion, the combination of severe left ventricular dysfunction, idiopathic dilated cardiomyopathy, elevated Pro-BNP levels, and ECG findings, along with the patient's age and comorbidities, contributed to the patient's outcome of pump failure death."
54,54,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is a complex result of multiple factors, which I will break down below:

1. Idiopathic dilated cardiomyopathy: The patient has a pre-existing condition that affects the heart's pumping efficiency, leading to a reduced left ventricular ejection fraction (LVEF) of 30.0%. This condition increases the risk of heart failure and pump failure.

2. Reduced LVEF (30.0%): A severely reduced LVEF is a strong indicator of heart failure and increased risk of pump failure. The patient's heart is not pumping efficiently, leading to decreased cardiac output and increased pressure on the heart.

3. High Pro-BNP (475.0 ng/L): B-type natriuretic peptide (BNP) is a biomarker of heart failure. Elevated levels indicate increased stress on the heart, which can lead to pump failure. The patient's high Pro-BNP level suggests that the heart is under significant stress, contributing to the development of pump failure.

4. Hypertension: The patient's blood pressure is 140/80 mmHg, which is within a relatively normal range. However, hypertension can contribute to heart failure and pump failure over time by increasing the workload on the heart.

5. Medications: The patient is taking Amiodarone, Spironolactone, and an ACE Inhibitor. While these medications are commonly used to manage heart failure and arrhythmias, they do not directly address the underlying cause of the patient's reduced LVEF and pump failure.

6. ECG findings: The patient has non-sustained ventricular tachycardia (NSVT), which can be a sign of cardiac ischemia or other underlying cardiac conditions that may contribute to pump failure.

7. Low HDL and high LDL cholesterol: The patient's lipid profile is concerning, with low HDL (1.32 mmol/L) and high LDL (2.69 mmol/L) cholesterol levels. Dyslipidemia can contribute to atherosclerosis and cardiac disease, which may have contributed to the development of idiopathic dilated cardiomyopathy.

8. Elevated TSH (78.34 mIU/L): Hyperthyroidism can contribute to heart failure and pump failure. The patient's elevated TSH level suggests hypothyroidism, which may not be directly contributing to the pump failure but could be a comorbidity that needs to be managed.

In conclusion, the patient's outcome of pump failure death is likely a result of the combination of idiopathic dilated cardiomyopathy, reduced LVEF, high Pro-BNP levels, hypertension, and other underlying cardiac conditions, as well as potential comorbidities such as dyslipidemia and hypothyroidism."
55,55,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors from their medical history, laboratory results, and ECG findings. 

The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. This condition is often associated with a poor prognosis and increased risk of heart failure.

The patient's low left ventricular ejection fraction (LVEF) of 30% indicates severely impaired heart function, which is a strong predictor of poor outcomes in patients with heart failure. The elevated Pro-BNP (Brain Natriuretic Peptide) level of 475.0 ng/L is also indicative of heart failure, as it is a biomarker that is released by the heart in response to increased wall tension and stretching.

The patient's ECG findings of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles suggest electrical instability of the heart, which can further compromise cardiac function and increase the risk of sudden cardiac death.

The patient's laboratory results also show elevated creatinine levels (125.0 mmol/L), indicating impaired kidney function, which is often seen in patients with advanced heart failure. Additionally, the patient's low total cholesterol level of 4.5 mmol/L and low HDL (good cholesterol) level of 1.32 mmol/L may indicate malnutrition or malabsorption, which can further compromise cardiac function.

The patient's high TSH level of 78.34 mIU/L suggests hypothyroidism, which can also contribute to heart failure. The patient's low T3 level of 0.03 pg/dL and low T4 level of 5 ng/L confirm this diagnosis.

The patient's medications, including amiodarone, spironolactone, and an ACE inhibitor, are appropriate for managing heart failure and arrhythmias, but may not be sufficient to control the patient's condition given the severity of their symptoms and laboratory results.

Overall, the combination of the patient's underlying heart disease, impaired heart function, electrical instability, kidney dysfunction, malnutrition, and hypothyroidism likely contributed to their outcome of pump failure death."
56,56,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's data, the primary reason for the patient's outcome of pump failure death is likely due to the advanced stage of idiopathic dilated cardiomyopathy, as indicated by a left ventricular ejection fraction (LVEF) of 30%. This is a significant reduction in the heart's ability to pump blood effectively, which can lead to heart failure.

The patient's high levels of brain natriuretic peptide (BNP) (475.0 ng/L) also support this diagnosis, as elevated BNP levels are associated with increased ventricular wall stress and poor cardiac function. The patient's symptoms and medical history, including hypertension and previous heart failure, further support the diagnosis of advanced heart failure.

The patient's medication regimen, including amiodarone, spironolactone, and an ACE inhibitor, is consistent with the treatment of heart failure and arrhythmias. However, despite these treatments, the patient's condition has progressed to pump failure, leading to death.

The patient's laboratory results, including the elevated creatinine level (125.0 mol/L) and low albumin level (45.4 g/L), suggest advanced kidney dysfunction, which is a common complication of heart failure. The patient's low T3 and T4 levels may also indicate hypothyroidism, which can be a consequence of long-term amiodarone therapy.

The patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia suggest arrhythmias that may have contributed to the patient's cardiac dysfunction. However, these findings are likely a consequence of the underlying heart failure rather than the primary cause of the patient's outcome.

In summary, the patient's advanced stage of idiopathic dilated cardiomyopathy, elevated BNP levels, and medication regimen are the primary factors contributing to the patient's outcome of pump failure death."
57,57,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of factors. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to a decrease in its pumping efficiency. This is further supported by the low left ventricular ejection fraction (LVEF) of 30%, indicating that the heart is not pumping blood efficiently.

The patient's laboratory results also suggest that they have a high level of B-type natriuretic peptide (BNP), which is a marker of heart failure. A BNP level of 475 ng/L is significantly elevated, indicating that the heart is under strain and not functioning properly. Additionally, the patient's creatinine level of 125.0 mol/L is elevated, suggesting impaired kidney function, which is a common complication of heart failure.

The patient's medication regimen includes amiodarone, spironolactone, and an ACE inhibitor, which are all commonly used to treat heart failure. However, despite these medications, the patient's condition has progressed to pump failure, leading to death.

The patient's ECG results show polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can indicate underlying heart disease. The presence of these arrhythmias, combined with the patient's other risk factors, suggests that their heart was not functioning properly, leading to pump failure.

Furthermore, the patient's TSH level of 78.34 mIU/L is elevated, which may indicate hypothyroidism. Hypothyroidism can contribute to heart failure by slowing down the heart rate and reducing its pumping efficiency, further exacerbating the patient's condition.

In conclusion, the patient's outcome of pump failure death can be attributed to a combination of their underlying heart disease, impaired kidney function, abnormal heart rhythms, and other contributing factors such as hypothyroidism."
58,58,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient is a 71-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension. His current medications include Amiodarone, Spironolactone, and an ACE Inhibitor, which are all appropriate for managing heart failure and arrhythmias.

The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 30%, indicating severe left ventricular dysfunction. This is a strong predictor of poor outcomes in heart failure patients. Additionally, the patient has a high Pro-BNP level of 475.0 ng/L, which is a marker of heart failure severity and is associated with increased mortality.

The patient's ECG shows non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can be a sign of underlying cardiac disease. The presence of polymorphic ventricular extrasystoles also indicates abnormal heart rhythm and may be a sign of increased cardiac vulnerability.

The patient's laboratory results show elevated creatinine levels (125.0 mmol/L), which may indicate renal impairment, a common comorbidity in patients with heart failure. The patient's total cholesterol and LDL levels are within relatively normal limits, but his HDL level is low (1.32 mmol/L), which may be a risk factor for cardiovascular disease.

The patient's TSH level is elevated at 78.34 mIU/L, which may indicate hypothyroidism. However, the T3 and T4 levels are within normal limits, which may suggest that the patient is euthyroid. However, an elevated TSH level in the context of heart failure can be a marker of poor prognosis.

The patient's overall clinical presentation and laboratory results suggest that he has advanced heart failure with significant left ventricular dysfunction, renal impairment, and abnormal cardiac rhythms. The combination of these factors, along with his age and comorbidities, likely contributed to his outcome of pump failure death."
59,59,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors evident from the provided data. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to a decrease in the heart's ability to pump blood effectively. This condition is further supported by the patient's low left ventricular ejection fraction (LVEF) of 30.0%, which indicates a reduced ability of the heart to pump blood efficiently.

Furthermore, the patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 475.0 ng/L is indicative of heart failure. BNP is a hormone produced by the heart in response to increased wall tension, which is a hallmark of heart failure. The elevated levels suggest that the patient's heart is under significant stress and is struggling to pump blood effectively.

Additionally, the patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia indicate abnormal heart rhythms that can further compromise cardiac function and contribute to the development of heart failure.

The patient's TSH (Thyroid-Stimulating Hormone) level of 78.34 mIU/L is elevated, which may suggest hypothyroidism. Hypothyroidism can contribute to the development of heart failure by reducing cardiac output and increasing peripheral resistance. Although the patient's T3 and T4 levels are within normal limits, the elevated TSH level suggests that the patient may have a subclinical hypothyroid state, which could be contributing to the development of heart failure.

Lastly, the patient's medications, including Amiodarone, Spironolactone, and ACE Inhibitor, are commonly used to manage heart failure and arrhythmias, but their effectiveness may be limited in this patient given the severity of the underlying condition.

In summary, the patient's outcome of pump failure death can be attributed to the combination of idiopathic dilated cardiomyopathy, elevated Pro-BNP levels, abnormal heart rhythms, potential hypothyroidism, and the limitations of the patient's current medication regimen."
60,60,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are both risk factors for heart failure. The patient's left ventricular ejection fraction (LVEF) of 42% indicates that the left ventricle is not pumping efficiently, which is a hallmark of heart failure.

The elevated levels of pro-BNP (1160.0 ng/L) and troponin (0.01 ng/mL) indicate that the patient's heart is experiencing stress and damage, likely due to the underlying heart disease. The patient's high total cholesterol level (5.92 mmol/L) and low HDL (1.14 mmol/L) also contribute to the risk of atherosclerosis and further cardiac damage.

The patient's renal function is also compromised, as indicated by the elevated creatinine level (106.0 mmol/L) and urea level (6.82 mg/dL). This can be a result of decreased cardiac output leading to reduced perfusion of the kidneys. The patient's low albumin level (38 g/L) may also indicate malnutrition or liver disease, which can further exacerbate the patient's condition.

The patient's medication regimen, which includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, is aimed at managing heart failure symptoms and slowing the progression of the disease. However, the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

The ECG findings of polymorphic ventricular extrasystoles and paroxysmal supraventricular tachycardia (PSVT) indicate arrhythmias that can further compromise cardiac function. The presence of these arrhythmias, combined with the patient's underlying heart disease, may have contributed to the development of pump failure.

In conclusion, the patient's outcome of pump failure death is likely due to a combination of factors, including ischemic dilated cardiomyopathy, myocardial infarction, reduced LVEF, elevated troponin and pro-BNP levels, renal dysfunction, malnutrition, and arrhythmias."
61,61,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient outcome of pump failure death can be attributed to a combination of several factors.

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or coronary artery disease. This condition can lead to reduced heart function and pump failure.

2.  Low LVEF (42%): The left ventricular ejection fraction (LVEF) is significantly reduced at 42%, indicating that the heart is not pumping efficiently. An LVEF below 50% is generally considered a sign of heart failure.

3.  Elevated Pro-BNP (1160.0 ng/L): The B-type natriuretic peptide (BNP) level is elevated, which is a marker of heart failure. High BNP levels indicate that the heart is under strain and is not pumping efficiently.

4.  Medication regimen: Although the patient is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, these medications may not have been sufficient to manage the patient's heart failure symptoms, leading to progression of the disease.

5.  Other comorbidities: The patient has a history of myocardial infarction, which can contribute to the development of heart failure. Additionally, the patient's total cholesterol level (5.92 mmol/L) and LDL level (3.7 mmol/L) are elevated, which can contribute to atherosclerosis and coronary artery disease.

6.  Nutritional status: The patient's albumin level (38 g/L) is slightly low, indicating potential malnutrition or liver dysfunction, which can contribute to muscle wasting and decreased cardiac function.

7.  Electrocardiogram (ECG) findings: The presence of ventricular extrasystoles and TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG may indicate arrhythmias that can further compromise cardiac function.

Given these factors, it is likely that the patient's heart failure progressed to pump failure, ultimately leading to death."
62,62,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of factors related to his underlying cardiac condition, comorbidities, and laboratory results. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a decrease in the heart's pumping efficiency. His left ventricular ejection fraction (LVEF) of 42% indicates a reduced cardiac function, which further supports this diagnosis.

The patient's elevated levels of Pro-BNP (brain natriuretic peptide) at 1160.0 ng/L also indicate increased ventricular wall stress and a poor cardiac function, consistent with heart failure.

Additionally, his high total cholesterol level (5.92 mmol/L) and low HDL level (1.14 mmol/L) suggest dyslipidemia, which is a significant risk factor for cardiovascular disease and can exacerbate cardiac dysfunction.

The patient's elevated creatinine level (106.0 mol/L) indicates impaired renal function, which is a common comorbidity in patients with heart failure. This can lead to a vicious cycle of worsening cardiac function and further renal impairment.

The patient's laboratory results also show elevated liver enzymes (ALT and AST), which may indicate liver dysfunction, possibly due to non-alcoholic fatty liver disease (NAFLD) or other underlying conditions. This can contribute to further metabolic and cardiovascular complications.

Furthermore, the patient's low T3 level (0.03 pg/dL) and TSH level within the normal range (4.34 mIU/L) suggest hypothyroidism, which can be associated with heart failure and further compromise cardiac function.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. However, despite these medications, the patient's cardiac function has not improved, and he has progressed to pump failure death.

In conclusion, the combination of the patient's underlying cardiac condition, comorbidities, and laboratory results, including elevated Pro-BNP, impaired renal function, dyslipidemia, liver dysfunction, and hypothyroidism, have likely contributed to his outcome of pump failure death."
63,63,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient outcome of pump failure death in this 71-year-old male patient with a history of ischemic dilated cardiomyopathy and myocardial infarction can be attributed to a combination of factors.

Firstly, the patient's left ventricular ejection fraction (LVEF) is significantly reduced at 42%, indicating a compromised heart function. This is a critical risk factor for heart failure and pump failure. The patient's history of ischemic dilated cardiomyopathy further supports this, as it is a condition characterized by a weakened heart muscle due to reduced blood flow to the heart, leading to a decrease in LVEF.

The elevated pro-BNP (brain natriuretic peptide) level of 1160.0 ng/L is another indicator of heart failure, as it is a biomarker released by the heart in response to increased wall tension and stretch. This suggests that the patient's heart is under significant stress and is not functioning properly.

The patient's laboratory results also show elevated liver enzymes (ALT and AST), which can indicate liver congestion due to right-sided heart failure. The patient's total cholesterol and LDL levels are elevated, which can contribute to atherosclerosis and worsen cardiac function.

The patient's medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are standard treatments for heart failure and ischemic cardiomyopathy. However, despite these treatments, the patient's condition has progressed to pump failure death.

The patient's TSH level is within the normal range, and the T3 and T4 levels are also within the normal range, indicating that hypothyroidism is unlikely to be a contributing factor to the patient's condition.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac ischemia or arrhythmia. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is not the primary cause of the pump failure.

In summary, the patient's outcome of pump failure death can be attributed to a combination of his compromised heart function, elevated pro-BNP levels, liver congestion, and atherosclerosis, despite being on standard treatments for heart failure and ischemic cardiomyopathy."
64,64,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors related to his underlying heart condition, medication, and laboratory results. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, a condition where the heart muscle becomes weakened due to reduced blood flow to the heart. This condition can lead to heart failure, which in turn can cause pump failure.

2.  Low LVEF (42%): The patient's left ventricular ejection fraction (LVEF) is 42%, which is below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, leading to reduced cardiac output and potentially contributing to pump failure.

3.  High Pro-BNP (1160 ng/L): The patient's Pro-BNP level is significantly elevated, which is a marker of heart failure. High Pro-BNP levels indicate that the heart is under strain and is not functioning properly.

4.  Medication non-adherence or inadequate dosing: Although the patient is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, these medications may not be sufficient to manage the patient's condition effectively. Inadequate dosing or non-adherence to medication can lead to uncontrolled heart failure.

5.  Electrocardiogram (ECG) findings: The patient has a polymorphic ventricular extrasystole, which can be a sign of abnormal heart rhythm. Although the patient does not have sustained ventricular tachycardia or non-sustained ventricular tachycardia, the presence of polymorphic ventricular extrasystole may indicate underlying electrical instability in the heart.

6.  Metabolic and electrolyte imbalances: The patient has a low potassium level (4.5 mEq/L), which can contribute to arrhythmias and worsen heart failure. Additionally, the patient's low albumin level (38 g/L) may indicate malnutrition or liver disease, which can further compromise cardiac function.

7.  Other comorbidities: The patient's elevated creatinine level (106.0 mol/L) indicates impaired renal function, which can exacerbate heart failure. The patient's high total cholesterol level (5.92 mmol/L) and low HDL level (1.14 mmol/L) may also contribute to atherosclerosis and worsen ischemic dilated cardiomyopathy.

In summary, the patient's pump failure death can be attributed to a combination of factors, including ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, inadequate medication management, ECG abnormalities, metabolic and electrolyte imbalances, and other comorbidities."
65,65,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors from the provided data. 

1.  Ischemic Dilated Cardiomyopathy and Myocardial Infarction: The patient has a history of ischemic dilated cardiomyopathy and a myocardial infarction, which suggests that the heart muscle has been damaged due to a lack of blood flow. This condition can lead to a decrease in the heart's pumping efficiency, ultimately resulting in heart failure.

2.  Low LVEF (Left Ventricular Ejection Fraction) of 42%: The LVEF is a critical indicator of the heart's pumping efficiency. A value of 42% is below the normal range (50-70%), indicating that the patient's heart is not pumping efficiently. This can lead to a buildup of fluid in the body, causing symptoms such as shortness of breath, fatigue, and swelling in the legs.

3.  High Pro-BNP (Brain Natriuretic Peptide) level of 1160.0 ng/L: Elevated Pro-BNP levels are associated with heart failure. The higher the level, the more severe the heart failure. In this case, the patient's Pro-BNP level is significantly elevated, indicating severe heart failure.

4.  Medication regimen: While the patient is on medications such as beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, these medications are primarily used to manage symptoms and slow the progression of heart failure. However, they do not address the underlying cause of the heart failure, which is the damage to the heart muscle.

5.  Electrocardiogram (ECG) findings: The ECG shows polymorphic ventricular extrasystoles, which can be a sign of electrical instability in the heart. This can contribute to the patient's risk of arrhythmias and further compromise the heart's pumping function.

6.  Elevated Creatinine level of 106.0 mmol/L: This indicates impaired kidney function, which can be a complication of heart failure. The kidneys rely on the heart to pump blood efficiently, and when the heart is not pumping well, the kidneys can become damaged.

7.  Low HDL cholesterol level of 1.14 mmol/L: Low HDL cholesterol is a risk factor for heart disease, which can contribute to the progression of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely a result of the combination of ischemic dilated cardiomyopathy, myocardial infarction, and the progression of heart failure over time. The patient's medications and other medical conditions may have helped manage symptoms, but they did not address the underlying cause of the heart failure, ultimately leading to the patient's demise."
66,66,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data.

1.  Ischemic Dilated Cardiomyopathy and Myocardial Infarction History: The patient has a history of ischemic dilated cardiomyopathy and a previous myocardial infarction, which are significant risk factors for heart failure and reduced left ventricular ejection fraction (LVEF). The patient's LVEF of 42% indicates a reduced cardiac function.

2.  Reduced LVEF and Elevated Pro-BNP: The patient's LVEF of 42% indicates a reduced cardiac function, which is consistent with heart failure. Elevated Pro-BNP (Brain Natriuretic Peptide) levels (1160.0 ng/L) are also indicative of heart failure.

3.  Electrocardiogram (ECG) Findings: The presence of polymorphic ventricular extrasystoles may indicate arrhythmias, which can be a sign of underlying cardiac disease and may contribute to the patient's reduced cardiac function.

4.  Medications: The patient is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications are commonly used to manage heart failure, but their effectiveness may be limited in advanced cases.

5.  Laboratory Results: Elevated creatinine levels (106.0 mol/L) suggest renal impairment, which is a common comorbidity in patients with heart failure. The patient's low albumin (38 g/L) and low hemoglobin (113.0 g/L) levels may indicate malnutrition or chronic disease.

6.  Low HDL and High LDL Cholesterol: The patient's low HDL (1.14 mmol/L) and high LDL (3.7 mmol/L) cholesterol levels may contribute to the progression of atherosclerosis, which can exacerbate ischemic dilated cardiomyopathy.

7.  TSH and T3/T4 Levels: The patient's TSH level is within the normal range, but the low T3 level (0.03 pg/dL) may indicate a low thyroid hormone state, which can contribute to heart failure.

Given these factors, the patient's outcome of pump failure death can be attributed to the progression of ischemic dilated cardiomyopathy, reduced cardiac function, and the presence of comorbidities such as renal impairment, malnutrition, and electrolyte imbalances."
67,67,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's profile, the outcome of pump failure death can be attributed to a combination of factors. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart's pumping ability is impaired. This is likely due to previous myocardial infarction (heart attack), which has caused damage to the heart muscle.

The patient's left ventricular ejection fraction (LVEF) of 42% is below the normal range of 50-70%, indicating that the heart is not pumping efficiently. This is consistent with the diagnosis of heart failure.

The elevated levels of N-terminal pro b-type natriuretic peptide (Pro-BNP) at 1160.0 ng/L suggest that the heart is under strain and is producing more natriuretic peptides in an attempt to compensate for the decreased pumping ability. This is a marker of heart failure.

The patient's total cholesterol level of 5.92 mmol/L is slightly elevated, which can contribute to the progression of heart disease. The low HDL (good cholesterol) level of 1.14 mmol/L and high LDL (bad cholesterol) level of 3.7 mmol/L also indicate a high risk of cardiovascular disease.

The patient's creatinine level of 106.0 mol/L is slightly elevated, suggesting impaired kidney function, which can be a complication of heart failure.

The patient's T3 level of 0.03 pg/dL is low, which can indicate hypothyroidism, a condition that can contribute to heart failure.

The patient's medications, including beta blockers, loop diuretics, spironolactone, and ACE inhibitor, are typical for heart failure treatment, but the combination of these medications may not have been sufficient to manage the patient's condition effectively.

The ECG findings of polymorphic ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia (PSVT) suggest arrhythmias, which can further compromise cardiac function and contribute to the patient's outcome.

In conclusion, the patient's outcome of pump failure death is likely due to the combination of ischemic dilated cardiomyopathy, previous myocardial infarction, impaired cardiac function (LVEF 42%), elevated Pro-BNP levels, high cholesterol levels, impaired kidney function, and the presence of arrhythmias."
68,68,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of several factors.

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a decrease in the heart's pumping efficiency. This underlying condition sets the stage for potential heart failure.

2.  Low LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 42%, which is significantly lower than the normal range (50-70%). A low LVEF indicates that the heart is not pumping blood efficiently, making it harder for the body to receive the oxygen and nutrients it needs.

3.  Elevated Pro-BNP (Brain Natriuretic Peptide): The patient's Pro-BNP level is 1160.0 ng/L, which is significantly elevated. Pro-BNP is a hormone produced by the heart when it is under strain. High levels of Pro-BNP are often associated with heart failure.

4.  Medication Non-Adherence or Inadequate Management: The patient is taking beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. However, despite these medications, the patient's condition has progressed to pump failure death. This suggests that the treatment may not have been adequate or that the patient may not have adhered to the medication regimen.

5.  Comorbidities: The patient has several comorbidities, including hypertension, diabetes (indicated by a glucose level of 6.7 mmol/L), and elevated liver enzymes (ALT and AST). These comorbidities can further strain the heart and contribute to the development of heart failure.

6.  Electrocardiogram (ECG) Findings: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of abnormal heart rhythms that can lead to arrhythmias and decreased cardiac function.

7.  Nutritional Status: The patient's albumin level is slightly low (38 g/L), which may indicate malnutrition or liver dysfunction, both of which can contribute to heart failure.

8.  Hypotension: The patient's blood pressure is 120/60 mmHg, which is lower than normal. Hypotension can further reduce cardiac output and worsen heart failure.

In conclusion, the patient's outcome of pump failure death can be attributed to a combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, medication non-adherence or inadequate management, comorbidities, ECG findings, nutritional status, and hypotension."
69,69,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's age (71), history of ischemic dilated cardiomyopathy, and previous myocardial infarction, the patient is at high risk for heart failure. The patient's left ventricular ejection fraction (LVEF) of 42% is below the normal range (50-70%), indicating reduced cardiac function. 

The elevated Pro-BNP (Brain Natriuretic Peptide) level of 1160 ng/L is a strong indicator of heart failure, as it is a biomarker that reflects the level of stress on the heart. The patient's NYHA Class II classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath, with minimal exertion.

The patient's lipid profile shows high total cholesterol (5.92 mmol/L) and LDL (3.7 mmol/L) levels, which are risk factors for cardiovascular disease and may contribute to the progression of heart failure.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure. However, despite these medications, the patient's condition has progressed to pump failure, resulting in death.

The presence of polymorphic ventricular extrasystoles on the ECG suggests abnormal electrical activity in the heart, which may be a contributing factor to the patient's cardiac dysfunction.

The patient's low T3 level (0.03 pg/dL) may indicate hypothyroidism, which can contribute to heart failure. However, the patient's TSH level is within the normal range (4.34 mIU/L), suggesting that hypothyroidism is unlikely.

The patient's urea level (6.82 mg/dL) is slightly elevated, which may indicate impaired renal function, which can be a consequence of heart failure.

Considering these factors, the patient's pump failure and death are likely a result of the progression of ischemic dilated cardiomyopathy, exacerbated by high cholesterol levels, abnormal cardiac electrical activity, and possibly impaired renal function."
70,70,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and weakened due to high blood pressure, leading to impaired heart function. The patient's ejection fraction (LVEF) of 60% is below the normal range (60-70%), indicating a compromised cardiac output.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 339.0 ng/L is also indicative of heart failure, as this biomarker is often used to diagnose and monitor heart failure. Additionally, the patient's history of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystole further supports the presence of cardiac dysfunction.

The patient's hypertension (140/80 mmHg) and peripheral vascular disease may also contribute to the development of heart failure, as high blood pressure can put additional strain on the heart. The patient's low HDL (1.03 mmol/L) and high LDL (3.44 mmol/L) cholesterol levels may also contribute to the progression of atherosclerosis, which can further impair cardiac function.

Furthermore, the patient's elevated creatinine level (88.0 mol/L) indicates impaired renal function, which can be a consequence of heart failure. The patient's elevated gamma-glutamil transpeptidase (115 IU/L) and ALT (40.0 IU/L) levels suggest liver dysfunction, which can also be a consequence of heart failure.

The patient's medications, including Amiodarone, Digoxin, and ACE Inhibitor, may be contributing to the patient's cardiac dysfunction, as these medications can have adverse effects on the heart. Amiodarone can cause arrhythmias, Digoxin can cause bradycardia, and ACE inhibitors can cause hypotension.

Overall, the combination of the patient's underlying conditions, laboratory results, and medication regimen likely contributed to the development of pump failure, ultimately leading to the patient's death."
71,71,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of several factors. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and stiff due to high blood pressure, leading to reduced heart function. The patient's NYHA Class II classification indicates that the patient experiences some limitation in physical activity, but is comfortable at rest, which suggests that the heart is not functioning optimally.

The patient's LVEF (Left Ventricular Ejection Fraction) is 60%, which is below the normal range of 55-70%. This indicates that the left ventricle is not pumping blood efficiently, leading to reduced cardiac output and increased risk of heart failure.

The patient's high Pro-BNP (B-type Natriuretic Peptide) level of 339.0 ng/L is a biomarker of heart failure, indicating that the heart is under strain and producing excess natriuretic peptides to compensate for the increased pressure.

The presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG suggests that the patient's heart is experiencing abnormal electrical activity, which can lead to arrhythmias and decreased cardiac output.

Additionally, the patient's high total cholesterol and LDL levels, as well as low HDL levels, indicate that the patient has dyslipidemia, which is a risk factor for cardiovascular disease and heart failure.

The patient's high creatinine level of 88.0 mol/L indicates impaired kidney function, which can further exacerbate heart failure by reducing the kidneys' ability to regulate fluid balance and electrolytes.

The patient's medication regimen, including Amiodarone and Digoxin, is aimed at managing arrhythmias and heart failure, but the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

The patient's age of 65 and weight of 113 kg also contribute to the increased risk of heart failure, as obesity and aging can both impair cardiac function.

Overall, the combination of Hypertensive cardiomyopathy, reduced LVEF, high Pro-BNP levels, abnormal ECG findings, dyslipidemia, impaired kidney function, and the patient's age and weight all contributed to the patient's outcome of pump failure death."
72,72,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data. 

1.  Hypertensive cardiomyopathy and Hypertension: The patient has a history of hypertensive cardiomyopathy and hypertension, which can lead to left ventricular hypertrophy and diastolic dysfunction, ultimately resulting in heart failure. The elevated blood pressure (140/80 mmHg) and high total cholesterol (5.09 mmol/L) levels further contribute to the progression of cardiac disease.

2.  Low LVEF (60%): The patient's left ventricular ejection fraction (LVEF) of 60% is below the normal range (typically > 65%), indicating reduced cardiac function. This reduced LVEF is a strong predictor of heart failure and pump failure.

3.  Elevated Pro-BNP (339.0 ng/L): The elevated level of brain natriuretic peptide (BNP) is a biomarker of cardiac strain and heart failure. Elevated BNP levels are associated with increased morbidity and mortality in patients with heart failure.

4.  Non-sustained ventricular tachycardia: The presence of non-sustained ventricular tachycardia (VT) on the ECG indicates abnormal ventricular electrical activity, which can contribute to reduced cardiac function and increase the risk of sudden cardiac death.

5.  Medications: While the patient is on ACE inhibitor, which is beneficial for heart failure management, the presence of Amiodarone and Digoxin may have adverse effects on cardiac function. Amiodarone can cause hypotension, and Digoxin can lead to bradycardia, which may further compromise cardiac output.

6.  Other factors: The patient's age (65), weight (113 kg), and height (176 cm) contribute to a higher body mass index (BMI), which is associated with an increased risk of cardiovascular disease. The elevated gamma-glutamyl transferase (GGT) and glucose levels may indicate underlying metabolic disorders that can exacerbate cardiac disease.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of these risk factors and comorbidities, which have compromised cardiac function and led to heart failure."
73,73,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of factors related to their cardiac and overall health status. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which is a condition where the heart muscle becomes weakened due to high blood pressure, leading to reduced cardiac function. This condition is evident from the patient's low Left Ventricular Ejection Fraction (LVEF) of 60.0%, which is below the normal range of 65-70%.

The patient's blood pressure is also elevated at 140/80 mmHg, which further exacerbates the strain on the heart. Additionally, the patient has a history of peripheral vascular disease, which can lead to reduced blood flow to the heart muscle, further impairing its function.

The patient's laboratory results also indicate elevated levels of Troponin (0.01 ng/mL), which is a marker of cardiac damage. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing abnormal electrical activity, which can further compromise cardiac function.

Furthermore, the patient's low HDL cholesterol level (1.03 mmol/L) and high LDL cholesterol level (3.44 mmol/L) suggest that the patient has dyslipidemia, which can contribute to the progression of atherosclerosis and further impair cardiac function.

The patient's high Pro-BNP level (339.0 ng/L) is also indicative of heart failure, as BNP is a hormone released by the heart in response to increased ventricular wall stress.

The patient's medications, including Amiodarone, Digoxin, and ACE Inhibitor, are aimed at managing arrhythmias, heart failure, and hypertension, but may not be sufficient to address the underlying causes of the patient's cardiac dysfunction.

Overall, the combination of the patient's cardiac history, laboratory results, and ECG findings suggest that the patient's outcome of pump failure death is likely due to the cumulative effect of these factors, which have led to irreversible damage to the heart muscle and impaired cardiac function."
74,74,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death can be attributed to a combination of factors reflected in the patient's medical history, laboratory results, and ECG findings.

1.  Hypertensive cardiomyopathy: The patient's history of hypertensive cardiomyopathy is a significant risk factor for heart failure. Chronic high blood pressure can lead to left ventricular hypertrophy, reduced left ventricular function, and ultimately, heart failure.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 60%, which is below the normal range (typically considered to be above 55%). A reduced LVEF indicates that the heart is not pumping efficiently, which can lead to heart failure.

3.  Elevated Pro-BNP levels: The patient's Pro-BNP level is 339.0 ng/L, which is elevated. Pro-BNP is a biomarker for heart failure, and high levels are associated with increased risk of mortality and hospitalization in patients with heart failure.

4.  Non-sustained ventricular tachycardia (NSVT): The patient's ECG shows NSVT, which is a risk factor for sudden cardiac death and heart failure. NSVT can lead to cardiac arrhythmias and decreased cardiac function, contributing to pump failure.

5.  Medications: The patient is on Amiodarone, Digoxin, and an ACE Inhibitor. While these medications are commonly used to manage heart failure and arrhythmias, they may also have side effects that contribute to the patient's outcome. For example, Amiodarone can have toxic effects on the heart, and Digoxin can have adverse interactions with other medications.

6.  Laboratory results: The patient's creatinine level is elevated at 88.0 mmol/L, indicating impaired renal function, which is a common comorbidity in patients with heart failure. The patient's glucose level is also elevated at 8.3 mmol/L, which may indicate insulin resistance or diabetes, a risk factor for heart failure.

7.  Age and comorbidities: The patient is 65 years old and has a history of peripheral vascular disease, hypertension, and hypothyroidism (indicated by a TSH level of 5.21 mIU/L). These comorbidities increase the risk of heart failure and pump failure.

In summary, the patient's outcome of pump failure death can be attributed to a combination of factors, including hypertensive cardiomyopathy, reduced LVEF, elevated Pro-BNP levels, NSVT, medications, laboratory abnormalities, and age and comorbidities."
75,75,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided medical data.

1. Hypertensive Cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure causes the heart muscle to thicken, leading to reduced heart function and increased risk of heart failure.

2. Reduced LVEF (60%): The patient's left ventricular ejection fraction (LVEF) is 60%, which is below the normal range (typically 55-70%). This indicates that the heart is not pumping efficiently, which can lead to heart failure.

3. Elevated Pro-BNP (339 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart when it is under strain. Elevated levels of BNP are associated with heart failure and can indicate that the heart is working harder than normal.

4. Medications: While the patient is taking medications such as ACE Inhibitor, Amiodarone, and Digoxin, these medications are typically used to manage heart failure and arrhythmias. However, the presence of these medications may indicate a history of heart failure or arrhythmias, which could have contributed to the patient's outcome.

5. Other risk factors: The patient's age (65), hypertension, and peripheral vascular disease also contribute to the increased risk of heart failure.

6. ECG findings: The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles on the ECG suggests that the patient has underlying cardiac arrhythmias, which can increase the risk of sudden cardiac death.

7. Laboratory values: The patient's elevated creatinine level (88.0 mmol/L) and urea level (3.83 mg/dL) suggest that the patient may have underlying kidney disease, which can be a complication of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely a result of a combination of hypertensive cardiomyopathy, reduced LVEF, elevated BNP, and underlying arrhythmias, which ultimately led to cardiac decompensation and death."
76,76,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors evident from the provided data.

1.  Hypertensive Cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure damages the heart muscle, leading to decreased cardiac function. This condition can lead to heart failure, which ultimately resulted in pump failure death.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 60%, which is below the normal range of 65-70%. A reduced LVEF indicates that the heart is not pumping efficiently, which can lead to heart failure and ultimately pump failure death.

3.  Elevated Pro-BNP Levels: The patient's Pro-BNP level is 339.0 ng/L, which is significantly elevated. Pro-BNP is a biomarker that indicates increased ventricular stress and is associated with heart failure. Elevated levels are often seen in patients with heart failure and can predict adverse outcomes.

4.  Electrocardiogram (ECG) Findings: The ECG shows non-sustained ventricular tachycardia (NSVT), which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. The presence of NSVT, combined with the patient's reduced LVEF and hypertensive cardiomyopathy, further increased the risk of pump failure.

5.  Medication Non-Optimization: Although the patient is on medications such as Amiodarone, Digoxin, and an ACE inhibitor, these medications may not have been optimized to control the patient's symptoms and underlying conditions effectively, contributing to the progression of heart failure.

6.  Comorbidities: The patient has multiple comorbidities, including peripheral vascular disease, hypertension, and elevated liver enzymes (ALT and GGT), which can further compromise cardiac function and increase the risk of pump failure.

7.  Poor Nutritional Status: The patient's albumin level is low (38 g/L), indicating poor nutritional status, which can contribute to cardiac dysfunction and increase the risk of pump failure.

In conclusion, the patient's outcome of pump failure death can be attributed to a combination of hypertensive cardiomyopathy, reduced LVEF, elevated Pro-BNP levels, ECG findings, medication non-optimization, comorbidities, and poor nutritional status."
77,77,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is likely due to a combination of factors. The patient has a history of hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and weakened due to high blood pressure, leading to impaired heart function. The patient's current NYHA Class II classification indicates that they experience symptoms of heart failure, such as shortness of breath and fatigue, when engaging in physical activity.

The patient's laboratory results also suggest that they have significant cardiac strain. The elevated Pro-BNP (Brain Natriuretic Peptide) level of 339.0 ng/L is a marker of heart failure and is associated with increased mortality risk. The patient's LVEF (Left Ventricular Ejection Fraction) of 60% is below the normal range, indicating that the left ventricle is not pumping efficiently, which can lead to heart failure.

Additionally, the patient's medications, including Amiodarone and Digoxin, are commonly used to treat arrhythmias and heart failure, but they may also have adverse effects on the heart, particularly in patients with pre-existing cardiac conditions.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests that the patient has arrhythmias, which can further compromise cardiac function and increase the risk of heart failure.

The patient's laboratory results also show elevated liver enzymes (ALT and GGT), which may indicate liver dysfunction, and anemia (low hemoglobin level), which can exacerbate cardiac disease. The patient's low HDL cholesterol level and high LDL cholesterol level may also contribute to atherosclerosis, which can further compromise cardiac function.

The patient's creatinine level of 88.0 mol/L indicates impaired kidney function, which can be a consequence of heart failure. The patient's urea level of 3.83 mg/dL is also elevated, indicating impaired renal function.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of their underlying cardiac disease, arrhythmias, and other comorbidities, which have compromised their cardiac function and led to heart failure, ultimately resulting in pump failure and death."
78,78,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of factors. 

1. Hypertensive Cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure damages the heart muscle, leading to decreased heart function and potential heart failure. This condition is likely a contributing factor to the patient's eventual pump failure.

2. Reduced LVEF (60.0%): The patient's left ventricular ejection fraction (LVEF) is slightly below the normal range (50-70%), indicating reduced heart function. This suggests that the heart is not pumping efficiently, which can lead to pump failure.

3. Elevated Pro-BNP (339.0 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart in response to stress and strain. Elevated levels of BNP are associated with heart failure and can indicate that the heart is working harder to pump blood, which can lead to fatigue and eventually pump failure.

4. Non-sustained Ventricular Tachycardia (NSVT): The patient has a history of non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can lead to cardiac arrhythmias and decreased heart function.

5. Medications: The patient is taking amiodarone, digoxin, and an ACE inhibitor, which are medications commonly used to treat heart conditions such as arrhythmias and heart failure. However, the presence of these medications does not necessarily indicate that they contributed to the patient's outcome.

6. Other contributing factors: The patient's other medical conditions, such as peripheral vascular disease and hypertension, may have also contributed to the development of pump failure.

In summary, the combination of hypertensive cardiomyopathy, reduced LVEF, elevated Pro-BNP, non-sustained ventricular tachycardia, and other medical conditions likely contributed to the patient's outcome of pump failure death."
79,79,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data. 

Firstly, the patient has a history of hypertensive cardiomyopathy, which is a known risk factor for heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) of 60% is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. 

Additionally, the patient's blood pressure of 140/80 mmHg is slightly elevated, which may contribute to further strain on the heart. The patient's total cholesterol level of 5.09 mmol/L is high, which can increase the risk of atherosclerosis and further compromise cardiac function.

The patient's Pro-BNP (Brain Natriuretic Peptide) level of 339.0 ng/L is elevated, which is indicative of heart failure. Elevated Pro-BNP levels are associated with increased morbidity and mortality in patients with heart failure.

Furthermore, the patient's troponin level of 0.01 ng/mL is slightly elevated, which may indicate minor cardiac damage or stress. However, this is not significantly high, so it may not be the primary cause of the patient's outcome.

The patient's creatinine level of 88.0 mol/L is within the normal range, but the patient's urea level of 3.83 mg/dL is slightly elevated, which may indicate mild renal impairment. This could be a contributing factor to the patient's outcome, as renal dysfunction can exacerbate heart failure.

The patient's medications, including Amiodarone, Digoxin, and an ACE Inhibitor, are intended to manage heart failure and hypertension, but the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

The patient's ECG results show ventricular extrasystoles, non-sustained ventricular tachycardia, and an unknown paroxysmal supraventricular tachyarrhythmia, which can contribute to cardiac stress and further compromise cardiac function.

In summary, the combination of hypertensive cardiomyopathy, elevated Pro-BNP levels, high cholesterol, and the patient's ECG results likely contributed to the patient's outcome of pump failure death."
80,80,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of factors related to their underlying heart condition, comorbidities, and laboratory results.

1.  Idiopathic dilated cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to decreased cardiac function. This condition is a significant risk factor for heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 22%, which is significantly below the normal range (50-70%). This indicates that the patient's heart is not pumping efficiently, leading to reduced cardiac output and increased risk of heart failure.

3.  Elevated Pro-BNP levels: The patient's Pro-BNP level is 3311.0 ng/L, which is significantly elevated. BNP is a hormone produced by the heart in response to increased ventricular wall stress, and elevated levels are associated with heart failure.

4.  Diabetes: The patient has diabetes, which is a significant risk factor for heart failure. Diabetes can damage blood vessels and nerves, leading to decreased cardiac function and increased risk of heart failure.

5.  Dyslipemia: The patient has dyslipemia, which can contribute to the development of atherosclerosis and coronary artery disease, further compromising cardiac function.

6.  Medication non-adherence or inadequate treatment: Although the patient is taking an Angiotensin II Receptor Blocker and Digoxin, the patient's LVEF is still significantly low, suggesting that the current treatment may not be sufficient to manage the patient's condition effectively.

7.  ECG findings: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, indicating abnormal heart rhythms that can further compromise cardiac function.

8.  Low HDL and high LDL cholesterol levels: The patient's lipid profile is not optimal, with low HDL and high LDL levels, which can contribute to the development of atherosclerosis and coronary artery disease.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of the patient's underlying heart condition, comorbidities, and inadequate treatment."
81,81,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's profile, the outcome of pump failure death can be attributed to a combination of factors. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. The left ventricular ejection fraction (LVEF) of 22% is significantly below the normal range (50-70%), indicating severe left ventricular dysfunction.

The patient's blood pressure is within a relatively normal range (130/70 mmHg), but the elevated Pro-BNP (B-type natriuretic peptide) level of 3311 ng/L is indicative of heart failure. Elevated Pro-BNP levels are associated with increased stress on the heart, which can be a result of heart failure.

The patient's medications, including an angiotensin II receptor blocker and digoxin, are commonly used to manage heart failure symptoms and slow disease progression. However, the effectiveness of these medications may have been limited by the severity of the patient's heart condition.

Additionally, the patient's laboratory results show elevated glucose (6.3 mmol/L) and total cholesterol (4.94 mmol/L), which are risk factors for cardiovascular disease. The low HDL (1.58 mmol/L) and high LDL (2.4 mmol/L) levels further indicate a high risk of atherosclerotic cardiovascular disease, which can contribute to heart failure.

The patient's thyroid function test (TSH) is elevated at 33.39 mIU/L, which may indicate hypothyroidism. Hypothyroidism can contribute to heart failure by increasing peripheral vascular resistance and reducing cardiac output.

The presence of non-sustained ventricular tachycardia on the ECG suggests that the patient has a risk of arrhythmias, which can further compromise cardiac function.

In conclusion, the combination of idiopathic dilated cardiomyopathy, severe left ventricular dysfunction, elevated Pro-BNP levels, uncontrolled risk factors for cardiovascular disease, and potential hypothyroidism likely contributed to the patient's outcome of pump failure death."
82,82,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's age (69 years), female gender, and history of idiopathic dilated cardiomyopathy, the patient has a significant risk of heart failure. The patient's NYHA Class II classification indicates that she experiences some limitations in physical activity but is still able to perform light physical activity without discomfort.

The patient's laboratory results show elevated levels of Pro-BNP (3311.0 ng/L), which is a strong indicator of heart failure and increased risk of cardiac death. Additionally, the patient's LVEF (Left Ventricular Ejection Fraction) is severely reduced at 22%, indicating a significantly impaired heart function.

The patient's ECG results show polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both indicators of cardiac arrhythmias and increased risk of cardiac death. The patient's TSH level is elevated (33.39 mIU/L), which may indicate hypothyroidism, a condition that can contribute to heart failure.

The patient's medication list includes an Angiotensin II Receptor Blocker and Digoxin, which are commonly used to treat heart failure. However, the patient's elevated Pro-BNP level and severely reduced LVEF suggest that the current treatment regimen may not be sufficient to manage her condition.

The patient's creatinine level is elevated (91.0 mmol/L), indicating impaired kidney function, which is a common comorbidity in patients with heart failure. The patient's glucose level is also elevated (6.3 mmol/L), indicating diabetes, which is another risk factor for heart failure.

In conclusion, the patient's severe heart failure, indicated by a reduced LVEF, elevated Pro-BNP level, and ECG abnormalities, combined with comorbidities such as diabetes and impaired kidney function, likely contributed to her pump failure and subsequent death."
83,83,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors related to her underlying medical conditions and laboratory results. 

1. Severe Left Ventricular Dysfunction: The patient has an ejection fraction (LVEF) of 22%, indicating severe left ventricular dysfunction. This is a critical factor in the development of heart failure and increased risk of mortality.

2. High BNP Levels: The patient's Pro-BNP level is elevated at 3311 ng/L, which is indicative of heart failure. Elevated BNP levels are associated with increased risk of heart failure hospitalization and mortality.

3. Diabetes and Dyslipidemia: The patient's history of diabetes and dyslipidemia contribute to the progression of atherosclerosis and coronary artery disease, which can further compromise cardiac function.

4. Idiopathic Dilated Cardiomyopathy: This underlying condition is a known cause of heart failure, and its idiopathic nature suggests that it may be more challenging to manage.

5. Medication Non-Response: Although the patient is on Angiotensin II Receptor Blocker and Digoxin, which are standard treatments for heart failure, the patient's condition has progressed to pump failure death. This may indicate a lack of response to these medications or the presence of other underlying factors contributing to the patient's outcome.

6. Electrocardiogram Findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests arrhythmias that may have contributed to the patient's cardiac instability.

In summary, the patient's outcome of pump failure death can be attributed to the combination of severe left ventricular dysfunction, high BNP levels, underlying conditions such as diabetes and dyslipidemia, idiopathic dilated cardiomyopathy, potential medication non-response, and arrhythmias detected on the ECG."
84,84,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to several factors based on the provided data. 

1.  Severe Left Ventricular Dysfunction: The patient has a Left Ventricular Ejection Fraction (LVEF) of 22%, which is significantly below the normal range of 55-70%. This indicates severe left ventricular dysfunction, making the heart unable to pump enough blood to meet the body's needs, leading to pump failure.

2.  High Pro-BNP Levels: The patient's Pro-BNP level is 3311.0 ng/L, which is elevated. Pro-BNP is a marker of heart failure and is used to assess the severity of heart failure. High levels indicate increased stress on the heart, which is consistent with pump failure.

3.  Diabetes and Dyslipemia: The patient has diabetes and dyslipemia, which are both risk factors for heart failure. Diabetes can damage the heart muscle over time, leading to decreased heart function, while dyslipemia can lead to atherosclerosis, further impairing heart function.

4.  Medications: The patient is on Angiotensin II Receptor Blocker (ARB) and Digoxin. While these medications are commonly used to treat heart failure, their effectiveness may be limited in this case due to the severity of the patient's left ventricular dysfunction.

5.  ECG Findings: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, indicating abnormal heart rhythms that can further compromise cardiac function.

6.  Low T3 and T4 Levels: The patient's T3 and T4 levels are low, which can be associated with heart failure. Low thyroid hormone levels can lead to decreased cardiac function and increased risk of heart failure.

7.  Elevated Creatinine and Urea Levels: The patient's creatinine and urea levels are elevated, indicating impaired renal function, which can be a consequence of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely due to the combination of severe left ventricular dysfunction, high Pro-BNP levels, comorbidities (diabetes and dyslipemia), and abnormal ECG findings."
85,85,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death is likely due to the combination of her underlying conditions and laboratory results. 

The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to reduced heart function and potential heart failure. The low left ventricular ejection fraction (LVEF) of 22% indicates that the patient's heart is not pumping efficiently, which is consistent with dilated cardiomyopathy.

The elevated Pro-BNP (B-type natriuretic peptide) level of 3311 ng/L is a biomarker of heart failure, indicating that the patient's heart is under strain. The patient's elevated blood glucose level of 6.3 mmol/L may also be contributing to her heart failure, as diabetes is a known risk factor for heart disease.

The patient's medication regimen includes an angiotensin II receptor blocker (ARB) and digoxin, which are both commonly used to treat heart failure. However, despite these medications, the patient's condition has progressed to pump failure death.

The patient's ECG results show polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can be associated with heart failure. The absence of bradycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rate is not significantly affected by these rhythms.

The patient's laboratory results also show elevated liver enzymes (ALT and AST) and cholesterol levels, which may be contributing to her heart disease. The low HDL cholesterol level of 1.58 mmol/L is also a risk factor for heart disease.

Overall, the combination of the patient's underlying conditions, laboratory results, and ECG findings suggest that her outcome of pump failure death is likely due to the progression of her idiopathic dilated cardiomyopathy and associated heart failure."
86,86,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors evident from the provided data. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. This condition is further supported by a low left ventricular ejection fraction (LVEF) of 22%, which indicates severe systolic dysfunction.

Additionally, the patient's elevated Pro-BNP (B-type natriuretic peptide) level of 3311.0 ng/L is indicative of heart failure, as high levels of this hormone are released by the heart in response to increased ventricular wall stress. 

The patient's medications, Angiotensin II Receptor Blocker and Digoxin, are commonly used to manage heart failure, but their effectiveness may be limited in this case due to the severity of the patient's condition.

Furthermore, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests underlying electrical instability of the heart, which can contribute to the progression of heart failure.

The patient's other comorbidities, such as diabetes and dyslipidemia, may also have contributed to the development and progression of their heart disease.

Lastly, the patient's TSH level of 33.39 mIU/L is elevated, which may indicate hypothyroidism. Hypothyroidism can exacerbate heart failure by reducing cardiac output and increasing peripheral resistance, further contributing to the patient's poor outcome.

Given the combination of these factors, the patient's outcome of pump failure death is likely the result of the progression of their underlying heart disease, exacerbated by their comorbidities and suboptimal response to treatment."
87,87,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors from her medical history, laboratory results, and clinical presentation. 

1. Idiopathic dilated cardiomyopathy: This is a pre-existing condition that significantly affects the heart's ability to pump blood effectively. It has likely been present for some time, leading to a reduced left ventricular ejection fraction (LVEF) of 22%, which is significantly below the normal range (50-70%). This indicates that the heart is not pumping efficiently, leading to potential complications such as heart failure.

2. High Pro-BNP levels (3311.0 ng/L): Brain natriuretic peptide (BNP) is a hormone released by the heart in response to ventricular strain and volume overload. Elevated levels of BNP are associated with heart failure and can indicate increased pressure and volume overload on the heart.

3. Medications (Angiotensin II Receptor Blocker, Digoxin): Although the patient is on medications for heart failure, it appears that these medications have not been sufficient to manage her condition effectively. Angiotensin II receptor blockers are typically used to reduce blood pressure and alleviate symptoms in heart failure patients, while digoxin is used to slow the heart rate and increase the strength of heart contractions. However, the patient's continued heart failure symptoms and decreased LVEF suggest that these medications may not be adequately addressing the underlying issue.

4. Other laboratory results: The patient's total cholesterol level (4.94 mmol/L) is elevated, which can contribute to atherosclerosis and further compromise cardiac function. Additionally, her glucose level (6.3 mmol/L) is slightly elevated, indicating possible insulin resistance or diabetes-related complications. Her TSH level (33.39 mIU/L) is also elevated, suggesting hypothyroidism, which can contribute to heart failure symptoms.

5. ECG findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates abnormal heart rhythms, which can be a sign of electrical instability and further compromise cardiac function.

Given the combination of these factors, it is not surprising that the patient's outcome was pump failure death. Despite medical management, her underlying cardiac condition and associated comorbidities likely overwhelmed her heart's ability to function effectively, leading to this outcome."
88,88,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data. 

1. Idiopathic dilated cardiomyopathy: This is a pre-existing condition that has significantly reduced the patient's left ventricular ejection fraction (LVEF) to 22%, indicating severe heart failure. The low LVEF value indicates that the heart is not pumping efficiently, which can lead to pump failure.

2. High Pro-BNP levels: The patient's Pro-BNP level is 3311.0 ng/L, which is significantly elevated. BNP is a hormone released by the heart when it is under strain. High levels of BNP are associated with heart failure, and in this case, it suggests that the patient's heart is under significant stress, further supporting the likelihood of pump failure.

3. Medications: The patient is taking an Angiotensin II Receptor Blocker (ARB), which is a common medication for heart failure treatment. However, the fact that the patient is on this medication suggests that they have a history of heart failure, and the medication may not have been sufficient to prevent pump failure.

4. Electrocardiogram (ECG) findings: The ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can be associated with heart failure. These findings indicate that the patient's heart is experiencing arrhythmias, which can further compromise cardiac function and contribute to pump failure.

5. Other comorbidities: The patient has diabetes, dyslipidemia, and a low HDL level, which can contribute to the development and progression of heart failure. These conditions can increase the risk of cardiovascular disease and worsen heart function.

6. Low T3 and T4 levels: The patient's thyroid hormone levels are low, which can be associated with heart failure. Low thyroid hormone levels can impair cardiac function and contribute to the progression of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of the underlying idiopathic dilated cardiomyopathy, high Pro-BNP levels, arrhythmias, and comorbidities, which have compromised the patient's cardiac function and led to pump failure."
89,89,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors.

1. Low Left Ventricular Ejection Fraction (LVEF) of 22%: This indicates severe left ventricular dysfunction, which is a hallmark of advanced heart failure. The patient's LVEF is significantly reduced, suggesting that the heart is unable to pump blood efficiently, leading to decreased cardiac output and potentially fatal outcomes.

2. High Pro-BNP levels (3311.0 ng/L): B-type natriuretic peptide (BNP) is a hormone released by the heart in response to ventricular strain. Elevated BNP levels are associated with heart failure and are used as a marker of cardiac dysfunction. The patient's high BNP levels indicate severe heart failure and increased risk of mortality.

3. Idiopathic Dilated Cardiomyopathy: This condition is characterized by a weakened heart muscle, leading to reduced cardiac function and potentially fatal outcomes. The patient's history of idiopathic dilated cardiomyopathy further supports the likelihood of pump failure.

4. Medications: Although the patient is on Angiotensin II Receptor Blocker (ARB) and Digoxin, which are commonly used to manage heart failure, the patient's condition may not be adequately controlled. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart rhythm is unstable, which may be contributing to the pump failure.

5. Electrocardiogram (ECG) findings: The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG indicates arrhythmias, which can further compromise cardiac output and contribute to pump failure.

6. Other factors: The patient's diabetes and dyslipidemia may also contribute to the development of heart failure. However, the primary factors contributing to the patient's pump failure death appear to be the low LVEF, high BNP levels, and idiopathic dilated cardiomyopathy.

In conclusion, the patient's outcome of pump failure death is likely due to a combination of severe left ventricular dysfunction, high BNP levels, and idiopathic dilated cardiomyopathy, with potential contributions from arrhythmias and underlying comorbidities."
90,90,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and diabetes, it is not surprising that the patient has experienced pump failure death. Ischemic dilated cardiomyopathy is a condition where the heart muscle becomes weakened and enlarged due to a heart attack, leading to a decrease in the heart's ability to pump blood effectively. This condition is a significant risk factor for heart failure.

The patient's low left ventricular ejection fraction (LVEF) of 25% further supports this diagnosis. A normal LVEF is typically between 55-70%, so an LVEF of 25% indicates that the heart is not pumping blood efficiently. This is consistent with the patient's NYHA Class III classification, which indicates that the patient experiences symptoms of heart failure, such as shortness of breath, fatigue, and swelling, even at rest.

The patient's elevated pro-BNP (brain natriuretic peptide) level of 3190.0 ng/L is also indicative of heart failure. Pro-BNP is a hormone produced by the heart in response to increased wall stress, and high levels are associated with heart failure.

The patient's medications, including ACE inhibitor, calcium channel blocker, loop diuretics, and nitrovasodilator, are standard treatments for heart failure, but unfortunately, they were not enough to prevent the patient's pump failure death.

Additionally, the patient's diabetes and high cholesterol levels (total cholesterol 5.09 mmol/L, LDL 2.93 mmol/L) may have contributed to the development and progression of the patient's cardiovascular disease.

In summary, the patient's extensive medical history, low LVEF, elevated pro-BNP level, and medications suggest that the patient's pump failure death was likely a result of complications from ischemic dilated cardiomyopathy and other underlying cardiovascular conditions."
91,91,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data.

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to coronary artery disease, leading to poor heart function. This condition is a significant risk factor for heart failure and pump failure.

2.  Low LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 25.0%, which is significantly below the normal range of 55-70%. A low LVEF indicates poor heart function and is a strong predictor of heart failure and pump failure.

3.  Elevated Pro-BNP (N-terminal pro b-type natriuretic peptide): The patient's Pro-BNP level is 3190.0 ng/L, which is elevated. Elevated Pro-BNP levels are associated with heart failure and are used as a biomarker for diagnosing and monitoring heart failure.

4.  High Creatinine: The patient's creatinine level is 100.0 mol/L, which indicates impaired renal function. Chronic kidney disease is a common comorbidity in patients with heart failure, and impaired renal function can exacerbate heart failure symptoms.

5.  Diabetes: The patient has diabetes, which is a significant risk factor for heart failure. Diabetes can cause damage to the heart muscle, leading to heart failure.

6.  Medications: The patient is on several medications, including ACE inhibitors, which are commonly used to treat heart failure. However, the patient's low LVEF and high Pro-BNP level suggest that these medications may not be adequately controlling the patient's heart failure symptoms.

7.  ECG Findings: The patient has polymorphic ventricular extrasystoles, which can be a sign of electrical instability in the heart. While not directly related to pump failure, it may indicate underlying cardiac disease that contributes to the overall poor cardiac function.

In conclusion, the patient's outcome of pump failure death is likely due to a combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, impaired renal function, diabetes, and inadequate management of heart failure symptoms despite medication."
92,92,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's clinical presentation and laboratory results, the outcome of pump failure death is likely due to the combination of advanced heart failure and severe left ventricular dysfunction. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a previous heart attack or reduced blood flow to the heart. This is supported by the low left ventricular ejection fraction (LVEF) of 25%, indicating that the heart is not pumping efficiently.

The patient's NYHA Class III classification indicates that she has severe heart failure symptoms, including shortness of breath and fatigue, which are consistent with the advanced stage of the disease. The elevated pro-BNP (B-type natriuretic peptide) level of 3190 ng/L is a biomarker of heart failure and suggests that the patient's heart is under strain.

The patient's laboratory results also indicate elevated liver enzymes (ALT and AST), which may suggest liver congestion or cirrhosis, a common complication of advanced heart failure. The elevated creatinine level of 100.0 mol/L indicates impaired kidney function, which is a common comorbidity in patients with advanced heart failure.

The patient's medications, including loop diuretics, ACE inhibitor, and nitrovasodilator, are typical for managing heart failure, but the patient's symptoms and laboratory results suggest that these medications may not be adequately controlling her symptoms or improving her cardiac function.

The presence of polymorphic ventricular extrasystoles on the ECG may indicate electrical instability of the heart, which can contribute to the risk of arrhythmias and sudden cardiac death. However, in this case, the outcome of pump failure death is more likely due to the advanced stage of heart failure and its complications, rather than the arrhythmia itself.

Overall, the combination of advanced heart failure, severe left ventricular dysfunction, and comorbidities such as diabetes and impaired kidney function make it likely that the patient's outcome was pump failure death."
93,93,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death is likely due to a combination of factors related to her underlying heart condition and other comorbidities. 

1. Ischemic dilated cardiomyopathy: This condition is a result of a previous myocardial infarction, which has led to the dilation of the left ventricle and reduced left ventricular ejection fraction (LVEF) of 25%. This indicates a significant impairment of the heart's ability to pump blood efficiently.

2. Reduced LVEF: An LVEF of 25% is considered severely impaired, indicating that the heart is not pumping enough blood to meet the body's needs. This can lead to symptoms such as fatigue, shortness of breath, and swelling in the legs, which are consistent with the patient's NYHA Class III classification.

3. Elevated Pro-BNP: A Pro-BNP level of 3190.0 ng/L is significantly elevated, indicating that the heart is under strain and producing more BNP (B-type natriuretic peptide) in response to increased ventricular wall stress. This is consistent with heart failure.

4. Electrolyte imbalance: The patient's potassium level of 4.99 mEq/L is slightly low, which can contribute to arrhythmias and further compromise cardiac function.

5. Diabetes and high cholesterol: These conditions can contribute to the development and progression of heart disease, including ischemic dilated cardiomyopathy.

6. Medication regimen: While the patient is on various medications, including ACE inhibitors and loop diuretics, which are commonly used to manage heart failure, the patient's LVEF is still severely impaired, suggesting that these medications may not be sufficient to manage her condition effectively.

7. ECG findings: The presence of polymorphic ventricular extrasystoles may indicate further electrical instability of the heart, which can contribute to the risk of arrhythmias and sudden cardiac death.

Considering these factors, it is likely that the patient's outcome of pump failure death is a result of the combination of her underlying heart condition, comorbidities, and the progression of her disease despite treatment."
94,94,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided information.

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient's past medical history indicates that she has IDC, a condition where the heart muscle is weakened due to coronary artery disease, leading to a decrease in the heart's pumping efficiency. This condition is a significant risk factor for heart failure and, ultimately, pump failure death.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 25%, which is significantly below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, leading to decreased cardiac output and increased risk of pump failure.

3.  High Pro-BNP levels: The patient's Pro-BNP level is 3190.0 ng/L, which is elevated. BNP (B-type natriuretic peptide) is a hormone produced by the heart in response to increased wall stress, typically seen in heart failure. Elevated Pro-BNP levels are associated with worsening heart failure and increased mortality.

4.  Symptoms of Heart Failure: The patient's NYHA Class III classification indicates that she experiences symptoms of heart failure with moderate limitation in physical activity, such as fatigue, shortness of breath, and decreased exercise tolerance. These symptoms suggest that the patient's heart is not functioning optimally.

5.  Medications: Although the patient is on various medications, including ACE inhibitors, loop diuretics, and nitrovasodilators, which are commonly used to manage heart failure, the patient's condition has progressed to pump failure death, indicating that these medications may not have been sufficient to control the disease progression.

6.  Other Contributing Factors: The patient's diabetes, high cholesterol, and kidney dysfunction (elevated creatinine levels) may have contributed to the progression of heart failure and ultimately, pump failure death.

Considering these factors, it is reasonable to conclude that the patient's outcome of pump failure death is a result of the progression of her underlying heart disease, exacerbated by other comorbid conditions."
95,95,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient is a 70-year-old female with a history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25%, indicating severe left ventricular dysfunction. This is a strong predictor of poor outcomes in patients with heart failure. 

The patient's high levels of pro-BNP (3190 ng/L) also indicate severe heart failure, as elevated BNP levels are associated with increased morbidity and mortality in heart failure patients.

The patient's NYHA Class III classification indicates that she experiences symptoms of heart failure at rest or with minimal exertion, which further supports the severity of her condition.

The presence of ventricular extrasystoles on the ECG, although not life-threatening in this context, may indicate underlying cardiac electrical instability, which can be a risk factor for sudden cardiac death.

The patient's elevated creatinine levels (100.0 mmol/L) suggest compromised renal function, which can further exacerbate heart failure and reduce the effectiveness of certain medications.

The patient's diabetes and high total cholesterol levels (5.09 mmol/L) also contribute to the development and progression of cardiovascular disease.

Given the combination of these factors, the patient's severe left ventricular dysfunction, and the presence of multiple comorbidities, the patient's outcome of pump failure death is not unexpected."
96,96,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors indicated in the provided data. 

1.  Ischemic dilated cardiomyopathy: This underlying condition is a significant contributor to the patient's outcome. Ischemic cardiomyopathy is characterized by reduced left ventricular function due to coronary artery disease, leading to decreased cardiac output and eventual heart failure.

2.  Reduced LVEF (Left Ventricular Ejection Fraction) of 25%: A low LVEF indicates poor heart function, which is a critical predictor of adverse outcomes in heart failure patients. An LVEF below 35% is generally considered a sign of heart failure with reduced ejection fraction (HFrEF).

3.  High Pro-BNP levels (3190.0 ng/L): B-type natriuretic peptide (BNP) is a marker of cardiac stress and strain. Elevated BNP levels are associated with increased risk of mortality in heart failure patients.

4.  Diabetes and Myocardial Infarction: The patient's history of diabetes and myocardial infarction further exacerbates the cardiac condition, contributing to the development of ischemic cardiomyopathy and increased risk of heart failure.

5.  Medication regimen: Although the patient is on medications such as ACE inhibitors, loop diuretics, and calcium channel blockers, which are typically used to manage heart failure, the patient's condition has progressed to pump failure death, indicating that these medications may not have been sufficient to control the progression of the disease.

6.  Low Hemoglobin (121.0 g/L): Low hemoglobin levels can indicate anemia, which can further reduce cardiac output and contribute to heart failure.

7.  Electrocardiogram (ECG) findings: The presence of polymorphic ventricular extrasystoles may indicate abnormal cardiac electrical activity, which can contribute to the development of arrhythmias and further compromise cardiac function.

In summary, the patient's outcome of pump failure death is likely due to the combination of ischemic dilated cardiomyopathy, reduced LVEF, high Pro-BNP levels, diabetes, myocardial infarction, and the presence of other comorbidities and ECG abnormalities."
97,97,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient, a 70-year-old female with a history of ischemic dilated cardiomyopathy, has a left ventricular ejection fraction (LVEF) of 25%, indicating severe left ventricular dysfunction. The presence of a low LVEF, along with a high Pro-BNP level of 3190 ng/L, suggests that the patient is experiencing significant heart failure symptoms, which is consistent with her New York Heart Association (NYHA) Class III classification. 

The patient's ischemic dilated cardiomyopathy, likely resulting from previous myocardial infarctions, has led to a reduction in the heart's pumping efficiency, causing fluid buildup and congestion in the lungs and peripheral tissues. The elevated creatinine level of 100.0 mmol/L indicates impaired kidney function, which is a common complication of advanced heart failure.

The patient's high glucose level of 10.5 mmol/L and diabetes medication suggest that she has diabetes mellitus, a condition that can exacerbate heart failure by increasing the workload on the heart. The patient's total cholesterol level of 5.09 mmol/L is elevated, which may contribute to the progression of atherosclerosis and further reduce cardiac function.

The presence of a polymorphic ventricular extrasystole on the ECG suggests that the patient's heart rhythm is unstable, which can further compromise cardiac function. 

Given the patient's advanced heart failure symptoms, low LVEF, impaired kidney function, and unstable heart rhythm, the patient's outcome of pump failure death is not unexpected. The combination of these factors has likely overwhelmed the heart's ability to function effectively, leading to a fatal outcome."
98,98,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors, primarily related to her underlying cardiac condition and laboratory results.

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to coronary artery disease, leading to reduced heart function. This condition can cause the heart to become enlarged and less efficient at pumping blood, ultimately resulting in heart failure.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 25%, which is significantly lower than the normal range (50-70%). A low LVEF indicates that the left ventricle is not pumping efficiently, which can lead to fluid buildup in the lungs and other parts of the body, causing symptoms of heart failure.

3.  Elevated Pro-BNP Levels: The patient's Pro-BNP level is 3190.0 ng/L, which is significantly elevated. BNP (Brain Natriuretic Peptide) is a hormone produced by the heart when it is under strain. Elevated BNP levels are associated with heart failure and can indicate fluid buildup in the body.

4.  Diabetes and Myocardial Infarction: The patient's history of diabetes and myocardial infarction (heart attack) can also contribute to her heart failure. Diabetes can damage blood vessels and nerves, making it harder for the heart to function properly, while a myocardial infarction can further weaken the heart muscle.

5.  Medications: Although the patient is on medications such as ACE inhibitors, loop diuretics, and calcium channel blockers, which are typically used to manage heart failure, her symptoms and laboratory results suggest that these medications may not be sufficient to control her condition.

6.  ECG Findings: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of abnormal heart rhythm and further indicate that the heart is under strain.

Given these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of her underlying cardiac condition, reduced LVEF, elevated BNP levels, and the presence of other comorbidities such as diabetes and myocardial infarction."
99,99,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided information. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a decrease in the heart's pumping efficiency. This is further supported by the low left ventricular ejection fraction (LVEF) of 25.0%, indicating that the heart is not pumping effectively.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 3190.0 ng/L is also indicative of heart failure, as BNP is a hormone released by the heart in response to increased wall stress. This suggests that the heart is working harder to pump blood, leading to increased strain on the heart muscle.

The patient's past medical history of myocardial infarction (heart attack) further contributes to the development of heart failure. The presence of diabetes also increases the risk of heart failure, as it can damage the blood vessels and increase the risk of atherosclerosis, which can lead to heart failure.

The patient's medication list includes loop diuretics, which are often used to treat heart failure by removing excess fluid from the body. However, the presence of a calcium channel blocker and an ACE inhibitor suggests that the patient's heart failure is likely being managed, but not effectively controlled.

The patient's elevated troponin level of 0.5 ng/mL indicates that there is ongoing cardiac damage, which can contribute to heart failure.

The combination of these factors, including the patient's history of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, past myocardial infarction, diabetes, and ongoing cardiac damage, ultimately led to pump failure death."
100,100,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

This 89-year-old male patient with a history of hypertensive cardiomyopathy and hypertension presented with multiple indicators of advanced heart failure. The patient's New York Heart Association (NYHA) Class III classification suggests severe symptoms, with significant limitations in physical activity.

The patient's elevated blood pressure (160/90 mmHg) and high total cholesterol (6.1 mmol/L) levels suggest ongoing cardiovascular stress, which may have contributed to the progression of his cardiomyopathy. His creatinine level of 103.0 mol/L indicates impaired kidney function, which is often seen in patients with heart failure.

The patient's elevated Pro-BNP (3179.0 ng/L) level is a strong indicator of heart failure, with levels above 500 ng/L typically associated with severe symptoms. His low LVEF (70.0%) indicates reduced left ventricular function, which is consistent with heart failure with reduced ejection fraction (HFrEF).

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests arrhythmias, which can further compromise cardiac function and increase the risk of sudden cardiac death. The patient's TSH level of 0.99 mIU/L is within the normal range, which reduces the likelihood of thyroid-related heart failure.

The patient's low HDL (1.81 mmol/L) and high LDL (3.78 mmol/L) levels suggest dyslipidemia, which may have contributed to the development of his cardiomyopathy. His low hemoglobin level (143.0 g/L) may indicate anemia, which can exacerbate heart failure symptoms.

The patient's medications, including digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, are typical for heart failure management. However, despite these treatments, the patient's condition has progressed to pump failure, leading to death.

In summary, the combination of advanced age, severe heart failure symptoms, impaired kidney function, reduced LVEF, arrhythmias, and ongoing cardiovascular stress likely contributed to the patient's outcome of pump failure death."
101,101,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors present in the patient's profile. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and stiff due to high blood pressure, leading to reduced heart function. This condition is further exacerbated by the patient's current NYHA Class III classification, indicating severe symptoms of heart failure, such as shortness of breath and fatigue.

The elevated Creatinine levels (103.0 mmol/L) indicate impaired renal function, which is a common complication of heart failure. The patient's elevated Pro-BNP (3179.0 ng/L) levels, a marker of cardiac stress and strain, also support the presence of heart failure.

The presence of Non-sustained Ventricular Tachycardia (NSVT) on the ECG suggests that the patient has an increased risk of arrhythmias, which can further compromise cardiac function. The patient's low TSH (0.99 mIU/L) and T3 (0.0252 pg/dL) levels may indicate a possible thyroid dysfunction, which can also contribute to heart failure.

The patient's low HDL (1.81 mmol/L) and high LDL (3.78 mmol/L) cholesterol levels suggest dyslipidemia, which can contribute to the progression of atherosclerosis and further impair cardiac function.

The patient's current medications, including Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, and Nitrovasodilator, are aimed at managing heart failure symptoms and slowing disease progression. However, the patient's outcome of pump failure death suggests that these treatments may not have been sufficient to prevent the progression of the disease.

Overall, the combination of hypertensive cardiomyopathy, impaired renal function, elevated Pro-BNP levels, NSVT, possible thyroid dysfunction, dyslipidemia, and the presence of multiple comorbidities likely contributed to the patient's outcome of pump failure death."
102,102,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of factors.

Firstly, the patient's age of 89 years is a significant risk factor for cardiovascular disease and mortality. The patient's NYHA Class III classification indicates that he has severe symptoms of heart failure, such as shortness of breath and fatigue, even at rest or during minimal physical activity.

The patient's blood pressure of 160/90 mmHg is elevated, which is consistent with his past medical history of hypertension. Hypertension is a major risk factor for heart failure, as it can lead to left ventricular hypertrophy and diastolic dysfunction.

The patient's laboratory results show elevated levels of Pro-BNP (3179.0 ng/L), which is a marker of cardiac stress and is often used to diagnose and monitor heart failure. The elevated levels of troponin (1.2 ng/mL) also suggest myocardial injury, which can be a result of heart failure.

The patient's LVEF (left ventricular ejection fraction) of 70% is slightly below the normal range, indicating some degree of systolic dysfunction. The presence of non-sustained ventricular tachycardia (VT) on the ECG suggests that the patient's heart is experiencing arrhythmias, which can further compromise cardiac function.

The patient's medications, including digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, are typical for heart failure treatment, but the patient's outcome suggests that these medications may not have been sufficient to manage the disease.

The patient's electrolyte imbalance, with a potassium level of 4.4 mEq/L, may also have contributed to his outcome, as low potassium levels can exacerbate cardiac arrhythmias and worsen heart failure.

Lastly, the patient's low T3 and T4 levels, as well as his elevated TSH level, suggest that he may have had thyroid dysfunction, which can also contribute to heart failure.

In conclusion, the patient's outcome of pump failure death can be attributed to a combination of factors, including advanced age, severe symptoms of heart failure, hypertension, elevated Pro-BNP and troponin levels, reduced LVEF, arrhythmias, electrolyte imbalance, and possible thyroid dysfunction."
103,103,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors evident in the provided data. 

1.  Advanced Age (89 years): The patient's age is a significant risk factor for cardiovascular diseases and mortality. Older adults are more susceptible to cardiovascular complications, including heart failure.

2.  Hypertensive Cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure damages the heart muscle, leading to reduced heart function. This condition increases the risk of heart failure.

3.  NYHA Class III: The patient's New York Heart Association (NYHA) functional class is III, indicating severe symptoms of heart failure, including marked limitation in physical activity, and inability to perform any physical activity without discomfort.

4.  Elevated Blood Pressure (160/90 mmHg): Uncontrolled hypertension exacerbates heart failure by further increasing the workload on the heart.

5.  Reduced LVEF (70.0%): The left ventricular ejection fraction (LVEF) is lower than normal, indicating reduced heart function, which can lead to heart failure.

6.  Elevated Pro-BNP (3179.0 ng/L): B-type natriuretic peptide (BNP) is a hormone released by the heart in response to ventricular strain. Elevated levels indicate heart failure.

7.  Presence of Non-sustained Ventricular Tachycardia (VT): Non-sustained VT is a type of abnormal heart rhythm that can lead to cardiac arrhythmias and further compromise heart function.

8.  Sinus Node Dysfunction: Bradycardia, or a slow heart rate, can lead to inadequate cardiac output, further contributing to heart failure.

9.  Reduced Hemoglobin (143.0 g/L): Anemia can worsen heart failure symptoms by reducing oxygen delivery to the tissues.

10. Medication Non-Optimality: Although the patient is on medications for heart failure, the presence of non-sustained VT and sinus node dysfunction suggests that the current medication regimen may not be adequately managing the patient's condition.

The combination of these factors likely contributed to the patient's outcome of pump failure death."
104,104,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors. 

Firstly, the patient's age of 89 years and NYHA Class III classification indicate a high level of cardiovascular disease severity, which increases the risk of heart failure. 

The patient's past medical history of hypertensive cardiomyopathy and hypertension is a significant contributing factor to the development of heart failure. Hypertensive cardiomyopathy can lead to left ventricular hypertrophy and diastolic dysfunction, which can eventually progress to heart failure.

The patient's blood pressure of 160/90 mmHg is above the target range, indicating uncontrolled hypertension, which can exacerbate heart failure.

The elevated Pro-BNP level of 3179.0 ng/L is indicative of heart failure with reduced ejection fraction (HFrEF), as it is a well-established biomarker for cardiac stress and strain.

The patient's LVEF of 70% is below the normal range, indicating systolic dysfunction, which is a hallmark of HFrEF.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and sinus node dysfunction on the ECG further supports the diagnosis of heart failure.

The patient's renal function, as indicated by the elevated creatinine level of 103.0 mmol/L, is also compromised, which is a common comorbidity in patients with heart failure. 

The patient's medication regimen includes ACE inhibitor, which is a standard treatment for heart failure, but the presence of digoxin, loop diuretics, and spironolactone suggests a more advanced stage of heart failure.

The patient's low HDL cholesterol level of 1.81 mmol/L and high LDL cholesterol level of 3.78 mmol/L indicate dyslipidemia, which is a risk factor for cardiovascular disease and may have contributed to the development of heart failure.

The patient's elevated T3 level of 0.0252 pg/dL and decreased T4 level of 18.79 ng/L may indicate hypothyroidism, which can be a contributing factor to heart failure.

In summary, the patient's outcome of pump failure death can be attributed to a combination of advanced age, uncontrolled hypertension, hypertensive cardiomyopathy, systolic dysfunction, renal impairment, and other comorbidities, which ultimately led to the progression of heart failure."
105,105,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient outcome of pump failure death is likely due to a combination of factors contributing to his cardiomyopathy and heart failure. 

1.  Hypertensive cardiomyopathy and Hypertension: The patient has a history of hypertensive cardiomyopathy and hypertension, which is a significant risk factor for heart failure. The patient's blood pressure of 160/90 mmHg is elevated, indicating uncontrolled hypertension.

2.  Reduced LVEF: The patient's left ventricular ejection fraction (LVEF) is 70%, which is below the normal range (50-70% is considered mildly reduced, but not severe). However, the patient's symptoms and medical history suggest a more severe impairment of cardiac function.

3.  Pro-BNP levels: The patient's Pro-BNP level is elevated at 3179.0 ng/L, which is indicative of heart failure. Pro-BNP is a biomarker used to diagnose and monitor heart failure.

4.  ECG findings: The patient's ECG shows ventricular extrasystoles, non-sustained ventricular tachycardia, and sinus node dysfunction, indicating arrhythmias and impaired cardiac conduction.

5.  Medications: The patient is on multiple medications, including digoxin, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators, which are commonly used to treat heart failure. However, the patient's symptoms and outcome suggest that these medications may not have been sufficient to manage his heart failure.

6.  Other factors: The patient's age (89 years), weight (70 kg), and height (171 cm) are all factors that contribute to his risk of heart failure. His low HDL cholesterol and high LDL cholesterol levels also increase his risk of cardiovascular disease.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of his hypertensive cardiomyopathy, uncontrolled hypertension, reduced LVEF, elevated Pro-BNP levels, arrhythmias, and impaired cardiac conduction, which ultimately led to a failure of the heart to pump blood effectively, resulting in pump failure death."
106,106,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

This 89-year-old male patient with a history of hypertensive cardiomyopathy and hypertension has a high risk of cardiac complications. The patient's left ventricular ejection fraction (LVEF) is 70%, which is slightly below the normal range (60-70% is considered mildly reduced), indicating some degree of left ventricular dysfunction. 

The patient's high blood pressure (160/90 mmHg) and elevated Pro-BNP level (3179.0 ng/L) suggest that the patient is experiencing heart failure symptoms. The patient's creatinine level (103.0 mol/L) is elevated, indicating impaired renal function, which is a common complication of heart failure.

The patient's medications, including digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, are typical for heart failure management, but the patient's condition has progressed to a point where it has led to pump failure, ultimately resulting in death. 

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG, along with polymorphic ventricular extrasystoles, further increases the patient's risk of sudden cardiac death. The patient's TSH level is within the normal range, ruling out hypothyroidism as a contributing factor to the patient's condition. 

The patient's age, comorbidities, and the progression of heart failure symptoms have likely contributed to the development of pump failure, ultimately leading to the patient's death."
107,107,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

The patient is an 89-year-old male with a history of hypertensive cardiomyopathy and hypertension, indicating that his heart muscle has been weakened due to high blood pressure. He is classified as NYHA Class III, indicating that he experiences symptoms of heart failure with moderate limitation in physical activity. 

His blood pressure is elevated at 160/90 mmHg, which is concerning for continued cardiac stress. His laboratory results show elevated levels of creatinine (103.0 mmol/L), which indicates impaired kidney function, often a consequence of chronic heart failure. Additionally, his Pro-BNP level is significantly elevated at 3179.0 ng/L, which is a strong indicator of heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) is 70.0%, which is within a relatively normal range, but considering his age and symptoms, it may not accurately reflect the full extent of his cardiac function.

The patient's ECG shows evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and sinus node dysfunction, indicating that his heart is experiencing electrical instability. These findings, combined with his symptoms and laboratory results, suggest that the patient is at high risk for cardiac complications.

The patient's medication regimen includes digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, which are all standard treatments for heart failure. However, despite these treatments, the patient's condition has progressed to pump failure, ultimately leading to death.

The patient's advanced age, history of heart disease, and multiple comorbidities likely contributed to his poor outcome. The combination of these factors, along with the severity of his heart failure symptoms and laboratory results, made it challenging to manage his condition effectively, ultimately resulting in pump failure and death."
108,108,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of factors, primarily related to his underlying heart condition and laboratory results. 

1.  Advanced Age (89 years): The patient's age is a significant risk factor for cardiac complications, including heart failure and death. As people age, their hearts become less efficient, making them more susceptible to heart failure.

2.  NYHA Class III: The patient's New York Heart Association (NYHA) class III indicates that he experiences symptoms of heart failure, such as shortness of breath and fatigue, even at rest or during light physical activity. This suggests that his heart is not functioning optimally.

3.  Hypertensive Cardiomyopathy and Hypertension: The patient's history of hypertensive cardiomyopathy and hypertension indicates that his heart muscle has been subjected to prolonged stress due to high blood pressure. This can lead to heart failure over time.

4.  Elevated Creatinine Levels (103.0 mmol/L): Elevated creatinine levels indicate impaired kidney function, which can be a complication of heart failure. The kidneys require adequate blood flow to function properly, and when the heart is failing, it may not be able to provide the necessary blood flow, leading to kidney damage.

5.  Elevated Pro-BNP Levels (3179.0 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart in response to strain and stress. Elevated BNP levels are associated with heart failure and can indicate a poor prognosis.

6.  Ventricular Extrasystole and Non-sustained Ventricular Tachycardia: The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates abnormal heart rhythms, which can contribute to heart failure.

7.  Low LVEF (70.0%): A left ventricular ejection fraction (LVEF) of 70% indicates that the left ventricle is not pumping blood efficiently, which can lead to heart failure.

8.  Medications: Although the patient is on medications such as digoxin, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure, these medications may not have been sufficient to prevent the progression of heart failure in this case.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of his advanced age, underlying heart condition, and laboratory results, which indicate a high risk of heart failure and poor cardiac function."
109,109,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

Given the patient's advanced age (89 years) and history of Hypertensive cardiomyopathy, it is not surprising that he has developed heart failure, as hypertension can lead to left ventricular hypertrophy and eventually heart failure. The patient's NYHA Class III classification indicates that he experiences symptoms of heart failure, such as shortness of breath, fatigue, and swelling in the legs, during ordinary physical activity.

The patient's laboratory results show elevated levels of Creatinine (103.0 mmol/L), which suggests impaired kidney function. This is consistent with the patient's history of heart failure, as reduced kidney function is a common complication of heart failure. The elevated Pro-BNP (3179.0 ng/L) level further supports the diagnosis of heart failure, as this biomarker is often elevated in patients with heart failure.

The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The presence of polymorphic ventricular extrasystoles also suggests that the patient's heart rhythm is unstable, which can contribute to heart failure progression and increased risk of sudden cardiac death.

The patient's medication regimen includes Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, and Nitrovasodilator, which are commonly used to manage heart failure. However, despite these medications, the patient's condition has progressed to pump failure death, suggesting that the disease has progressed beyond the point where medical therapy can control the symptoms and progression of the disease.

The patient's low T3 and T4 levels, as well as the normal TSH level, suggest that there may be a component of thyroid hormone resistance or dysfunction contributing to the patient's heart failure. However, this is not the primary cause of the patient's outcome.

In summary, the patient's advanced age, history of Hypertensive cardiomyopathy, impaired kidney function, elevated Pro-BNP level, and ECG abnormalities all contributed to his progression to pump failure death."
110,110,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors from the provided data. 

1. Reduced LVEF (Left Ventricular Ejection Fraction) of 37%: This indicates a significant reduction in the heart's ability to pump blood efficiently, which is a hallmark of heart failure. The normal LVEF range is typically between 55-70%. A low LVEF increases the risk of heart failure and subsequent mortality.

2. High Pro-BNP (N-terminal pro b-type natriuretic peptide) levels of 950.0 ng/L: Elevated Pro-BNP levels are often associated with heart failure and are used as a diagnostic marker. High levels indicate increased ventricular wall stress and stretching, which can be a result of heart failure.

3. History of Hypertensive cardiomyopathy and Hypertension: The patient's history of hypertension and cardiomyopathy, a condition where the heart muscle becomes weakened and enlarged due to high blood pressure, increases the risk of heart failure.

4. Low Hemoglobin (Hb) levels of 112 g/L: Anemia, indicated by low hemoglobin levels, can contribute to reduced oxygen delivery to the body's tissues and exacerbate heart failure symptoms.

5. Kidney dysfunction (Creatinine 159.0 mmol/L and Urea 14.64 mg/dL): The patient's elevated creatinine and urea levels suggest impaired renal function, which can further worsen heart failure by increasing fluid overload and electrolyte imbalances.

6. Medication regimen: The patient is on a combination of medications, including Amiodarone, Loop Diuretics, Hydralazine, and Nitrovasodilator. While these medications are commonly used to manage heart failure, their effectiveness may be limited in this case, and the patient's condition may have progressed to a point where these treatments are no longer sufficient to manage the disease.

Considering these factors, the patient's outcome of pump failure death is likely a result of a combination of advanced heart failure, kidney dysfunction, anemia, and possibly inadequate management of their condition."
111,111,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors, primarily driven by the patient's underlying conditions and laboratory results. 

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) of 37% is significantly below the normal range (50-70%), indicating reduced cardiac function. This is a strong indicator of heart failure. The patient's NYHA Class II classification also suggests that the patient experiences symptoms of heart failure, such as shortness of breath, fatigue, and swelling, during physical activity or exertion.

The patient's laboratory results further support the presence of heart failure. Elevated Pro-BNP (950.0 ng/L) levels, which are typically associated with heart failure, are a strong indicator of cardiac strain. Additionally, the patient's creatinine level of 159.0 mmol/L suggests impaired renal function, which is a common complication of heart failure.

The patient's medication regimen, including loop diuretics, hydralazine, and nitrovasodilator, suggests that the patient is being treated for heart failure, but the patient's outcome suggests that these treatments may not have been sufficient to manage the patient's condition effectively.

Furthermore, the patient's past medical history of hypertensive cardiomyopathy and hypertension, along with dyslipemia, contributes to the development of heart failure. The patient's high total cholesterol level (4.63 mmol/L) and low HDL (1.06 mmol/L) also indicate a high risk of cardiovascular disease.

The patient's low hemoglobin level (112 g/L) and low potassium level (3.9 mEq/L) may also have contributed to the patient's outcome, as anemia and electrolyte imbalances can exacerbate heart failure.

The low T3 level (0.03 pg/dL) may indicate hypothyroidism, which can also contribute to heart failure.

In conclusion, the patient's outcome of pump failure death is likely due to a combination of factors, including reduced cardiac function (LVEF 37%), impaired renal function, high Pro-BNP levels, and underlying conditions such as hypertensive cardiomyopathy, hypertension, and dyslipemia."
112,112,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death in this 82-year-old female can be attributed to a combination of several factors evident from the provided data. 

1. Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 37%, which is significantly lower than the normal range (50-70%). This indicates reduced cardiac function, making the heart less efficient at pumping blood, which can lead to heart failure.

2. Elevated Pro-BNP: A Pro-BNP level of 950.0 ng/L is indicative of heart failure, as this biomarker is used to diagnose and monitor heart failure. Elevated levels suggest increased ventricular stretch and wall tension, which can be a result of reduced cardiac function.

3. Chronic Hypertension and Hypertensive Cardiomyopathy: The patient's history of hypertension and hypertensive cardiomyopathy suggests that the heart has been subjected to prolonged high blood pressure, leading to potential damage and reduced cardiac function over time.

4. Reduced Hemoglobin and Low Potassium Levels: The patient's hemoglobin level is slightly low (112.0 g/L), and potassium levels are low (3.9 mEq/L). These abnormalities can contribute to cardiac dysfunction and arrhythmias, further exacerbating heart failure.

5. Medications: While the patient is on medications that are commonly used to manage heart failure (Amiodarone, Loop Diuretics, Hydralazine, and Nitrovasodilator), the effectiveness of these medications may have been insufficient to manage the patient's condition, or the patient may have developed side effects that worsened their heart function.

6. Reduced LVEF and Elevated Creatinine Levels: The patient's reduced LVEF and elevated creatinine levels (159.0 mmol/L) suggest kidney dysfunction, which can be a complication of heart failure. This further indicates that the patient's heart failure has progressed to a point where it is affecting other organ systems, ultimately leading to pump failure and death.

Considering these factors, the patient's outcome of pump failure death is a result of the cumulative effect of reduced cardiac function, chronic hypertension, and potential kidney dysfunction, which ultimately overwhelmed the heart's ability to maintain adequate circulation, leading to pump failure and death."
113,113,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to several factors based on the provided data.

1.  Reduced LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 37%, which is significantly lower than the normal range (50-70%). A reduced LVEF is a strong indicator of heart failure, and in this case, it suggests that the patient's heart is not pumping efficiently, leading to decreased cardiac output and potentially fatal outcomes.

2.  Hypertensive Cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure damages the heart muscle, leading to decreased cardiac function. This underlying condition likely contributed to the patient's reduced LVEF and heart failure.

3.  Elevated Creatinine Levels: The patient's creatinine level is elevated at 159.0 mmol/L, indicating impaired kidney function. This is likely due to the decreased cardiac output and potential renal artery stenosis, which can be a consequence of uncontrolled hypertension.

4.  High Pro-BNP Levels: The patient's Pro-BNP (N-terminal pro-b-type natriuretic peptide) level is elevated at 950.0 ng/L. Pro-BNP is a biomarker for heart failure, and high levels indicate increased ventricular stretch and wall tension, which can lead to heart failure and potentially fatal outcomes.

5.  Medication Use: Although the patient is on medications like Amiodarone, Loop Diuretics, Hydralazine, and Nitrovasodilator, which are commonly used to manage heart failure, the patient's condition may have progressed beyond the point where these medications can effectively manage symptoms.

6.  Other Contributing Factors: The patient's other lab values, such as low hemoglobin, low HDL, and high LDL, may also contribute to the patient's overall poor health status and increased risk of cardiovascular events.

Considering these factors, it is reasonable to conclude that the patient's outcome of pump failure death was likely due to a combination of reduced LVEF, hypertensive cardiomyopathy, impaired kidney function, and elevated Pro-BNP levels, which ultimately led to a fatal outcome."
114,114,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors evident in the provided data. 

1.  Hypertensive cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure causes the heart muscle to thicken, leading to reduced heart function and potentially heart failure.

2.  Reduced LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 37%, which is significantly lower than the normal range of 55-70%. This indicates that the left ventricle is not pumping blood efficiently, leading to reduced cardiac output and increased risk of heart failure.

3.  Elevated Pro-BNP (N-terminal pro b-type natriuretic peptide): The patient's Pro-BNP level is 950.0 ng/L, which is significantly elevated. Elevated Pro-BNP levels are associated with heart failure, and levels above 400 ng/L are often used as a diagnostic marker for heart failure.

4.  Medications: The patient is on Amiodarone, Loop Diuretics, Hydralazine, and Nitrovasodilator, which are commonly used to manage heart failure symptoms and hypertension. However, the patient's outcome suggests that these medications may not have been sufficient to manage the underlying condition effectively.

5.  Other contributing factors: The patient's age (82 years) and NYHA Class II classification (moderate symptoms with ordinary physical activity) also contribute to the risk of heart failure. Additionally, the patient's creatinine level of 159.0 mmol/L suggests impaired renal function, which can further exacerbate heart failure.

In conclusion, the combination of hypertensive cardiomyopathy, reduced LVEF, elevated Pro-BNP, and the patient's age and comorbidities likely contributed to the patient's outcome of pump failure death."
115,115,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient, an 82-year-old female with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension, has a high risk of cardiovascular events due to her advanced age and multiple comorbidities. The patient's low left ventricular ejection fraction (LVEF) of 37% indicates reduced cardiac function, which is a hallmark of heart failure.

The patient's elevated creatinine level (159.0 mmol/L) suggests impaired renal function, which is often seen in patients with heart failure. The high level of B-type natriuretic peptide (BNP) (950.0 ng/L) is a strong indicator of heart failure, as it is released by the heart in response to increased wall stress.

The patient's use of loop diuretics and hydralazine suggests that she is being treated for heart failure, but her condition has likely progressed to a more advanced stage, leading to pump failure. The patient's low hemoglobin level (112.0 g/L) may indicate anemia, which can exacerbate heart failure symptoms.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which contribute to atherosclerosis and cardiovascular disease. The patient's low HDL level further increases her risk of cardiovascular events.

The patient's thyroid function tests (TSH, T3, and T4) are within normal limits, indicating that hypothyroidism is not a contributing factor to her heart failure.

Given the patient's advanced age, reduced LVEF, impaired renal function, and high BNP levels, it is not surprising that she has progressed to pump failure, leading to her eventual death. The patient's multiple comorbidities and advanced age made it challenging to manage her condition effectively, ultimately resulting in a poor outcome."
116,116,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors present in their medical history and laboratory results. 

1. Hypertensive cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and stiff due to high blood pressure, leading to reduced cardiac function. This condition can lead to heart failure.

2. Reduced LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 37%, which is significantly below the normal range of 55-70%. A low LVEF indicates that the heart is not pumping efficiently, which can lead to heart failure.

3. Elevated Pro-BNP (Brain Natriuretic Peptide): The patient's Pro-BNP level is 950.0 ng/L, which is significantly elevated. Elevated Pro-BNP levels are associated with heart failure, and high levels are often seen in patients with advanced heart failure.

4. Kidney dysfunction: The patient has a creatinine level of 159.0 mmol/L, indicating impaired kidney function. Kidney dysfunction is a common complication of heart failure, as the heart's reduced pumping efficiency can lead to decreased blood flow to the kidneys.

5. Medications: The patient is on Amiodarone, Loop Diuretics, Hydralazine, and Nitrovasodilator, which are all medications commonly used to treat heart failure. However, the fact that they are on these medications suggests that the patient's heart failure is already at an advanced stage.

6. Age and NYHA Class II: The patient is 82 years old and has a NYHA Class II heart failure, which indicates that they have symptoms of heart failure with minimal physical activity. The patient's age and NYHA class suggest that they may have had a long-standing history of heart failure.

Given these factors, it is likely that the patient's outcome of pump failure death was a result of the cumulative effect of their hypertensive cardiomyopathy, reduced LVEF, elevated Pro-BNP levels, kidney dysfunction, and advanced age."
117,117,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's age (82 years), the patient outcome of pump failure death is not unexpected. Advanced age is a significant risk factor for heart failure and mortality.

The patient's past medical history of hypertensive cardiomyopathy and hypertension (high blood pressure) is also a significant risk factor for heart failure. The patient's current NYHA Class II classification indicates that the patient experiences some limitations in physical activity due to heart disease, but is still able to perform everyday activities.

The laboratory results show elevated levels of creatinine (159.0 mmol/L), which indicates impaired kidney function, often seen in patients with heart failure. The elevated Pro-BNP (950.0 ng/L) level is consistent with heart failure, as BNP is a marker of cardiac stress and strain.

The patient's left ventricular ejection fraction (LVEF) is 37.0%, which is significantly reduced and indicates systolic heart failure. The LVEF is a critical measure of the heart's pumping efficiency, and a value below 40% is typically considered abnormal.

The patient's medications, including Amiodarone, Loop Diuretics, Hydralazine, and Nitrovasodilator, are commonly used to manage heart failure, but may not be sufficient to reverse the underlying cardiac damage in this case.

The patient's low hemoglobin level (112.0 g/L) may be indicative of anemia, which can contribute to decreased oxygen delivery to the tissues and exacerbate heart failure.

The patient's low sodium level (139.0 mEq/L) and high potassium level (3.9 mEq/L) may indicate electrolyte imbalances, which can also contribute to cardiac arrhythmias and heart failure.

The patient's low T3 and T4 levels, along with the low TSH level, suggest thyroid dysfunction, which can also contribute to heart failure.

Overall, the combination of advanced age, underlying heart disease, impaired kidney function, reduced LVEF, and multiple comorbidities (hypertension, dyslipemia, anemia, and thyroid dysfunction) makes the patient outcome of pump failure death a likely consequence of the patient's condition."
118,118,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to several factors that indicate severe left ventricular dysfunction and possible end-stage heart failure. 

1. Low LVEF (Left Ventricular Ejection Fraction) of 37%: This indicates significant left ventricular dysfunction, which is a hallmark of heart failure. An LVEF of 50-60% is generally considered normal, and values below 35% are often associated with severe heart failure.

2. High Pro-BNP (Brain Natriuretic Peptide) level of 950 ng/L: Elevated Pro-BNP levels are a strong indicator of heart failure and are used as a biomarker to diagnose and monitor the condition. High levels are associated with increased mortality and morbidity.

3. Hypertensive cardiomyopathy and hypertension: The patient's history of hypertensive cardiomyopathy and hypertension suggests long-standing high blood pressure, which has likely contributed to left ventricular hypertrophy and eventual failure.

4. Dyslipemia and low HDL levels: The patient's dyslipemia (abnormal lipid profile) and low HDL (good cholesterol) levels may have contributed to atherosclerosis and coronary artery disease, further compromising cardiac function.

5. Low Hemoglobin and high Creatinine levels: The patient's low hemoglobin level (112 g/L) may indicate anemia, which can exacerbate heart failure symptoms. The elevated creatinine level (159.0 mmol/L) suggests impaired renal function, which can be a consequence of heart failure.

6. Medications: The patient is taking loop diuretics, hydralazine, and nitrovasodilators, which are commonly used to manage heart failure symptoms. However, these medications may not have been sufficient to reverse the underlying cardiac dysfunction.

7. ECG findings: The absence of significant arrhythmias or other ECG abnormalities does not necessarily indicate the absence of cardiac disease, as the ECG is not always sensitive enough to detect all forms of cardiac dysfunction.

In summary, the combination of severe left ventricular dysfunction (low LVEF), high Pro-BNP levels, and a history of hypertension and dyslipemia likely contributed to the patient's outcome of pump failure death."
119,119,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's advanced age (82 years), the patient's NYHA Class II classification suggests that the patient has moderate symptoms of heart failure, but is still able to perform everyday activities without significant limitation. However, the patient's left ventricular ejection fraction (LVEF) of 37% indicates that the patient has severe systolic heart failure, which is a significant risk factor for adverse outcomes.

The patient's blood work shows elevated creatinine levels (159.0 mmol/L), indicating impaired renal function, which is a common comorbidity in patients with heart failure. The patient's low hemoglobin level (112.0 g/L) may indicate anemia, which can further exacerbate heart failure symptoms.

The patient's high Pro-BNP level (950.0 ng/L) is indicative of heart failure with preserved ejection fraction (HFpEF), but in this case, it may also suggest that the patient has heart failure with reduced ejection fraction (HFrEF), given the low LVEF.

The patient's medication regimen includes Amiodarone, which is an antiarrhythmic medication that can be used to treat atrial fibrillation and ventricular tachycardia, but may not be effective in this case given the absence of arrhythmias on the ECG.

The patient's ECG shows no signs of arrhythmias, but the absence of a clear indication of the type of heart failure (HFpEF or HFrEF) makes it difficult to determine the exact cause of the patient's pump failure.

Considering the patient's advanced age, severe systolic heart failure, impaired renal function, anemia, and high Pro-BNP levels, the most likely cause of the patient's pump failure death is likely related to the progression of their underlying heart failure, which has resulted in a decline in cardiac function and ultimately, death.

It is worth noting that the patient's medications, particularly the Loop Diuretics and Hydralazine, may not have been effective in managing the patient's heart failure symptoms, or may have had adverse effects that contributed to the patient's outcome. A more comprehensive review of the patient's medication regimen and potential interactions may be necessary to determine the specific factors that contributed to the patient's outcome."
120,120,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to several factors evident from the provided data. 

Firstly, the patient has a history of Ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to coronary artery disease, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) of 25.0% indicates severe left ventricular dysfunction, which is a hallmark of advanced heart failure.

The patient's elevated Pro-BNP (brain natriuretic peptide) level of 3258.0 ng/L is also indicative of heart failure. BNP is a hormone produced by the heart in response to increased ventricular wall tension, and elevated levels are associated with heart failure.

Furthermore, the patient's glucose level of 6.3 mmol/L indicates poorly controlled diabetes, which is a significant risk factor for heart failure. The presence of dyslipidemia (elevated total cholesterol and LDL levels) and peripheral vascular disease also contribute to the patient's cardiovascular risk profile.

Additionally, the patient's medications, while aimed at managing heart failure and its associated conditions, may not have been sufficient to prevent the progression of the disease. The use of calcium channel blockers, beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators is consistent with standard heart failure management, but the patient's severe symptoms and low LVEF suggest that these medications may not have been effective in halting disease progression.

Lastly, the patient's elevated creatinine level of 124.0 umol/L indicates impaired renal function, which is a common comorbidity in patients with heart failure. The patient's low T3 level of 0.05 pg/dL may also suggest a state of cardiac cachexia, which is a condition characterized by weight loss, muscle wasting, and decreased metabolism, often seen in advanced heart failure.

In summary, the combination of ischemic dilated cardiomyopathy, poorly controlled diabetes, dyslipidemia, peripheral vascular disease, and inadequate response to medical therapy likely contributed to the patient's outcome of pump failure death."
121,121,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is consistent with their advanced stage of ischemic dilated cardiomyopathy (IDC), as indicated by a low left ventricular ejection fraction (LVEF) of 25.0%. The patient's LVEF is significantly reduced, which is a hallmark of heart failure with reduced ejection fraction (HFrEF). 

The patient's NYHA Class III classification also suggests that they have severe symptoms of heart failure, including shortness of breath, fatigue, and decreased exercise tolerance. The elevated Pro-BNP (N-terminal pro b-type natriuretic peptide) level of 3258.0 ng/L further supports the diagnosis of heart failure, as high levels of BNP are associated with increased filling pressures and ventricular dysfunction.

The patient's past medical history of myocardial infarction (MI) and peripheral vascular disease (PVD) also contributes to their high risk of pump failure. The presence of diabetes and dyslipemia may have also contributed to the development of atherosclerosis and subsequent MI.

The patient's laboratory results show elevated creatinine levels (124.0 mmol/L), which suggests renal impairment, a common comorbidity in patients with advanced heart failure. The patient's low hemoglobin level (151.0 g/L) may indicate anemia, which can further exacerbate symptoms of heart failure.

The patient's medications, including calcium channel blockers, beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, are typical for managing heart failure and hypertension. However, despite these treatments, the patient's condition has progressed to pump failure death, likely due to the advanced nature of their disease.

The low T3 and T4 levels may indicate hypothyroidism, which can be a contributing factor to heart failure. The elevated gamma-glutamil transpeptidase (GGT) level may indicate liver dysfunction, which can also contribute to the development of heart failure.

In summary, the patient's advanced stage of ischemic dilated cardiomyopathy, severe symptoms of heart failure, elevated Pro-BNP levels, renal impairment, anemia, and hypothyroidism, among other factors, likely contributed to their outcome of pump failure death."
122,122,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to several factors evident in the provided data. 

1. Severe Left Ventricular Dysfunction (LVEF 25.0%): The patient's Left Ventricular Ejection Fraction (LVEF) is significantly reduced at 25%, indicating severe left ventricular dysfunction. This is a hallmark of heart failure with reduced ejection fraction (HFrEF), a condition where the heart's ability to pump blood is impaired.

2. Ischemic Dilated Cardiomyopathy: The patient's past medical history of ischemic dilated cardiomyopathy further supports the severe left ventricular dysfunction. This condition is often a result of a previous myocardial infarction (heart attack), leading to scarring and remodeling of the heart muscle, which can impair its pumping ability.

3. High Pro-BNP Levels (3258.0 ng/L): Elevated levels of B-type natriuretic peptide (BNP) are indicative of heart failure, as the heart releases BNP in response to increased ventricular wall stress. A high level of 3258.0 ng/L suggests that the patient's heart is under significant stress, which can be a precursor to pump failure.

4. Medication Non-Adherence or Inadequate Dosing: Despite being on a multidrug regimen (Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, and Nitrovasodilator), the patient's symptoms and lab results suggest that the current treatment may not be adequately addressing the underlying issues. This could be due to non-adherence or inadequate dosing of these medications.

5. Presence of Comorbidities: The patient's diabetes and peripheral vascular disease further complicate the clinical picture, increasing the risk of cardiovascular events and potentially contributing to the development of heart failure.

6. Electrocardiogram (ECG) Findings: Although the ECG does not show any acute arrhythmias, the absence of a more detailed description of the ECG makes it difficult to draw conclusions about the patient's cardiac rhythm and conduction system.

Given these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, and possibly inadequate management of these conditions."
123,123,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient outcome of pump failure death is likely due to the combination of several factors, including the patient's severe left ventricular dysfunction (LVEF of 25.0%), as indicated by the low left ventricular ejection fraction (LVEF) of 25.0%. This suggests that the patient's heart is not pumping efficiently, which can lead to inadequate blood flow and oxygen delivery to vital organs.

The patient's ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a previous heart attack or reduced blood flow, is also a contributing factor to the patient's poor cardiac function. The patient's history of myocardial infarction further supports this.

Additionally, the patient's elevated Pro-BNP (B-type natriuretic peptide) level of 3258.0 ng/L is indicative of heart failure, as this hormone is released by the heart in response to increased wall tension and stretching. The patient's high Pro-BNP level suggests that the heart is under significant stress and is not functioning properly.

The patient's medications, such as calcium channel blockers, beta blockers, loop diuretics, and spironolactone, are typically used to manage heart failure symptoms and slow disease progression, but in this case, they may not have been sufficient to prevent the progression of the patient's condition.

The patient's comorbidities, including diabetes, dyslipemia, and peripheral vascular disease, also contribute to the patient's overall cardiovascular risk and may have played a role in the development of their heart failure.

The patient's low hemoglobin level of 151.0 g/L may indicate anemia, which can further exacerbate heart failure symptoms by reducing oxygen delivery to the tissues.

The patient's laboratory results also show elevated creatinine levels (124.0 umol/L), which suggests impaired renal function, a common complication of heart failure. The elevated gamma-glutamyl transferase (GGT) level of 249 IU/L may indicate liver dysfunction, which can be associated with heart failure.

The patient's TSH level of 3.58 mIU/L is within the normal range, but the low T3 level of 0.05 pg/dL may indicate hypothyroidism, which can contribute to heart failure.

The patient's low HDL cholesterol level of 1.01 mmol/L and high LDL cholesterol level of 1.99 mmol/L suggest that the patient's dyslipemia is not well-controlled, which can contribute to the progression of atherosclerosis and worsen heart failure.

In summary, the patient's pump failure death is likely due to the combination of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, heart failure symptoms, and comorbidities, which have not been adequately managed by the patient's current medications and lifestyle."
124,124,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death is likely due to the combination of severe left ventricular dysfunction, as indicated by a left ventricular ejection fraction (LVEF) of 25%, and a history of ischemic dilated cardiomyopathy. The patient's NYHA Class III classification also suggests that the patient has significant symptoms of heart failure, such as shortness of breath and fatigue, which are consistent with advanced heart failure.

The patient's laboratory results show elevated levels of brain natriuretic peptide (BNP), which is a marker of heart failure and is associated with poor prognosis. Additionally, the patient's creatinine level of 124.0 mol/L indicates impaired renal function, which is a common comorbidity in patients with advanced heart failure.

The patient's medication regimen, which includes a calcium channel blocker, beta blockers, loop diuretics, spironolactone, statins, ACE inhibitor, and nitrovasodilator, suggests that the patient is receiving standard treatment for heart failure. However, despite this treatment, the patient's LVEF remains severely impaired, and the patient has experienced pump failure, leading to death.

The patient's other comorbidities, including diabetes, dyslipidemia, and peripheral vascular disease, may have contributed to the progression of heart failure, but the primary cause of the patient's outcome is likely the advanced left ventricular dysfunction and heart failure.

It is also worth noting that the patient's low T3 level (0.05 pg/dL) may be indicative of cardiac cachexia, a condition associated with advanced heart failure and poor prognosis. However, the T3 level alone is not sufficient to explain the patient's outcome, and it is likely that the combination of factors mentioned above contributed to the patient's pump failure death."
125,125,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient is a 54-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and myocardial infarction. The patient's New York Heart Association (NYHA) Class III classification indicates that the patient experiences symptoms of heart failure with moderate limitations in physical activity.

The patient's laboratory results reveal several concerning factors contributing to his poor prognosis:

1.  Low left ventricular ejection fraction (LVEF) of 25%, indicating severe left ventricular dysfunction.
2.  Elevated Pro-BNP levels (3258.0 ng/L), which is a marker of heart failure and poor prognosis.
3.  High creatinine levels (124.0 mmol/L), indicating impaired renal function, which is a common comorbidity in patients with heart failure.
4.  Elevated gamma-glutamil transpeptidase (GGT) levels (249 IU/L), suggesting liver dysfunction, which may be related to the patient's dyslipemia and diabetes.
5.  Low hemoglobin levels (151.0 g/L), which may indicate anemia, a common comorbidity in patients with heart failure.
6.  Low T3 levels (0.05 pg/dL), which may indicate hypothyroidism, a condition that can worsen heart failure.
7.  High TSH levels (3.58 mIU/L), which may indicate hypothyroidism.

The patient's medications, including calcium channel blockers, beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, are standard treatments for heart failure and may be contributing to the patient's poor prognosis by controlling symptoms and slowing disease progression.

The patient's ECG results are unremarkable, with no evidence of ventricular extrasystoles, ventricular tachycardia, non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering the patient's severe left ventricular dysfunction, elevated Pro-BNP levels, impaired renal function, liver dysfunction, anemia, hypothyroidism, and the complexity of his medication regimen, the patient's outcome of pump failure death is not unexpected. The combination of these factors likely contributed to the patient's poor cardiac function and ultimately led to pump failure and death."
126,126,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to several factors present in their medical history and laboratory results. 

1. Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or coronary artery disease. This condition can lead to reduced cardiac function and eventually heart failure.

2. Reduced LVEF (25.0%): The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25.0%, indicating poor heart function. A normal LVEF is typically above 55%. This reduced LVEF suggests that the patient's heart is not pumping efficiently, which can lead to heart failure.

3. High Pro-BNP (3258.0 ng/L): Elevated levels of B-type natriuretic peptide (BNP) are associated with heart failure. The patient's Pro-BNP level is significantly elevated, indicating increased stress on the heart and potential heart failure.

4. Presence of diabetes and dyslipemia: The patient has diabetes and dyslipemia, which are risk factors for cardiovascular disease and heart failure. Uncontrolled diabetes can damage blood vessels and nerves that control the heart, while dyslipemia can contribute to the development of atherosclerosis and coronary artery disease.

5. Medication regimen: Although the patient is on a comprehensive medication regimen, including beta blockers, ACE inhibitors, and statins, which are commonly used to manage heart failure, the patient's condition may not be adequately controlled, leading to pump failure.

6. Low HDL and high LDL cholesterol levels: The patient has low HDL (good cholesterol) and high LDL (bad cholesterol) levels, which can contribute to the development of atherosclerosis and worsen cardiovascular disease.

7. Kidney function impairment (Creatinine 124.0 mmol/L): The patient's elevated creatinine level indicates impaired kidney function, which can be a consequence of heart failure or a contributing factor to the development of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of their underlying medical conditions, laboratory results, and medication regimen."
127,127,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is likely due to a combination of factors related to his underlying heart condition and other comorbidities. 

Firstly, the patient has ischemic dilated cardiomyopathy, a condition where the heart muscle becomes weakened due to a heart attack or reduced blood flow, leading to a decrease in the heart's ability to pump blood effectively. The patient's low left ventricular ejection fraction (LVEF) of 25.0% indicates that his heart is not pumping efficiently, which is a hallmark of heart failure.

Additionally, the patient's elevated Pro-BNP (B-type natriuretic peptide) level of 3258.0 ng/L is indicative of heart failure, as it is a marker of cardiac stress and strain. The patient's NT-proBNP levels are significantly elevated, suggesting severe heart failure.

The patient's past medical history of myocardial infarction (heart attack) and peripheral vascular disease also contribute to his risk of heart failure. The patient's diabetes and dyslipidemia may have also played a role in the development of his ischemic dilated cardiomyopathy.

Furthermore, the patient's laboratory results show elevated levels of creatinine (124.0 mmol/L), which indicates impaired kidney function, a common complication of heart failure. The patient's low albumin level (47.19 g/L) and high gamma-glutamyl transferase (GGT) level (249 IU/L) may also be indicative of liver dysfunction, which can be a consequence of heart failure.

The patient's medications, including loop diuretics, beta blockers, and ACE inhibitors, are commonly used to manage heart failure, but the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

In summary, the patient's outcome of pump failure death is likely due to a combination of his underlying heart condition, comorbidities, and the severity of his heart failure, which was not adequately managed by his current treatment regimen."
128,128,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy, the patient's left ventricular ejection fraction (LVEF) of 25% indicates severe systolic dysfunction, which is a hallmark of heart failure. The patient's New York Heart Association (NYHA) Class III classification further supports this, indicating that the patient experiences symptoms of heart failure at moderate levels of physical activity.

The elevated Pro-BNP (Brain Natriuretic Peptide) level of 3258 ng/L is a strong indicator of heart failure and is consistent with the patient's symptoms. Additionally, the patient's creatinine level of 124.0 mmol/L suggests renal impairment, which is a common comorbidity in patients with heart failure.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which are risk factors for atherosclerosis and coronary artery disease, contributing to the progression of ischemic dilated cardiomyopathy.

The patient's blood glucose level of 6.3 mmol/L indicates poorly controlled diabetes, which is a significant risk factor for cardiovascular disease and heart failure.

The patient's medication regimen, including calcium channel blockers, beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, is typical for managing heart failure, but the patient's outcome of pump failure death suggests that these medications may not have been effective in halting the progression of the disease.

The absence of ventricular extrasystoles, ventricular tachycardia, non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG suggests that the patient's heart rhythm is not a primary concern, and the patient's outcome is more likely due to the progression of heart failure rather than arrhythmia.

In conclusion, the patient's outcome of pump failure death is likely due to the progression of ischemic dilated cardiomyopathy, exacerbated by poorly controlled diabetes, renal impairment, and atherosclerosis, despite optimal medical therapy."
129,129,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to several factors based on the provided medical history and test results. 

1. Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, a condition where the heart muscle becomes weakened due to reduced blood flow (ischemia), leading to a decrease in the heart's pumping efficiency. This condition is a significant risk factor for heart failure.

2. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 25%, indicating that the left ventricle is not pumping blood efficiently. A normal LVEF is typically above 55%. This low LVEF value is a strong indicator of heart failure.

3. Elevated B-type Natriuretic Peptide (BNP): The patient's Pro-BNP level is 3258.0 ng/L, which is significantly elevated. BNP is a hormone produced by the heart in response to increased ventricular stretch and pressure. Elevated BNP levels are associated with heart failure.

4. Diabetes and Dyslipemia: The patient has a history of diabetes and dyslipemia, which can contribute to the development and progression of atherosclerosis, a condition where plaque builds up in the arteries, reducing blood flow to the heart muscle. This can exacerbate ischemic dilated cardiomyopathy.

5. Peripheral Vascular Disease: The patient's history of peripheral vascular disease suggests that there may be widespread atherosclerosis, further compromising blood flow to the heart muscle.

6. Medications: While the patient is on various medications, including ACE inhibitors, beta blockers, and statins, which are commonly used to manage heart failure, the patient's condition is severe, and these medications may not have been sufficient to prevent pump failure.

7. ECG findings: The absence of significant arrhythmias or other ECG abnormalities does not necessarily indicate that the patient's heart failure is not severe. The patient's condition may be more related to the underlying structural and functional abnormalities of the heart rather than arrhythmias.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of ischemic dilated cardiomyopathy, low LVEF, elevated BNP levels, and comorbid conditions such as diabetes and dyslipemia, which have contributed to the progression of heart failure."
130,130,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to several factors based on the provided data and medical history. 

1. Idiopathic dilated cardiomyopathy: This underlying heart condition is a significant risk factor for heart failure, particularly when combined with other comorbidities such as hypertension and dyslipemia.

2. Reduced Left Ventricular Ejection Fraction (LVEF) of 25.0%: This indicates severe left ventricular dysfunction, which is a hallmark of heart failure. A normal LVEF is typically above 55%, and values below 40% are associated with significant morbidity and mortality.

3. Elevated Pro-BNP (Brain Natriuretic Peptide): A Pro-BNP level of 1693.0 ng/L is significantly elevated, indicating severe heart failure. Pro-BNP is a biomarker that correlates with the severity of heart failure and is used to diagnose and monitor the condition.

4. Ventricular Extrasystole and Non-sustained Ventricular Tachycardia (NSVT): These ECG findings suggest underlying ventricular dysfunction and increased risk of arrhythmias, which can contribute to heart failure progression and mortality.

5. Medications: Although the patient is on standard heart failure medications (Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone), these may not have been sufficient to manage the severity of the patient's heart failure, leading to the adverse outcome.

6. Comorbidities: The presence of hypertension, dyslipemia, and elevated creatinine levels (88.0 mmol/L) suggests that the patient had multiple comorbidities that may have contributed to the progression of heart failure.

In summary, the combination of idiopathic dilated cardiomyopathy, severe left ventricular dysfunction, elevated Pro-BNP, and presence of ventricular arrhythmias, along with comorbidities and suboptimal medication management, likely contributed to the patient's outcome of pump failure death."
131,131,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient outcome of pump failure death can be attributed to a combination of factors based on the provided data. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. This condition is reflected in the low left ventricular ejection fraction (LVEF) of 25%, indicating that the heart is not pumping efficiently.

Additionally, the patient's elevated Pro-BNP level of 1693.0 ng/L is a marker of heart failure, and a high level of this biomarker is associated with increased mortality and morbidity in patients with heart failure.

The patient's ECG shows evidence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can further compromise cardiac function.

Furthermore, the patient's low HDL cholesterol level (1.14 mmol/L) and high LDL cholesterol level (3.53 mmol/L) contribute to dyslipemia, a condition that can exacerbate cardiac disease.

The patient's renal function, as indicated by the elevated creatinine level of 88.0 mol/L, may also be compromised, which can further contribute to the progression of heart failure.

The patient's medications, including angiotensin II receptor blockers, beta blockers, loop diuretics, and spironolactone, are standard treatments for heart failure, but the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

Lastly, the patient's TSH level of 1.21 mIU/L is within the normal range, but the low T3 level of 0.0369 pg/dL may indicate hypothyroidism, which can also contribute to heart failure.

Considering these factors, the patient's outcome of pump failure death is likely the result of a combination of idiopathic dilated cardiomyopathy, heart failure, abnormal heart rhythms, dyslipemia, renal dysfunction, and possibly hypothyroidism."
132,132,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death is likely due to the combination of several factors, including his advanced age (70 years), severe left ventricular dysfunction (LVEF of 25.0%), and elevated B-type natriuretic peptide (BNP) level (1693.0 ng/L), which is indicative of heart failure. The patient's history of idiopathic dilated cardiomyopathy and hypertension also contribute to his increased risk of heart failure. Furthermore, his high total cholesterol level (4.99 mmol/L) and low HDL level (1.14 mmol/L) may have exacerbated his cardiovascular disease.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests that the patient has arrhythmogenic potential, which may have contributed to his cardiac decompensation and ultimately, pump failure.

The patient's kidney function, as indicated by his elevated creatinine level (88.0 mol/L), is also compromised, which is a common complication of heart failure. The patient's electrolyte imbalance, with a slightly low potassium level (4.57 mEq/L), may have also played a role in his cardiac arrhythmias and cardiac decompensation.

The patient's medications, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, are standard treatments for heart failure and may have been used to manage his symptoms and slow disease progression. However, despite these treatments, the patient's condition may have progressed to pump failure due to the underlying severity of his disease.

Overall, the combination of advanced age, severe left ventricular dysfunction, elevated BNP level, arrhythmogenic potential, kidney dysfunction, and electrolyte imbalance likely contributed to the patient's outcome of pump failure death."
133,133,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient is a 70-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) is severely decreased at 25%, indicating poor heart function.

The patient's Pro-BNP level is elevated at 1693.0 ng/L, which is a marker of heart failure and can indicate fluid overload and decreased cardiac function. The patient's creatinine level is also elevated at 88.0 mol/L, indicating impaired kidney function, which is common in patients with heart failure.

The patient's ECG shows evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, which are all indicators of abnormal heart rhythm and cardiac electrical activity. The presence of these arrhythmias can contribute to decreased cardiac function and increased risk of sudden cardiac death.

The patient's medications, including angiotensin II receptor blockers, beta blockers, loop diuretics, and spironolactone, are commonly used to manage heart failure and reduce symptoms. However, despite these treatments, the patient's condition has progressed to pump failure, leading to death.

The patient's age, sex, and comorbidities, including dyslipemia and hypertension, may also have contributed to the progression of his heart disease and eventual pump failure. The patient's low HDL and high LDL cholesterol levels may have contributed to the development of atherosclerosis, which can further impair cardiac function.

In conclusion, the combination of the patient's underlying heart condition, elevated Pro-BNP level, impaired kidney function, abnormal ECG findings, and progression of symptoms despite medical treatment likely contributed to his pump failure and eventual death."
134,134,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's profile, the outcome of pump failure death can be attributed to a combination of factors. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, reducing the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 25%, indicating that the heart is not pumping efficiently.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 1693 ng/L is indicative of heart failure, as it is a marker of cardiac stress and strain. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further supports the diagnosis of heart failure and increased risk of cardiac arrhythmias.

The patient's medications, including angiotensin II receptor blocker, beta blockers, loop diuretics, and spironolactone, are commonly used to manage heart failure, but it appears that they may not have been effective in improving the patient's condition. The patient's high total cholesterol and LDL levels (4.99 mmol/L and 3.53 mmol/L, respectively) may also contribute to the progression of heart disease.

The patient's low hemoglobin level (138 g/L) may indicate anemia, which can exacerbate heart failure. The elevated creatinine level (88.0 umol/L) suggests impaired renal function, which is a common comorbidity in patients with heart failure.

The patient's TSH level is within the normal range, but the low T3 level (0.0369 pg/dL) may indicate hypothyroidism, which can contribute to heart failure.

The combination of these factors, including the patient's underlying heart condition, medication regimen, and comorbidities, likely contributed to the outcome of pump failure death."
135,135,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors, primarily driven by the patient's underlying condition of idiopathic dilated cardiomyopathy. The patient's left ventricular ejection fraction (LVEF) of 25% is significantly below the normal range (50-70%), indicating severe left ventricular dysfunction. This reduced LVEF compromises the heart's ability to efficiently pump blood, leading to potential heart failure.

Additionally, the patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 1693.0 ng/L is a marker of cardiac stress and strain, often seen in patients with heart failure. The elevated levels of troponin (0.3 ng/mL) also suggest cardiac injury or stress, further supporting the diagnosis of heart failure.

The patient's NYHA Class II classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath and fatigue, during physical activity or exertion, but is able to perform daily activities without significant limitations.

The patient's past medical history of hypertension and dyslipidemia likely contributed to the development of idiopathic dilated cardiomyopathy. The elevated total cholesterol level (4.99 mmol/L) and LDL cholesterol level (3.53 mmol/L) are also risk factors for cardiovascular disease.

The patient's current medications, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, are standard treatments for heart failure and may have been prescribed to manage symptoms and slow disease progression. However, the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further indicate underlying cardiac electrical instability, which may have contributed to the patient's poor outcome.

In summary, the combination of idiopathic dilated cardiomyopathy, severe left ventricular dysfunction, elevated Pro-BNP and troponin levels, and the presence of cardiac arrhythmias on the ECG likely led to the patient's outcome of pump failure death."
136,136,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death is likely due to a combination of several factors contributing to the progression of his idiopathic dilated cardiomyopathy. 

Firstly, the patient has a significantly reduced left ventricular ejection fraction (LVEF) of 25.0%, which is a critical indicator of heart failure. This suggests that the patient's heart is not pumping efficiently, leading to decreased cardiac output and potentially fatal consequences.

Secondly, the patient's pro-BNP (N-terminal pro b-type natriuretic peptide) level is elevated at 1693.0 ng/L, which is a marker of heart failure and cardiac strain. Elevated pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

Thirdly, the patient's ECG shows evidence of non-sustained ventricular tachycardia (NSVT), which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. Additionally, the presence of polymorphic ventricular extrasystoles further suggests that the patient's heart is experiencing abnormal electrical activity, which can lead to arrhythmias and cardiac arrest.

Furthermore, the patient's laboratory results show elevated creatinine levels (88.0 mol/L), which indicates impaired renal function, often seen in patients with advanced heart failure. This suggests that the patient's kidneys are not functioning optimally, which can further exacerbate the progression of heart failure.

Lastly, the patient's medications, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, are typically used to manage heart failure symptoms and slow disease progression. However, in this case, the patient's outcome suggests that these medications may not have been sufficient to prevent the progression of his heart failure to a fatal outcome.

In conclusion, the combination of the patient's reduced LVEF, elevated pro-BNP levels, abnormal ECG findings, impaired renal function, and medication regimen likely contributed to his outcome of pump failure death."
137,137,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's profile, the outcome of pump failure death can be attributed to a combination of factors. 

1.  Severe Left Ventricular Dysfunction (LVEF 25.0%): The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating severe left ventricular dysfunction. This is a strong indicator of heart failure and increased risk of pump failure.

2.  History of Idiopathic Dilated Cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to poor heart function.

3.  High BNP Levels (1693.0 ng/L): Elevated brain natriuretic peptide (BNP) levels are a marker of heart failure and indicate that the heart is under strain. High BNP levels are associated with increased risk of mortality and morbidity in heart failure patients.

4.  Electrocardiogram (ECG) Findings: The patient's ECG shows non-sustained ventricular tachycardia and ventricular extrasystoles, which are abnormal heart rhythms that can indicate underlying cardiac disease and increase the risk of cardiac arrhythmias.

5.  Medication Non-Optimization: Although the patient is on Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, which are standard medications for heart failure, the patient's LVEF is still severely reduced, indicating that these medications may not be adequately managing the patient's condition.

6.  Comorbidities: The patient has multiple comorbidities, including hypertension, dyslipidemia, and elevated liver enzymes, which can contribute to the progression of heart failure and increase the risk of pump failure.

7.  Poor Nutritional Status (Albumin 39 g/L): Low albumin levels may indicate malnutrition or liver disease, which can further exacerbate heart failure and increase the risk of pump failure.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of severe left ventricular dysfunction, underlying heart disease, high BNP levels, and inadequate medication management, compounded by multiple comorbidities and poor nutritional status."
138,138,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death is likely due to a combination of factors contributing to his advanced heart failure.

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. The low left ventricular ejection fraction (LVEF) of 25% indicates severe heart failure, as the normal range is typically considered to be 55-70%.

The elevated pro-BNP (brain natriuretic peptide) level of 1693 ng/L is a strong indicator of heart failure, as high levels of pro-BNP are associated with increased ventricular stretch and wall tension, which can occur in heart failure. Additionally, the patient's creatinine level of 88.0 mol/L suggests impaired renal function, which is a common complication of advanced heart failure.

The patient's medications, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, are typical for managing heart failure, but the fact that the patient is still experiencing non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles suggests that these medications may not be fully effective in controlling the patient's arrhythmias.

Furthermore, the patient's lipid profile shows high total cholesterol (4.99 mmol/L) and low HDL cholesterol (1.14 mmol/L), which can contribute to the progression of coronary artery disease and worsening heart failure.

The patient's ECG findings of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles indicate significant arrhythmia activity, which can lead to cardiac decompensation and pump failure.

In conclusion, the combination of idiopathic dilated cardiomyopathy, low LVEF, high pro-BNP levels, impaired renal function, arrhythmia activity, and poor lipid profile likely contributed to the patient's outcome of pump failure death."
139,139,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors that indicate advanced heart failure and a high risk of mortality. 

1. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 25%, which is significantly below the normal range of 55-70%. This indicates that the patient's heart is not pumping efficiently, leading to decreased cardiac output and increased risk of heart failure.

2. Elevated Pro-BNP: The patient's Pro-BNP level is 1693.0 ng/L, which is significantly elevated. BNP is a biomarker for heart failure, and high levels indicate increased ventricular stretch and increased risk of adverse outcomes.

3. Medications: Although the patient is on Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, which are standard treatments for heart failure, the patient's condition has progressed to pump failure death, indicating that these medications may not have been effective in halting the progression of the disease.

4. ECG Findings: The patient has non-sustained ventricular tachycardia, which is a marker of increased risk of sudden cardiac death. Additionally, the presence of polymorphic ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia indicates arrhythmia and increased risk of cardiac arrest.

5. Comorbidities: The patient has idiopathic dilated cardiomyopathy, dyslipemia, and hypertension, which are all contributing factors to the progression of heart failure.

6. Lab Results: The patient's creatinine level is elevated at 88.0 mol/L, indicating renal dysfunction, which is a common complication of advanced heart failure. The patient's glucose level is also elevated at 5.82 mmol/L, which can contribute to the progression of heart failure.

Considering these factors, the patient's outcome of pump failure death is not unexpected, given the advanced stage of heart failure and the presence of multiple risk factors for adverse outcomes."
140,140,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors, primarily related to his underlying ischemic dilated cardiomyopathy and previous myocardial infarction. 

1. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is significantly low at 15%, indicating severe left ventricular dysfunction. This is a strong predictor of poor prognosis and increased risk of heart failure complications, including pump failure.

2. Hemodynamic Instability: The patient's blood pressure is low (90/55 mmHg), indicating hemodynamic instability, which is a critical factor in the development of pump failure. The patient may not be able to maintain adequate circulation, leading to end-organ hypoperfusion.

3. Renal Dysfunction: The patient has elevated creatinine levels (154.0 mmol/L), indicating renal dysfunction. This is a common complication of heart failure and can further exacerbate pump failure due to the vicious cycle of fluid overload and electrolyte imbalances.

4. Electrolyte Imbalance: The patient's potassium level is slightly low (4.63 mEq/L), which can contribute to arrhythmias and further compromise cardiac function.

5. Medication Overlap: The patient is taking multiple medications, including Amiodarone, Digoxin, Loop Diuretics, Hydralazine, and Nitrovasodilator. While these medications are intended to manage the patient's heart failure and arrhythmias, they can also have adverse interactions and contribute to the development of pump failure.

6. Nutritional Deficiencies: The patient's albumin level is low (41.9 g/L), which can indicate malnutrition or liver dysfunction. Malnutrition can further compromise cardiac function and increase the risk of complications.

7. Chronic Inflammation: The patient's elevated gamma-glutamil transpeptidase (GGT) level (69 IU/L) suggests chronic inflammation, which can contribute to cardiac remodeling and pump failure.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of his underlying heart disease, hemodynamic instability, renal dysfunction, electrolyte imbalance, medication interactions, nutritional deficiencies, and chronic inflammation."
141,141,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to reduced heart function. This condition is further exacerbated by the patient's low left ventricular ejection fraction (LVEF) of 15.0%, indicating that the heart is not pumping efficiently.

The patient's blood pressure is also significantly low at 90/55 mmHg, which may be a result of the heart's inability to pump enough blood to maintain adequate circulation. This is a common issue in patients with heart failure, as the heart is not able to generate enough pressure to maintain blood flow.

Furthermore, the patient's serum creatinine level is elevated at 154.0 mmol/L, indicating impaired kidney function, which is often a complication of heart failure. The patient's urea level is also slightly elevated at 11.9 mg/dL, further supporting the notion of impaired kidney function.

Additionally, the patient's medication regimen includes loop diuretics, which are often used to treat heart failure by reducing fluid buildup in the body. However, in this case, the patient's albumin level is slightly low at 41.9 g/L, indicating possible malnutrition or muscle wasting, which can be a sign of advanced heart failure.

The patient's troponin level is within normal limits at 0.01 ng/mL, indicating that there is no current myocardial infarction. However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy suggests that the heart muscle has been previously damaged.

The patient's TSH level is within the normal range at 4.74 mIU/L, indicating that there are no signs of thyroid dysfunction, which can sometimes contribute to heart failure.

The patient's potassium level is slightly low at 4.63 mEq/L, which can be a sign of diuretic use or heart failure. The patient's sodium level is within the normal range at 141.0 mEq/L, indicating that there is no significant issue with sodium balance.

In conclusion, the patient's outcome of pump failure death can be attributed to a combination of ischemic dilated cardiomyopathy, low LVEF, low blood pressure, impaired kidney function, and possible malnutrition or muscle wasting, which are all contributing factors to the progression of heart failure."
142,142,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of factors related to his underlying heart condition, comorbidities, and medication regimen. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to coronary artery disease. This condition can lead to reduced cardiac function and increased risk of heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 15%, which is significantly below the normal range (50-70%). This indicates that the left ventricle is not pumping efficiently, leading to decreased cardiac output and increased risk of heart failure.

3.  Medication-Induced Cardiac Toxicity: The patient is on multiple medications, including Amiodarone, Digoxin, Loop Diuretics, Hydralazine, and Nitrovasodilator. While these medications are used to manage heart conditions, they can also have adverse effects, such as electrolyte imbalances, arrhythmias, and decreased cardiac function, which may have contributed to the patient's outcome.

4.  Electrolyte Imbalance: The patient's potassium level is slightly low (4.63 mEq/L), which can lead to arrhythmias and decreased cardiac function.

5.  Chronic Kidney Disease (CKD): The patient's creatinine level is elevated (154.0 mmol/L), indicating impaired kidney function. CKD can lead to fluid overload, electrolyte imbalances, and decreased cardiac function, contributing to heart failure.

6.  Malnutrition: The patient's albumin level is low (41.9 g/L), indicating malnutrition or chronic inflammation. Malnutrition can impair cardiac function and increase the risk of heart failure.

7.  Hypotension: The patient's blood pressure is low (90/55 mmHg), which can lead to decreased cardiac output and increased risk of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of his underlying heart condition, comorbidities, and medication-induced complications."
143,143,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient is a 63-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, indicating significant cardiac damage and dysfunction. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 15%, which is a strong indicator of heart failure. The patient is already classified as NYHA Class II, suggesting that he has symptoms of heart failure with mild limitation of physical activity.

The patient's laboratory results show elevated creatinine levels (154.0 mmol/L), indicating renal dysfunction, which is a common comorbidity in patients with heart failure. Additionally, the patient has hyperglycemia (Glucose 4.9 mmol/L), which can be a result of the body's stress response to chronic heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of electrical instability in the heart. However, it is essential to note that the patient does not have sustained ventricular tachycardia, which might have been a more immediate concern.

The patient's medication regimen includes Amiodarone, Digoxin, Loop Diuretics, Hydralazine, and Nitrovasodilator, which are all typical treatments for heart failure and arrhythmias. However, despite these treatments, the patient's condition has progressed to pump failure death.

Considering the patient's advanced age, history of ischemic dilated cardiomyopathy, and severe heart failure symptoms, it is likely that the patient's heart function was severely compromised, leading to a failure of the heart's pumping ability, ultimately resulting in pump failure death."
144,144,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided information. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged, leading to poor heart function. This condition is a significant risk factor for heart failure and is often associated with a poor prognosis.

Secondly, the patient's left ventricular ejection fraction (LVEF) is severely reduced at 15%, indicating that the heart is not pumping efficiently. A normal LVEF is typically above 55%, and an LVEF below 20-25% is often associated with severe heart failure.

Thirdly, the patient's blood pressure is low at 90/55 mmHg, which may indicate decreased cardiac output and reduced blood pressure. This can be a sign of heart failure, particularly when combined with the low LVEF.

Furthermore, the patient's electrolyte levels, particularly potassium (4.63 mEq/L), are within a relatively normal range, but slightly on the lower side. However, it is essential to note that potassium levels can fluctuate and may not accurately reflect the patient's cardiac function.

The patient's medication regimen includes amiodarone, digoxin, loop diuretics, hydralazine, and nitrovasodilators, which are commonly used to manage heart failure symptoms and arrhythmias. However, the presence of these medications does not necessarily indicate that the patient's condition is well-controlled.

The ECG findings of polymorphic ventricular extrasystoles may indicate arrhythmias, which can further compromise cardiac function.

Lastly, the patient's creatinine level is elevated at 154.0 mol/L, indicating impaired kidney function, which is often seen in advanced heart failure.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of ischemic dilated cardiomyopathy, severely reduced LVEF, low blood pressure, and possible arrhythmias, which ultimately led to cardiac decompensation and failure."
145,145,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of factors, primarily related to their underlying ischemic dilated cardiomyopathy and severe left ventricular dysfunction (LVEF 15.0%). The patient's low left ventricular ejection fraction (LVEF) is a strong indicator of heart failure, which can lead to pump failure. 

The patient's history of myocardial infarction further supports this, as it is a common cause of dilated cardiomyopathy. Additionally, their NYHA Class II classification indicates that they have symptoms of heart failure, such as shortness of breath and fatigue, which are consistent with the patient's overall clinical presentation.

The patient's laboratory results also support the diagnosis of heart failure. Their low serum albumin level (41.9 g/L) and elevated creatinine level (154.0 mmol/L) are indicative of fluid overload and renal impairment, respectively, which are common complications of heart failure. The patient's elevated troponin level (0.01 ng/mL) suggests ongoing myocardial damage, which may be contributing to their heart failure.

The patient's medications, including amiodarone, digoxin, loop diuretics, hydralazine, and nitrovasodilator, are consistent with a treatment plan for heart failure, but the patient's outcome suggests that these medications were not sufficient to prevent pump failure.

The patient's low blood pressure (90/55 mmHg) may also be a contributing factor to their outcome, as hypotension can further compromise cardiac output and lead to pump failure.

In conclusion, the combination of the patient's underlying ischemic dilated cardiomyopathy, severe left ventricular dysfunction, history of myocardial infarction, and laboratory results, along with their medication regimen and low blood pressure, all contributed to their outcome of pump failure death."
146,146,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death can be attributed to several factors present in the patient's data. 

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to reduced heart function. This condition is a significant risk factor for heart failure and pump failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is severely reduced at 15%, indicating that the heart is not pumping efficiently. An LVEF below 20-30% is typically associated with heart failure and increased risk of pump failure.

3.  Hypotension: The patient's blood pressure is low (90/55 mmHg), which can compromise cardiac output and contribute to pump failure.

4.  Electrolyte Imbalance: The patient has a slightly low potassium level (4.63 mEq/L), which can affect cardiac function and contribute to arrhythmias and pump failure.

5.  Medication Side Effects: The patient is on several medications, including Amiodarone, Digoxin, Loop Diuretics, Hydralazine, and Nitrovasodilator. While these medications are used to manage heart conditions, they can also have side effects that may contribute to pump failure, such as hypotension and electrolyte imbalances.

6.  Reduced Renal Function: The patient's creatinine level is elevated (154.0 mmol/L), indicating reduced renal function, which can further compromise cardiac function and contribute to pump failure.

7.  Low Albumin Level: The patient's albumin level is low (41.9 g/L), which can indicate liver dysfunction or malnutrition, both of which can contribute to cardiac dysfunction.

Considering these factors, the patient's pump failure and subsequent death can be attributed to a combination of their underlying heart condition, reduced cardiac function, hypotension, electrolyte imbalance, medication side effects, reduced renal function, and low albumin level."
147,147,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to heart attack(s) and results in the heart becoming enlarged and less efficient. This is further supported by the patient's low left ventricular ejection fraction (LVEF) of 15%, indicating severe left ventricular dysfunction. 

Additionally, the patient's blood pressure is low at 90/55 mmHg, which is indicative of hypotension, a common complication in patients with heart failure. The patient's use of medications such as loop diuretics and hydralazine suggests that they are being treated for fluid overload and hypertension, which is often seen in heart failure patients.

The patient's elevated creatinine level of 154.0 mmol/L indicates impaired kidney function, which is a common comorbidity in patients with heart failure. The elevated urea level of 11.9 mg/dL further supports this finding.

The patient's low hemoglobin level of 134.0 g/L may indicate anemia, which can exacerbate heart failure symptoms.

The patient's troponin level of 0.01 ng/mL is slightly elevated, indicating some level of myocardial damage, which may be contributing to the patient's heart failure.

The combination of these factors, including the patient's history of ischemic dilated cardiomyopathy, low LVEF, hypotension, impaired kidney function, anemia, and myocardial damage, likely contributed to the patient's outcome of pump failure death."
148,148,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors from the provided data.

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or other forms of heart damage, leading to decreased heart function. This condition is indicated by the patient's low left ventricular ejection fraction (LVEF) of 15%, which is significantly below the normal range (50-70%).

Additionally, the patient's blood pressure is low (90/55 mmHg), which can lead to inadequate perfusion of vital organs, including the heart itself, further exacerbating the heart failure. The patient's medications, including loop diuretics and hydralazine, are typically used to manage heart failure symptoms, but in this case, they may not be sufficient to counteract the severity of the patient's condition.

The patient's high creatinine level (154.0 mmol/L) indicates impaired kidney function, which is a common complication of heart failure. This can further worsen the patient's condition by leading to fluid overload and electrolyte imbalances, which can contribute to arrhythmias and further compromise heart function.

The patient's troponin level is elevated (0.01 ng/mL), indicating recent myocardial damage, which can contribute to the progression of heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac electrical instability, further increasing the risk of arrhythmias and sudden cardiac death.

Given the combination of these factors, including the patient's history of ischemic dilated cardiomyopathy, low LVEF, low blood pressure, high creatinine level, elevated troponin, and ECG abnormalities, the patient's outcome of pump failure death is not unexpected."
149,149,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death is likely due to a combination of factors contributing to the progression of his ischemic dilated cardiomyopathy. 

1. Low Left Ventricular Ejection Fraction (LVEF) of 15%: This indicates severe left ventricular dysfunction, which is a hallmark of advanced heart failure. The LVEF is a critical predictor of mortality in heart failure patients.

2. History of Myocardial Infarction: The patient's past history of myocardial infarction likely contributed to the development of ischemic dilated cardiomyopathy, leading to the current state of heart failure.

3. Medications: Although the patient is on various medications such as Amiodarone, Digoxin, Loop Diuretics, Hydralazine, and Nitrovasodilator, which are commonly used to manage heart failure and arrhythmias, these medications may not have been sufficient to reverse the progression of the disease.

4. Low Blood Pressure (90/55 mmHg): The patient's low blood pressure may be indicative of severe cardiac dysfunction, as the heart is unable to maintain adequate circulation.

5. Elevated Creatinine (154.0 mmol/L): This suggests renal dysfunction, which is a common complication of advanced heart failure. The kidneys may not be receiving adequate blood flow due to the heart's decreased pumping efficiency.

6. Low Albumin (41.9 g/L): Hypoalbuminemia can be a sign of malnutrition, liver disease, or nephrotic syndrome, but in this context, it may also indicate severe cardiac cachexia, a condition associated with advanced heart failure.

7. Low HDL (1.17 mmol/L) and High LDL (2.84 mmol/L): Dyslipidemia is a known risk factor for cardiovascular disease, and in this case, it may have contributed to the progression of the patient's ischemic dilated cardiomyopathy.

8. Elevated Troponin (0.01 ng/mL): Although the troponin level is slightly elevated, it may indicate ongoing myocardial injury or damage, which can contribute to the progression of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of these contributing factors, leading to a severe decline in cardiac function and ultimately, death."
150,150,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient is a 73-year-old female with a history of valvular cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction. Her left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating severe heart failure. She is classified as NYHA Class III, indicating significant limitations in physical activity due to symptoms such as shortness of breath and fatigue.

Her laboratory results show elevated liver enzymes (ALT and AST), suggesting liver dysfunction, which could be secondary to right heart failure or cirrhosis. The elevated total cholesterol and low albumin levels may indicate malnutrition or liver disease. The elevated creatinine level indicates impaired renal function, which can be seen in advanced heart failure. The elevated pro-BNP level is consistent with heart failure.

The patient is on multiple medications, including ACE inhibitors, beta blockers, digoxin, and loop diuretics, which are commonly used to manage heart failure. However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests ongoing arrhythmia and potential for sudden cardiac death.

The patient's sudden cardiac death is likely due to the combination of severe heart failure, arrhythmias, and potential electrolyte imbalances (low potassium level). The reduced LVEF and NYHA Class III classification put her at high risk for sudden cardiac death. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases this risk. The patient's overall clinical presentation and laboratory results suggest that she was at high risk for sudden cardiac death, which ultimately occurred."
151,151,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of her underlying medical conditions and laboratory results. 

1. Reduced Left Ventricular Ejection Fraction (LVEF): The patient has a severely reduced LVEF of 20%, indicating significant left ventricular dysfunction. This is a major risk factor for sudden cardiac death, as it increases the likelihood of arrhythmias and decreased cardiac output.

2. Valvular Cardiomyopathy: The patient has a history of valvular cardiomyopathy, which can lead to decreased cardiac function and increased risk of arrhythmias.

3. Non-sustained Ventricular Tachycardia (NSVT): The presence of NSVT on the ECG is a significant risk factor for sudden cardiac death. Although it is non-sustained, it indicates that the patient's heart is prone to ventricular arrhythmias.

4. Elevated Pro-BNP (Brain Natriuretic Peptide): A high Pro-BNP level (3527.0 ng/L) is indicative of heart failure and increased ventricular wall stress, which can contribute to arrhythmias and sudden cardiac death.

5. Severe Electrolyte Imbalance: The patient's potassium level is slightly low (4.23 mEq/L), which can contribute to arrhythmias.

6. Medication Non-Adherence: Although the patient is on various medications, including ACE inhibitors, beta blockers, and loop diuretics, there is no information on whether she is adhering to her medication regimen. Non-adherence can lead to inadequate control of her heart failure and arrhythmias.

7. Comorbidities: The patient has multiple comorbidities, including peripheral vascular disease, hypertension, and myocardial infarction, which can further increase her risk of sudden cardiac death.

Given these factors, it is not surprising that the patient experienced sudden cardiac death. The combination of reduced LVEF, valvular cardiomyopathy, NSVT, elevated Pro-BNP, electrolyte imbalance, and comorbidities all contributed to an increased risk of sudden cardiac death."
152,152,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of her underlying medical conditions and laboratory findings. 

1.  Valvular cardiomyopathy and Myocardial Infarction (MI): The patient has a history of valvular cardiomyopathy and MI, which have likely led to significant damage to the heart muscle and potentially compromised cardiac function. The patient's left ventricular ejection fraction (LVEF) of 20% is severely reduced, indicating poor cardiac function.

2.  Electrocardiogram (ECG) Findings: The presence of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia (VT), and a history of MI indicate a high risk of life-threatening arrhythmias. Non-sustained VT can degenerate into sustained VT, which can be fatal if not promptly treated.

3.  Elevated Pro-BNP levels: A Pro-BNP level of 3527 ng/L is significantly elevated, suggesting severe heart failure and increased risk of mortality. Elevated BNP levels are associated with poor outcomes in patients with heart failure.

4.  Medications: Although the patient is on various medications, including ACE inhibitors, beta blockers, and digoxin, these medications may not have been sufficient to control her heart failure and arrhythmias, given her underlying conditions and laboratory findings.

5.  Hypertension and Peripheral Vascular Disease: The patient's hypertension and peripheral vascular disease may have contributed to further strain on the heart, exacerbating her cardiac condition.

6.  Lab results: Elevated liver enzymes (ALT and AST) may indicate liver dysfunction, which can be a complication of heart failure. The patient's low albumin level may indicate malnutrition or liver dysfunction, which can further compromise cardiac function.

Considering these factors, the patient's sudden cardiac death is likely a result of the cumulative effect of her severe cardiac disease, poor cardiac function, and life-threatening arrhythmias."
153,153,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's clinical presentation and laboratory results, the patient's outcome of sudden cardiac death can be attributed to several factors contributing to her high-risk cardiac status. 

1. Severe Left Ventricular Dysfunction (LVEF 20.0%): The patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating significant left ventricular dysfunction. This is a major risk factor for sudden cardiac death.

2. History of Myocardial Infarction: The patient has a history of myocardial infarction, which can lead to scarring and fibrosis in the heart, increasing the risk of arrhythmias and sudden cardiac death.

3. Valvular Cardiomyopathy: The patient has valvular cardiomyopathy, which can further compromise cardiac function and increase the risk of sudden cardiac death.

4. Non-sustained Ventricular Tachycardia (VT): The presence of non-sustained VT on the ECG indicates abnormal electrical activity in the heart, which can be a precursor to sustained VT or ventricular fibrillation, leading to sudden cardiac death.

5. Elevated Pro-BNP (Brain Natriuretic Peptide): A high Pro-BNP level indicates elevated filling pressures in the left ventricle, suggesting severe heart failure. Elevated Pro-BNP is associated with an increased risk of sudden cardiac death.

6. Medication Non-Optimization: Although the patient is on multiple medications (Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor), the high Pro-BNP level and LVEF suggest that the medications may not be adequately managing the patient's heart failure and arrhythmia risk.

7. Peripheral Vascular Disease: The patient's peripheral vascular disease may contribute to reduced cardiac output and increased risk of cardiac events.

8. Electrolyte Imbalance (Low Potassium): The patient's low potassium level (4.23 mEq/L) may contribute to arrhythmias and increased risk of sudden cardiac death.

Considering these factors, the patient's sudden cardiac death is likely a result of the cumulative effect of these high-risk conditions and suboptimal management of her cardiac disease."
154,154,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to several factors based on the provided information.

1.  Severe Left Ventricular Dysfunction: The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 20%, indicating severe left ventricular dysfunction. This is a major risk factor for sudden cardiac death, as it increases the likelihood of arrhythmias and cardiac arrest.

2.  Non-Sustained Ventricular Tachycardia: The presence of non-sustained ventricular tachycardia (VT) on the ECG, with a cycle length >10, suggests that the patient is at risk for potentially life-threatening arrhythmias. Non-sustained VT can degenerate into sustained VT, which can lead to cardiac arrest and sudden cardiac death.

3.  Polymorphic Ventricular Extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG also increases the risk of arrhythmias and sudden cardiac death. These abnormal heartbeats can disrupt the normal heart rhythm, leading to cardiac arrest.

4.  Pro-BNP Levels: The patient's Pro-BNP level is significantly elevated at 3527.0 ng/L, which is a marker of heart failure and increased ventricular stretch. Elevated Pro-BNP levels are associated with an increased risk of sudden cardiac death.

5.  Medication Non-Optimization: Although the patient is on various medications, including ACE inhibitors, beta blockers, and digoxin, it is unclear if the medications are optimized for the patient's specific condition. Inadequate medication optimization may have contributed to the patient's outcome.

6.  Underlying Valvular Cardiomyopathy: The patient's history of valvular cardiomyopathy may have contributed to the development of left ventricular dysfunction, which, in turn, increased the risk of sudden cardiac death.

7.  Other Contributing Factors: The patient's history of peripheral vascular disease, hypertension, and myocardial infarction may also have contributed to the development of left ventricular dysfunction and increased the risk of sudden cardiac death.

In conclusion, the patient's outcome of sudden cardiac death can be attributed to a combination of severe left ventricular dysfunction, non-sustained ventricular tachycardia, polymorphic ventricular extrasystoles, elevated Pro-BNP levels, potential medication non-optimization, and underlying valvular cardiomyopathy."
155,155,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in her medical history and current clinical presentation.

Firstly, the patient has a history of valvular cardiomyopathy, which indicates significant damage to the heart muscle, leading to a decrease in left ventricular ejection fraction (LVEF) of 20%. This is a critical factor in the development of heart failure, which is reflected in the patient's New York Heart Association (NYHA) Class III classification, indicating severe symptoms of heart failure.

The patient's elevated levels of Pro-BNP (3527.0 ng/L) further support the diagnosis of heart failure, as this biomarker is commonly used to diagnose and monitor heart failure. Additionally, the patient's low LVEF and elevated Pro-BNP levels are consistent with a high risk of sudden cardiac death.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG is also a concerning finding, as these arrhythmias can increase the risk of sudden cardiac death. Non-sustained VT is a known predictor of sudden cardiac death, particularly in patients with heart failure.

The patient's history of myocardial infarction and peripheral vascular disease also increases her risk of sudden cardiac death. Hypertension and elevated levels of creatinine (77.0 mmol/L) suggest underlying renal impairment, which can further contribute to the development of cardiovascular disease and increase the risk of sudden cardiac death.

Furthermore, the patient's low hemoglobin level (149.0 g/L) and elevated levels of AST and ALT (62.0 IU/L and 54.0 IU/L, respectively) suggest underlying liver dysfunction, which can be a contributing factor to the development of cardiovascular disease.

In summary, the patient's outcome of sudden cardiac death can be attributed to a combination of her underlying valvular cardiomyopathy, heart failure, arrhythmias, history of myocardial infarction, peripheral vascular disease, hypertension, and renal impairment, as well as underlying liver dysfunction."
156,156,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's profile, the outcome of sudden cardiac death is not entirely unexpected. Several factors contribute to this outcome:

1. Advanced Age and NYHA Class III: The patient is 73 years old and has a New York Heart Association (NYHA) Class III, indicating severe symptoms of heart failure, such as shortness of breath and fatigue, even at rest or with minimal exertion. This suggests a high risk of cardiac complications.

2. Valvular Cardiomyopathy and Low LVEF: The patient has valvular cardiomyopathy, which can lead to reduced left ventricular ejection fraction (LVEF) of 20%. This indicates a severely impaired heart function, making the heart less efficient at pumping blood, and increasing the risk of cardiac arrest.

3. High Pro-BNP Levels: The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is 3527.0 ng/L, which is significantly elevated. Elevated Pro-BNP levels are associated with increased risk of heart failure and mortality.

4. History of Myocardial Infarction: The patient has a history of myocardial infarction, which can lead to scarring of the heart muscle and further reduce heart function.

5. Ventricular Extrasystole and Non-sustained Ventricular Tachycardia: The presence of polymorphic ventricular extrasystole and non-sustained ventricular tachycardia on the ECG indicates abnormal heart rhythms, which can increase the risk of cardiac arrhythmias and sudden cardiac death.

6. Medication Non-Optimal: Although the patient is on multiple medications, including ACE inhibitors, beta blockers, and digoxin, the presence of valvular cardiomyopathy and severely reduced LVEF suggests that the current medication regimen may not be optimal for this patient's condition.

7. Lab Results: The patient's albumin level is slightly low (36.7 g/L), which can indicate malnutrition or liver disease, potentially contributing to the overall poor prognosis. Elevated AST and ALT levels (62.0 IU/L and 54.0 IU/L, respectively) suggest liver dysfunction, which can also contribute to the patient's overall poor health status.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of advanced age, severe heart failure, and underlying cardiac conditions, compounded by suboptimal medication management and potential liver dysfunction."
157,157,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided data. 

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is significantly reduced at 20%, indicating severe left ventricular dysfunction, which is a well-established risk factor for sudden cardiac death. This reduction in LVEF suggests that the patient's heart is not pumping efficiently, making it difficult for the body to receive sufficient oxygen and nutrients.

2.  Elevated Pro-BNP Levels: The patient's Pro-BNP level is elevated at 3527.0 ng/L, which is a marker of heart failure and increased ventricular wall stress. Elevated Pro-BNP levels are associated with an increased risk of sudden cardiac death.

3.  History of Myocardial Infarction: The patient has a history of myocardial infarction, which can lead to scar tissue formation in the heart. This scarring can disrupt the heart's electrical pathways, increasing the risk of arrhythmias and sudden cardiac death.

4.  Ventricular Extrasystoles and Non-sustained Ventricular Tachycardia: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests an abnormal heart rhythm. These arrhythmias can be a precursor to more severe arrhythmias that may lead to sudden cardiac death.

5.  Valvular Cardiomyopathy and Peripheral Vascular Disease: These conditions can further compromise cardiac function and increase the risk of sudden cardiac death.

6.  Medication Non-Optimization: Although the patient is on various medications, including ACE inhibitors, beta blockers, and digoxin, the presence of non-sustained ventricular tachycardia and elevated Pro-BNP levels suggest that these medications may not be adequately managing the patient's heart failure symptoms or arrhythmias.

Considering these factors, the patient's outcome of sudden cardiac death can be attributed to the combination of severe left ventricular dysfunction, elevated Pro-BNP levels, history of myocardial infarction, arrhythmias, and other comorbidities that compromised cardiac function."
158,158,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death is multifactorial and can be attributed to several contributing factors. 

1. Advanced Age and Comorbidities: The patient is 73 years old with a history of valvular cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction. These comorbidities significantly increase the risk of cardiac complications.

2. Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 20%, indicating severe left ventricular dysfunction, which increases the risk of sudden cardiac death.

3. High BNP Levels: The patient's pro-BNP level is significantly elevated at 3527 ng/L, indicating severe heart failure and increased risk of adverse cardiac events, including sudden cardiac death.

4. Electrocardiographic Abnormalities: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG suggests an increased risk of malignant arrhythmias, which can lead to sudden cardiac death.

5. Medication Non-Optimization: Although the patient is on several medications, including ACE inhibitors, beta blockers, and loop diuretics, the presence of non-sustained VT and high BNP levels suggests that the medications may not be adequately controlling the patient's heart failure and arrhythmias.

6. Malnutrition and Liver Dysfunction: The patient's low albumin level (36.7 g/L) and elevated liver enzymes (AST and ALT) suggest malnutrition and liver dysfunction, which can contribute to increased mortality risk.

7. Hypokalemia: The patient's low potassium level (4.23 mEq/L) may contribute to arrhythmias and increased risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of advanced age, severe cardiac comorbidities, and inadequate management of heart failure and arrhythmias."
159,159,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in her medical history and current clinical status. 

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is severely impaired at 20%, indicating significant left ventricular dysfunction. This is likely a result of her valvular cardiomyopathy, which can lead to reduced cardiac output and increased risk of arrhythmias and sudden cardiac death.

2.  Polymorphic Ventricular Extrasystoles and Non-Sustained Ventricular Tachycardia: The presence of these arrhythmias on the ECG suggests an increased risk of life-threatening arrhythmias. Polymorphic ventricular extrasystoles can be a marker of electrical instability in the heart, and non-sustained ventricular tachycardia can degenerate into sustained ventricular tachycardia or ventricular fibrillation, which can be fatal.

3.  Elevated Pro-BNP Levels: A Pro-BNP level of 3527.0 ng/L is significantly elevated, indicating severe heart failure and increased risk of sudden cardiac death. Elevated BNP levels are associated with increased mortality and morbidity in patients with heart failure.

4.  Peripheral Vascular Disease and Hypertension: The presence of peripheral vascular disease and hypertension can contribute to decreased cardiac output and increased risk of arrhythmias.

5.  Medication Non-Adherence or Inadequate Treatment: Although the patient is on several medications, including ACE inhibitors, beta-blockers, and digoxin, her LVEF remains severely impaired, suggesting that the treatment may not be adequately addressing her underlying condition.

6.  Malnutrition: The patient's low albumin level (36.7 g/L) suggests malnutrition, which can exacerbate cardiac dysfunction and increase the risk of complications.

7.  Elevated Liver Enzymes: Elevated AST and ALT levels indicate liver dysfunction, which can contribute to cardiac dysfunction and increase the risk of arrhythmias.

Given these factors, the patient's outcome of sudden cardiac death is not unexpected. A comprehensive evaluation of her condition and adjustment of her treatment plan may have potentially altered the outcome, but unfortunately, it appears that her condition was too advanced for successful intervention."
160,160,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or coronary artery disease. This condition is associated with a poor prognosis and increased risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 30% is significantly below the normal range, indicating severe left ventricular dysfunction.

The patient's low LVEF, combined with the presence of ventricular extrasystoles on the ECG, suggests that the patient may have a high risk of arrhythmias, which can lead to sudden cardiac death. The patient's Pro-BNP level of 2037.0 ng/L is also elevated, indicating increased stress on the heart, which can further contribute to the risk of arrhythmias.

The patient's medication regimen, including beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitor, is aimed at managing heart failure and reducing the risk of arrhythmias. However, despite these medications, the patient's condition has likely progressed to the point where sudden cardiac death occurred.

Additionally, the patient's low HDL cholesterol level (0.98 mmol/L) and high LDL cholesterol level (2.4 mmol/L) may have contributed to the development of coronary artery disease, which is a risk factor for ischemic dilated cardiomyopathy.

The patient's low T3 level (0.04 pg/dL) may also be a contributing factor, as low T3 levels have been associated with poor outcomes in patients with heart failure.

In summary, the combination of ischemic dilated cardiomyopathy, low LVEF, ventricular extrasystoles, elevated Pro-BNP, and the patient's medication regimen all contributed to the patient's outcome of sudden cardiac death."
161,161,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in the provided data. 

1. Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 30%, indicating severe left ventricular dysfunction. This is a significant risk factor for sudden cardiac death, as it increases the likelihood of life-threatening arrhythmias.

2. Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to coronary artery disease, leading to a decrease in heart function. This condition increases the risk of sudden cardiac death.

3. Elevated Pro-BNP Levels: The patient's Pro-BNP level is significantly elevated at 2037.0 ng/L. Pro-BNP is a marker of heart failure and has been associated with an increased risk of sudden cardiac death.

4. Ventricular Extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death, as it indicates abnormal electrical activity in the heart.

5. Low Potassium Levels: The patient's potassium level is slightly low at 4.4 mEq/L. Low potassium levels can increase the risk of arrhythmias, which can lead to sudden cardiac death.

6. Suboptimal Medication Management: Although the patient is on medications for heart failure and hypertension, the presence of a TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG suggests that the patient may not be adequately controlled on their current medication regimen.

7. Severe Hypertension: Although the patient's blood pressure is currently within a relatively normal range, his past history of hypertension may have contributed to the development of his ischemic dilated cardiomyopathy and subsequent left ventricular dysfunction.

Given the combination of these factors, the patient's outcome of sudden cardiac death is not unexpected. However, it highlights the importance of optimal medication management, close monitoring, and aggressive management of heart failure and hypertension to reduce the risk of sudden cardiac death in patients with severe left ventricular dysfunction."
162,162,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient is a 45-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and a low left ventricular ejection fraction (LVEF) of 30%. This indicates a significantly reduced heart function, which increases the risk of sudden cardiac death.

The patient's low LVEF is a critical factor in this case. An LVEF of 30% indicates that the heart is not pumping efficiently, leading to a buildup of fluid in the lungs and other organs. This can cause symptoms such as shortness of breath, fatigue, and swelling in the legs and feet.

The patient's blood work shows elevated levels of Pro-BNP (2037.0 ng/L), which is a marker of heart failure. Elevated Pro-BNP levels indicate that the heart is under strain and is not functioning properly. Additionally, the patient's high creatinine level (97.0 mmol/L) suggests impaired kidney function, which is common in patients with heart failure.

The patient's medications, including beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitor, are all aimed at managing heart failure and reducing the risk of sudden cardiac death. However, despite these treatments, the patient's condition has progressed to sudden cardiac death.

The ECG findings of monomorphic ventricular extrasystoles are concerning, as they can be a precursor to life-threatening arrhythmias. The presence of TPSV (paroxysmal supraventricular tachyarrhythmia) also increases the risk of sudden cardiac death.

The patient's low T3 and T4 levels, as well as the slightly elevated TSH level, suggest that he may have hypothyroidism, which can contribute to heart failure and sudden cardiac death.

In summary, the combination of the patient's low LVEF, elevated Pro-BNP levels, impaired kidney function, and the presence of ventricular extrasystoles and TPSV on the ECG, along with his history of ischemic dilated cardiomyopathy and hypertension, make him at high risk for sudden cardiac death. Despite his medications, his condition has progressed to this outcome."
163,163,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's profile, I will attempt to explain the patient outcome of sudden cardiac death.

The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death (SCD). The patient's left ventricular ejection fraction (LVEF) of 30% indicates severe left ventricular dysfunction, further increasing the risk of SCD.

The patient's high level of brain natriuretic peptide (BNP) at 2037 ng/L suggests significant left ventricular dysfunction and increased filling pressures, which is consistent with heart failure. The patient's NT-proBNP level is a well-established predictor of cardiovascular events, including SCD.

The patient's low hemoglobin level at 143 g/L may indicate anemia, which can further compromise cardiac output and increase the risk of SCD.

The presence of ventricular extrasystoles on the ECG is a common finding in patients with cardiomyopathy and can be a marker of increased cardiac electrical instability. While the patient does not have sustained ventricular tachycardia, the presence of ventricular extrasystoles may still contribute to the risk of SCD.

The patient's low T3 level at 0.04 pg/dL and TSH level at 2.87 mIU/L suggest hypothyroidism, which can be a risk factor for cardiac dysfunction and SCD.

The patient's medications, including beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, are standard treatments for heart failure and may have helped to manage the patient's symptoms, but may not have been sufficient to prevent SCD.

Given the combination of these factors, including severe left ventricular dysfunction, high BNP levels, anemia, ventricular extrasystoles, and hypothyroidism, the patient's sudden cardiac death can be attributed to the progression of their underlying cardiomyopathy and the inability to prevent or mitigate the risk of SCD with current medical therapy."
164,164,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and the heart chambers are enlarged, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) of 30% indicates severe heart failure, which is a significant risk factor for sudden cardiac death.

The patient's low blood pressure of 100/60 mmHg may indicate hypotension, which can further compromise cardiac output and increase the risk of sudden cardiac death. Additionally, the patient's low albumin level (45 g/L) suggests hypoalbuminemia, which can be a sign of malnutrition or liver disease, both of which can contribute to cardiac dysfunction.

The elevated gamma-glutamyl transpeptidase (GGT) level (206 IU/L) indicates liver enzyme elevation, which can be associated with non-alcoholic fatty liver disease (NAFLD), a condition that can lead to cardiac dysfunction.

The patient's high pro-BNP level (2037 ng/L) is indicative of severe heart failure, and the patient's low T3 and T4 levels, along with a slightly elevated TSH level, suggest subclinical hypothyroidism, which can contribute to cardiac dysfunction and increase the risk of sudden cardiac death.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, which are all appropriate for managing heart failure and reducing the risk of sudden cardiac death. However, despite these medications, the patient's condition has progressed to sudden cardiac death.

The presence of monomorphic ventricular extrasystoles on the ECG suggests that the patient has abnormal electrical activity in the heart, which can be a precursor to life-threatening arrhythmias. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia may suggest that the patient's cardiac rhythm is unstable and prone to sudden changes.

In conclusion, the combination of ischemic dilated cardiomyopathy, severe heart failure, hypotension, hypoalbuminemia, liver enzyme elevation, subclinical hypothyroidism, and abnormal cardiac electrical activity on the ECG all contributed to the patient's risk of sudden cardiac death."
165,165,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to his underlying heart condition and laboratory results. 

1.  Ischemic dilated cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. This condition increases the risk of sudden cardiac death.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 30%, which is significantly lower than the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, increasing the risk of sudden cardiac death.

3.  Elevated Pro-BNP (B-type Natriuretic Peptide): The patient's Pro-BNP level is 2037.0 ng/L, which is significantly elevated. Elevated Pro-BNP levels are associated with heart failure and increased risk of sudden cardiac death.

4.  Ventricular Extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythms, which can increase the risk of sudden cardiac death.

5.  Hypotension: The patient's blood pressure is 100/60 mmHg, which is lower than the normal range (110/70 mmHg). Hypotension can reduce blood flow to the heart muscle, increasing the risk of sudden cardiac death.

6.  Electrolyte imbalance: The patient's potassium level is 4.4 mEq/L, which is slightly lower than the normal range (3.5-5.5 mEq/L). Potassium imbalance can disrupt heart function and increase the risk of arrhythmias, which can lead to sudden cardiac death.

7.  Medication non-adherence: Although the patient is on medications, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, the effectiveness of these medications may be limited by non-adherence or inadequate dosing.

8.  Underlying hypertension: The patient has a history of hypertension, which can further strain the heart and increase the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death can be attributed to a combination of his underlying heart condition, reduced heart function, abnormal heart rhythms, hypotension, electrolyte imbalance, and potential medication non-adherence."
166,166,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in their medical history and current condition.

1. Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a previous heart attack or coronary artery disease. This condition can lead to reduced left ventricular ejection fraction (LVEF), as seen in this patient with an LVEF of 30%, indicating severe heart failure.

2. Reduced LVEF and NYHA Class II: The patient's LVEF of 30% is significantly reduced, indicating severe left ventricular dysfunction. Their NYHA Class II classification also suggests that the patient experiences symptoms of heart failure, such as shortness of breath and fatigue, with minimal physical activity.

3. High Pro-BNP levels: The patient's Pro-BNP level of 2037 ng/L is elevated, indicating severe heart failure. B-type natriuretic peptide (BNP) is a hormone released by the heart in response to ventricular stretch and increased wall tension. Elevated BNP levels are associated with heart failure and can predict increased risk of mortality.

4. Hypotension: The patient's blood pressure is 100/60 mmHg, which is below the normal range (typically 90-120 mmHg systolic and 60-80 mmHg diastolic). Hypotension can exacerbate heart failure and reduce cardiac output, leading to decreased perfusion of vital organs.

5. Electrocardiogram (ECG) findings: Although the ECG does not show ventricular tachycardia, the presence of ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia (PSVT) may indicate underlying cardiac conduction abnormalities, which can increase the risk of sudden cardiac death.

6. Medications: The patient is on beta-blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic cardiomyopathy. However, despite these treatments, the patient's condition has progressed to sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to the combination of ischemic dilated cardiomyopathy, reduced LVEF, high Pro-BNP levels, hypotension, and underlying cardiac conduction abnormalities, despite being on standard heart failure medications."
167,167,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient had a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack or other forms of ischemia, leading to a decrease in the left ventricular ejection fraction (LVEF). The patient's LVEF was 30%, indicating severe heart failure. The patient was also on medications for heart failure, including beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, which are standard treatments for heart failure.

The patient's Pro-BNP level was elevated at 2037 ng/L, which is a biomarker for heart failure. The patient's creatinine level was 97.0 mmol/L, indicating impaired renal function, which is a common complication of heart failure. The patient's low hemoglobin level (143 g/L) may indicate anemia, which can contribute to fatigue, shortness of breath, and decreased exercise tolerance.

The patient's ECG showed monomorphic ventricular extrasystoles, which are premature heartbeats originating from the ventricles. While not typically a cause for concern on its own, in the context of this patient's history of heart failure and low LVEF, it may indicate increased electrical instability of the heart.

The patient's sudden cardiac death may have been caused by a combination of factors, including:

1. Severe heart failure: The patient's low LVEF and impaired renal function indicate severe heart failure, which increases the risk of sudden cardiac death.
2. Electrical instability: The presence of monomorphic ventricular extrasystoles on the ECG may indicate increased electrical instability of the heart, which can increase the risk of arrhythmias and sudden cardiac death.
3. Anemia: The patient's low hemoglobin level may have contributed to fatigue, shortness of breath, and decreased exercise tolerance, which can increase the risk of sudden cardiac death.
4. Medication non-adherence: The patient was on multiple medications, but it is possible that the patient may not have been adhering to their medication regimen, which can lead to inadequate control of heart failure and increase the risk of sudden cardiac death.

In conclusion, the patient's sudden cardiac death was likely caused by a combination of factors related to their severe heart failure, electrical instability, anemia, and potential medication non-adherence."
168,168,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of several factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or other coronary artery disease. This condition is often associated with a poor prognosis and increased risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 30% is significantly below the normal range (50-70%), indicating severe left ventricular dysfunction.

Secondly, the patient's elevated Pro-BNP (brain natriuretic peptide) level of 2037.0 ng/L is indicative of heart failure with reduced ejection fraction (HFrEF), which is a condition characterized by high levels of BNP and a poor prognosis. Elevated BNP levels are associated with increased mortality and morbidity in patients with heart failure.

Thirdly, the patient's ECG shows ventricular extrasystoles, which are abnormal heartbeats originating from the ventricles. While not necessarily life-threatening in isolation, ventricular extrasystoles can be a sign of underlying cardiac disease and may increase the risk of arrhythmias and sudden cardiac death.

Fourthly, the patient's TSH level of 2.87 mIU/L is slightly elevated, which may indicate subclinical hypothyroidism. Subclinical hypothyroidism has been associated with an increased risk of cardiovascular disease and mortality.

Lastly, the patient's medication regimen, while comprehensive, may not have been sufficient to control his condition. The patient is on beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, which are all standard treatments for heart failure and hypertension. However, the patient's condition may have progressed to a point where these medications were no longer effective in preventing sudden cardiac death.

In summary, the patient's outcome of sudden cardiac death is likely due to a combination of his underlying ischemic dilated cardiomyopathy, elevated Pro-BNP levels, ventricular extrasystoles on ECG, subclinical hypothyroidism, and potential inadequate medication control."
169,169,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy, which is characterized by reduced left ventricular ejection fraction (LVEF of 30%), the patient is at high risk for sudden cardiac death (SCD). The LVEF of 30% indicates severe left ventricular dysfunction, which can lead to arrhythmias and sudden cardiac death. 

Additionally, the patient has a high Pro-BNP level of 2037 ng/L, which is indicative of severe heart failure. Elevated Pro-BNP levels are associated with increased risk of mortality and sudden cardiac death in patients with heart failure.

The presence of ventricular extrasystoles on the ECG further increases the risk of SCD. Although the patient's ECG does not show sustained ventricular tachycardia, the presence of ventricular extrasystoles can be a harbinger of more serious arrhythmias.

The patient's medication regimen, which includes beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, is appropriate for managing heart failure and reducing the risk of SCD. However, despite this treatment, the patient's condition appears to be severe, and the risk of SCD remains high.

Furthermore, the patient's low T3 level (0.04 pg/dL) and slightly elevated TSH level (2.87 mIU/L) may indicate hypothyroidism, which is a known risk factor for heart failure and sudden cardiac death.

In conclusion, the combination of severe left ventricular dysfunction, high Pro-BNP levels, ventricular extrasystoles, and potential hypothyroidism makes the patient highly susceptible to sudden cardiac death."
170,170,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of factors related to their underlying heart condition, idiopathic dilated cardiomyopathy, and the presence of various cardiac arrhythmias. 

1. Idiopathic Dilated Cardiomyopathy: This condition is characterized by a weakened heart muscle that cannot pump blood effectively, leading to reduced left ventricular ejection fraction (LVEF) of 40%. The patient's LVEF of 40% indicates that the heart is not pumping efficiently, which increases the risk of sudden cardiac death.

2. Ventricular Extrasystoles and Non-sustained Ventricular Tachycardia (VT): The presence of polymorphic ventricular extrasystoles and non-sustained VT on the ECG indicates abnormal heart rhythm disturbances, which can lead to cardiac arrhythmias and potentially life-threatening conditions such as ventricular fibrillation.

3. High Pro-BNP Levels: A Pro-BNP level of 10297.0 ng/L is significantly elevated, indicating severe heart failure and increased risk of cardiac complications, including sudden cardiac death.

4. Reduced LVEF and Cardiac Function: The patient's LVEF of 40% and other indicators of cardiac dysfunction, such as reduced total cholesterol and elevated creatinine levels, suggest compromised cardiac function, increasing the risk of sudden cardiac death.

5. Medication Non-Response or Insufficient Management: Although the patient is on medications such as beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, their LVEF and Pro-BNP levels suggest that the current medication regimen may not be adequately managing the patient's heart condition, contributing to the risk of sudden cardiac death.

6. Potential Underlying Thyroid Dysfunction: The patient's slightly elevated TSH level (2.54 mIU/L) and low T3 level (0.05 pg/dL) may indicate subclinical hypothyroidism, which can contribute to cardiac dysfunction and increase the risk of sudden cardiac death.

Given these factors, it is likely that the patient's sudden cardiac death was caused by a combination of their underlying heart condition, cardiac arrhythmias, and inadequate management of their heart failure, possibly exacerbated by potential thyroid dysfunction."
171,171,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying idiopathic dilated cardiomyopathy and other clinical indicators. 

1. Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 40%, which is significantly below the normal range (50-70%). This indicates a compromised left ventricular function, making the heart less efficient at pumping blood and increasing the risk of sudden cardiac death.

2. High BNP Levels: The patient's BNP level is 10297.0 ng/L, which is elevated. BNP is a biomarker for heart failure, and high levels indicate increased ventricular wall stress and potential heart failure.

3. Electrocardiogram (ECG) Findings: The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests abnormal ventricular function and an increased risk of arrhythmias, which can lead to sudden cardiac death.

4. Medications: Although the patient is on beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, these medications may not be sufficient to control the patient's heart failure and arrhythmias effectively. Beta blockers are essential for reducing mortality in heart failure patients, but their effectiveness may be limited in this case due to the patient's low LVEF.

5. Other Factors: The patient's low HDL cholesterol (0.83 mmol/L) and high LDL cholesterol (1.97 mmol/L) may contribute to atherosclerosis, which can further compromise cardiac function and increase the risk of sudden cardiac death.

Considering these factors, the patient's underlying idiopathic dilated cardiomyopathy, combined with the presence of non-sustained ventricular tachycardia, high BNP levels, and inadequate medication management, likely contributed to their sudden cardiac death."
172,172,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's history of idiopathic dilated cardiomyopathy, the patient's LVEF of 40% indicates a significantly reduced left ventricular ejection fraction, which is a strong predictor of increased risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death.

The patient's elevated Pro-BNP level of 10297 ng/L is also indicative of heart failure and increased ventricular wall stress, which can contribute to the development of life-threatening arrhythmias.

Additionally, the patient's history of reduced ejection fraction and the presence of NSVT may indicate a high risk of sudden cardiac death due to arrhythmic events.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor, are standard treatments for heart failure and may help to reduce the risk of sudden cardiac death, but they do not eliminate the risk entirely.

Given the combination of these factors, the patient's risk of sudden cardiac death is significantly increased, and it is not surprising that the patient experienced a sudden cardiac death."
173,173,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death is likely due to a combination of factors, including his underlying idiopathic dilated cardiomyopathy, reduced left ventricular ejection fraction (LVEF) of 40%, and the presence of non-sustained ventricular tachycardia (NSVT) on the ECG. The patient's LVEF is significantly reduced, indicating poor heart function, which increases the risk of sudden cardiac death. The presence of NSVT is a known risk factor for sudden cardiac death, particularly in patients with heart failure and reduced LVEF.

Additionally, the patient's elevated Pro-BNP level (10297 ng/L) suggests that he is experiencing heart failure with increased filling pressures, which may have contributed to the development of NSVT. The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor, are standard treatments for heart failure and may have been inadequate to prevent sudden cardiac death.

The patient's electrolyte levels, including potassium (4 mEq/L), are within normal limits, but slightly low. However, this is not considered a significant factor in this case. The patient's TSH level is slightly elevated (2.54 mIU/L), but this is not a significant factor in this case.

The patient's overall clinical presentation and the combination of reduced LVEF, NSVT, and elevated Pro-BNP level suggest that sudden cardiac death was a likely outcome."
174,174,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death is likely due to a combination of factors related to their underlying idiopathic dilated cardiomyopathy and other clinical findings. The patient's left ventricular ejection fraction (LVEF) of 40% indicates reduced cardiac function, which is a significant risk factor for sudden cardiac death. 

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is also a concerning finding, as it suggests an increased risk of arrhythmias and sudden cardiac death. The patient's elevated pro-BNP level of 10297.0 ng/L indicates elevated levels of B-type natriuretic peptide, which is a marker of heart failure and increased cardiac stress.

Furthermore, the patient's low HDL cholesterol level (0.83 mmol/L) and high LDL cholesterol level (1.97 mmol/L) may contribute to atherosclerotic plaque formation, which can increase the risk of cardiac arrhythmias and sudden cardiac death.

The patient's use of medications such as beta blockers, digoxin, and ACE inhibitors suggests that they are being treated for heart failure, but the presence of sudden cardiac death suggests that these medications may not have been sufficient to mitigate the patient's risk.

Additionally, the patient's low T3 level (0.05 pg/dL) and slightly elevated TSH level (2.54 mIU/L) may indicate subclinical hypothyroidism, which can contribute to cardiac dysfunction and increased risk of sudden cardiac death.

In summary, the combination of reduced LVEF, NSVT, elevated pro-BNP, dyslipidemia, and potential subclinical hypothyroidism likely contributed to the patient's outcome of sudden cardiac death."
175,175,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying condition, medication regimen, and cardiac function.

1.  Idiopathic Dilated Cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle that can lead to reduced cardiac function and increased risk of arrhythmias. The left ventricular ejection fraction (LVEF) of 40% indicates a significant reduction in cardiac function, which can increase the risk of sudden cardiac death.

2.  Ventricular Extrasystole and Non-sustained Ventricular Tachycardia: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG indicates abnormal heart rhythms, which can increase the risk of sudden cardiac death. Non-sustained VT, in particular, is a known risk factor for sudden cardiac death in patients with heart failure.

3.  Elevated Pro-BNP Levels: A Pro-BNP level of 10297.0 ng/L is significantly elevated, indicating severe heart failure. Elevated Pro-BNP levels are associated with increased risk of adverse cardiovascular events, including sudden cardiac death.

4.  Medication Regimen: While the patient is on a standard heart failure medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, it is unclear if these medications were optimized for the patient's specific condition. Inadequate medication optimization can increase the risk of adverse outcomes.

5.  Other Contributing Factors: The patient's low HDL cholesterol (0.83 mmol/L) and high LDL cholesterol (1.97 mmol/L) may contribute to atherosclerotic disease, which can further compromise cardiac function and increase the risk of sudden cardiac death. Additionally, the patient's slightly low potassium level (4 mEq/L) may be a sign of diuretic-induced hypokalemia, which can increase the risk of arrhythmias.

Given the combination of these factors, it is reasonable to conclude that the patient's outcome of sudden cardiac death was likely due to a complex interplay of their underlying heart condition, abnormal heart rhythms, and potential medication-related issues."
176,176,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's past medical history of idiopathic dilated cardiomyopathy, which is a condition characterized by a weakened heart muscle leading to poor heart function, the patient's low left ventricular ejection fraction (LVEF) of 40% further supports this diagnosis. The patient's high Pro-BNP level of 10297.0 ng/L, which is significantly elevated, is also indicative of heart failure. 

The presence of non-sustained ventricular tachycardia (VT) on the ECG is a concerning finding, as it suggests an increased risk of sudden cardiac death. Additionally, the patient's polymorphic ventricular extrasystole and unknown paroxysmal supraventricular tachyarrhythmia code may also contribute to the risk of sudden cardiac death.

Furthermore, the patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, are commonly used to manage heart failure and arrhythmias, but may not have been sufficient to prevent sudden cardiac death in this case.

The patient's laboratory results, including the normal electrolyte levels, do not suggest electrolyte imbalances that could have contributed to the sudden cardiac death. The patient's low T3 and T4 levels and slightly elevated TSH level suggest a euthyroid state, which is not typically associated with sudden cardiac death.

Considering the combination of the patient's underlying heart condition, the presence of non-sustained VT, and the lack of other contributing factors, the most likely reason for the patient's sudden cardiac death is the progression of their idiopathic dilated cardiomyopathy and the associated arrhythmias."
177,177,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's history of idiopathic dilated cardiomyopathy, which is characterized by a reduced left ventricular ejection fraction (LVEF) of 40%, the patient is at high risk for adverse cardiac events. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further indicates that the patient is prone to potentially life-threatening arrhythmias.

The elevated pro-BNP (brain natriuretic peptide) level of 10297 ng/L is a strong indicator of heart failure and increased ventricular wall stress, which is consistent with the patient's dilated cardiomyopathy. The patient's NYHA Class II classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath, with minimal exertion.

The patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, is consistent with standard treatment for heart failure with reduced ejection fraction. However, despite this treatment, the patient's condition has progressed to sudden cardiac death, which is often due to arrhythmias or cardiac arrest.

Other factors that may have contributed to the patient's outcome include the patient's age (35 years) and the lack of significant improvement in LVEF despite medical treatment. Additionally, the patient's electrolyte levels, including potassium (4 mEq/L), which is within the normal range but may be a concern given the patient's arrhythmias, and the elevated creatinine level (88.0 umol/L), which may indicate underlying kidney dysfunction.

In summary, the combination of idiopathic dilated cardiomyopathy, NSVT, polymorphic ventricular extrasystoles, and elevated pro-BNP levels, along with the patient's age and lack of response to medical treatment, likely contributed to the patient's sudden cardiac death."
178,178,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's history of idiopathic dilated cardiomyopathy and a left ventricular ejection fraction (LVEF) of 40%, the patient is at high risk for sudden cardiac death (SCD). The presence of non-sustained ventricular tachycardia (NSVT) on the ECG further increases the risk of SCD. NSVT is a known predictor of cardiac arrest and SCD in patients with heart failure and reduced ejection fraction.

The patient's elevated Pro-BNP (brain natriuretic peptide) level of 10297.0 ng/L is also indicative of severe heart failure, which further increases the risk of SCD. Pro-BNP is a marker of cardiac stress and is used to diagnose and monitor heart failure.

The patient's use of medications such as beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors suggests that they are being managed for heart failure and arrhythmias, but the presence of NSVT and the patient's history of idiopathic dilated cardiomyopathy may indicate that these medications are not adequately controlling the patient's cardiac condition.

The patient's low T3 level of 0.05 pg/dL and high TSH level of 2.54 mIU/L may indicate hypothyroidism, which can contribute to heart failure and arrhythmias. However, this is not a direct cause of SCD.

The patient's potassium level of 4 mEq/L is slightly low, which can contribute to arrhythmias and increase the risk of SCD.

In conclusion, the combination of idiopathic dilated cardiomyopathy, non-sustained ventricular tachycardia, elevated Pro-BNP level, and the patient's use of medications for heart failure and arrhythmias, along with other laboratory values, make the patient's sudden cardiac death outcome likely due to a cardiac arrhythmia, possibly a ventricular arrhythmia, which was not adequately controlled by the patient's current treatment regimen."
179,179,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying condition and clinical presentation. 

1. Severe left ventricular dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 40%, indicating severe left ventricular dysfunction, which is a known risk factor for sudden cardiac death. This is likely a result of their idiopathic dilated cardiomyopathy.

2. High B-type Natriuretic Peptide (BNP) levels: The patient's Pro-BNP level of 10297 ng/L is significantly elevated, which suggests that the patient's heart is under strain, and there is a high likelihood of heart failure. Elevated BNP levels are associated with an increased risk of sudden cardiac death.

3. Presence of ventricular arrhythmias: The patient's ECG shows non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles. These arrhythmias are risk factors for sudden cardiac death, especially in patients with underlying heart disease.

4. Poor electrolyte balance: The patient's potassium level is slightly low at 4 mEq/L, which can contribute to arrhythmias and increase the risk of sudden cardiac death.

5. Inadequate treatment: Although the patient is on beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, the combination and dosage of medications may not be optimal for this patient's condition. The presence of NSVT and high BNP levels suggests that the current treatment may not be effectively managing the patient's heart failure and arrhythmias.

6. Suboptimal lipid profile: The patient's total cholesterol and LDL levels are elevated, which may contribute to cardiac remodeling and increase the risk of sudden cardiac death.

7. Potential thyroid dysfunction: Although the patient's TSH level is within the normal range, their T3 and T4 levels are low, which may indicate subclinical hypothyroidism. Thyroid dysfunction can contribute to cardiac remodeling and increase the risk of sudden cardiac death.

In summary, the patient's outcome of sudden cardiac death can be attributed to a combination of severe left ventricular dysfunction, high BNP levels, presence of ventricular arrhythmias, poor electrolyte balance, inadequate treatment, suboptimal lipid profile, and potential thyroid dysfunction."
180,180,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying cardiac condition and medication regimen.

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to reduced heart function and decreased left ventricular ejection fraction (LVEF). The LVEF in this patient is 22%, indicating severe heart failure.

2.  Reduced LVEF and Pro-BNP levels: The low LVEF of 22% and elevated Pro-BNP levels (3362.0 ng/L) suggest that the patient is at an increased risk for sudden cardiac death. Elevated Pro-BNP is a marker of heart failure and can indicate an increased risk of cardiac arrhythmias and sudden death.

3.  Presence of Non-sustained Ventricular Tachycardia (NSVT): The ECG findings of non-sustained ventricular tachycardia (CH>10) indicate abnormal heart rhythms that can increase the risk of sudden cardiac death.

4.  Medication regimen: The patient is on a combination of medications, including Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone. While these medications are commonly used to manage heart failure and arrhythmias, they may not have been sufficient to prevent sudden cardiac death in this case.

5.  TSH levels: The elevated TSH level of 18.16 mIU/L may indicate hypothyroidism, which can contribute to cardiac dysfunction and increase the risk of sudden cardiac death.

6.  Other factors: The patient's age (72), weight (82 kg), and height (175 cm) are within the average range, but his creatinine level of 146.0 mmol/L and urea level of 15.6 mg/dL indicate impaired renal function, which can further compromise cardiac function and increase the risk of sudden cardiac death.

Given the combination of these factors, it is likely that the patient's sudden cardiac death was a result of the progression of his underlying cardiac disease, exacerbated by his medication regimen and other comorbid conditions."
181,181,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors evident from the provided data. 

1. Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 22%, indicating severe left ventricular dysfunction. This is a significant risk factor for sudden cardiac death.

2. Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a decrease in heart function. This condition further increases the risk of sudden cardiac death.

3. High Pro-BNP Levels: The patient's pro-b-type natriuretic peptide (BNP) level is significantly elevated at 3362 ng/L. Elevated BNP levels are associated with heart failure and are a marker of increased risk of sudden cardiac death.

4. Presence of Non-Sustained Ventricular Tachycardia (VT): The ECG findings show non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can be a precursor to sudden cardiac death.

5. Polymorphic Ventricular Extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG also indicates abnormal heart rhythm, which can contribute to the risk of sudden cardiac death.

6. Suboptimal Medication Management: Although the patient is on several medications, including angiotensin II receptor blockers, beta blockers, digoxin, loop diuretics, and spironolactone, it is unclear if these medications are at optimal dosages or if they are sufficient to control the patient's symptoms and prevent sudden cardiac death.

7. Poor LVEF and Low Hemoglobin: The patient's low LVEF and low hemoglobin levels may indicate inadequate cardiac output and oxygen delivery to the tissues, further increasing the risk of sudden cardiac death.

In summary, the combination of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, high BNP levels, non-sustained VT, polymorphic ventricular extrasystoles, and potential suboptimal medication management likely contributed to the patient's outcome of sudden cardiac death."
182,182,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors from the provided data.

1.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 22%, indicating severe left ventricular dysfunction. This is a significant risk factor for sudden cardiac death, as it increases the likelihood of life-threatening arrhythmias.

2.  High BNP Levels: The patient's Pro-BNP level is 3362.0 ng/L, which is significantly elevated. Elevated BNP levels are associated with heart failure and increased risk of sudden cardiac death.

3.  History of Ischemic Dilated Cardiomyopathy and Myocardial Infarction: The patient's past medical history of ischemic dilated cardiomyopathy and myocardial infarction further increases the risk of sudden cardiac death due to scarring and fibrosis of the heart muscle, which can lead to life-threatening arrhythmias.

4.  Non-sustained Ventricular Tachycardia: The presence of non-sustained ventricular tachycardia (NSVT) on the ECG indicates a high risk of sudden cardiac death. NSVT is a marker of increased risk for sudden cardiac death, especially in patients with structural heart disease.

5.  Low HDL Cholesterol and High LDL Cholesterol: The patient's lipid profile shows low HDL (0.83 mmol/L) and high LDL (1.89 mmol/L) levels, which are risk factors for coronary artery disease and increased risk of sudden cardiac death.

6.  Hypokalemia: The patient's potassium level is slightly low at 4.54 mEq/L, which can contribute to the development of life-threatening arrhythmias.

7.  Thyroid Dysfunction: The patient's TSH level is elevated at 18.16 mIU/L, indicating hypothyroidism. Thyroid dysfunction can exacerbate heart failure and increase the risk of sudden cardiac death.

8.  Medication Non-Optimization: Although the patient is on medications for heart failure and arrhythmias, the presence of non-sustained ventricular tachycardia and low LVEF suggests that the medications may not be optimized, and further adjustments may be necessary to reduce the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely a result of a combination of severe left ventricular dysfunction, high BNP levels, history of ischemic dilated cardiomyopathy and myocardial infarction, non-sustained ventricular tachycardia, and other contributing factors."
183,183,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying cardiac condition and medication regimen.

1.  Ischemic Dilated Cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack, significantly increases his risk of sudden cardiac death. This condition is characterized by reduced left ventricular ejection fraction (LVEF), which in this case is 22%, indicating severe left ventricular dysfunction.

2.  Low LVEF: The patient's LVEF of 22% indicates a severely reduced ability of the left ventricle to pump blood, making it difficult for the heart to meet the body's oxygen and nutrient needs. This can lead to symptoms such as fatigue, shortness of breath, and potentially life-threatening arrhythmias.

3.  Non-sustained Ventricular Tachycardia (NSVT): The presence of NSVT, as indicated by the ECG, is a risk factor for sudden cardiac death. NSVT is a type of abnormal heart rhythm that can degenerate into a life-threatening arrhythmia.

4.  High Pro-BNP levels: The patient's Pro-BNP level of 3362 ng/L is significantly elevated, indicating severe heart failure. BNP (B-type natriuretic peptide) is a hormone produced by the heart in response to increased wall stress, which is often seen in heart failure. High levels of BNP are associated with increased risk of adverse outcomes, including sudden cardiac death.

5.  Medication Non-Optimization: Although the patient is on a standard regimen of medications for heart failure and hypertension, including an Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone, it is possible that the medications may not be optimized for this patient's specific condition. For instance, the use of digoxin in patients with low LVEF is controversial, as it may increase the risk of arrhythmias.

6.  Electrolyte Imbalance: The patient's potassium level of 4.54 mEq/L is slightly low, which can predispose him to arrhythmias. Although the sodium level is within the normal range, it's worth noting that electrolyte imbalances can contribute to arrhythmias, which may have led to sudden cardiac death.

7.  TSH and T4 levels: The patient's TSH level of 18.16 mEq/L is elevated, indicating hypothyroidism, which can contribute to cardiac dysfunction and increase the risk of arrhythmias.

Given these factors, the patient's outcome of sudden cardiac death can be attributed to a combination of his underlying cardiac condition, the presence of NSVT, high Pro-BNP levels, potential medication non-optimization, and electrolyte imbalances, which together created a high-risk scenario for life-threatening arrhythmias."
184,184,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of his underlying medical conditions and laboratory findings. 

1. Ischemic dilated cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy suggests that his heart muscle has been damaged due to reduced blood flow, leading to a decrease in cardiac function. This condition is a significant risk factor for sudden cardiac death.

2. Low LVEF (22.0%): The patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating poor heart function. An LVEF below 30% is considered a high-risk factor for sudden cardiac death.

3. Elevated Pro-BNP (3362.0 ng/L): The high level of B-type natriuretic peptide (BNP) indicates that the patient's heart is under significant stress, which is a marker for heart failure and increased risk of sudden cardiac death.

4. Presence of non-sustained ventricular tachycardia (NSVT): The ECG findings of non-sustained ventricular tachycardia suggest that the patient's heart is experiencing abnormal heart rhythms, which can increase the risk of sudden cardiac death.

5. Ventricular extrasystoles: The presence of polymorphic ventricular extrasystoles further increases the risk of arrhythmias and sudden cardiac death.

6. Medication regimen: While the patient is on a comprehensive medication regimen, including angiotensin II receptor blockers, beta blockers, digoxin, loop diuretics, and spironolactone, these medications may not have been sufficient to control his underlying conditions, given the patient's outcome.

7. Advanced age (72 years): The patient's age is a risk factor for sudden cardiac death, as the likelihood of cardiac arrhythmias and other cardiac events increases with age.

Considering these factors, the patient's outcome of sudden cardiac death can be attributed to a combination of his underlying ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, NSVT, ventricular extrasystoles, and advanced age."
185,185,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors, including his underlying heart condition and laboratory results. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or reduced blood flow, leading to a decrease in left ventricular ejection fraction (LVEF). His LVEF of 22% indicates severe left ventricular dysfunction, making him at high risk for sudden cardiac death.

The patient's elevated Pro-BNP level of 3362.0 ng/L is also indicative of heart failure, which is consistent with his dilated cardiomyopathy. Furthermore, his elevated Troponin level of 0.09 ng/mL suggests recent or ongoing myocardial damage, which can also contribute to the risk of sudden cardiac death.

Additionally, the patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia are indicative of arrhythmias, which can be a precursor to life-threatening arrhythmias, including ventricular fibrillation, a common cause of sudden cardiac death.

The patient's medication regimen includes Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone, which are all commonly used to manage heart failure and arrhythmias. However, despite these treatments, the patient's underlying condition and laboratory results suggest that he may have been at high risk for sudden cardiac death.

It is also worth noting that the patient's TSH level of 18.16 mIU/L is elevated, which may indicate hypothyroidism. Hypothyroidism can contribute to cardiac dysfunction and increase the risk of sudden cardiac death.

In summary, the combination of the patient's underlying heart condition, laboratory results, and ECG findings, along with his medication regimen, likely contributed to his outcome of sudden cardiac death."
186,186,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying cardiac conditions and laboratory results.

1. Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which indicates that his heart muscle has been damaged due to a heart attack. This condition can lead to a decrease in the heart's pumping efficiency, resulting in reduced cardiac output and potentially life-threatening arrhythmias.

2. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is severely reduced at 22%, indicating that his heart is not pumping effectively. This can lead to reduced cardiac output, decreased blood flow to vital organs, and increased risk of arrhythmias.

3. High Pro-BNP levels: The patient's Pro-BNP level is significantly elevated at 3362.0 ng/L, which is a marker of heart failure and increased risk of adverse cardiac events, including sudden cardiac death.

4. Presence of ventricular arrhythmias: The patient has a history of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can increase the risk of sudden cardiac death.

5. Electrolyte imbalance: The patient's potassium level is slightly low at 4.54 mEq/L, which can increase the risk of arrhythmias and cardiac arrest.

6. Medication non-adherence or inadequate management: The patient is on a regimen of medications that are commonly used to manage heart failure and arrhythmias, but the effectiveness of these medications may be limited by the patient's underlying condition and potential non-adherence.

7. Other contributing factors: The patient's age, hypertension, and history of myocardial infarction also contribute to his increased risk of sudden cardiac death.

Considering these factors, the patient's sudden cardiac death is likely the result of a combination of his underlying cardiac conditions, laboratory results, and potential medication non-adherence or inadequate management."
187,187,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of several factors that indicate a high risk of cardiac complications.

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack or coronary artery disease. This condition is a significant risk factor for sudden cardiac death.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 22%, which is significantly below the normal range of 50-70%. A low LVEF indicates that the heart is not pumping efficiently, increasing the risk of cardiac complications, including sudden cardiac death.

3.  High Pro-BNP levels: The patient's Pro-BNP level is 3362.0 ng/L, which is significantly elevated. Elevated Pro-BNP levels are associated with heart failure and increased risk of sudden cardiac death.

4.  Ventricular Extrasystole and Non-sustained Ventricular Tachycardia (VT): The presence of polymorphic ventricular extrasystoles and non-sustained VT on the ECG indicates abnormal heart rhythms, which can increase the risk of sudden cardiac death.

5.  Medication regimen: While the patient is on a medication regimen that includes an angiotensin II receptor blocker, beta blockers, digoxin, loop diuretics, and spironolactone, these medications are primarily aimed at managing heart failure and arrhythmias, but they may not have been sufficient to prevent sudden cardiac death in this patient.

6.  Electrolyte imbalance: The patient's potassium level is 4.54 mEq/L, which is slightly low. While not critically low, this may contribute to arrhythmias and increase the risk of cardiac complications.

7.  Hemoglobin level: The patient's hemoglobin level is 150 g/L, which is slightly low. Anemia can contribute to reduced oxygen delivery to the heart muscle, increasing the risk of cardiac complications.

8.  Elevated TSH: The patient's TSH level is 18.16 mIU/L, indicating hyperthyroidism, which can contribute to cardiac complications, including arrhythmias and sudden cardiac death.

In summary, the patient's history of ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, abnormal heart rhythms, and the presence of other risk factors likely contributed to the patient's outcome of sudden cardiac death."
188,188,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in the patient's medical history and current clinical status. 

1. Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. IDC is characterized by a decreased left ventricular ejection fraction (LVEF) and is a common cause of heart failure. The patient's LVEF is 22%, indicating severe left ventricular dysfunction.

2. Reduced LVEF and High Pro-BNP Levels: The patient's low LVEF of 22% and elevated Pro-BNP levels of 3362.0 ng/L indicate a high level of cardiac stress and strain, which increases the risk of sudden cardiac death.

3. History of Myocardial Infarction: The patient has a history of myocardial infarction, which further increases the risk of sudden cardiac death due to the potential for scarring and electrical instability in the heart.

4. Electrocardiographic Abnormalities: The patient's ECG shows polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia. These findings indicate electrical instability in the heart, which can lead to life-threatening arrhythmias and sudden cardiac death.

5. Medication Non-Optimization: Although the patient is on medications such as beta-blockers, angiotensin II receptor blockers, digoxin, loop diuretics, and spironolactone, the combination and dosages may not be optimal for this patient's specific condition. For example, beta-blockers are essential in reducing the risk of sudden cardiac death, but the patient's beta-blocker therapy may not be adequately titrated.

6. Hypertension: The patient has a history of hypertension, which can contribute to cardiac remodeling and further increase the risk of sudden cardiac death.

7. Elevated Creatinine Levels: The patient's elevated creatinine levels (146.0 mmol/L) indicate impaired renal function, which can further compromise cardiac function and increase the risk of sudden cardiac death.

8. Hyperthyroidism: The patient's elevated TSH levels (18.16 mIU/L) suggest hyperthyroidism, which can contribute to cardiac dysfunction and increase the risk of sudden cardiac death.

Given the combination of these factors, the patient's risk of sudden cardiac death was likely high, and it is not surprising that this outcome occurred."
189,189,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors related to his underlying cardiac condition and laboratory results. 

1. Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which significantly reduces his left ventricular ejection fraction (LVEF) to 22%. This indicates a poor pumping function of the heart, making it unable to meet the body's demands for oxygen and nutrients, leading to potential sudden cardiac death.

2. Low LVEF: The patient's LVEF of 22% is critically low, indicating severe left ventricular dysfunction. This level of dysfunction increases the risk of sudden cardiac death due to arrhythmias or pump failure.

3. Non-sustained ventricular tachycardia (NSVT): The presence of NSVT on the ECG suggests that the patient has an increased risk of arrhythmias, which can be a precursor to sudden cardiac death.

4. High Pro-BNP levels: The patient's Pro-BNP level of 3362.0 ng/L is significantly elevated, indicating severe heart failure and increased risk of sudden cardiac death.

5. Medication non-adherence or inadequate management: Although the patient is on medications such as Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone, the effectiveness of these medications may have been compromised due to non-adherence or inadequate dosing, which could have contributed to the patient's outcome.

6. Electrolyte imbalance: The patient's potassium level of 4.54 mEq/L is slightly low, which can increase the risk of arrhythmias and contribute to sudden cardiac death.

7. TSH level: The patient's TSH level of 18.16 mIU/L is elevated, suggesting hypothyroidism. Hypothyroidism can contribute to cardiac dysfunction and increase the risk of sudden cardiac death.

In conclusion, the patient's combination of ischemic dilated cardiomyopathy, low LVEF, NSVT, high Pro-BNP levels, medication non-adherence or inadequate management, electrolyte imbalance, and hypothyroidism likely contributed to his outcome of sudden cardiac death."
190,190,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors, primarily related to her underlying heart condition and laboratory results. 

1. Ischemic Dilated Cardiomyopathy (IDC): The patient's history of IDC indicates that her heart muscle has been weakened due to previous heart attacks, leading to a reduced left ventricular ejection fraction (LVEF) of 35%. This significantly increases the risk of sudden cardiac death.

2. Low Left Ventricular Ejection Fraction (LVEF): An LVEF of 35% is considered severely reduced, indicating that the heart is not pumping efficiently, which can lead to a buildup of fluid in the lungs and other parts of the body, further compromising cardiac function.

3. Elevated Pro-BNP (Brain Natriuretic Peptide): A Pro-BNP level of 910.0 ng/L is significantly elevated, suggesting that the heart is under strain and releasing natriuretic peptides as a compensatory mechanism. High Pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

4. Diabetes and Hypertension: The patient's history of diabetes and hypertension contributes to the progression of heart failure and increased the risk of cardiac arrhythmias and sudden cardiac death.

5. Ventricular Extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythm, which can be a sign of underlying cardiac disease. While not necessarily a direct cause of sudden cardiac death, it is a concerning sign that may indicate a higher risk of arrhythmias.

6. Elevated Creatinine and Urea: The patient's elevated creatinine and urea levels indicate impaired renal function, which can be a sign of advanced heart failure or other underlying conditions that may contribute to sudden cardiac death.

7. Medication Non-Adherence or Inadequate Dosing: The patient is taking several medications, including angiotensin II receptor blockers, beta blockers, loop diuretics, and statins. However, the effectiveness of these medications may be compromised due to non-adherence or inadequate dosing, which can lead to inadequate control of symptoms and increased risk of cardiac events.

In summary, the patient's history of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, diabetes, hypertension, and the presence of ventricular extrasystoles, along with impaired renal function, likely contributed to her outcome of sudden cardiac death."
191,191,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death is likely due to a combination of factors contributing to her high risk of cardiac complications. 

Firstly, her age of 77 and NYHA Class III classification indicate a high level of cardiovascular disease severity. Her history of ischemic dilated cardiomyopathy, myocardial infarction, hypertension, and peripheral vascular disease further increase her risk of cardiac events. 

Her laboratory results also indicate significant cardiac stress, including elevated Pro-BNP levels (910.0 ng/L), which is a marker of heart failure and cardiac strain, and an LVEF of 35.0%, indicating severely reduced left ventricular function. 

Additionally, her elevated glucose levels (15.5 mmol/L) and dyslipidemia (Total Cholesterol 4.68 mmol/L and LDL 2.33 mmol/L) contribute to her increased risk of cardiovascular disease. 

Furthermore, her medication regimen, including beta blockers, angiotensin II receptor blockers, loop diuretics, and statins, suggests that she is being managed for heart failure and hypertension, but the high Pro-BNP levels and LVEF indicate that her condition is not well-controlled.

The presence of ventricular extrasystole on the ECG also indicates an increased risk of arrhythmias, which can contribute to sudden cardiac death. 

In conclusion, the patient's combination of advanced age, severe cardiac disease, high-risk laboratory results, and uncontrolled cardiac strain likely contributed to her sudden cardiac death."
192,192,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided information. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or reduced blood flow. This condition is associated with a higher risk of sudden cardiac death.

Secondly, the patient has a low left ventricular ejection fraction (LVEF) of 35%, indicating that the heart is not pumping efficiently, which can lead to a buildup of fluid in the lungs and other organs, further increasing the risk of sudden cardiac death.

Thirdly, the patient's elevated troponin level (0.01 ng/mL) suggests that there may have been a recent myocardial infarction or ongoing cardiac damage, which can also contribute to sudden cardiac death.

Additionally, the patient's high levels of creatinine (118.0 mmol/L) and urea (9.35 mg/dL) indicate impaired kidney function, which can further strain the heart and increase the risk of sudden cardiac death.

Furthermore, the patient's high levels of Pro-BNP (910.0 ng/L) and elevated liver enzymes (ALT 108.0 IU/L and AST 55.0 IU/L) suggest that the patient may have heart failure and liver dysfunction, respectively, which can also contribute to sudden cardiac death.

The patient's medication regimen, which includes beta blockers and loop diuretics, is typical for heart failure management, but may not be sufficient to control the patient's underlying conditions, leading to a higher risk of sudden cardiac death.

Lastly, the patient's age (77) and NYHA Class III classification, indicating severe heart failure symptoms, also increase the risk of sudden cardiac death.

In conclusion, the combination of the patient's underlying conditions, laboratory results, and medication regimen, along with their age and NYHA classification, make sudden cardiac death a plausible outcome."
193,193,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of her underlying cardiovascular conditions and laboratory results. 

1. Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which significantly increases her risk of sudden cardiac death. IDC is characterized by a weakened heart muscle, making it less efficient at pumping blood, and increasing the risk of arrhythmias and sudden cardiac death.

2. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly below the normal range of 50-70%. A low LVEF indicates that the heart is not pumping efficiently, making it more susceptible to sudden cardiac death.

3. High Pro-BNP Levels: The patient's Pro-BNP level is 910.0 ng/L, which is elevated. Pro-BNP is a biomarker of heart failure and stress on the heart. Elevated levels are associated with increased risk of sudden cardiac death.

4. Diabetes and Dyslipidemia: The patient has a history of diabetes and dyslipidemia, which can contribute to the progression of IDC and increase the risk of sudden cardiac death.

5. Medications: While the patient is on medications that are beneficial for heart failure and IDC (Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins), the presence of diabetes and dyslipidemia may not be adequately controlled, which can still pose a risk.

6. ECG Findings: Although the ECG shows a monomorphic ventricular extrasystole, it is not a significant arrhythmia that would directly lead to sudden cardiac death. However, it may indicate underlying cardiac electrical instability.

7. Other Factors: The patient's age (77 years), NYHA Class III, and laboratory results (elevated creatinine and glucose levels) also contribute to her overall risk profile for sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death can be attributed to a combination of her underlying IDC, low LVEF, high Pro-BNP levels, uncontrolled diabetes and dyslipidemia, and potential cardiac electrical instability."
194,194,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to her underlying medical conditions and laboratory results. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in the heart's pumping efficiency. The left ventricular ejection fraction (LVEF) of 35% indicates a severe reduction in the heart's pumping ability, which increases the risk of sudden cardiac death.

The patient's diabetes and dyslipidemia (elevated total cholesterol and LDL levels) contribute to the development of atherosclerosis, which can lead to coronary artery disease and further compromise cardiac function. The elevated creatinine level (118.0 mmol/L) suggests kidney dysfunction, which is a common comorbidity in patients with heart failure and can exacerbate the condition.

The patient's blood pressure is within a relatively normal range (140/80 mmHg), but the presence of hypertension and peripheral vascular disease indicates that the patient has experienced significant vascular damage. The elevated Pro-BNP level (910.0 ng/L) is indicative of heart failure with reduced ejection fraction, which is consistent with the patient's ischemic dilated cardiomyopathy.

The patient's laboratory results also show elevated liver enzymes (AST and ALT), which may indicate liver dysfunction or fatty liver disease, which can be a consequence of diabetes and dyslipidemia. The low HDL level (1.5 mmol/L) and high LDL level (2.33 mmol/L) further contribute to the patient's cardiovascular risk.

The patient's medications, including beta-blockers, angiotensin II receptor blockers, and statins, are appropriate for managing heart failure and dyslipidemia, but may not be sufficient to prevent sudden cardiac death in a patient with such a high risk profile.

The presence of ventricular extrasystoles on the ECG indicates abnormal heart rhythm, which can be a precursor to life-threatening arrhythmias. While the patient does not have sustained ventricular tachycardia, the presence of ventricular extrasystoles and the patient's overall medical history increase the risk of sudden cardiac death.

In summary, the patient's outcome of sudden cardiac death can be attributed to a combination of her underlying medical conditions, including ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and peripheral vascular disease, as well as laboratory results indicating kidney dysfunction, liver enzyme elevation, and abnormal heart rhythm."
195,195,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to several contributing factors. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient's history of IDC, indicated by an ejection fraction (LVEF) of 35%, suggests that the heart muscle is weakened due to previous myocardial infarctions. This condition increases the risk of sudden cardiac death.

2.  Diabetes: The patient's glucose level of 15.5 mmol/L indicates poorly controlled diabetes. Diabetes is a significant risk factor for cardiovascular disease and can contribute to the progression of IDC.

3.  Electrocardiogram (ECG) findings: Although the ECG impression does not indicate sustained ventricular tachycardia, the presence of monomorphic ventricular extrasystoles may be a sign of underlying electrical instability, which can increase the risk of sudden cardiac death.

4.  High Troponin levels: The patient's troponin level of 0.01 ng/mL is within the normal range, but it is still elevated, indicating some degree of cardiac muscle damage, which can contribute to the risk of sudden cardiac death.

5.  Elevated Pro-BNP levels: The patient's Pro-BNP level of 910.0 ng/L is significantly elevated, indicating increased stress on the heart, which can be a sign of heart failure or other cardiac conditions. High Pro-BNP levels are associated with an increased risk of sudden cardiac death.

6.  Poorly controlled lipid profile: The patient's total cholesterol level of 4.68 mmol/L and LDL level of 2.33 mmol/L are elevated, indicating a high risk of atherosclerotic cardiovascular disease, which can contribute to the progression of IDC and increase the risk of sudden cardiac death.

7.  Kidney dysfunction: The patient's creatinine level of 118.0 mol/L indicates kidney dysfunction, which can be a comorbidity in patients with IDC and may contribute to the risk of sudden cardiac death.

In summary, the combination of ischemic dilated cardiomyopathy, poorly controlled diabetes, elevated Pro-BNP levels, high troponin levels, poorly controlled lipid profile, and kidney dysfunction likely contributed to the patient's outcome of sudden cardiac death."
196,196,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of several factors that indicate a high risk of cardiac complications. 

1. Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced cardiac function. This condition increases the risk of cardiac arrhythmias, heart failure, and sudden cardiac death.

2. Low Left Ventricular Ejection Fraction (LVEF) of 35%: The patient's LVEF is significantly reduced, indicating poor cardiac function. An LVEF of 35% is considered severely impaired and increases the risk of cardiac complications, including sudden cardiac death.

3. High Pro-BNP levels (910.0 ng/L): Elevated Pro-BNP levels are a marker of heart failure and cardiac stress. High levels are associated with increased risk of mortality and cardiac events.

4. Diabetes and Dyslipemia: The patient has diabetes and dyslipemia, which are both risk factors for cardiovascular disease and increase the risk of cardiac complications.

5. Medications: The patient is on a combination of medications, including beta blockers, loop diuretics, and statins, which are commonly used to manage heart failure, hypertension, and dyslipemia. However, the patient's outcome suggests that these medications may not have been sufficient to prevent cardiac complications.

6. Electrocardiogram (ECG) findings: The ECG shows ventricular extrasystoles, which are abnormal heartbeats that can increase the risk of cardiac arrhythmias and sudden cardiac death.

7. Laboratory results: The patient's elevated creatinine levels (118.0 mmol/L) and low albumin levels (38 g/L) suggest renal impairment, which can further increase the risk of cardiac complications.

8. Hypertension: The patient's blood pressure is within a relatively normal range (140/80 mmHg), but hypertension can still contribute to cardiac complications, especially in the context of other risk factors.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of the above factors, including ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, diabetes, dyslipemia, renal impairment, and ECG abnormalities."
197,197,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in the patient's medical history and laboratory results.

1. Ischemic dilated cardiomyopathy: This condition indicates that the patient's heart muscle has been damaged due to a heart attack, leading to a decrease in the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) of 35% is significantly below the normal range (50-70%), indicating severe left ventricular dysfunction.

2. Diabetes: The patient's elevated glucose level (15.5 mmol/L) and use of diabetes medication suggest that the patient has uncontrolled diabetes, which is a significant risk factor for cardiovascular disease, including heart failure and sudden cardiac death.

3. Hypertension: The patient's blood pressure of 140/80 mmHg indicates that the patient has hypertension, which is a major risk factor for cardiovascular disease and heart failure.

4. Elevated troponin levels: The patient's troponin level of 0.01 ng/mL is slightly elevated, indicating minor myocardial damage, which may be a result of previous myocardial infarction or ongoing cardiac stress.

5. Pro-BNP level: The patient's pro-BNP level of 910.0 ng/L is significantly elevated, indicating that the patient has severe heart failure, which is a strong predictor of sudden cardiac death.

6. Ventricular extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythm, which can be a precursor to more serious arrhythmias, including ventricular tachycardia, which can lead to sudden cardiac death.

7. Low HDL cholesterol and high LDL cholesterol: The patient's HDL cholesterol level of 1.5 mmol/L is low, and LDL cholesterol level of 2.33 mmol/L is high, indicating an increased risk of atherosclerotic cardiovascular disease.

8. Kidney dysfunction: The patient's creatinine level of 118.0 mmol/L indicates kidney dysfunction, which can exacerbate heart failure and increase the risk of sudden cardiac death.

9. Thyroid function: The patient's TSH level of 4.43 mIU/L is slightly elevated, indicating subclinical hypothyroidism, which can contribute to heart failure and increase the risk of sudden cardiac death.

Given these factors, the patient's outcome of sudden cardiac death is likely due to a combination of severe heart failure, uncontrolled diabetes, hypertension, and abnormal heart rhythm, which ultimately led to cardiac arrest."
198,198,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to several factors that have contributed to their high risk of cardiac complications. 

1. Ischemic dilated cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy is a significant risk factor for sudden cardiac death. This condition is characterized by a weakened heart muscle that cannot pump blood efficiently, making it prone to arrhythmias and cardiac arrest.

2. Low left ventricular ejection fraction (LVEF) of 35%: The patient's LVEF is significantly low, indicating that the heart is not pumping blood effectively. This is a known predictor of increased risk of sudden cardiac death.

3. Elevated Pro-BNP levels (910 ng/L): The patient's elevated Pro-BNP levels indicate increased stress on the heart, which can be a sign of heart failure and increased risk of sudden cardiac death.

4. History of myocardial infarction: The patient's history of myocardial infarction suggests that they have experienced a previous heart attack, which can lead to scarring and further weakening of the heart muscle, increasing the risk of sudden cardiac death.

5. Medication non-adherence or inadequate management: Although the patient is taking medications such as beta blockers, angiotensin II receptor blockers, and statins, it is unclear if they are adhering to the treatment plan or if the medications are effective in managing their condition. Inadequate management of these conditions can lead to increased risk of cardiac complications.

6. Electrocardiogram (ECG) findings: The presence of ventricular extrasystoles and unknown paroxysmal supraventricular tachyarrhythmia code on the ECG suggest abnormal heart rhythms, which can increase the risk of sudden cardiac death.

7. Other comorbidities: The patient's comorbidities, including diabetes, dyslipemia, peripheral vascular disease, and hypertension, can also contribute to their increased risk of cardiac complications.

In summary, the combination of the patient's ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP levels, history of myocardial infarction, medication non-adherence or inadequate management, ECG findings, and other comorbidities have likely contributed to their outcome of sudden cardiac death."
199,199,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's advanced age of 77, the presence of multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, the patient is at high risk for cardiac complications. The patient's left ventricular ejection fraction (LVEF) of 35% indicates severe systolic heart failure, which is a significant risk factor for sudden cardiac death.

The elevated levels of troponin (0.01 ng/mL) and pro-BNP (910.0 ng/L) suggest ongoing cardiac damage and increased stress on the heart, further increasing the risk of sudden cardiac death. The presence of ventricular extrasystole on the ECG also indicates abnormal heart rhythm, which can increase the risk of arrhythmias and sudden cardiac death.

The patient's high total cholesterol level (4.68 mmol/L) and low HDL level (1.5 mmol/L) indicate poor lipid management, which contributes to the progression of atherosclerosis and increases the risk of cardiac events. The patient's elevated glucose level (15.5 mmol/L) also suggests poor glycemic control, which can exacerbate cardiac damage and increase the risk of sudden cardiac death.

The patient's medication regimen, which includes diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, and statins, is consistent with the management of heart failure and other comorbidities. However, the presence of ventricular extrasystole and the patient's high risk profile suggest that the patient may require more aggressive management of their heart failure and arrhythmias.

In conclusion, the combination of the patient's advanced age, severe systolic heart failure, abnormal heart rhythm, poor lipid and glycemic control, and ongoing cardiac damage make sudden cardiac death a plausible outcome."
200,200,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death due to the potential for life-threatening arrhythmias. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 18%, indicating poor cardiac function, which is a well-known predictor of adverse outcomes.

The patient's high levels of B-type natriuretic peptide (BNP) (15509 ng/L) and elevated troponin (0.01 ng/mL) suggest that the patient has significant cardiac strain and potential ongoing myocardial injury, which may have contributed to the patient's fatal outcome.

Furthermore, the patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia (VT) are indicative of abnormal cardiac electrical activity, which can increase the risk of life-threatening arrhythmias. The presence of these arrhythmias, combined with the patient's reduced LVEF and history of myocardial infarction, further supports the likelihood of sudden cardiac death.

Additionally, the patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, which are commonly used to manage heart failure and reduce the risk of sudden cardiac death. However, despite these treatments, the patient's condition may have progressed to the point where the risk of sudden cardiac death outweighed the benefits of these medications.

Lastly, the patient's age (72 years) and NYHA class III classification also contribute to the increased risk of sudden cardiac death. Older patients with severe heart failure are at higher risk of sudden cardiac death due to decreased cardiac reserve and increased comorbidities.

In summary, the combination of the patient's history of ischemic dilated cardiomyopathy, reduced LVEF, abnormal ECG findings, high BNP levels, and ongoing cardiac strain, along with the patient's age and NYHA class, likely contributed to the outcome of sudden cardiac death."
201,201,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided data. 

1. Severe Left Ventricular Dysfunction (LVEF 18%): The patient has a significantly reduced left ventricular ejection fraction (LVEF) of 18%, indicating severe left ventricular dysfunction. This is a major risk factor for sudden cardiac death.

2. Ischemic Dilated Cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy, a condition where the heart muscle is weakened due to a previous heart attack, further increases the risk of sudden cardiac death.

3. High Pro-BNP Levels: The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 15509.0 ng/L indicates severe heart failure, which is a significant predictor of sudden cardiac death.

4. Non-sustained Ventricular Tachycardia (VT): The presence of non-sustained VT on the ECG indicates abnormal heart rhythms that can increase the risk of sudden cardiac death.

5. Ventricular Extrasystole and Polymorphic Ventricular Extrasystole: These arrhythmias can also contribute to the increased risk of sudden cardiac death.

6. Reduced Creatinine Clearance: The patient's elevated creatinine level of 225.0 mol/L suggests impaired renal function, which can further increase the risk of sudden cardiac death.

7. Hypokalemia: The patient's low potassium level of 4.7 mEq/L may contribute to arrhythmias and increase the risk of sudden cardiac death.

8. Tachyarrhythmias and Bradycardia: Although the specific codes for paroxysmal supraventricular tachyarrhythmia and bradycardia are unknown, the presence of any tachyarrhythmia or bradycardia can increase the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, high Pro-BNP levels, and the presence of various arrhythmias and other risk factors."
202,202,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge due to a heart attack. This condition significantly reduces the heart's ability to pump blood effectively, leading to decreased cardiac output and increased risk of arrhythmias. The patient's left ventricular ejection fraction (LVEF) of 18% is severely reduced, indicating poor heart function.

Secondly, the patient has a history of myocardial infarction, which further compromised the heart muscle, leading to a reduced ability to pump blood effectively. The elevated troponin level of 0.01 ng/mL indicates that the heart muscle is still experiencing damage.

Thirdly, the patient's NT-proBNP level of 15509 ng/L is significantly elevated, indicating severe heart failure. Elevated NT-proBNP levels are associated with increased risk of mortality and sudden cardiac death in patients with heart failure.

Fourthly, the patient's ECG shows polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia. These arrhythmias can lead to sudden cardiac death if not properly managed.

Lastly, the patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, which are all standard treatments for heart failure. However, the patient's severe heart failure and reduced LVEF suggest that these medications may not have been effective in improving cardiac function.

In conclusion, the combination of ischemic dilated cardiomyopathy, history of myocardial infarction, severe heart failure, elevated NT-proBNP levels, and arrhythmias on ECG, along with inadequate response to medications, likely contributed to the patient's sudden cardiac death."
203,203,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors based on the provided data. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or reduced blood flow. This condition can lead to reduced cardiac function, decreased ejection fraction, and increased risk of sudden cardiac death.

2.  Low LVEF (18.0%): The patient's left ventricular ejection fraction (LVEF) is significantly low at 18.0%, indicating that the heart is not pumping efficiently, which can lead to reduced cardiac output and increased risk of sudden cardiac death.

3.  High Pro-BNP (15509.0 ng/L): Elevated levels of B-type natriuretic peptide (BNP) are often associated with heart failure and increased risk of sudden cardiac death.

4.  Ventricular Extrasystole and Non-sustained Ventricular Tachycardia (VT): The presence of polymorphic ventricular extrasystoles and non-sustained VT on the ECG indicates abnormal heart rhythm, which can increase the risk of sudden cardiac death.

5.  Medication Non-Adherence or Inadequate Dosing: Although the patient is on medications such as beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, the effectiveness of these medications may be compromised due to non-adherence or inadequate dosing, which can lead to inadequate control of cardiac function and increased risk of sudden cardiac death.

6.  Electrolyte Imbalance (Potassium 4.7 mEq/L): The patient's low potassium level may indicate an electrolyte imbalance, which can contribute to cardiac arrhythmias and increased risk of sudden cardiac death.

7.  Advanced Age (72 years): The patient's age is a significant risk factor for sudden cardiac death, as the likelihood of cardiac disease and mortality increases with age.

In conclusion, the combination of ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP, abnormal heart rhythm, potential medication non-adherence, electrolyte imbalance, and advanced age likely contributed to the patient's outcome of sudden cardiac death."
204,204,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death is likely due to a combination of factors related to their underlying ischemic dilated cardiomyopathy, which is a known risk factor for sudden cardiac death. 

The patient's low left ventricular ejection fraction (LVEF) of 18% indicates severe systolic dysfunction, which is a significant predictor of sudden cardiac death. Additionally, the presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death.

The patient's high pro-BNP level (15509 ng/L) is also indicative of heart failure, which is a known risk factor for sudden cardiac death. Furthermore, the patient's low hemoglobin level (151 g/L) and high creatinine level (225.0 umol/L) suggest the presence of anemia and renal dysfunction, respectively, which can also contribute to the development of sudden cardiac death.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitor, are appropriate for managing heart failure and ischemic cardiomyopathy but may not be sufficient to prevent sudden cardiac death in this high-risk patient.

The patient's age (72 years) and NYHA Class III classification also contribute to their high risk of sudden cardiac death. The presence of dyslipidemia and a high total cholesterol level (6.72 mmol/L) may also be contributing factors.

In summary, the combination of severe systolic dysfunction, NSVT, high pro-BNP level, anemia, renal dysfunction, and other comorbidities make the patient a high-risk candidate for sudden cardiac death."
205,205,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to several factors:

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is severely impaired at 18%, indicating significant left ventricular dysfunction. This is a known predictor of increased mortality and sudden cardiac death in patients with ischemic dilated cardiomyopathy.

2.  High BNP Levels: The patient's Pro-BNP level is elevated at 15,509 ng/L, which is indicative of heart failure and increased risk of sudden cardiac death.

3.  History of Myocardial Infarction: The patient has a history of myocardial infarction, which increases the risk of sudden cardiac death due to potential underlying coronary artery disease.

4.  Dyslipidemia: The patient's total cholesterol level is elevated at 6.72 mmol/L, and LDL is 4.78 mmol/L. Dyslipidemia is a known risk factor for coronary artery disease and sudden cardiac death.

5.  Hypotension: The patient's blood pressure is low at 95/70 mmHg, which may indicate decreased cardiac output and reduced perfusion of vital organs, increasing the risk of sudden cardiac death.

6.  Presence of Non-sustained Ventricular Tachycardia: The patient's ECG shows non-sustained ventricular tachycardia, which is a known predictor of sudden cardiac death in patients with heart failure and reduced LVEF.

7.  Reduced Potassium Levels: The patient's potassium level is low at 4.7 mEq/L, which may contribute to arrhythmias and increased risk of sudden cardiac death.

8.  Medication Non-adherence or Inadequate Dosing: Although the patient is on beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, there is no information on whether the patient is adhering to the medication regimen or if the dosages are adequate to manage the patient's condition effectively.

9.  Poor Nutritional Status: The patient's albumin level is low at 38.1 g/L, indicating poor nutritional status, which may contribute to muscle wasting and increased risk of sudden cardiac death.

10. Elevated Creatinine Levels: The patient's creatinine level is elevated at 225.0 umol/L, indicating renal impairment, which may contribute to electrolyte imbalances and increased risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of these factors, including reduced LVEF, high BNP levels, history of myocardial infarction, dyslipidemia, hypotension, non-sustained ventricular tachycardia, low potassium levels, potential medication non-adherence or inadequate dosing, poor nutritional status, and renal impairment."
206,206,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors, primarily related to his underlying heart condition and comorbidities. 

The patient has ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a previous heart attack, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) of 18% is significantly below the normal range (50-70%), indicating severe heart failure. This compromised heart function increases the risk of arrhythmias and sudden cardiac death.

The presence of non-sustained ventricular tachycardia (VT) on the ECG further supports this concern. Non-sustained VT is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death, especially in patients with a history of heart disease.

Additionally, the patient's elevated Pro-BNP level (15509.0 ng/L) is a biomarker of heart failure and indicates that the patient's heart is under significant stress, which can lead to arrhythmias and cardiac arrest.

The patient's low HDL cholesterol (0.96 mmol/L) and high LDL cholesterol (4.78 mmol/L) levels suggest dyslipidemia, which is a known risk factor for cardiovascular disease and sudden cardiac death.

Furthermore, the patient's electrolyte imbalance, particularly low potassium levels (4.7 mEq/L), can also contribute to cardiac arrhythmias and sudden death.

The patient's TSH level of 2.56 mIU/L is within the normal range, but the low T3 level (0.05 pg/dL) may indicate hypothyroidism, which can also contribute to cardiovascular disease and sudden cardiac death.

The combination of these factors, including the patient's severe heart failure, arrhythmias, electrolyte imbalance, and underlying comorbidities, increases the risk of sudden cardiac death. The patient's age and NYHA Class III classification also contribute to his increased risk."
207,207,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying heart condition, ischemic dilated cardiomyopathy, and other comorbidities. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient's LVEF (Left Ventricular Ejection Fraction) of 18% is significantly reduced, indicating severe left ventricular dysfunction. IDC is a condition where the heart muscle becomes weakened due to coronary artery disease, leading to impaired heart function and reduced ability to pump blood efficiently. This condition increases the risk of sudden cardiac death.

2.  Reduced LVEF and Pro-BNP levels: The patient's LVEF of 18% and a high Pro-BNP (B-type Natriuretic Peptide) level of 15509 ng/L indicate severe heart failure and increased ventricular wall stress. Elevated Pro-BNP levels are associated with increased risk of adverse outcomes, including sudden cardiac death.

3.  Non-sustained ventricular tachycardia (NSVT): The presence of NSVT is a known risk factor for sudden cardiac death, particularly in patients with heart failure and reduced LVEF. The patient's ECG findings of non-sustained ventricular tachycardia further increase his risk.

4.  Electrolyte imbalance and Potassium levels: The patient's potassium level of 4.7 mEq/L is slightly below the normal range. Hypokalemia (low potassium levels) can predispose to arrhythmias, including ventricular tachycardia, which can lead to sudden cardiac death.

5.  Medication regimen: While the patient is on various medications, including beta blockers, digoxin, and ACE inhibitors, which are generally beneficial for heart failure and arrhythmia management, the presence of non-sustained ventricular tachycardia and reduced LVEF suggests that these medications may not be fully effective in this case.

6.  Age and comorbidities: The patient's age (72) and presence of comorbidities such as dyslipemia, myocardial infarction, and reduced kidney function (elevated creatinine) further increase his risk of adverse cardiac events.

Considering these factors, the patient's outcome of sudden cardiac death is likely a result of the cumulative effect of his severe heart condition, reduced LVEF, NSVT, and other comorbidities, which ultimately led to a life-threatening arrhythmia."
208,208,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to their underlying heart condition and laboratory results. 

Firstly, the patient has ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a reduced ejection fraction (LVEF of 18%). This condition increases the risk of sudden cardiac death. The patient's LVEF of 18% indicates severe heart failure, which is a significant predictor of mortality.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 15509.0 ng/L is a strong indicator of heart failure, particularly acute decompensated heart failure. Elevated Pro-BNP levels are associated with increased mortality in patients with heart failure.

Additionally, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy suggests a high risk of arrhythmias, which can lead to sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG further supports this risk.

The patient's laboratory results also indicate chronic kidney disease (CKD) with an elevated creatinine level of 225.0 mol/L, which can contribute to cardiovascular mortality. The patient's low hemoglobin level (151.0 g/L) may indicate anemia, which can further increase the risk of cardiovascular events.

The patient's medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, is typical for heart failure management. However, despite the medications, the patient's condition remains severe, and the combination of these factors likely contributed to the sudden cardiac death.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases the risk of sudden cardiac death. The patient's TSH level is within the normal range, which suggests that hypothyroidism is unlikely to be a contributing factor to the sudden cardiac death.

In summary, the patient's outcome of sudden cardiac death is likely due to a combination of severe heart failure, chronic kidney disease, anemia, and a history of myocardial infarction and ischemic dilated cardiomyopathy, along with the presence of arrhythmias on the ECG."
209,209,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors from the provided data. 

1. Severe Left Ventricular Dysfunction: The patient has an ejection fraction (LVEF) of 18%, indicating severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death. This is likely due to his ischemic dilated cardiomyopathy.

2. High Pro-BNP Levels: The patient has a significantly elevated Pro-BNP level of 15509.0 ng/L, which is indicative of heart failure and increased ventricular wall stress. High Pro-BNP levels are associated with increased risk of adverse cardiovascular events, including sudden cardiac death.

3. History of Myocardial Infarction: The patient has a history of myocardial infarction, which can lead to scarring of the heart muscle, increasing the risk of arrhythmias and sudden cardiac death.

4. Non-Sustained Ventricular Tachycardia: The presence of non-sustained ventricular tachycardia on the ECG is a risk factor for sudden cardiac death.

5. Severe Electrolyte Imbalance: The patient has a low potassium level (4.7 mEq/L), which can contribute to arrhythmias and increase the risk of sudden cardiac death.

6. Medication Non-Optimization: Although the patient is on beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, there may be room for optimization of these medications to improve cardiac function and reduce the risk of sudden cardiac death.

7. Advanced Age: The patient's age of 72 is a risk factor for sudden cardiac death.

8. Poor Renal Function: The patient's creatinine level of 225.0 mol/L indicates poor renal function, which can contribute to the progression of heart failure and increase the risk of sudden cardiac death.

9. Low HDL and High LDL Cholesterol: The patient's lipid profile shows low HDL and high LDL levels, which are risk factors for cardiovascular disease and may contribute to the progression of his heart condition.

Given these factors, it is not surprising that the patient experienced sudden cardiac death."
210,210,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors, primarily related to his underlying ischemic dilated cardiomyopathy. The patient's left ventricular ejection fraction (LVEF) of 35% indicates severe systolic dysfunction, which increases the risk of sudden cardiac death.

The presence of polymorphic ventricular extrasystoles on the ECG suggests electrical instability, which can predispose the patient to life-threatening arrhythmias. The patient's elevated pro-BNP levels (170 ng/L) further indicate cardiac stress and potential heart failure, increasing the risk of sudden cardiac death.

Additionally, the patient's ischemic dilated cardiomyopathy, coupled with a history of hypertension and dyslipidemia, has likely contributed to the development of coronary artery disease, which may have led to a previous myocardial infarction. The patient's low HDL (1.09 mmol/L) and high LDL (2.4 mmol/L) levels indicate poor lipid profile, which exacerbates atherosclerosis and further increases the risk of cardiac events.

The patient's medications, including beta blockers, spironolactone, statins, and ACE inhibitors, are standard treatments for heart failure and may have been insufficient to prevent sudden cardiac death in this case. The absence of sustained ventricular tachycardia or other specific arrhythmias on the ECG does not rule out the possibility of a sudden arrhythmic event, as polymorphic ventricular extrasystoles can degenerate into more severe arrhythmias.

Overall, the combination of severe left ventricular dysfunction, electrical instability, cardiac stress, and underlying coronary artery disease increases the risk of sudden cardiac death in this patient."
211,211,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of his underlying medical conditions and laboratory results. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or long-standing coronary artery disease. This condition can lead to a reduced left ventricular ejection fraction (LVEF), which in this case is 35.0%, indicating a significant impairment of the heart's pumping function.

The patient's LVEF of 35.0% is below the normal range (50-70%), indicating that the heart is not pumping efficiently, leading to reduced cardiac output and potentially life-threatening arrhythmias. The presence of ventricular extrasystoles, which are abnormal heartbeats originating from the ventricles, further increases the risk of sudden cardiac death.

The patient's laboratory results also indicate elevated levels of B-type natriuretic peptide (BNP), which is a marker of heart failure and increased ventricular wall stress. A BNP level of 170.0 ng/L is significantly elevated, indicating that the patient's heart is under strain.

Additionally, the patient's low HDL cholesterol (1.09 mmol/L) and high LDL cholesterol (2.4 mmol/L) levels suggest a high risk of atherosclerotic cardiovascular disease, which can further compromise cardiac function.

The patient's medications, including beta blockers, spironolactone, statins, and ACE inhibitors, are standard treatments for heart failure and ischemic cardiomyopathy. However, despite these treatments, the patient's condition has progressed to sudden cardiac death, suggesting that the medications may not have been effective in stabilizing the patient's cardiac function.

In conclusion, the patient's outcome of sudden cardiac death can be attributed to the combination of his underlying ischemic dilated cardiomyopathy, reduced LVEF, ventricular extrasystoles, elevated BNP levels, and high cholesterol levels, which have compromised his cardiac function and increased his risk of life-threatening arrhythmias."
212,212,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to several factors. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or reduced blood flow. This condition can lead to a decrease in the heart's ability to pump blood efficiently, increasing the risk of sudden cardiac death.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly lower than the normal range of 55-70%. A low LVEF indicates that the heart is not pumping efficiently, which can lead to a decrease in cardiac output and increase the risk of sudden cardiac death.

3.  High Pro-BNP levels: The patient's Pro-BNP level is 170.0 ng/L, which is elevated. Pro-BNP is a biomarker of heart failure, and high levels indicate increased strain on the heart, which can increase the risk of sudden cardiac death.

4.  Ventricular Extrasystole: The patient has polymorphic ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles. While not typically a cause for sudden cardiac death, it can be a sign of underlying cardiac disease and increase the risk of arrhythmias.

5.  Medication non-adherence: Although the patient is taking medications for their condition, including beta blockers, spironolactone, statins, and ACE inhibitors, the effectiveness of these medications can be reduced if the patient is not adhering to their prescribed treatment plan. Non-adherence can lead to uncontrolled hypertension, dyslipidemia, and heart failure, increasing the risk of sudden cardiac death.

6.  Advanced age: The patient is 71 years old, which increases their risk of sudden cardiac death due to age-related decline in cardiac function and increased comorbidities.

7.  Comorbidities: The patient has hypertension, dyslipemia, and hypothyroidism, which are all risk factors for cardiovascular disease and can increase the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death can be attributed to a combination of their underlying cardiac disease, medication non-adherence, advanced age, and comorbidities."
213,213,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying heart condition and other comorbidities. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a previous heart attack. This condition can lead to a reduced left ventricular ejection fraction (LVEF), which in this case is 35.0%. A low LVEF is a significant risk factor for sudden cardiac death.

Additionally, the patient's high levels of troponin (0.01 ng/mL) indicate recent myocardial damage, which may be a sign of a previous heart attack or ongoing cardiac stress. The presence of ventricular extrasystoles on the ECG further suggests that the heart muscle is under strain.

The patient's low HDL cholesterol level (1.09 mmol/L) and high LDL cholesterol level (2.4 mmol/L) indicate poor lipid management, which can contribute to the progression of coronary artery disease and further exacerbate the patient's cardiac condition.

The elevated Pro-BNP level (170.0 ng/L) is a marker of cardiac stress and strain, which can indicate that the patient's heart is working harder to pump blood effectively. This, combined with the patient's NYHA Class II classification, suggests that the patient has symptoms of heart failure, such as shortness of breath or fatigue, which can increase the risk of sudden cardiac death.

Furthermore, the patient's medications, including beta blockers and spironolactone, are typically used to manage heart failure and reduce the risk of sudden cardiac death. However, the patient's low LVEF and high Pro-BNP level suggest that these medications may not be adequately controlling the patient's cardiac condition.

In conclusion, the patient's outcome of sudden cardiac death can be attributed to a combination of factors, including their underlying ischemic dilated cardiomyopathy, recent myocardial damage, poor lipid management, cardiac stress, and inadequate medication management."
214,214,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's age, history of ischemic dilated cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 35%, the patient is at high risk for sudden cardiac death. The presence of ventricular extrasystoles, particularly polymorphic, on the ECG further increases this risk. Polymorphic ventricular extrasystoles can be a sign of electrical instability in the heart, which can lead to life-threatening arrhythmias.

The patient's low HDL cholesterol (1.09 mmol/L) and high LDL cholesterol (2.4 mmol/L) suggest that the patient may not be adequately controlled on statin therapy, which could contribute to ongoing atherosclerotic disease and cardiac ischemia. The elevated total cholesterol (4.09 mmol/L) and low HDL levels are also risk factors for cardiac events.

The patient's elevated Pro-BNP (170 ng/L) is indicative of heart failure, which is consistent with the patient's history of ischemic dilated cardiomyopathy. The presence of heart failure increases the risk of sudden cardiac death.

Additionally, the patient's medications, including beta blockers, spironolactone, statins, and ACE inhibitors, are standard treatments for heart failure and ischemic cardiomyopathy, but it is unclear if they are optimized for this patient's specific condition. The patient's creatinine level (133.0 umol/L) is elevated, which may indicate underlying renal impairment, which can further increase the risk of sudden cardiac death.

The patient's TSH level (1.77 mIU/L) is within the normal range, but the patient's T4 level (17 ng/L) is slightly elevated, which may indicate hypothyroidism. Hypothyroidism can contribute to heart failure and increase the risk of cardiac events.

In conclusion, the combination of the patient's history of ischemic dilated cardiomyopathy, reduced LVEF, ventricular extrasystoles, high cholesterol levels, elevated Pro-BNP, and suboptimal medication regimen likely contributed to the patient's sudden cardiac death."
215,215,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy and a left ventricular ejection fraction (LVEF) of 35%, which is significantly below the normal range (50-70%), the patient is at an increased risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG further increases this risk, as it may indicate abnormal ventricular automaticity and potentially life-threatening arrhythmias.

Additionally, the patient's high Pro-BNP level (170 ng/L) is indicative of heart failure, which is a known risk factor for sudden cardiac death. The patient's NYHA Class II classification also suggests that the patient experiences symptoms of heart failure, such as shortness of breath or fatigue, even at rest or with minimal exertion.

The patient's low HDL cholesterol (1.09 mmol/L) and high LDL cholesterol (2.4 mmol/L) may contribute to the progression of atherosclerotic disease, which is a common cause of ischemic dilated cardiomyopathy. The patient's statin therapy is likely intended to manage this aspect of their cardiovascular disease.

The patient's medication regimen includes beta blockers, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. However, the presence of ventricular extrasystoles and a low LVEF suggests that these medications may not be sufficient to adequately manage the patient's cardiac risk.

In conclusion, the combination of ischemic dilated cardiomyopathy, low LVEF, polymorphic ventricular extrasystoles, and high Pro-BNP levels places the patient at a high risk of sudden cardiac death. Despite the patient's medication regimen, the risk of sudden cardiac death remains a concern, and further evaluation and management strategies, such as implantable cardioverter-defibrillator (ICD) placement or closer monitoring, may be necessary to prevent this outcome."
216,216,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors from their medical history, laboratory results, and ECG findings. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or other heart problems, leading to a reduced left ventricular ejection fraction (LVEF). The patient's LVEF is 35%, which is significantly below the normal range of 55-70%, indicating a severely compromised heart function.

The patient's Pro-BNP level is elevated at 170.0 ng/L, which is a marker of heart failure and can indicate increased stress on the heart. The patient's Creatinine level is also elevated at 133.0 mmol/L, suggesting impaired kidney function, which can be a complication of heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats originating in the ventricles. While not necessarily life-threatening on their own, in the context of the patient's underlying heart disease, these arrhythmias can increase the risk of sudden cardiac death.

Furthermore, the patient is on beta blockers, spironolactone, statins, and ACE inhibitors, which are standard medications for heart failure and ischemic cardiomyopathy management. However, the presence of these medications does not rule out the possibility of sudden cardiac death.

Given the patient's advanced age (71 years), reduced LVEF, elevated Pro-BNP, and history of ischemic dilated cardiomyopathy, the risk of sudden cardiac death is significantly increased. The polymorphic ventricular extrasystoles on the ECG may have triggered a fatal arrhythmia, leading to sudden cardiac death.

In summary, the combination of the patient's underlying heart disease, impaired kidney function, and abnormal ECG findings likely contributed to their sudden cardiac death."
217,217,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying cardiac condition and laboratory findings. 

1. Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened due to a heart attack or coronary artery disease. This condition can lead to a significant reduction in the heart's ability to pump blood effectively, increasing the risk of sudden cardiac death.

2. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly lower than the normal range of 55-70%. A low LVEF indicates that the heart is not pumping blood efficiently, making it harder for the body to get the oxygen and nutrients it needs. This can lead to a range of complications, including sudden cardiac death.

3. Elevated Pro-BNP (Brain Natriuretic Peptide): The patient's Pro-BNP level is 170.0 ng/L, which is elevated. Elevated Pro-BNP levels are associated with heart failure and are used as a marker of cardiac stress. High levels can indicate that the heart is working harder than normal, which can increase the risk of sudden cardiac death.

4. Electrocardiogram (ECG) Findings: The patient has polymorphic ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles. While not necessarily a direct cause of sudden cardiac death, these extrasystoles can be a sign of underlying cardiac disease and may increase the risk of arrhythmias.

5. Medication Non-Adherence: Although the patient is on beta blockers, spironolactone, statins, and an ACE inhibitor, it is unclear if these medications are being taken as prescribed. Non-adherence to these medications can worsen the patient's condition and increase the risk of sudden cardiac death.

6. Other Contributing Factors: The patient's age (71), weight (78 kg), and hypertension history also contribute to his increased risk of sudden cardiac death. The presence of dyslipemia and elevated creatinine levels may also be contributing factors, as they are associated with cardiovascular disease.

In summary, the patient's history of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP levels, ECG findings, and potential medication non-adherence all contribute to his increased risk of sudden cardiac death."
218,218,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's age (71) and past medical history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, making it harder for the heart to pump blood effectively, the patient is at a higher risk for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 35% is significantly reduced, indicating that the heart is not pumping blood efficiently, which is a major risk factor for sudden cardiac death.

Additionally, the patient's high levels of pro-BNP (170 ng/L) indicate that the heart is under strain, and the patient's Troponin level (0.01 ng/mL) is slightly elevated, suggesting that there may be ongoing myocardial damage. The presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of arrhythmias and sudden cardiac death.

The patient's medication regimen includes beta blockers, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy. However, despite these treatments, the patient's condition has progressed to sudden cardiac death, likely due to the severity of the underlying disease.

Other contributing factors may include the patient's hypertension, dyslipidemia, and renal impairment (evidenced by elevated creatinine levels), which can further exacerbate the heart's workload and increase the risk of cardiac complications.

Overall, the combination of the patient's underlying heart disease, reduced LVEF, high pro-BNP levels, and the presence of arrhythmias on the ECG make sudden cardiac death a likely outcome in this patient."
219,219,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

1.  Ischemic dilated cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened due to coronary artery disease, leading to a decrease in left ventricular ejection fraction (LVEF). The LVEF in this patient is 35%, which is significantly below the normal range (50-70%). This suggests that the patient's heart is not pumping efficiently, increasing the risk of sudden cardiac death.

2.  Low LVEF: A low LVEF is a significant predictor of sudden cardiac death. The patient's LVEF of 35% indicates that the heart is not pumping enough blood, which can lead to a sudden drop in cardiac output, causing cardiac arrest.

3.  Elevated Pro-BNP levels: The patient's Pro-BNP level is 170 ng/L, which is elevated. BNP is a hormone produced by the heart in response to strain. Elevated levels indicate that the heart is under strain, which can be a sign of heart failure or cardiac dysfunction, increasing the risk of sudden cardiac death.

4.  Ventricular Extrasystole: The patient has polymorphic ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles. While not uncommon in healthy individuals, in patients with a history of heart disease, these extrasystoles can be a sign of underlying cardiac dysfunction and may increase the risk of sudden cardiac death.

5.  Medication non-adherence or inadequate: Although the patient is on beta blockers, spironolactone, statins, and an ACE inhibitor, the patient's outcome suggests that the medications may not have been sufficient to manage the patient's condition effectively. Adherence to medication and adjustment of the treatment plan may have been inadequate.

Considering these factors, the patient's sudden cardiac death can be attributed to the combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP levels, and possibly inadequate medication management."
220,220,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors that are evident from the provided data.

1.  Ischemic Dilated Cardiomyopathy and Low LVEF (30.0%): The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a reduced ejection fraction (LVEF). A low LVEF of 30% indicates that the heart is not pumping effectively, making it more susceptible to sudden cardiac death.

2.  High Pro-BNP Levels (2206.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are a marker of heart failure. A high level of 2206.0 ng/L suggests that the patient's heart is under significant strain, which increases the risk of sudden cardiac death.

3.  Hypotension (85/50 mmHg): The patient's blood pressure is significantly low, which may indicate decreased cardiac output or vasodilation. Hypotension can lead to decreased perfusion of vital organs and may contribute to sudden cardiac death.

4.  Electrocardiogram (ECG) Abnormalities: The presence of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia on the ECG suggest abnormal heart rhythms, which can increase the risk of sudden cardiac death.

5.  Medication Non-Optimization: Although the patient is on medications such as Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator, the patient's condition suggests that these medications may not be adequately managing the patient's heart failure and arrhythmias.

6.  Malnutrition and Liver Function Abnormalities: The patient's albumin level (44.6 g/L) is below the normal range, indicating possible malnutrition, which can worsen heart failure. Elevated liver enzymes (ALT and AST) suggest liver dysfunction, which can contribute to malnutrition and further compromise the patient's condition.

7.  Low T3 and T4 Levels: The patient's thyroid hormone levels are low, which can be associated with heart failure and may contribute to the patient's overall poor condition.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of advanced heart failure, abnormal heart rhythms, hypotension, and possible malnutrition, which may have been exacerbated by suboptimal medication management."
221,221,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease, it is not surprising that the patient's left ventricular ejection fraction (LVEF) is severely reduced at 30%. This indicates that the patient's heart is not pumping efficiently, which can lead to a decrease in cardiac output and potentially life-threatening arrhythmias.

The presence of non-sustained ventricular tachycardia (VT) on the ECG further increases the risk of sudden cardiac death (SCD). Non-sustained VT is a type of abnormal heart rhythm that can degenerate into sustained VT, which can be life-threatening. The fact that the patient has had multiple episodes of non-sustained VT suggests that their heart is prone to arrhythmias, which increases the risk of SCD.

The patient's low blood pressure (85/50 mmHg) and low albumin levels (44.6 g/L) may indicate fluid overload and potential heart failure, which can also contribute to the risk of SCD. The patient's elevated Pro-BNP (2206 ng/L) level, which is a biomarker for heart failure, supports this hypothesis.

Additionally, the patient's low T3 level (0.05 pg/dL) may indicate hypothyroidism, which can contribute to cardiovascular disease and increase the risk of SCD.

The patient's medications, including calcium channel blockers, loop diuretics, spironolactone, statins, and nitrovasodilators, are commonly used to manage heart failure and hypertension, but may not have been sufficient to prevent SCD in this case.

The combination of these factors, including the patient's severe heart disease, history of myocardial infarction, non-sustained VT, low blood pressure, fluid overload, and potential hypothyroidism, likely contributed to the patient's sudden cardiac death."
222,222,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors. Firstly, the patient has a history of ischemic dilated cardiomyopathy (IDC), which significantly reduces the left ventricular ejection fraction (LVEF) to 30%, indicating severe heart failure. The LVEF is a strong predictor of cardiac mortality.

The patient's Pro-BNP level of 2206 ng/L is significantly elevated, indicating severe heart failure. Elevated Pro-BNP levels are associated with increased risk of cardiac events and mortality.

The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a known risk factor for sudden cardiac death. NSVT is a marker of electrical instability in the heart, and in this patient, it may be a sign of underlying cardiac disease.

The patient's low blood pressure of 85/50 mmHg suggests orthostatic hypotension, which can lead to reduced cardiac output and further compromise cardiac function.

The patient's medications, including Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator, are aimed at managing heart failure and hypertension, but may not be sufficient to control the patient's condition given the severity of his symptoms and the presence of NSVT.

The patient's low T3 level (0.05 pg/dL) and TSH level (0.954 mIU/L) suggest possible hypothyroidism, which can contribute to heart failure and increased risk of cardiac events.

The patient's low HDL level (1.86 mmol/L) and high LDL level (3.36 mmol/L) indicate dyslipidemia, which is a risk factor for atherosclerotic cardiovascular disease and may have contributed to the development of IDC.

The patient's electrolyte imbalance, particularly low potassium level (4.5 mEq/L), can lead to cardiac arrhythmias, which may have contributed to the patient's sudden cardiac death.

In summary, the patient's outcome of sudden cardiac death can be attributed to a combination of severe heart failure, NSVT, orthostatic hypotension, possible hypothyroidism, dyslipidemia, and electrolyte imbalance, all of which are contributing factors to his increased risk of cardiac events and mortality."
223,223,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided information. 

1. Ischemic Dilated Cardiomyopathy (IDC): The patient's history of ischemic dilated cardiomyopathy is a significant risk factor for sudden cardiac death. IDC is a condition where the heart muscle becomes weakened and enlarged, leading to a decrease in the heart's pumping efficiency. This can cause a sudden cardiac arrest, which may result in sudden cardiac death.

2. Low Left Ventricular Ejection Fraction (LVEF) of 30%: The patient's LVEF is severely reduced, indicating that the left ventricle is not pumping efficiently, which is a common cause of sudden cardiac death in patients with IDC.

3. High Pro-BNP Levels: The patient's Pro-BNP level of 2206.0 ng/L is significantly elevated, indicating severe heart failure. Elevated Pro-BNP levels are associated with an increased risk of sudden cardiac death.

4. History of Myocardial Infarction: The patient's history of myocardial infarction further increases the risk of sudden cardiac death, as it can lead to scarring of the heart muscle and electrical instability.

5. Electrocardiogram (ECG) Findings: The ECG shows non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can be a precursor to sudden cardiac death. Additionally, the presence of ventricular extrasystoles (premature ventricular contractions) can also contribute to the risk of sudden cardiac death.

6. Medications: The patient is on a combination of medications, including a calcium channel blocker, loop diuretics, spironolactone, statins, and nitrovasodilators. While these medications are intended to manage the patient's heart failure and other conditions, they may not have been sufficient to prevent sudden cardiac death.

7. Other Factors: The patient's age, weight, and other laboratory values, such as low hemoglobin and high creatinine levels, may also contribute to the risk of sudden cardiac death. However, these factors are less directly related to the outcome compared to the above-mentioned factors.

In conclusion, the patient's history of ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, history of myocardial infarction, ECG findings, and other risk factors have likely contributed to the patient's outcome of sudden cardiac death."
224,224,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors, primarily related to his underlying heart condition and laboratory results. 

Firstly, the patient has ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to heart attacks or coronary artery disease. This condition is associated with a high risk of sudden cardiac death. 

The patient's left ventricular ejection fraction (LVEF) is 30%, indicating that his heart is not pumping efficiently, which is a significant predictor of mortality in patients with heart failure. 

Additionally, the patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 2206 ng/L, which is indicative of heart failure and further supports the diagnosis of ischemic dilated cardiomyopathy. 

Furthermore, the patient has a history of myocardial infarction, which increases his risk of sudden cardiac death. His laboratory results, including the elevated troponin level, suggest ongoing cardiac damage.

The patient's medication regimen includes a nitrovasodilator, which is a medication used to treat angina and heart failure. However, in this case, the medication may not be sufficient to control the patient's condition, and his heart function is not improving.

The patient's blood pressure is also significantly low at 85/50 mmHg, which may indicate orthostatic hypotension, a condition that can lead to dizziness, fainting, and even sudden cardiac death. 

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases the risk of sudden cardiac death. These arrhythmias can be life-threatening and may be a sign of an unstable heart rhythm.

In conclusion, the combination of the patient's underlying heart condition, laboratory results, and ECG findings, along with his medication regimen and low blood pressure, contributed to his sudden cardiac death."
225,225,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's age (71) and NYHA Class III, which indicates severe symptoms of heart failure, the patient is at high risk for sudden cardiac death. The patient's LVEF of 30% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. The presence of ischemic dilated cardiomyopathy, a history of myocardial infarction, and peripheral vascular disease further contribute to the patient's high risk.

The patient's blood pressure is low (85/50 mmHg), which may be a result of the patient's heart failure and may also contribute to a higher risk of sudden cardiac death. The elevated Pro-BNP level (2206.0 ng/L) is consistent with heart failure and also suggests a high risk of sudden cardiac death.

The patient's ECG shows non-sustained ventricular tachycardia, which is a known risk factor for sudden cardiac death. The presence of polymorphic ventricular extrasystoles also increases the risk of arrhythmias and sudden cardiac death.

The patient's medications, including a calcium channel blocker, loop diuretics, spironolactone, statins, and nitrovasodilator, are standard treatments for heart failure and may help to manage some of the patient's symptoms, but they may not be sufficient to prevent sudden cardiac death in this high-risk patient.

Additionally, the patient's low T3 level (0.05 pg/dL) and low T4 level (17 ng/L) may indicate hypothyroidism, which can contribute to heart failure and increase the risk of sudden cardiac death.

Given the patient's high risk factors, the presence of non-sustained ventricular tachycardia, polymorphic ventricular extrasystoles, and severe left ventricular dysfunction, the patient's outcome of sudden cardiac death is not unexpected."
226,226,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors, primarily related to his underlying cardiac conditions and laboratory findings. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to reduced heart function. This is reflected in his low left ventricular ejection fraction (LVEF) of 30%, which indicates poor heart function.

Additionally, the patient has a history of myocardial infarction, which further compromised his heart muscle and may have contributed to the development of his current cardiac condition.

The patient's laboratory results show elevated levels of pro-BNP (2206.0 ng/L), which is a marker of heart failure and increased ventricular wall stress. This suggests that the patient's heart is under significant strain, likely due to his cardiomyopathy.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is also a concerning finding, as it indicates abnormal electrical activity in the heart that can potentially lead to life-threatening arrhythmias. The fact that the patient has had more than 10 episodes of NSVT (CH>10) further increases the risk of sudden cardiac death.

The patient's low blood pressure (85/50 mmHg) may also contribute to his cardiac instability, as it suggests that his heart is not able to effectively pump blood to meet the body's needs.

Furthermore, the patient's medication regimen, while intended to manage his cardiac conditions, may not be sufficient to prevent sudden cardiac death. The use of calcium channel blockers, loop diuretics, and spironolactone may help manage symptoms, but the patient's underlying cardiac dysfunction may not be adequately addressed.

The patient's low T3 level (0.05 pg/dL) may also be a contributing factor, as low thyroid hormone levels can worsen heart failure and increase the risk of arrhythmias.

In conclusion, the combination of the patient's underlying cardiac conditions, laboratory findings, and ECG results suggests that he was at high risk for sudden cardiac death, which ultimately occurred."
227,227,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to his underlying cardiac conditions and laboratory results.

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is characterized by a weakened heart muscle due to a heart attack. This condition can lead to reduced left ventricular ejection fraction (LVEF), which is confirmed in this patient with an LVEF of 30%. A low LVEF increases the risk of sudden cardiac death.

2.  Non-Sustained Ventricular Tachycardia (NSVT): The patient's ECG shows NSVT, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. NSVT is often a precursor to sustained ventricular tachycardia or fibrillation, which can be life-threatening.

3.  High Pro-BNP Levels: The patient's Pro-BNP level is elevated at 2206.0 ng/L, indicating severe heart failure. Elevated Pro-BNP levels are associated with increased risk of mortality and sudden cardiac death in patients with heart failure.

4.  Low Blood Pressure: The patient's blood pressure is low at 85/50 mmHg, which can lead to inadequate perfusion of vital organs, including the brain, heart, and kidneys. This can increase the risk of sudden cardiac death.

5.  Reduced LVEF and High Creatinine Levels: The patient's reduced LVEF and high creatinine levels suggest advanced heart failure and kidney dysfunction, both of which are associated with increased risk of sudden cardiac death.

6.  Medication Non-Adherence or Insufficient Titration: Although the patient is on medications such as Calcium Channel Blockers, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilators, it is possible that the medications may not be adequately titrated or that the patient may not be adhering to the prescribed regimen, which can increase the risk of sudden cardiac death.

7.  Electrolyte Imbalance: The patient's potassium level is slightly low at 4.5 mEq/L, which can increase the risk of arrhythmias and sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of his underlying cardiac conditions, laboratory abnormalities, and potential medication non-adherence or insufficient titration."
228,228,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient is a 71-year-old male with a complex medical history, including ischemic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and a previous myocardial infarction. He has a severely reduced left ventricular ejection fraction (LVEF) of 30%, indicating significant heart failure. His NYHA Class III classification indicates that he experiences symptoms of heart failure with moderate limitations in physical activity.

The patient's blood pressure is low (85/50 mmHg), which may indicate hypotension, a common issue in patients with heart failure. His elevated Pro-BNP (brain natriuretic peptide) level of 2206 ng/L is consistent with heart failure and suggests a high risk of cardiac events.

The presence of non-sustained ventricular tachycardia (VT) on the ECG is concerning, as it can be a precursor to sustained VT, which can lead to sudden cardiac death. Additionally, the patient's low T3 level (0.05 pg/dL) may indicate hypothyroidism, which can contribute to heart failure and increase the risk of cardiac arrhythmias.

The patient's laboratory results show elevated creatinine levels (123.0 mmol/L), indicating renal impairment, which is common in patients with heart failure. His low hemoglobin level (129.0 g/L) may indicate anemia, which can further exacerbate heart failure.

The patient's medication regimen includes a calcium channel blocker, loop diuretics, spironolactone, statins, and nitrovasodilators, which are commonly used to manage heart failure and hypertension. However, the patient's low blood pressure and non-sustained VT suggest that his current treatment regimen may not be adequately managing his condition.

Considering the patient's complex medical history, reduced LVEF, low blood pressure, non-sustained VT, and elevated Pro-BNP level, the most likely reason for his sudden cardiac death is a cardiac arrhythmia, likely ventricular tachycardia, which was not adequately managed by his current medication regimen."
229,229,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors present in the patient's medical history and laboratory results.

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a decrease in the heart's ability to pump blood effectively. This condition is a significant risk factor for sudden cardiac death.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 30%, which is significantly lower than the normal range of 55-70%. A low LVEF indicates that the heart is not pumping efficiently, making it harder for the body to get the blood it needs, and increasing the risk of sudden cardiac death.

3.  High Pro-BNP levels: The patient's Pro-BNP level is 2206.0 ng/L, which is significantly elevated. Pro-BNP is a marker of heart failure, and high levels indicate that the heart is under strain, increasing the risk of sudden cardiac death.

4.  Ventricular Extrasystole and Non-sustained Ventricular Tachycardia: The patient's ECG shows polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can increase the risk of sudden cardiac death.

5.  Low Blood Pressure: The patient's blood pressure is 85/50 mmHg, which is lower than the normal range. Low blood pressure can lead to inadequate blood flow to the heart, increasing the risk of cardiac arrest and sudden cardiac death.

6.  Electrolyte imbalance: The patient's potassium level is 4.5 mEq/L, which is slightly low. Electrolyte imbalances, particularly potassium, can contribute to arrhythmias and increase the risk of sudden cardiac death.

7.  Medication non-adherence or inadequate management: Although the patient is on various medications, including calcium channel blockers, loop diuretics, spironolactone, statins, and nitrovasodilators, the patient's condition suggests that these medications may not be adequately managing their heart failure, arrhythmias, or electrolyte imbalances, contributing to the risk of sudden cardiac death.

Considering these factors, the patient's sudden cardiac death is likely the result of a combination of their ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, abnormal heart rhythms, low blood pressure, electrolyte imbalance, and inadequate management of their condition."
230,230,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

1. Low Left Ventricular Ejection Fraction (LVEF) of 35%: The patient's LVEF is significantly reduced, indicating severe left ventricular dysfunction. This is a strong predictor of adverse cardiac events, including sudden cardiac death.

2. Hypertensive Cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which can lead to left ventricular hypertrophy and decreased LVEF. This condition can increase the risk of sudden cardiac death.

3. High Pro-BNP levels (4999.0 ng/L): Elevated BNP levels are associated with heart failure and increased risk of sudden cardiac death.

4. Polymorphic Ventricular Extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG indicates abnormal ventricular electrical activity, which can increase the risk of arrhythmias and sudden cardiac death.

5. Reduced Hemoglobin (119.0 g/L): Anemia can contribute to reduced cardiac output and increased oxygen demand, which may exacerbate heart failure and increase the risk of sudden cardiac death.

6. Medication Non-Adherence or Inadequate Dosage: Although the patient is on multiple medications, including beta-blockers, which are typically used to reduce the risk of sudden cardiac death, the patient's LVEF and BNP levels suggest that these medications may not be adequately managing the patient's condition.

7. Electrolyte Imbalance: The patient's creatinine level (124.0 mmol/L) indicates impaired renal function, which can lead to electrolyte imbalances (e.g., hypokalemia, hypomagnesemia) that can contribute to arrhythmias and sudden cardiac death.

8. Malnutrition: The patient's low albumin level (39 g/L) and protein level (70 g/L) suggest malnutrition, which can impair cardiac function and increase the risk of cardiac complications.

In summary, the combination of severe left ventricular dysfunction, hypertensive cardiomyopathy, high BNP levels, abnormal ventricular electrical activity, anemia, potential medication non-adherence or inadequate dosage, electrolyte imbalance, and malnutrition all contributed to the patient's outcome of sudden cardiac death."
231,231,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors in his medical history and current condition. 

1. Hypertensive cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure causes the heart muscle to thicken, leading to decreased heart function. This condition can lead to reduced left ventricular ejection fraction (LVEF), which is evident in this patient with an LVEF of 35%. 

2. Reduced LVEF: The patient's LVEF is significantly reduced, indicating that the heart is not pumping efficiently, which increases the risk of sudden cardiac death. 

3. High Pro-BNP levels: The patient's Pro-BNP (brain natriuretic peptide) level is elevated at 4999.0 ng/L, which is indicative of heart failure. Elevated Pro-BNP levels are associated with increased risk of adverse cardiac events, including sudden cardiac death.

4. Ventricular extrasystoles: The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats originating in the ventricles. This can be a sign of underlying cardiac disease and may indicate an increased risk of arrhythmias, including ventricular tachycardia, which can lead to sudden cardiac death.

5. Medication regimen: While the patient is on a regimen of Calcium Channel Blockers, Beta Blockers, Loop Diuretics, Statins, and Hydralazine, these medications are primarily aimed at managing hypertension, heart failure, and dyslipidemia. However, the presence of ventricular extrasystoles and reduced LVEF suggests that the patient may require more aggressive treatment, such as an implantable cardioverter-defibrillator (ICD), to prevent sudden cardiac death.

6. Other factors: The patient's age (69 years) and NYHA Class II classification indicate that he has some limitations in physical activity due to heart disease. The presence of hypertension and heart failure further increases his risk of adverse cardiac events.

Given these factors, the patient's outcome of sudden cardiac death is likely due to a combination of his underlying cardiac disease, reduced LVEF, and the presence of ventricular extrasystoles."
232,232,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors from the provided data. 

1. Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is significantly reduced at 35%, indicating severe left ventricular dysfunction. This is a strong indicator of heart failure, which is a major risk factor for sudden cardiac death.

2. Elevated BNP levels: The patient's Pro-BNP level is 4999.0 ng/L, which is significantly elevated. BNP is a marker of heart failure and fluid overload. Elevated levels are associated with increased risk of cardiovascular events, including sudden cardiac death.

3. Hypertensive cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure damages the heart muscle, leading to reduced heart function. This condition increases the risk of heart failure and sudden cardiac death.

4. Medication regimen: While the patient is on several medications, including beta blockers, loop diuretics, and statins, which are beneficial for heart failure and hypertension, the presence of hydralazine, a vasodilator, may have contributed to a sudden drop in blood pressure, potentially leading to decreased cardiac output and sudden cardiac death.

5. ECG findings: Although the ECG does not show sustained ventricular tachycardia or other specific arrhythmias, the presence of polymorphic ventricular extrasystoles may indicate underlying electrical instability, which can contribute to sudden cardiac death.

6. Other factors: The patient's age (69 years) and reduced hemoglobin level (119.0 g/L) may also have contributed to his overall vulnerability to cardiac events.

Considering these factors, the patient's sudden cardiac death can be attributed to a combination of severe left ventricular dysfunction, heart failure, hypertension, and potential medication-related complications."
233,233,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history of hypertensive cardiomyopathy, the presence of a reduced left ventricular ejection fraction (LVEF) of 35%, and elevated Pro-BNP levels (4999.0 ng/L), which is indicative of heart failure, the patient was at high risk for cardiac complications. The patient's medications, including calcium channel blockers, beta blockers, loop diuretics, statins, and hydralazine, suggest that they were being managed for heart failure and hypertension.

The patient's ECG findings of polymorphic ventricular extrasystoles, while concerning, do not directly contribute to the cause of sudden cardiac death. However, the presence of these arrhythmias may have been a contributing factor to the overall cardiac instability.

The patient's low T3 levels (0.05 pg/dL) and normal T4 levels (23 ng/L) suggest that the patient may have had some degree of hypothyroidism, which can contribute to cardiac dysfunction and arrhythmias. However, the TSH level of 2.17 mIU/L is within the normal range, which may indicate that the hypothyroidism was not severe.

The patient's elevated creatinine levels (124.0 mmol/L) indicate impaired renal function, which can further compromise cardiac function and increase the risk of cardiac complications.

The patient's Troponin level of 0.01 ng/mL is within the normal range, indicating that there was no recent acute myocardial infarction contributing to the sudden cardiac death.

The patient's ECG impression of paroxysmal supraventricular tachyarrhythmia (PSVT) may have been a contributing factor to the sudden cardiac death, as PSVT can increase the risk of cardiac arrhythmias and cardiac arrest.

In summary, the combination of the patient's reduced LVEF, elevated Pro-BNP levels, impaired renal function, and the presence of arrhythmias, including polymorphic ventricular extrasystoles and PSVT, likely contributed to the patient's sudden cardiac death."
234,234,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors present in the patient's medical history, physical examination, and laboratory results.

1.  Hypertensive cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure causes the heart muscle to thicken, leading to decreased heart function. This condition can increase the risk of sudden cardiac death.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is below the normal range (50-70%). A reduced LVEF indicates that the heart is not pumping efficiently, increasing the risk of cardiac complications, including sudden cardiac death.

3.  Elevated Pro-BNP levels: The patient's Pro-BNP level is 4999.0 ng/L, which is significantly elevated. Pro-BNP is a marker of heart failure and can indicate increased stress on the heart. Elevated levels are associated with a higher risk of cardiac complications, including sudden cardiac death.

4.  Ventricular Extrasystole: The patient has polymorphic ventricular extrasystoles, which are abnormal heartbeats originating from the ventricles. This can be a sign of underlying cardiac disease and may increase the risk of cardiac arrhythmias, including ventricular fibrillation, which can lead to sudden cardiac death.

5.  Medication regimen: The patient is on a combination of medications, including calcium channel blockers, beta blockers, loop diuretics, statins, and hydralazine. While these medications are typically used to manage heart failure and hypertension, their effectiveness may be limited in this patient, given the severity of the patient's condition.

6.  Other laboratory results: The patient's creatinine level is elevated (124.0 mmol/L), indicating impaired kidney function, which can further compromise cardiac function. The patient's total cholesterol level is also elevated (6.41 mmol/L), which may contribute to atherosclerosis and increase the risk of cardiac complications.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to the combination of hypertensive cardiomyopathy, reduced LVEF, elevated Pro-BNP levels, ventricular extrasystoles, and the patient's overall compromised cardiac function."
235,235,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's past medical history of hypertensive cardiomyopathy and current NYHA Class II, it is evident that the patient has a compromised cardiac function. The low left ventricular ejection fraction (LVEF) of 35% suggests significant left ventricular dysfunction, which increases the risk of sudden cardiac death.

The elevated Pro-BNP (B-type natriuretic peptide) level of 4999 ng/L indicates increased ventricular wall stress and volume overload, further supporting the presence of heart failure. The presence of polymorphic ventricular extrasystoles on the ECG suggests electrical instability in the heart, which can be a precursor to arrhythmias.

The patient's medication regimen includes a combination of calcium channel blockers, beta blockers, loop diuretics, statins, and hydralazine, which are commonly used to manage hypertension, heart failure, and arrhythmias. However, despite this treatment, the patient's condition appears to have deteriorated, leading to sudden cardiac death.

The patient's age (69) and low body mass index (BMI) of 18.5 (calculated from weight and height) may also have contributed to their increased risk of cardiac complications. The low T3 and normal T4 levels, as well as the slightly elevated TSH, suggest euthyroidism, which is unlikely to be a contributing factor to the cardiac event.

The elevated creatinine level of 124.0 umol/L indicates impaired renal function, which can be a consequence of chronic heart failure. However, this is not likely to be the primary cause of the sudden cardiac death.

In conclusion, the combination of the patient's history of hypertensive cardiomyopathy, low LVEF, elevated Pro-BNP, and presence of polymorphic ventricular extrasystoles on the ECG, likely contributed to the sudden cardiac death."
236,236,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death is likely due to a combination of factors related to his underlying heart condition, medication regimen, and laboratory results. 

The patient has a history of hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and weakened due to high blood pressure. His left ventricular ejection fraction (LVEF) is significantly reduced at 35%, indicating poor heart function. This is a strong predictor of increased risk of sudden cardiac death.

Additionally, the patient's elevated Pro-BNP level of 4999.0 ng/L is a marker of heart failure and increased risk of sudden cardiac death. High levels of Pro-BNP are associated with increased mortality and morbidity in patients with heart failure.

The presence of polymorphic ventricular extrasystoles on the ECG is also a concerning finding. Polymorphic ventricular extrasystoles can be a sign of underlying cardiac disease, such as cardiomyopathy or coronary artery disease, and can increase the risk of sudden cardiac death.

Furthermore, the patient's medication regimen includes hydralazine, which can have pro-arrhythmic effects and increase the risk of sudden cardiac death. However, the patient's overall medication regimen, which includes beta blockers and calcium channel blockers, is generally considered to be protective against sudden cardiac death.

In terms of laboratory results, the patient's elevated creatinine level of 124.0 mol/L suggests impaired kidney function, which can further increase the risk of sudden cardiac death.

While the patient's TSH level is within the normal range, the low T3 level of 0.05 pg/dL may indicate hypothyroidism, which can contribute to heart failure and increase the risk of sudden cardiac death.

In conclusion, the patient's combination of underlying heart disease, reduced LVEF, elevated Pro-BNP level, polymorphic ventricular extrasystoles, and impaired kidney function likely contributed to his outcome of sudden cardiac death."
237,237,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient had a history of hypertensive cardiomyopathy, which indicates a weakened heart muscle due to high blood pressure. The patient's left ventricular ejection fraction (LVEF) was 35%, which is significantly below the normal range (50-70%), indicating reduced cardiac function.

The patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 4999.0 ng/L is a strong indicator of heart failure, as it is a biomarker released by the heart in response to increased ventricular wall stress. The patient's creatinine level of 124.0 umol/L also suggests impaired renal function, which can be a consequence of heart failure.

The patient's ECG showed polymorphic ventricular extrasystoles, which can be a sign of abnormal heart rhythm and increased risk of arrhythmias. The presence of paroxysmal supraventricular tachycardia (PSVT) on the ECG further indicates arrhythmia.

The patient's medications, including Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, and Hydralazine, were aimed at managing hypertension, heart failure, and arrhythmias. However, despite these treatments, the patient's condition may have been too severe to manage effectively.

The patient's low hemoglobin level of 119.0 g/L may indicate anemia, which can further compromise cardiac function. The patient's slightly elevated glucose level of 4.6 mmol/L may also contribute to cardiac stress and worsen heart failure.

Given the combination of these factors, including reduced cardiac function, heart failure, arrhythmias, and potential anemia, the patient's sudden cardiac death is likely a result of a fatal arrhythmia or cardiac arrest, possibly triggered by a sudden increase in ventricular workload or other cardiac stressors."
238,238,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in the patient's medical history and laboratory results.

1. Hypertensive Cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which can lead to left ventricular dysfunction and reduced ejection fraction (LVEF). The patient's LVEF is 35%, indicating a significant reduction in heart function, making the heart more susceptible to arrhythmias and sudden cardiac death.

2. Elevated Pro-BNP levels: The patient's Pro-BNP level is significantly elevated at 4999.0 ng/L, which is a marker of heart failure and cardiac dysfunction. Elevated Pro-BNP levels are associated with an increased risk of sudden cardiac death.

3. Ventricular Extrasystole: Polymorphic: The presence of polymorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythms, which can be a sign of underlying cardiac disease and may contribute to the risk of sudden cardiac death.

4. Reduced LVEF and Cardiac Function: The patient's reduced LVEF and cardiac function, as indicated by the low hemoglobin levels and elevated creatinine levels, suggest that the heart is not pumping efficiently, which can lead to sudden cardiac death.

5. Medication Non-Adherence: Although the patient is on multiple medications, including beta blockers, calcium channel blockers, loop diuretics, statins, and hydralazine, it is unclear if the patient is adhering to the treatment plan. Non-adherence to medication can lead to inadequate control of cardiac function, increasing the risk of sudden cardiac death.

6. Other Contributing Factors: The patient's elevated total cholesterol level and reduced T3 levels may also contribute to the increased risk of sudden cardiac death, as they are associated with cardiac disease and reduced cardiac function.

In conclusion, the combination of the patient's hypertensive cardiomyopathy, elevated Pro-BNP levels, polymorphic ventricular extrasystoles, reduced LVEF, and potential medication non-adherence likely contributed to the patient's outcome of sudden cardiac death."
239,239,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors from his medical history, laboratory results, and ECG findings. 

1. Hypertensive cardiomyopathy: The patient's history of hypertensive cardiomyopathy indicates that his heart muscle has been damaged due to high blood pressure, leading to reduced left ventricular function (LVEF of 35%). This condition increases the risk of arrhythmias, heart failure, and sudden cardiac death.

2. Low LVEF: The patient's left ventricular ejection fraction (LVEF) of 35% is significantly below the normal range (50-70%), indicating severe left ventricular dysfunction. This reduced LVEF increases the risk of sudden cardiac death.

3. High Pro-BNP levels: A Pro-BNP level of 4999 ng/L is elevated, indicating that the patient's heart is under significant strain, which can be a marker of heart failure and increased risk of sudden cardiac death.

4. ECG findings: The presence of polymorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythms, which can increase the risk of sudden cardiac death.

5. Medication regimen: Although the patient is on a medication regimen that includes beta blockers, calcium channel blockers, and loop diuretics, which are typically used to manage heart failure and hypertension, the patient's LVEF remains low, indicating that the medications may not be adequately managing his condition.

6. Other contributing factors: The patient's high blood pressure, low hemoglobin level, and elevated urea levels may also contribute to his risk of sudden cardiac death.

Given the combination of these factors, the patient's outcome of sudden cardiac death is not unexpected, and it is likely a result of the progression of his underlying heart disease and related complications."
240,240,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient outcome of sudden cardiac death in this 70-year-old male patient with a history of enolic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension can be attributed to a combination of several factors. 

Firstly, the patient's left ventricular ejection fraction (LVEF) is severely reduced at 40%, indicating significant left ventricular dysfunction. This is a known risk factor for sudden cardiac death. 

Secondly, the patient has a high level of B-type natriuretic peptide (BNP) at 437 ng/L, which is a marker of heart failure and increased ventricular wall stress. Elevated BNP levels are associated with an increased risk of sudden cardiac death.

Thirdly, the patient's past medical history of enolic dilated cardiomyopathy is a significant risk factor for sudden cardiac death. Dilated cardiomyopathy is a condition where the heart muscle becomes weak and the heart chambers enlarge, leading to poor heart function.

Fourthly, the patient's ECG shows monomorphic ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles. While this is not a direct cause of sudden cardiac death, it may indicate underlying cardiac electrical instability.

Lastly, the patient's medications, including loop diuretics and ACE inhibitors, are not sufficient to manage his heart failure symptoms, as evidenced by his reduced LVEF and elevated BNP levels.

Given these factors, the patient's risk of sudden cardiac death was likely increased, and the combination of these factors may have contributed to his fatal outcome."
241,241,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors, primarily related to his underlying cardiovascular conditions and laboratory results. 

Firstly, the patient has a history of enolic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced cardiac function. This is reflected in his low left ventricular ejection fraction (LVEF) of 40%, which is below the normal range. The patient's LVEF indicates that his heart is not pumping efficiently, which increases the risk of sudden cardiac death.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 437.0 ng/L is also indicative of heart failure and increased ventricular wall stress. Elevated Pro-BNP levels are associated with an increased risk of adverse cardiovascular events, including sudden cardiac death.

Additionally, the patient has a history of diabetes, which is a significant risk factor for cardiovascular disease and sudden cardiac death. His high glucose level of 10.8 mmol/L suggests poorly controlled diabetes, which can lead to cardiac damage and increased cardiovascular risk.

Furthermore, the patient's low HDL cholesterol level of 0.98 mmol/L and high LDL cholesterol level of 2.22 mmol/L indicate dyslipidemia, which is a major risk factor for atherosclerotic cardiovascular disease and sudden cardiac death.

The patient's ECG findings of monomorphic ventricular extrasystoles also suggest underlying cardiac electrical instability, which can increase the risk of sudden cardiac death.

Given the patient's complex medical history, laboratory results, and ECG findings, it is likely that his sudden cardiac death was caused by a combination of his underlying cardiovascular conditions, including enolic dilated cardiomyopathy, heart failure, diabetes, and dyslipidemia, as well as his poorly controlled glucose levels and cardiac electrical instability."
242,242,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors. Firstly, the patient has a history of enolic dilated cardiomyopathy, a condition where the heart's ability to pump blood is weakened due to a dilated left ventricle. This condition is indicated by a left ventricular ejection fraction (LVEF) of 40%, which is below the normal range of 50-70%. 

Additionally, the patient has diabetes, which is a significant risk factor for cardiovascular disease, including heart failure and sudden cardiac death. The patient's blood glucose level is elevated at 10.8 mmol/L, indicating poor glycemic control, which can exacerbate cardiac dysfunction.

The patient's hypertension and dyslipidemia also contribute to the risk of cardiovascular disease. The total cholesterol level is elevated at 3.49 mmol/L, with an LDL of 2.22 mmol/L, which is above the recommended target. The patient is on diabetes medication, loop diuretics, and an ACE inhibitor, which suggests that the patient's hypertension is being managed, but the patient's blood pressure is not provided, which is a concern.

The elevated Pro-BNP level of 437 ng/L indicates that the patient's heart is under strain, which is consistent with heart failure. The patient's TSH level is within the normal range, ruling out hypothyroidism as a contributing factor.

The ECG shows monomorphic ventricular extrasystoles, which can be a sign of underlying cardiac disease. While the patient does not have sustained ventricular tachycardia, the presence of ventricular extrasystoles suggests that the heart is experiencing abnormal electrical activity, which can increase the risk of sudden cardiac death.

Given the patient's complex medical history, including heart failure, diabetes, hypertension, and dyslipidemia, the combination of these factors likely contributed to the patient's sudden cardiac death."
243,243,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

Firstly, the patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to a decrease in the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) of 40% is below the normal range (50-70%), indicating compromised cardiac function.

Additionally, the patient has a high level of brain natriuretic peptide (BNP) at 437 ng/L, which is a marker of heart failure and increased ventricular wall stress. This suggests that the patient's heart is working harder to pump blood, leading to increased stress on the heart muscle, which may have contributed to the sudden cardiac death.

The patient's diabetes and dyslipemia also play a role in the development of atherosclerosis, which can lead to coronary artery disease and decreased blood flow to the heart muscle, increasing the risk of sudden cardiac death.

Furthermore, the patient's high total cholesterol level of 3.49 mmol/L and low HDL level of 0.98 mmol/L indicate poor lipid profiles, which can contribute to atherosclerosis and cardiovascular disease.

The patient's potassium level of 5.4 mEq/L is within the normal range, but the use of loop diuretics may have contributed to hypokalemia, which can increase the risk of arrhythmias and sudden cardiac death.

Lastly, the presence of ventricular extrasystoles on the ECG suggests that the patient's heart muscle is experiencing abnormal electrical activity, which can be a precursor to life-threatening arrhythmias.

Considering these factors, the patient's sudden cardiac death can be attributed to a combination of his underlying cardiac condition, medication side effects, and other comorbidities."
244,244,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history and laboratory results, several factors contribute to the risk of sudden cardiac death. 

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient has a LVEF of 40%, which is below the normal range (50-70%). This indicates reduced cardiac function, increasing the risk of sudden cardiac death.

2.  Dilated Cardiomyopathy: The patient has a history of enolic dilated cardiomyopathy, a condition characterized by enlargement and weakening of the heart muscle, which can lead to reduced cardiac function and increased risk of arrhythmias.

3.  Elevated Pro-BNP Levels: The patient's Pro-BNP level is elevated at 437.0 ng/L, indicating increased ventricular wall stress and potential cardiac dysfunction.

4.  Electrocardiogram (ECG) Findings: The presence of monomorphic ventricular extrasystoles on the ECG suggests abnormal heart rhythms, which can increase the risk of sudden cardiac death.

5.  Medications: Although the patient is on ACE inhibitors and loop diuretics, these medications are primarily used to manage heart failure symptoms and hypertension, but they may not be sufficient to prevent sudden cardiac death.

6.  Age and Comorbidities: The patient is 70 years old with multiple comorbidities, including diabetes, dyslipemia, and hypertension, which further increase the risk of cardiovascular events.

7.  Reduced HDL Cholesterol: The patient's HDL cholesterol level is low (0.98 mmol/L), which is a risk factor for cardiovascular disease.

8.  Elevated Creatinine Levels: The patient's creatinine level is elevated at 85.0 mol/L, indicating impaired renal function, which can contribute to the development of cardiovascular disease.

Considering these factors, the patient's history of dilated cardiomyopathy, reduced LVEF, and the presence of monomorphic ventricular extrasystoles on the ECG, along with other comorbidities and laboratory abnormalities, contribute to the increased risk of sudden cardiac death."
245,245,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors. 

Firstly, the patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged. This condition is a significant risk factor for sudden cardiac death due to the potential for arrhythmias and cardiac arrest.

The patient's left ventricular ejection fraction (LVEF) of 40% is significantly reduced, indicating that the heart is not pumping efficiently, which further increases the risk of sudden cardiac death. The patient's Pro-BNP level of 437.0 ng/L is elevated, which is a marker of heart failure and increased risk of sudden cardiac death.

The patient's ECG shows ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles. While the patient does not have sustained ventricular tachycardia, the presence of ventricular extrasystoles can be a sign of underlying cardiac disease and may contribute to the risk of sudden cardiac death.

Additionally, the patient's medication regimen includes loop diuretics, which can lead to electrolyte imbalances, particularly hypokalemia (low potassium levels). The patient's potassium level is slightly elevated at 5.4 mEq/L, but this may not be sufficient to prevent arrhythmias.

The patient's history of diabetes and hypertension further increases the risk of cardiovascular disease, including sudden cardiac death.

The patient's TSH level is slightly elevated at 3.99 mIU/L, which may indicate subclinical hypothyroidism. Hypothyroidism is associated with an increased risk of cardiovascular disease, including sudden cardiac death.

The patient's low T3 level (0.04 pg/dL) and normal T4 level (16 ng/L) suggest that the patient may have a euthyroid sick syndrome, which is a condition where the thyroid hormone levels are normal or slightly abnormal in the context of non-thyroidal illness.

In conclusion, the patient's outcome of sudden cardiac death can be attributed to a combination of factors, including enolic dilated cardiomyopathy, reduced LVEF, elevated Pro-BNP, ventricular extrasystoles, potential electrolyte imbalances, history of diabetes and hypertension, and subclinical hypothyroidism."
246,246,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to his underlying medical conditions and laboratory results.

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient has a significantly reduced LVEF of 40.0%, indicating impaired left ventricular function, which is a major risk factor for sudden cardiac death. This is a result of his enolic dilated cardiomyopathy.

2.  Elevated Pro-BNP: The patient's Pro-BNP level is elevated at 437.0 ng/L, indicating increased ventricular wall stress, which is consistent with heart failure. Elevated Pro-BNP levels are associated with an increased risk of adverse cardiovascular events, including sudden cardiac death.

3.  Diabetes and Dyslipemia: The patient's history of diabetes and dyslipemia (elevated total cholesterol and LDL levels) contributes to the development of atherosclerotic cardiovascular disease, which can lead to cardiac arrhythmias and sudden cardiac death.

4.  Hypertension: Although the patient's blood pressure is within a relatively normal range, his history of hypertension may have contributed to the development of cardiac hypertrophy and fibrosis, further impairing cardiac function.

5.  Ventricular Extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG may indicate abnormal electrical activity in the heart, which can increase the risk of sudden cardiac death.

6.  Medication Non-Adherence: Although the patient is on medications for diabetes, loop diuretics, and an ACE inhibitor, it is essential to consider the possibility of medication non-adherence, which may have contributed to the patient's poor cardiac function and outcome.

In conclusion, the patient's reduced LVEF, elevated Pro-BNP, history of diabetes and dyslipemia, hypertension, and ventricular extrasystoles on the ECG, along with potential medication non-adherence, likely contributed to his outcome of sudden cardiac death."
247,247,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's age (70 years) and past medical history of enolic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, the patient is at high risk for cardiac complications. The patient's left ventricular ejection fraction (LVEF) of 40% indicates a significantly reduced cardiac function, which is a common consequence of dilated cardiomyopathy. The presence of ventricular extrasystoles on the ECG suggests underlying ventricular arrhythmias, which can further increase the risk of sudden cardiac death.

The patient's elevated pro-BNP (brain natriuretic peptide) level of 437.0 ng/L indicates increased ventricular wall stress, which is consistent with heart failure. The patient's blood pressure is within a relatively normal range, but the patient's medication regimen includes loop diuretics, which suggests that the patient is experiencing fluid overload and possibly heart failure symptoms.

The patient's total cholesterol level of 3.49 mmol/L is elevated, which is a risk factor for cardiovascular disease. The patient's low HDL (good cholesterol) level of 0.98 mmol/L further increases the risk of cardiovascular disease.

The patient's TSH level of 3.99 mIU/L is slightly elevated, which may indicate subclinical hypothyroidism. However, this is unlikely to be the primary cause of the patient's cardiac issues.

The patient's troponin level of 0.01 ng/mL is slightly elevated, indicating some degree of cardiac damage. However, this is not significantly elevated, and it is unlikely to be the primary cause of the patient's cardiac issues.

The patient's potassium level of 5.4 mEq/L is slightly elevated, which may be a concern for cardiac arrhythmias. However, this is not significantly elevated, and it is unlikely to be the primary cause of the patient's cardiac issues.

The patient's medications, including diabetes medication, loop diuretics, and ACE inhibitor, are appropriate for managing the patient's conditions. However, the patient's condition is likely to be complex and multifactorial, and the patient's cardiac issues may not be fully controlled.

In summary, the patient's high-risk profile, reduced LVEF, ventricular extrasystoles, elevated pro-BNP, and elevated total cholesterol level make sudden cardiac death a plausible outcome. The patient's complex medical history and medication regimen also suggest that the patient's cardiac issues are multifactorial and may not be fully controlled."
248,248,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors that indicate high-risk cardiovascular disease. 

1. Reduced Left Ventricular Ejection Fraction (LVEF): The patient has an LVEF of 40%, which is below the normal range (50-70%). This indicates reduced heart function, making it difficult for the heart to pump blood efficiently. A lower LVEF is a well-established risk factor for sudden cardiac death.

2. Elevated Pro-BNP levels: The patient's Pro-BNP level is 437.0 ng/L, which is significantly elevated. Pro-BNP is a marker of heart failure and cardiac strain. Elevated levels indicate increased ventricular wall stress, which is a strong predictor of sudden cardiac death.

3. History of Enolic dilated cardiomyopathy: The patient has a history of Enolic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge. This condition increases the risk of sudden cardiac death.

4. Ventricular Extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythm. While not a direct cause of sudden cardiac death, it can contribute to an increased risk of arrhythmias and sudden cardiac death.

5. Medication non-adherence or inadequate treatment: Despite the patient's complex medical history and high-risk profile, the patient is only taking diabetes medication, loop diuretics, and an ACE inhibitor. It is possible that the patient may not be receiving optimal treatment for their heart condition, increasing their risk of sudden cardiac death.

6. Other risk factors: The patient has hypertension, dyslipidemia, and diabetes, all of which are well-established risk factors for cardiovascular disease and sudden cardiac death. The patient's high total cholesterol and low HDL levels further exacerbate their risk.

In summary, the patient's reduced LVEF, elevated Pro-BNP levels, history of Enolic dilated cardiomyopathy, and other risk factors, combined with potential medication non-adherence or inadequate treatment, likely contributed to the patient's outcome of sudden cardiac death."
249,249,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of factors related to his underlying medical conditions and laboratory results. 

Firstly, the patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced cardiac function. The patient's left ventricular ejection fraction (LVEF) of 40% indicates that his heart is not pumping efficiently, which increases the risk of sudden cardiac death.

The patient's elevated Pro-BNP level of 437 ng/L is a marker of cardiac stress and can indicate heart failure or cardiac dysfunction. The combination of reduced LVEF and elevated Pro-BNP suggests that the patient's heart is under significant stress, which may have led to a fatal arrhythmia.

The patient's ECG shows ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles. While these are not necessarily life-threatening on their own, they can be a sign of underlying cardiac disease and may increase the risk of sudden cardiac death.

Additionally, the patient's diabetes and dyslipidemia contribute to the development of atherosclerosis, which can lead to coronary artery disease and increase the risk of cardiac arrhythmias.

The patient's medications, including loop diuretics and an ACE inhibitor, are aimed at managing his heart failure and hypertension, but may not have been sufficient to prevent the fatal outcome.

The patient's age and NYHA Class II classification also contribute to the risk of sudden cardiac death, as older adults with heart disease are at a higher risk of cardiac complications.

In conclusion, the combination of the patient's underlying heart disease, reduced LVEF, elevated Pro-BNP, ventricular extrasystoles, and other comorbidities likely contributed to his sudden cardiac death."
250,250,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in their medical history and current condition. 

Firstly, the patient has a history of hypertrophic cardiomyopathy, a condition characterized by thickening of the heart muscle, which can lead to impaired cardiac function and increased risk of arrhythmias and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 15% indicates severely impaired cardiac function, which further increases the risk of sudden cardiac death.

Additionally, the patient's elevated Pro-BNP level of 8831.0 ng/L suggests severe heart failure, which is a known risk factor for sudden cardiac death. The presence of a first-degree atrioventricular block (AVB) on the ECG indicates an abnormal heart rhythm, which can also contribute to the risk of sudden cardiac death.

Furthermore, the patient's low potassium level (3.92 mEq/L) may have contributed to the development of life-threatening arrhythmias, as potassium is essential for maintaining a normal heart rhythm. The patient's medications, including beta blockers and spironolactone, may not have been sufficient to control their condition, given their severely impaired cardiac function and high Pro-BNP level.

The patient's age of 75 and NYHA Class II classification also indicate that they have a compromised cardiac status, which increases the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG further suggests that the patient's heart is experiencing abnormal electrical activity, which can increase the risk of arrhythmias and sudden cardiac death.

In conclusion, the patient's combination of severe cardiac impairment, high Pro-BNP level, abnormal ECG findings, and low potassium level, along with their age and NYHA classification, made them susceptible to sudden cardiac death."
251,251,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of several factors, primarily related to their underlying heart condition and laboratory results.

1.  Hypertrophic Cardiomyopathy: The patient has a history of hypertrophic cardiomyopathy, a condition where the heart muscle becomes thickened, which can lead to reduced cardiac output and increased risk of arrhythmias.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is significantly low at 15.0%, indicating poor heart function and a high risk of cardiac complications, including sudden cardiac death.

3.  High Pro-BNP Levels: The patient's Pro-BNP level is elevated at 8831.0 ng/L, indicating increased stress on the heart, likely due to heart failure or other cardiac issues.

4.  Electrocardiogram (ECG) Findings: The presence of polymorphic ventricular extrasystoles on the ECG suggests abnormal heart rhythms, which can increase the risk of arrhythmias and cardiac arrest.

5.  Medication Use: Although the patient is taking beta blockers, loop diuretics, and spironolactone, these medications may not be sufficient to manage the patient's condition, especially considering the severity of their heart failure and arrhythmias.

6.  Laboratory Abnormalities: The patient's high creatinine level (119.0 mmol/L) suggests impaired kidney function, which can be a result of reduced cardiac output. Additionally, the low hemoglobin level (130.0 g/L) may indicate anemia, which can further compromise cardiac function.

Considering these factors, the patient's history of hypertrophic cardiomyopathy, reduced LVEF, high Pro-BNP levels, and ECG abnormalities, along with laboratory abnormalities, likely contributed to their sudden cardiac death."
252,252,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying medical conditions and laboratory results. 

1. Hypertrophic Cardiomyopathy (HCM): The patient has a history of HCM, which is a condition characterized by thickening of the heart muscle, leading to impaired heart function and potential arrhythmias. This condition can increase the risk of sudden cardiac death.

2. Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is severely reduced at 15%, indicating poor heart function. A low LVEF is a significant risk factor for sudden cardiac death.

3. High Pro-BNP levels: The patient's Pro-BNP level is significantly elevated at 8831.0 ng/L, indicating severe heart failure and increased risk of sudden cardiac death.

4. Electrocardiogram (ECG) findings: The presence of polymorphic ventricular extrasystoles on the ECG suggests abnormal heart rhythm, which can be a precursor to life-threatening arrhythmias.

5. Medication regimen: While the patient is on beta blockers, loop diuretics, and spironolactone, these medications are not adequately addressing the underlying pathophysiology of HCM and heart failure, which may be contributing to the high risk of sudden cardiac death.

6. Other laboratory results: The patient's elevated creatinine level (119.0 mmol/L) and low hemoglobin (130.0 g/L) may indicate chronic kidney disease and anemia, respectively, which can further exacerbate heart failure and increase the risk of sudden cardiac death.

Given these factors, the patient's outcome of sudden cardiac death is likely due to the cumulative effect of their underlying HCM, reduced LVEF, high Pro-BNP levels, ECG abnormalities, and inadequate management of their heart failure and arrhythmias."
253,253,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors present in the provided data.

1.  Hypertrophic Cardiomyopathy (HCM): The patient has a history of HCM, a condition characterized by thickening of the heart muscle that can lead to reduced cardiac function and increased risk of arrhythmias. This condition is a known risk factor for sudden cardiac death.

2.  Low LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is severely reduced at 15.0%, indicating significant left ventricular dysfunction. A low LVEF is a strong predictor of increased risk of sudden cardiac death.

3.  High Pro-BNP: The patient's Pro-BNP level is elevated at 8831.0 ng/L, indicating increased ventricular stretch and/or elevated filling pressures. Elevated Pro-BNP levels are associated with increased risk of adverse cardiac events, including sudden cardiac death.

4.  Ventricular Extrasystole: The presence of polymorphic ventricular extrasystoles on the ECG suggests abnormal ventricular automaticity, which can be a risk factor for sudden cardiac death.

5.  Medication Non-Adherence or Inadequate Dosing: The patient is on beta blockers, loop diuretics, and spironolactone, which are standard treatments for heart failure and HCM. However, the patient's medication regimen may not be optimized, or the patient may not be adhering to their medication as prescribed, contributing to the patient's poor cardiac function and increased risk of sudden cardiac death.

6.  Electrolyte Imbalance: The patient's potassium level is low at 3.92 mEq/L, which can contribute to arrhythmias and increase the risk of sudden cardiac death.

7.  Other Contributing Factors: The patient's high cholesterol, elevated creatinine, and slightly elevated liver enzymes (AST and ALT) may also contribute to his overall poor cardiac health and increased risk of adverse outcomes.

In conclusion, the combination of the patient's underlying hypertrophic cardiomyopathy, low LVEF, high Pro-BNP, ventricular extrasystoles, potential medication non-adherence or inadequate dosing, electrolyte imbalance, and other contributing factors likely contributed to the patient's outcome of sudden cardiac death."
254,254,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is significantly reduced at 15%, indicating severe systolic dysfunction, which is a hallmark of heart failure. This suggests that the patient's heart is not pumping efficiently, leading to a decrease in cardiac output and increased risk of sudden cardiac death.

2.  Elevated Pro-BNP (Brain Natriuretic Peptide): A Pro-BNP level of 8831.0 ng/L is extremely high, indicating severe heart failure. Elevated Pro-BNP levels are associated with increased risk of cardiovascular events, including sudden cardiac death.

3.  Hypertrophic Cardiomyopathy: The patient's past medical history of hypertrophic cardiomyopathy, a condition characterized by abnormal thickening of the heart muscle, increases the risk of sudden cardiac death due to potential arrhythmias and decreased cardiac output.

4.  Electrocardiogram (ECG) Findings: The presence of polymorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythms, which can increase the risk of sudden cardiac death.

5.  Medication Non-Adherence or Inadequate Dosing: Although the patient is on beta blockers, loop diuretics, and spironolactone, which are commonly used to manage heart failure, it is essential to ensure that the medications are being taken as prescribed and at the correct doses. Inadequate treatment can lead to worsening heart failure and increased risk of sudden cardiac death.

6.  Reduced Potassium Levels: A potassium level of 3.92 mEq/L is low, which can lead to arrhythmias and increase the risk of sudden cardiac death. The patient's medications, such as loop diuretics, can cause hypokalemia (low potassium levels).

7.  Reduced Hemoglobin: A hemoglobin level of 130 g/L is slightly below the normal range, which can lead to decreased oxygen delivery to the heart muscle, increasing the risk of arrhythmias and sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely a result of the cumulative effect of these conditions, which have increased the risk of life-threatening arrhythmias and cardiac dysfunction."
255,255,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death is likely due to a combination of several factors. Firstly, the patient has a history of hypertrophic cardiomyopathy, which is a known risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 15%, indicating significant left ventricular dysfunction. This is a critical risk factor for sudden cardiac death.

The patient's elevated Pro-BNP (brain natriuretic peptide) level of 8831.0 ng/L is indicative of severe heart failure and further supports the presence of significant cardiac dysfunction. Additionally, the patient's troponin level of 0.03 ng/mL is within normal limits, but the patient's overall clinical context, including the severely reduced LVEF and elevated Pro-BNP, suggests that cardiac ischemia or infarction may have occurred.

The presence of first-degree atrioventricular block (AVB) on the ECG may also be a contributing factor to the patient's outcome. AVB can lead to a decrease in cardiac output, particularly in the setting of pre-existing cardiac dysfunction.

Furthermore, the patient's low potassium level of 3.92 mEq/L may have contributed to the development of arrhythmias, including ventricular extrasystoles. Hypokalemia can prolong the QT interval and increase the risk of arrhythmias.

The patient's use of beta blockers and loop diuretics may have also played a role in the patient's outcome. While these medications are commonly used to manage heart failure and hypertension, they can also contribute to hypotension and decreased cardiac output in some cases.

In summary, the patient's outcome of sudden cardiac death is likely due to a combination of severe left ventricular dysfunction, elevated Pro-BNP, first-degree AVB, hypokalemia, and the potential effects of beta blockers and loop diuretics."
256,256,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying hypertrophic cardiomyopathy, severely reduced left ventricular ejection fraction (LVEF of 15%), and elevated levels of brain natriuretic peptide (BNP). 

1.  Hypertrophic Cardiomyopathy: This condition is characterized by thickening of the heart muscle, which can lead to impaired heart function and increased risk of sudden cardiac death. The patient's history of hypertrophic cardiomyopathy puts him at a higher risk for this outcome.

2.  Reduced LVEF: The patient's LVEF of 15% indicates severely impaired heart function, which increases the risk of sudden cardiac death. A reduced LVEF indicates that the heart is unable to efficiently pump blood, leading to decreased cardiac output and increased strain on the heart.

3.  Elevated BNP levels: The patient's Pro-BNP level of 8831.0 ng/L is significantly elevated, indicating increased ventricular stress and strain. Elevated BNP levels are associated with heart failure and increased risk of adverse cardiac events, including sudden cardiac death.

4.  Medication regimen: Although the patient is on beta blockers, loop diuretics, and spironolactone, these medications are primarily used to manage symptoms and slow disease progression in heart failure. However, they may not have been sufficient to prevent the patient's sudden cardiac death.

5.  Other contributing factors: The patient's elevated creatinine levels (119.0 mmol/L) may indicate underlying kidney disease, which can further exacerbate heart failure and increase the risk of sudden cardiac death. Additionally, his low HDL cholesterol level (1.3 mmol/L) and high LDL cholesterol level (5.23 mmol/L) may have contributed to atherosclerotic disease, further compromising cardiac function.

In conclusion, the patient's sudden cardiac death is likely the result of a combination of his underlying hypertrophic cardiomyopathy, severely reduced LVEF, elevated BNP levels, and other contributing factors, despite being on medications for heart failure."
257,257,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: 

The patient is a 75-year-old male with a history of hypertrophic cardiomyopathy, a condition characterized by thickening of the heart muscle, which can lead to impaired heart function and increased risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 15%, indicating poor heart function. The elevated Pro-BNP (brain natriuretic peptide) level of 8831 ng/L is a marker of heart failure and further supports the presence of significant cardiac dysfunction.

The presence of polymorphic ventricular extrasystoles on the ECG indicates abnormal electrical activity in the heart, which can be a precursor to life-threatening arrhythmias. Although the patient is on beta blockers and loop diuretics, which are commonly used to manage heart failure and reduce the risk of arrhythmias, the patient's condition remains severe.

The patient's electrolyte imbalance, with a low potassium level (3.92 mEq/L), may also contribute to the risk of arrhythmias and cardiac arrest. The patient's total cholesterol level is elevated, which can contribute to atherosclerosis and further compromise cardiac function.

The patient's age and NYHA class II classification also indicate that the patient has a compromised cardiovascular system, making them more susceptible to sudden cardiac death. The patient's medications, including spironolactone, are aimed at managing heart failure and reducing the risk of arrhythmias, but the patient's condition is severe and life-threatening.

In conclusion, the combination of the patient's severe heart failure, low LVEF, elevated Pro-BNP, polymorphic ventricular extrasystoles, electrolyte imbalance, and the presence of hypertrophic cardiomyopathy, all contributed to the patient's outcome of sudden cardiac death."
258,258,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of factors, primarily related to their underlying hypertrophic cardiomyopathy and severely reduced left ventricular ejection fraction (LVEF of 15.0%). Hypertrophic cardiomyopathy is a condition where the heart muscle becomes thickened, leading to impaired cardiac function and increased risk of arrhythmias and sudden cardiac death.

The patient's elevated Pro-BNP level (8831.0 ng/L) indicates severe heart failure, which is consistent with their NYHA Class II classification. The presence of a first-degree atrioventricular block (AVB) on the ECG suggests conduction system disease, which may be a contributing factor to their cardiac instability.

The patient's low hemoglobin level (130.0 g/L) may indicate anemia, which can further exacerbate cardiac dysfunction. Additionally, their low sodium level (134.0 mEq/L) and slightly elevated potassium level (3.92 mEq/L) may indicate electrolyte imbalances, which can contribute to cardiac arrhythmias.

The patient's medications, including beta blockers and spironolactone, are typically used to manage heart failure and hypertension. However, their effectiveness in this case may have been insufficient to prevent sudden cardiac death.

The patient's troponin level is slightly elevated (0.03 ng/mL), indicating some degree of myocardial injury, which may be a consequence of their underlying cardiomyopathy.

The presence of polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, which may have ultimately led to the patient's sudden cardiac death.

In conclusion, the patient's outcome of sudden cardiac death is likely due to a combination of their underlying hypertrophic cardiomyopathy, severe heart failure, conduction system disease, electrolyte imbalances, and possibly inadequate medication management."
259,259,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, I will attempt to deduce the possible reasons for the patient's outcome of sudden cardiac death. 

1. Severe Reduced Left Ventricular Ejection Fraction (LVEF): The patient has a LVEF of 15%, which is significantly below the normal range (50-70%). This indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death.

2. Hypertrophic Cardiomyopathy (HCM): The patient has a history of HCM, a condition characterized by thickening of the heart muscle, which can lead to impaired cardiac function and increase the risk of sudden cardiac death.

3. High Pro-BNP Levels: The patient has an elevated Pro-BNP level of 8831 ng/L, which is indicative of severe heart failure and increased risk of sudden cardiac death.

4. Electrocardiogram (ECG) Findings: The presence of polymorphic ventricular extrasystoles and a first-degree atrioventricular block (AVB) on the ECG suggests underlying cardiac conduction abnormalities, which can contribute to the risk of sudden cardiac death.

5. Medication Non-Adherence or Inadequate Dosage: Although the patient is on beta blockers, loop diuretics, and spironolactone, the combination and dosage of these medications may not be sufficient to adequately manage the patient's severe cardiac dysfunction and HCM.

6. Age and Comorbidities: The patient is 75 years old, which is an advanced age for a patient with severe cardiac dysfunction. Additionally, the patient has other comorbidities such as hypertension, which can further contribute to the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of severe cardiac dysfunction, underlying HCM, and inadequate management of the condition, which ultimately led to a catastrophic cardiac event."
260,260,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death is likely due to a combination of several factors contributing to his high risk of cardiac mortality. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in the heart's ability to pump blood effectively. The left ventricular ejection fraction (LVEF) of 25% indicates severe systolic dysfunction, which increases the risk of sudden cardiac death.

Secondly, the patient's high levels of B-type natriuretic peptide (BNP) (3736 ng/L) and elevated troponin levels (0.01 ng/mL) suggest that the heart is under significant stress and there is ongoing cardiac damage. 

Additionally, the patient's low albumin level (43.5 g/L) and high creatinine level (102.0 mmol/L) indicate compromised renal function, which is a known risk factor for cardiovascular disease and sudden cardiac death.

Furthermore, the patient's ECG findings of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia suggest arrhythmias, which are a common cause of sudden cardiac death in patients with heart failure.

The patient's low hemoglobin level (149 g/L) may also contribute to reduced cardiac output and increased risk of sudden cardiac death.

The patient's medications, including digoxin, loop diuretics, statins, and ACE inhibitors, are standard treatments for heart failure, but may not be sufficient to control the patient's condition given the severity of his symptoms and test results.

Overall, the combination of ischemic dilated cardiomyopathy, severe systolic dysfunction, high BNP and troponin levels, compromised renal function, arrhythmias, and reduced hemoglobin level likely contributed to the patient's outcome of sudden cardiac death."
261,261,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and a low left ventricular ejection fraction (LVEF) of 25%, the patient is at high risk for sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles on the ECG further increases this risk.

The patient's low blood pressure of 85/60 mmHg suggests compromised cardiac output, which may be contributing to the patient's overall instability. The elevated Pro-BNP level of 3736.0 ng/L is indicative of heart failure and further supports the patient's high risk for sudden cardiac death.

The patient's medications, including digoxin and loop diuretics, are typically used to manage heart failure symptoms and may help stabilize the patient, but they do not address the underlying cause of the patient's condition.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver dysfunction, but this is not directly related to the patient's cardiac condition. The patient's lipid profile shows high LDL levels, which may contribute to the development of atherosclerosis and further compromise cardiac function.

The patient's low T4 level and slightly elevated TSH level may indicate hypothyroidism, which can contribute to cardiovascular disease and potentially increase the risk of sudden cardiac death.

The combination of the patient's advanced heart failure, NSVT, ventricular extrasystoles, and compromised cardiac output likely led to a fatal arrhythmia, resulting in sudden cardiac death."
262,262,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to several factors evident in the provided data.

1.  Severe Left Ventricular Dysfunction: The patient has an ejection fraction (LVEF) of 25%, indicating severe left ventricular dysfunction. This is a significant risk factor for sudden cardiac death.

2.  History of Ischemic Dilated Cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy suggests that the heart muscle has been damaged due to a previous heart attack, leading to a weakened heart that is more susceptible to sudden cardiac death.

3.  High Pro-BNP Levels: The patient's Pro-BNP level is 3736.0 ng/L, which is significantly elevated. Pro-BNP is a marker of heart failure and can indicate increased ventricular wall stress, which may be a contributing factor to the patient's sudden cardiac death.

4.  Ventricular Extrasystole and Non-sustained Ventricular Tachycardia: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates abnormal heart rhythm disturbances. These arrhythmias can increase the risk of sudden cardiac death.

5.  Low Blood Pressure: The patient's blood pressure is 85/60 mmHg, which is lower than normal. This could indicate a decrease in cardiac output, contributing to the patient's risk of sudden cardiac death.

6.  Medication Non-Response or Non-Optimal Dosing: Although the patient is on medications such as digoxin, loop diuretics, statins, and ACE inhibitors, the effectiveness of these medications may be limited by the patient's severe heart failure and ischemic dilated cardiomyopathy. Non-response or suboptimal dosing of these medications could contribute to the patient's poor outcome.

7.  Other Contributing Factors: The patient's low hemoglobin (149.0 g/L), low HDL (0.93 mmol/L), and elevated LDL (3.8 mmol/L) levels may also contribute to the patient's cardiovascular risk and potentially worsen the prognosis.

Considering these factors, the patient's sudden cardiac death can be attributed to a combination of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, abnormal heart rhythm disturbances, and possibly inadequate management of their heart failure."
263,263,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of factors, including his underlying heart condition and laboratory results. 

The patient has ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a reduced ability of the heart to pump blood effectively. This is indicated by his low left ventricular ejection fraction (LVEF) of 25%, which is a significant decrease from the normal range of 55-70%. 

Additionally, the patient's elevated Pro-BNP (brain natriuretic peptide) level of 3736.0 ng/L is indicative of heart failure, which is consistent with his NYHA Class III classification. The high Pro-BNP level suggests that the patient's heart is under significant stress, which may have led to the polymorphic ventricular extrasystole and non-sustained ventricular tachycardia observed on his ECG.

The patient's low blood pressure of 85/60 mmHg may indicate hypotension, which can further compromise cardiac output and increase the risk of cardiac arrest. His elevated creatinine level of 102.0 mmol/L suggests impaired renal function, which can also contribute to a higher risk of sudden cardiac death.

The patient's laboratory results also indicate a slight elevation in liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction. This can be a contributing factor to his overall poor cardiac function and increased risk of sudden cardiac death.

Furthermore, the patient's low T3 level of 0.04 pg/dL may indicate hypothyroidism, which can contribute to decreased cardiac function and increased risk of arrhythmias.

The patient's medication regimen, including digoxin, loop diuretics, statins, and ACE inhibitors, may have been insufficient to manage his condition effectively, leading to a higher risk of sudden cardiac death.

In summary, the combination of the patient's underlying heart condition, laboratory results, and medication regimen likely contributed to his outcome of sudden cardiac death."
264,264,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and significantly reduced left ventricular ejection fraction (LVEF) of 25%, the patient is at high risk for sudden cardiac death (SCD). The presence of non-sustained ventricular tachycardia (NSVT) on the ECG further increases the risk of SCD. 

The patient's low blood pressure (85/60 mmHg) and low hemoglobin (149.0 g/L) may indicate compromised cardiac output, which can lead to decreased perfusion of vital organs and potentially result in cardiac arrest.

Additionally, the elevated Pro-BNP level of 3736.0 ng/L suggests severe heart failure, which is a known risk factor for SCD. The patient's NYHA Class III classification also indicates that the patient experiences symptoms of heart failure, such as shortness of breath and fatigue, which can further increase the risk of SCD.

The patient's medications, including digoxin, loop diuretics, statins, and ACE inhibitor, are standard treatments for heart failure and may have been insufficient to prevent SCD in this case.

The patient's low T4 level (18 ng/L) and high TSH level (5.04 mIU/L) may indicate hypothyroidism, which can contribute to cardiac dysfunction and increase the risk of SCD.

The combination of these factors likely contributed to the patient's sudden cardiac death."
265,265,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of multiple factors contributing to his high-risk cardiac status. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy (IDC), which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) of 25% is significantly below the normal range (50-70%), indicating severe left ventricular dysfunction. This increased risk of sudden cardiac death is a well-known complication of IDC.

Additionally, the patient's high level of B-type natriuretic peptide (BNP) (3736 ng/L) is indicative of severe heart failure, which further increases the risk of sudden cardiac death. Elevated BNP levels are associated with increased mortality and morbidity in patients with heart failure.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is also a significant risk factor for sudden cardiac death. NSVT is a type of abnormal heart rhythm that can increase the risk of cardiac arrest and sudden death, particularly in patients with underlying heart disease.

Furthermore, the patient's low blood pressure (85/60 mmHg) and low hemoglobin level (149 g/L) may indicate reduced cardiac output, which can contribute to a higher risk of sudden cardiac death.

The patient's medications, including digoxin and loop diuretics, are commonly used to manage heart failure and arrhythmias, but may not be sufficient to mitigate the patient's high-risk cardiac status.

Lastly, the patient's age (67) and male gender also contribute to an increased risk of sudden cardiac death.

In conclusion, the combination of the patient's severe IDC, high BNP levels, NSVT, low blood pressure, and low hemoglobin level, along with his age and gender, make him a high-risk candidate for sudden cardiac death."
266,266,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history and current clinical presentation, the outcome of sudden cardiac death can be attributed to several factors. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged, reducing its ability to pump blood effectively. This is further supported by the patient's low left ventricular ejection fraction (LVEF) of 25%, indicating severe heart failure.

The patient's low blood pressure of 85/60 mmHg suggests that the heart is not pumping efficiently, leading to decreased cardiac output and reduced blood pressure. This is also consistent with the patient's NYHA Class III classification, indicating severe symptoms of heart failure.

The elevated Pro-BNP level of 3736.0 ng/L is a marker of heart failure and indicates that the patient's heart is under strain. Additionally, the patient's troponin level of 0.01 ng/mL suggests some degree of cardiac damage, likely due to previous myocardial infarctions.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia on the ECG suggests arrhythmias, which can further compromise cardiac function and increase the risk of sudden cardiac death.

The patient's low potassium level of 4.1 mEq/L may also contribute to arrhythmias and cardiac instability. The low T3 level of 0.04 pg/dL suggests hypothyroidism, which can also contribute to heart failure and increased risk of sudden cardiac death.

The combination of these factors, including severe heart failure, arrhythmias, and electrolyte imbalances, likely contributed to the patient's outcome of sudden cardiac death."
267,267,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided information.

1.  Severe Left Ventricular Dysfunction (LVEF 25%): The patient has a significantly reduced left ventricular ejection fraction (LVEF) of 25%, indicating severe left ventricular dysfunction. This is a strong predictor of increased mortality and sudden cardiac death in patients with heart failure.

2.  Ischemic Dilated Cardiomyopathy (IDC): The patient's past medical history of ischemic dilated cardiomyopathy suggests that the heart muscle has been damaged due to a previous heart attack, leading to the current state of left ventricular dysfunction.

3.  High Pro-BNP Levels: The patient's elevated pro-B-type natriuretic peptide (Pro-BNP) level of 3736 ng/L is indicative of severe heart failure. Elevated Pro-BNP levels are associated with increased risk of adverse outcomes, including sudden cardiac death.

4.  Non-Sustained Ventricular Tachycardia (NSVT): The presence of non-sustained ventricular tachycardia on the ECG suggests that the patient is at risk of developing sustained ventricular tachycardia, which can lead to sudden cardiac death.

5.  Bradycardia: Although the specific code for bradycardia is unknown, the patient's low blood pressure (85/60 mmHg) and low heart rate are indicative of bradycardia, which can further compromise cardiac output and increase the risk of sudden cardiac death.

6.  Electrolyte Imbalance: The patient's low potassium level (4.1 mEq/L) may contribute to arrhythmias and sudden cardiac death, as potassium plays a crucial role in maintaining normal heart rhythm.

7.  Medication Non-Adherence or Inadequate Dosing: Although the patient is on medications such as digoxin, loop diuretics, statins, and ACE inhibitors, the lack of specific information on medication adherence and dosing makes it difficult to assess the effectiveness of these treatments.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to the combination of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, high Pro-BNP levels, non-sustained ventricular tachycardia, bradycardia, and potential electrolyte imbalances, which may have been exacerbated by inadequate medication management."
268,268,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge due to previous heart attacks or coronary artery disease. This condition significantly reduces the heart's ability to pump blood effectively, leading to decreased cardiac output and increased risk of arrhythmias.

Secondly, the patient's left ventricular ejection fraction (LVEF) is severely reduced at 25%, indicating poor heart function. This is a significant risk factor for sudden cardiac death, as the heart is unable to pump blood efficiently, leading to inadequate perfusion of vital organs.

Thirdly, the patient has a high level of brain natriuretic peptide (BNP) at 3736.0 ng/L, which is a marker of heart failure and increased ventricular wall stress. Elevated BNP levels are associated with a higher risk of sudden cardiac death.

Fourthly, the patient has a history of myocardial infarction, which further compromises the heart's pumping ability and increases the risk of arrhythmias.

Fifthly, the patient's ECG shows non-sustained ventricular tachycardia (VT), which is a type of abnormal heart rhythm that can lead to sudden cardiac death if not properly managed.

Lastly, the patient's medications, including digoxin, loop diuretics, statins, and ACE inhibitors, are aimed at managing heart failure and reducing the risk of arrhythmias. However, despite these treatments, the patient's condition appears to have progressed to a point where sudden cardiac death has occurred.

In conclusion, the combination of ischemic dilated cardiomyopathy, reduced LVEF, high BNP levels, history of myocardial infarction, and ECG abnormalities, particularly non-sustained VT, contributed to the patient's outcome of sudden cardiac death."
269,269,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying heart condition and laboratory results. 

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or reduced blood flow. This condition significantly increases the risk of sudden cardiac death.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 25%, which is significantly below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, making it harder for the body to get the blood it needs, which increases the risk of sudden cardiac death.

3.  Elevated Pro-BNP: The patient's Pro-BNP level is 3736.0 ng/L, which is significantly elevated. Pro-BNP is a biomarker that is released by the heart when it is under strain. High levels of Pro-BNP are associated with heart failure and increased risk of sudden cardiac death.

4.  Hypotension: The patient's blood pressure is 85/60 mmHg, which is lower than the normal range. Hypotension can lead to inadequate blood flow to the heart, brain, and other vital organs, increasing the risk of sudden cardiac death.

5.  Electrocardiogram (ECG) Findings: The patient's ECG shows polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and an unknown paroxysmal supraventricular tachyarrhythmia. These ECG findings indicate abnormal heart rhythms that can increase the risk of sudden cardiac death.

6.  Medications: The patient is on digoxin, loop diuretics, statins, and ACE inhibitors. While these medications are commonly used to manage heart failure and related conditions, they do not address the underlying causes of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to the combination of their underlying heart condition, low LVEF, elevated Pro-BNP, hypotension, and abnormal ECG findings."
270,270,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's extensive medical history, which includes ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, it is not surprising that the patient experienced sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 40% indicates significant left ventricular dysfunction, which increases the risk of sudden cardiac death.

The patient's elevated Pro-BNP level of 2125 ng/L suggests severe heart failure symptoms, which is consistent with the patient's NYHA Class II classification. The presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of arrhythmic events, including sudden cardiac death.

The patient's TSH level of 32.51 mIU/L is elevated, indicating hyperthyroidism, which can exacerbate cardiac dysfunction and increase the risk of arrhythmias. The patient's low T3 and T4 levels suggest that the hyperthyroidism may be due to the effect of amiodarone, a medication that can cause thyroid dysfunction.

The patient's renal function, as indicated by the creatinine level of 112.0 umol/L, is impaired, which can contribute to the progression of heart failure and increase the risk of sudden cardiac death.

The patient's medication regimen, which includes amiodarone, loop diuretics, and nitrovasodilators, is consistent with the treatment of heart failure and arrhythmias. However, the presence of diabetes and dyslipemia suggests that the patient may not be adequately controlled on his current medications, which could contribute to the progression of his cardiac disease.

Overall, the combination of the patient's extensive medical history, severe heart failure symptoms, arrhythmias, and impaired renal function, along with potential medication-related complications, increases the risk of sudden cardiac death."
271,271,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors based on the provided data. 

1. Reduced Left Ventricular Ejection Fraction (LVEF) of 40%: This indicates that the patient's heart is not pumping efficiently, which can lead to decreased cardiac output and potentially life-threatening arrhythmias.

2. Elevated Pro-BNP levels (2125.0 ng/L): B-type natriuretic peptide (BNP) is a marker of cardiac strain, and elevated levels are associated with heart failure and increased mortality. High BNP levels suggest that the patient's heart is under significant stress.

3. Presence of Ischemic Dilated Cardiomyopathy: This condition is a type of heart failure that occurs when the heart muscle is weakened due to a heart attack or coronary artery disease. It can lead to a reduced LVEF and increased risk of arrhythmias.

4. History of Myocardial Infarction: Previous heart attacks can lead to scarring and further weakening of the heart muscle, increasing the risk of sudden cardiac death.

5. Atrial Fibrillation (AF): The patient has a history of paroxysmal AF, which can lead to a reduced cardiac output, increased risk of stroke, and potentially life-threatening arrhythmias.

6. Medication Non-Adherence or Inadequate Dosage: Although the patient is on various medications, including Amiodarone (an anti-arrhythmic medication) and ACE inhibitor (which can help reduce blood pressure and strain on the heart), the patient's condition may not be adequately controlled, contributing to the increased risk of sudden cardiac death.

7. Electrocardiogram (ECG) findings: The presence of polymorphic ventricular extrasystoles suggests that the patient's heart is experiencing abnormal electrical activity, which can increase the risk of life-threatening arrhythmias.

8. Other contributing factors: The patient's history of diabetes, dyslipemia, and hypertension may also contribute to the development of cardiovascular disease and increase the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death can be attributed to a combination of his underlying heart conditions, medication non-adherence, and other contributing factors."
272,272,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors from their medical history, laboratory results, and current medications. 

1. Ischemic dilated cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy indicates a weakened heart muscle due to previous heart attacks, which can lead to reduced cardiac function and an increased risk of sudden cardiac death.

2. Reduced LVEF (40%): The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating poor heart function. An LVEF of 40% is below the normal range, which further increases the risk of sudden cardiac death.

3. High Pro-BNP levels (2125.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are a marker of heart failure and increased ventricular wall stress. High Pro-BNP levels in this patient indicate that their heart is under significant stress, which can lead to arrhythmias and sudden cardiac death.

4. Paroxysmal atrial fibrillation (AF): The patient's ECG impression shows paroxysmal AF, which is an irregular heartbeat that can increase the risk of stroke, heart failure, and other heart-related complications. AF can also lead to reduced cardiac function and increased risk of sudden cardiac death.

5. Medication regimen: Although the patient is on medications such as ACE inhibitors, statins, and loop diuretics, which are beneficial for heart health, the presence of amiodarone, a medication used to treat arrhythmias, may not have been sufficient to control the patient's arrhythmias, particularly given the presence of paroxysmal AF.

6. Electrolyte imbalance: The patient's potassium level is slightly low (4.6 mEq/L), which can contribute to arrhythmias and increase the risk of sudden cardiac death.

7. Reduced T3 and T4 levels: The patient's thyroid hormone levels are low, which can contribute to heart failure and arrhythmias, further increasing the risk of sudden cardiac death.

Considering these factors, the combination of the patient's reduced LVEF, high Pro-BNP levels, paroxysmal AF, and medication regimen likely contributed to their sudden cardiac death."
273,273,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

1. Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is significantly reduced at 40%, indicating impaired heart function. This is likely a result of the patient's ischemic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and enlarged due to a heart attack, leading to reduced heart function.

2. Elevated Pro-BNP (Brain Natriuretic Peptide): The patient's Pro-BNP level is elevated at 2125.0 ng/L, which is a marker of heart failure and cardiac stress. Elevated Pro-BNP levels are associated with increased risk of adverse cardiovascular events, including sudden cardiac death.

3. History of Myocardial Infarction: The patient has a history of myocardial infarction, which increases the risk of sudden cardiac death.

4. Atrial Fibrillation (AF): The patient has paroxysmal AF, which is a type of irregular heartbeat that can increase the risk of stroke, heart failure, and other heart-related complications. AF can also lead to the formation of blood clots, which can cause a heart attack or stroke.

5. Reduced HDL Cholesterol and Elevated LDL Cholesterol: The patient's HDL (good) cholesterol is low (0.98 mmol/L), and LDL (bad) cholesterol is high (2.35 mmol/L), which can contribute to the development and progression of atherosclerosis, increasing the risk of heart disease and sudden cardiac death.

6. Diabetes: The patient has diabetes, which is a significant risk factor for cardiovascular disease, including sudden cardiac death.

7. Medication Non-Adherence or Inadequate Dosing: Although the patient is on medications for diabetes, hypertension, and heart failure, it is possible that the medications may not be sufficient or effective in managing the patient's condition, leading to inadequate control of heart failure and increased risk of sudden cardiac death.

8. Electrocardiogram (ECG) Findings: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of abnormal heart rhythms and increased risk of arrhythmias, including ventricular fibrillation, which can lead to sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely a result of a combination of these underlying conditions and factors, which have compromised the patient's cardiovascular health and increased the risk of a fatal arrhythmia."
274,274,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's past medical history, including ischemic dilated cardiomyopathy, myocardial infarction, diabetes, dyslipemia, and hypertension, it is clear that the patient has a complex and severe cardiovascular disease profile. The patient's left ventricular ejection fraction (LVEF) of 40% indicates reduced cardiac function, which increases the risk of sudden cardiac death.

The presence of a high level of B-type natriuretic peptide (BNP) at 2125 ng/L suggests that the patient's heart is under significant stress, likely due to the reduced LVEF and possibly due to the presence of heart failure symptoms. The elevated TSH level of 32.51 mIU/L may indicate hypothyroidism, which can be a contributing factor to cardiac dysfunction.

The patient's medication regimen, including amiodarone, loop diuretics, statins, ACE inhibitor, and nitrovasodilator, is aimed at managing the patient's cardiovascular conditions. However, the presence of polymorphic ventricular extrasystoles on the ECG suggests that the patient may be at risk for arrhythmias, which can increase the risk of sudden cardiac death.

The patient's low hemoglobin level of 116 g/L may indicate anemia, which can further compromise cardiac function. The elevated creatinine level of 112 umol/L suggests impaired renal function, which can contribute to the development of cardiovascular disease.

The patient's lipid profile, including a total cholesterol level of 4.14 mmol/L and LDL level of 2.35 mmol/L, indicates that the patient has dyslipemia, which is a risk factor for cardiovascular disease. The patient's low HDL level of 0.98 mmol/L further increases the risk of cardiovascular disease.

Given the combination of these factors, the patient's history of ischemic dilated cardiomyopathy, reduced LVEF, and the presence of arrhythmias, the patient's risk of sudden cardiac death is significantly increased. The patient's sudden cardiac death outcome is likely a result of the cumulative effect of these risk factors, which have compromised the patient's cardiac function and increased the risk of life-threatening arrhythmias."
275,275,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in their medical history and current clinical status.

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death due to the heart's reduced pumping efficiency and potential for arrhythmias.

2.  Low LVEF (40%): The left ventricular ejection fraction (LVEF) of 40% indicates that the heart is not pumping efficiently, which is a significant risk factor for sudden cardiac death.

3.  Paroxysmal atrial fibrillation (AF): The presence of paroxysmal AF increases the risk of thromboembolic events and tachyarrhythmias, which can lead to sudden cardiac death.

4.  High Pro-BNP levels (2125.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are associated with heart failure and increased risk of sudden cardiac death.

5.  Medication regimen: While the patient is on various medications (Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator), Amiodarone, in particular, is an antiarrhythmic medication that can be associated with a higher risk of sudden cardiac death due to its pro-arrhythmic effects.

6.  TSH levels (32.51 mIU/L): Although not directly related to cardiac death, elevated TSH levels can indicate thyroid dysfunction, which can be a contributing factor to cardiac disease.

7.  Other comorbidities: The patient's history of diabetes, dyslipemia, hypertension, and myocardial infarction also contribute to the overall increased risk of cardiac complications, including sudden cardiac death.

Considering these factors, the patient's history and clinical status make them particularly vulnerable to sudden cardiac death."
276,276,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors based on the provided medical history and test results.

1. Ischemic dilated cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened due to coronary artery disease, leading to impaired heart function. This condition is a significant risk factor for sudden cardiac death.

2. Low Left Ventricular Ejection Fraction (LVEF) of 40%: The patient's LVEF is significantly below the normal range (50-70%), indicating that the heart is not pumping efficiently, which increases the risk of sudden cardiac death.

3. High Pro-BNP levels (2125.0 ng/L): Elevated BNP levels are associated with heart failure and increased risk of sudden cardiac death.

4. Presence of arrhythmias: The patient has a history of paroxysmal atrial fibrillation (AF), which increases the risk of sudden cardiac death due to the irregular heart rhythm.

5. Medications: While the patient is on medications that are commonly used to manage heart failure and arrhythmias, such as ACE inhibitors, statins, and beta-blockers (implied by amiodarone), the effectiveness of these medications may be limited in this patient due to his advanced disease state.

6. Electrolyte imbalance: The patient has a slightly low potassium level (4.6 mEq/L), which can contribute to arrhythmias and increase the risk of sudden cardiac death.

7. Other comorbidities: The patient has diabetes, dyslipidemia, and hypertension, which are all risk factors for cardiovascular disease and may have contributed to the development of his ischemic dilated cardiomyopathy.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of his underlying heart disease, arrhythmias, and electrolyte imbalance, which ultimately led to a fatal cardiac arrhythmia."
277,277,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying medical conditions and the presence of certain laboratory and ECG findings.

1.  Ischemic dilated cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack, significantly increases their risk of sudden cardiac death. This condition impairs the heart's ability to pump blood efficiently, leading to a higher risk of cardiac arrest.

2.  Low LVEF (40%): The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 40%. A low LVEF is a strong indicator of heart failure and increases the risk of sudden cardiac death.

3.  High Pro-BNP levels (2125.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are associated with heart failure and indicate increased stress on the heart. High BNP levels can be a predictor of adverse outcomes, including sudden cardiac death.

4.  Tachyarrhythmias (Paroxysmal AF): The presence of paroxysmal atrial fibrillation (AF) increases the risk of thromboembolic events and cardiac arrhythmias, which can lead to sudden cardiac death.

5.  Electrolyte imbalance (Potassium 4.6 mEq/L): The patient's low potassium level may be a contributing factor to their cardiac arrhythmias and increased risk of sudden cardiac death.

6.  TSH level (32.51 mIU/L): The patient's elevated TSH level suggests hypothyroidism, which can contribute to heart failure and increase the risk of sudden cardiac death.

7.  Medication non-adherence or inadequate management: The patient is on multiple medications, including ACE inhibitors, statins, and loop diuretics. However, the effectiveness of these medications may be compromised due to non-adherence or inadequate dosing, contributing to the patient's poor outcome.

In summary, the combination of the patient's ischemic dilated cardiomyopathy, low LVEF, high BNP levels, paroxysmal AF, electrolyte imbalance, and hypothyroidism, along with potential medication non-adherence or inadequate management, likely contributed to their outcome of sudden cardiac death."
278,278,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's extensive medical history, which includes ischemic dilated cardiomyopathy, myocardial infarction, hypertension, and diabetes, the patient is at a high risk for cardiac complications. The patient's low left ventricular ejection fraction (LVEF) of 40% indicates reduced cardiac function, which further increases the risk of sudden cardiac death.

The presence of paroxysmal atrial fibrillation (AF) is a significant risk factor for thromboembolic events, which can lead to cardiac arrest. The patient's low hemoglobin level (116 g/L) may indicate anemia, which can contribute to reduced cardiac output and increase the risk of cardiac complications.

The patient's elevated pro-BNP level (2125 ng/L) suggests increased ventricular stress and volume overload, which can be a result of heart failure. The combination of heart failure, reduced LVEF, and AF increases the risk of sudden cardiac death.

The patient's medication regimen, including amiodarone, loop diuretics, and ACE inhibitor, is aimed at managing heart failure and arrhythmias. However, the presence of polymorphic ventricular extrasystoles on the ECG may indicate underlying cardiac electrical instability, which can increase the risk of arrhythmias and cardiac arrest.

The patient's low T3 level (0.02 pg/dL) and high TSH level (32.51 mIU/L) suggest subclinical hypothyroidism, which can contribute to cardiac dysfunction and increase the risk of cardiac complications.

The patient's low HDL cholesterol level (0.98 mmol/L) and high LDL cholesterol level (2.35 mmol/L) indicate dyslipidemia, which can contribute to atherosclerotic disease and increase the risk of cardiac events.

The combination of these factors, including reduced cardiac function, AF, anemia, elevated pro-BNP, and subclinical hypothyroidism, increases the risk of sudden cardiac death in this patient."
279,279,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's profile, the outcome of sudden cardiac death can be attributed to a combination of several factors.

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's pumping ability is impaired due to scarring from previous heart attacks. This condition can lead to reduced left ventricular ejection fraction (LVEF), which in this case is 40%, indicating a significant reduction in the heart's ability to pump blood effectively.

2.  Reduced LVEF: The patient's LVEF of 40% indicates that the heart is not pumping efficiently, leading to decreased cardiac output and increased risk of heart failure. This can contribute to a higher risk of sudden cardiac death.

3.  Paroxysmal Atrial Fibrillation (AF): The presence of paroxysmal AF indicates an irregular heartbeat, which can lead to decreased cardiac output and increased risk of stroke and cardiac arrhythmias. AF can also contribute to the progression of heart failure.

4.  High Pro-BNP Levels: The patient's Pro-BNP level of 2125.0 ng/L is significantly elevated, indicating increased stress on the heart. Elevated Pro-BNP levels are associated with heart failure, and high levels can indicate a higher risk of adverse cardiac events, including sudden cardiac death.

5.  Medication Non-Adherence or Inadequate Management: Although the patient is on various medications, including ACE inhibitors, statins, and diuretics, the effectiveness of these treatments may be compromised due to non-adherence or inadequate dosing. This could contribute to the progression of the patient's heart failure and increase the risk of sudden cardiac death.

6.  Electrocardiogram (ECG) Findings: The presence of polymorphic ventricular extrasystoles may indicate an abnormal heart rhythm, which can increase the risk of sudden cardiac death.

7.  Comorbidities: The patient has multiple comorbidities, including diabetes, dyslipemia, hypertension, and myocardial infarction, which can all contribute to the progression of heart failure and increase the risk of sudden cardiac death.

In summary, the combination of ischemic dilated cardiomyopathy, reduced LVEF, paroxysmal AF, high Pro-BNP levels, potential medication non-adherence or inadequate management, ECG findings, and comorbidities all contribute to the patient's increased risk of sudden cardiac death."
280,280,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying cardiovascular conditions and laboratory results. 

1. Reduced Left Ventricular Ejection Fraction (LVEF): The patient has an LVEF of 35%, indicating severe left ventricular dysfunction, which increases the risk of sudden cardiac death. This is consistent with his ischemic dilated cardiomyopathy.

2. High Blood Pressure: The patient's blood pressure of 190/110 mmHg is significantly elevated, which can exacerbate the strain on the heart and contribute to cardiac dysfunction. Hypertension is a known risk factor for cardiovascular disease and sudden cardiac death.

3. Diabetes and Dyslipidemia: The patient's history of diabetes and dyslipidemia further increases his risk of cardiovascular disease. Diabetes can lead to diabetic cardiomyopathy, a condition that can cause heart failure, and dyslipidemia can contribute to the development of atherosclerosis, which can lead to myocardial infarction.

4. High Pro-BNP Levels: The patient's Pro-BNP level of 597.0 ng/L is elevated, indicating increased stress on the heart, which can be a sign of heart failure or other cardiac conditions. Elevated Pro-BNP levels are associated with an increased risk of sudden cardiac death.

5. Ventricular Extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG suggests abnormal electrical activity in the heart, which can increase the risk of arrhythmias and sudden cardiac death.

6. Medication Non-Adherence or Inadequacy: Although the patient is taking medications for his conditions, the high blood pressure and low LVEF suggest that the medications may not be adequately controlling his conditions, or he may not be adhering to the prescribed treatment regimen.

7. Other Contributing Factors: The patient's age (67) and NYHA Class II classification also contribute to his risk of sudden cardiac death, as age and reduced functional capacity are risk factors for cardiovascular disease.

Considering these factors, the patient's sudden cardiac death is likely a result of the cumulative effect of his underlying cardiovascular conditions, high blood pressure, and inadequate management of his conditions, leading to a high-risk cardiac state."
281,281,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying cardiovascular disease and its complications. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a decrease in the heart's ability to pump blood efficiently. The patient's left ventricular ejection fraction (LVEF) of 35% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death.

2.  Severe Hypertension: The patient's blood pressure of 190/110 mmHg is significantly elevated, indicating uncontrolled hypertension. Hypertension can lead to cardiac remodeling and further weaken the heart, increasing the risk of sudden cardiac death.

3.  Diabetes and Dyslipidemia: The patient's history of diabetes and dyslipidemia further exacerbates the cardiovascular risk. Diabetes can cause damage to blood vessels, increasing the risk of heart disease, while dyslipidemia contributes to the buildup of plaque in the arteries, which can lead to cardiac events.

4.  Myocardial Infarction: The patient's history of myocardial infarction (heart attack) indicates that he has suffered significant damage to the heart muscle, which can lead to arrhythmias, heart failure, and sudden cardiac death.

5.  High Pro-BNP Levels: The patient's Pro-BNP level of 597 ng/L is significantly elevated, indicating severe heart failure. Elevated Pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

6.  Ventricular Extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythms, which can be a precursor to more severe arrhythmias, including ventricular tachycardia, which can lead to sudden cardiac death.

7.  Suboptimal Medication Management: Although the patient is on medications such as beta blockers, calcium channel blockers, statins, and nitrovasodilators, these medications may not be adequately controlling his hypertension, heart failure, or arrhythmias, increasing the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death can be attributed to the cumulative effect of his underlying cardiovascular disease, uncontrolled hypertension, and suboptimal medication management, leading to severe left ventricular dysfunction and life-threatening arrhythmias."
282,282,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of several factors that can be inferred from the provided data. 

1. Ischemic dilated cardiomyopathy: This condition is a significant contributor to the patient's poor cardiac function, as indicated by a left ventricular ejection fraction (LVEF) of 35%. This suggests that the patient's heart is not pumping efficiently, making it more susceptible to arrhythmias and sudden cardiac death.

2. High Blood Pressure (190/110 mmHg): Uncontrolled hypertension can lead to cardiac remodeling and increased cardiac workload, further contributing to the progression of heart failure and increasing the risk of sudden cardiac death.

3. Low HDL (1.19 mmol/L): Low HDL cholesterol is a risk factor for cardiovascular disease and can contribute to the development of atherosclerosis, which may have played a role in the patient's ischemic dilated cardiomyopathy.

4. High LDL (1.55 mmol/L): Elevated LDL cholesterol can also contribute to atherosclerosis, which may have contributed to the patient's ischemic dilated cardiomyopathy.

5. Pro-BNP (597.0 ng/L): Elevated levels of brain natriuretic peptide (BNP) indicate increased ventricular wall stress and are associated with a higher risk of adverse cardiac events, including sudden cardiac death.

6. Ventricular extrasystoles: The presence of monomorphic ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing abnormal electrical activity, which can increase the risk of arrhythmias and sudden cardiac death.

7. Medication regimen: While the patient is taking medications to manage their hypertension, dyslipidemia, and heart failure, it is unclear if these medications were optimized to manage their specific cardiac condition. 

8. Age and comorbidities: The patient's age (67) and presence of multiple comorbidities (diabetes, peripheral vascular disease, and myocardial infarction) increase the risk of sudden cardiac death.

Given these factors, it is likely that the patient's sudden cardiac death was a result of a combination of his underlying cardiac conditions, uncontrolled hypertension, and possibly an arrhythmic event triggered by his ischemic dilated cardiomyopathy."
283,283,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying medical conditions and laboratory results. 

The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a reduced left ventricular ejection fraction (LVEF) of 35%. This suggests that the patient's heart is not pumping efficiently, increasing the risk of sudden cardiac death.

The patient's high blood pressure (190/110 mmHg) and history of hypertension further contribute to cardiac strain. Hypertension can lead to left ventricular hypertrophy, which can worsen the heart's pumping function.

Additionally, the patient's elevated Pro-BNP level (597.0 ng/L) indicates increased ventricular wall stress, which is a marker of heart failure and a predictor of adverse cardiac events.

The patient's history of myocardial infarction, peripheral vascular disease, and dyslipemia also contribute to the overall cardiovascular risk.

The patient's laboratory results show an elevated LDL cholesterol level (1.55 mmol/L), which is a risk factor for atherosclerosis and cardiac events. The low HDL cholesterol level (1.19 mmol/L) also contributes to the increased risk.

The patient's ECG shows ventricular extrasystoles, which can be a sign of underlying cardiac electrical instability, further increasing the risk of sudden cardiac death.

Given the patient's complex medical history and laboratory results, the combination of these factors likely contributed to their sudden cardiac death. The patient's medications, including calcium channel blockers, beta blockers, statins, and nitrovasodilators, were likely not sufficient to mitigate the risk of sudden cardiac death in this case."
284,284,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death due to the potential for arrhythmias and decreased cardiac function. The patient's left ventricular ejection fraction (LVEF) of 35% indicates severely impaired cardiac function, further increasing the risk.

The patient's blood pressure of 190/110 mmHg is significantly elevated, indicating uncontrolled hypertension. This is a major risk factor for cardiovascular disease and can lead to cardiac arrhythmias, heart failure, and cardiac death.

The patient's medication regimen includes beta blockers and calcium channel blockers, which are typically used to manage hypertension and heart failure. However, the patient's blood pressure remains elevated, suggesting inadequate control.

The patient's T3 and T4 levels are within normal limits, but the TSH level is slightly low, which may indicate subclinical hypothyroidism. However, this is not a direct contributor to the patient's outcome.

The patient's Pro-BNP level of 597 ng/L is elevated, indicating increased cardiac stress and strain, which is consistent with heart failure.

The ECG findings of monomorphic ventricular extrasystoles may be a sign of underlying cardiac disease, but it is not a direct cause of sudden cardiac death.

The patient's weight of 90 kg and height of 166 cm result in a body mass index (BMI) of approximately 29.6, which is in the overweight category, further increasing the risk of cardiovascular disease.

The patient's past medical history of myocardial infarction, dyslipemia, and peripheral vascular disease also contribute to the overall risk of cardiovascular events.

In conclusion, the combination of the patient's severe cardiac dysfunction, uncontrolled hypertension, and history of cardiovascular disease likely contributed to the outcome of sudden cardiac death."
285,285,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors evident from the provided data. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which significantly increases the risk of sudden cardiac death. IDC is a condition where the heart's pumping function is impaired due to coronary artery disease, leading to scarring and enlargement of the heart. This condition can lead to life-threatening arrhythmias and decreased cardiac function.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly lower than the normal range of 55-70%. A low LVEF indicates poor heart function, making it difficult for the heart to pump blood effectively. This reduced cardiac function increases the risk of sudden cardiac death.

3.  High Blood Pressure: The patient has a blood pressure of 190/110 mmHg, which is significantly elevated. Hypertension can further strain the heart, increasing the risk of cardiac complications, including sudden cardiac death.

4.  Ventricular Extrasystole: The ECG shows monomorphic ventricular extrasystoles, which are abnormal heartbeats originating from the ventricles. While not necessarily life-threatening on their own, they can be a sign of underlying cardiac disease and may increase the risk of arrhythmias.

5.  High Pro-BNP Levels: The patient's Pro-BNP level is 597.0 ng/L, which is elevated. BNP is a hormone produced by the heart in response to strain or stress. High levels of BNP can indicate heart failure or other cardiac conditions that increase the risk of sudden cardiac death.

6.  Medication Non-Optimization: Although the patient is on medications like Calcium Channel Blockers, Beta Blockers, Statins, and Nitrovasodilators, the presence of monomorphic ventricular extrasystoles and high blood pressure despite these medications suggests potential medication non-optimization or inadequate treatment of underlying conditions.

7.  Other Contributing Factors: The patient's age (67), diabetes, dyslipemia, and peripheral vascular disease are also contributing factors that increase the risk of cardiovascular events, including sudden cardiac death.

Given these factors, it is likely that the combination of ischemic dilated cardiomyopathy, low LVEF, high blood pressure, and other comorbidities contributed to the patient's outcome of sudden cardiac death."
286,286,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's profile, the outcome of sudden cardiac death can be attributed to a combination of several factors. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which significantly increases the risk of sudden cardiac death. IDC is characterized by a weakened left ventricle, leading to reduced ejection fraction (LVEF of 35% in this case), and increased risk of arrhythmias and cardiac arrest.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF of 35% indicates a severely reduced heart function, making the heart unable to pump enough blood to meet the body's needs. This further increases the risk of cardiac arrest and sudden death.

3.  Hypertension: The patient has uncontrolled hypertension (190/110 mmHg), which can lead to further strain on the heart and increase the risk of cardiac complications.

4.  Diabetes: The patient has diabetes, which can damage the blood vessels and nerves, making it harder for the heart to function properly. This can also increase the risk of cardiac arrhythmias and sudden death.

5.  Pro-BNP levels: The patient's Pro-BNP level is elevated at 597 ng/L, indicating increased stress on the heart and potential heart failure.

6.  ECG Findings: The presence of monomorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythms, which can increase the risk of sudden cardiac death.

7.  Medication Non-Adherence: Although the patient is on medications like Calcium Channel Blockers, Beta Blockers, Statins, and Nitrovasodilators, the effectiveness of these medications may have been compromised due to non-adherence or inadequate dosing, which can lead to uncontrolled hypertension and cardiac complications.

Considering these factors, the patient's outcome of sudden cardiac death is likely a result of a combination of these conditions, which have compromised the heart's ability to function properly, leading to cardiac arrest and sudden death."
287,287,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors based on the provided data. 

1.  Ischemic dilated cardiomyopathy with LVEF 35%: This condition significantly increases the risk of sudden cardiac death due to the heart's inability to pump blood efficiently. The reduced left ventricular ejection fraction (LVEF) indicates a compromised cardiac function.

2.  History of Myocardial Infarction: Previous MI further compromises the heart's ability to function, making it more susceptible to arrhythmias and cardiac arrest.

3.  Hypertension (BP 190/110 mmHg): Elevated blood pressure strains the heart, increasing the workload and contributing to the progression of cardiomyopathy.

4.  Diabetes: This condition can lead to cardiac complications, such as diabetic cardiomyopathy, and is a risk factor for sudden cardiac death.

5.  Ventricular Extrasystole (Monomorphic): The presence of ventricular extrasystoles indicates an abnormal heart rhythm, which can be a precursor to more serious arrhythmias, including ventricular tachycardia or fibrillation, leading to cardiac arrest.

6.  Elevated Pro-BNP (597 ng/L): High levels of B-type natriuretic peptide (BNP) are associated with heart failure and increased risk of sudden cardiac death.

7.  Medication non-adherence or inadequate management: Although the patient is taking medications like Calcium Channel Blocker, Beta Blockers, Statins, and Nitrovasodilator, the effectiveness of these treatments may be compromised due to non-adherence or inadequate dosing, contributing to the patient's condition.

Considering these factors, the patient's high-risk profile for sudden cardiac death was likely due to the cumulative effect of ischemic dilated cardiomyopathy, previous MI, uncontrolled hypertension, diabetes, and abnormal heart rhythms, which collectively increased the risk of a fatal cardiac event."
288,288,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's complex medical history, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, the patient was at high risk for cardiac complications. The presence of a left ventricular ejection fraction (LVEF) of 35% indicates severe systolic dysfunction, which is a strong predictor of adverse outcomes in heart failure patients.

The patient's blood pressure of 190/110 mmHg further increases the risk of cardiac events, as uncontrolled hypertension can exacerbate heart failure and increase the risk of cardiac arrhythmias. The elevated pro-BNP level of 597 ng/L is indicative of heart failure, and the patient's NYHA Class II classification suggests moderate symptoms of heart failure.

The presence of ventricular extrasystoles on the ECG, although monomorphic, may indicate underlying cardiac ischemia or scarring, which can contribute to the risk of sudden cardiac death. The absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) suggests that the patient did not experience a sudden, life-threatening arrhythmia at the time of the ECG.

The patient's medication regimen includes calcium channel blockers, beta blockers, statins, and nitrovasodilators, which are standard treatments for heart failure and hypertension. However, the effectiveness of these medications may have been limited by the patient's underlying disease severity and comorbidities.

Considering the patient's complex medical history, severe systolic dysfunction, uncontrolled hypertension, and elevated pro-BNP level, the patient was at high risk for sudden cardiac death. The presence of ventricular extrasystoles on the ECG and the patient's overall clinical presentation likely contributed to the increased risk of sudden cardiac death."
289,289,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which significantly reduces the heart's pumping efficiency. The left ventricular ejection fraction (LVEF) of 35% indicates severe heart failure. This condition increases the risk of sudden cardiac death due to arrhythmias and decreased cardiac output.

The patient's blood pressure is elevated at 190/110 mmHg, which can lead to increased cardiac workload and further strain on the heart. Hypertension is also a risk factor for cardiovascular disease and sudden cardiac death.

The patient's Pro-BNP level of 597.0 ng/L is elevated, indicating increased ventricular stretch and wall tension, which is often seen in heart failure. This suggests that the patient's heart is under significant stress, increasing the risk of arrhythmias and cardiac arrest.

Additionally, the patient has a history of myocardial infarction, which can cause scarring in the heart muscle, leading to arrhythmias and sudden cardiac death.

The presence of ventricular extrasystoles on the ECG indicates abnormal heart rhythms, which can be a precursor to more serious arrhythmias like ventricular tachycardia, a known cause of sudden cardiac death.

The patient's low HDL cholesterol and high LDL cholesterol levels indicate dyslipidemia, which is a risk factor for cardiovascular disease and sudden cardiac death.

Furthermore, the patient's age of 67 and NYHA Class II classification indicate that he has moderate to severe heart failure symptoms, which can increase the risk of sudden cardiac death.

The patient's medications, including Calcium Channel Blocker, Beta Blockers, Statins, and Nitrovasodilator, are commonly used to manage heart failure and hypertension, but may not have been sufficient to prevent the patient's cardiac event.

In summary, the combination of ischemic dilated cardiomyopathy, severe heart failure, hypertension, elevated Pro-BNP levels, history of myocardial infarction, ventricular extrasystoles, and dyslipidemia all contributed to the patient's outcome of sudden cardiac death."
290,290,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history and the provided test results, the patient's outcome of sudden cardiac death is likely due to a combination of factors contributing to a high risk of cardiac arrhythmias and reduced cardiac function. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or coronary artery disease, leading to reduced cardiac function. The patient's left ventricular ejection fraction (LVEF) of 25% indicates severely reduced cardiac function, making the heart unable to pump enough blood to meet the body's needs.

The patient's ECG results show non-sustained ventricular tachycardia (VT), which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. Additionally, the presence of polymorphic ventricular extrasystoles and unknown paroxysmal supraventricular tachyarrhythmia further increases the risk of arrhythmias.

The patient's high Pro-BNP (B-type natriuretic peptide) level of 2542.0 ng/L is indicative of heart failure, which is consistent with the patient's history of ischemic dilated cardiomyopathy and reduced LVEF.

The patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, is aimed at managing heart failure, reducing arrhythmias, and improving cardiac function. However, despite these medications, the patient's cardiac function remains severely compromised, and the risk of sudden cardiac death remains high.

The patient's laboratory results, including elevated creatinine levels (118.0 mmol/L) and urea levels (8.91 mg/dL), indicate impaired renal function, which can further contribute to cardiac dysfunction and increase the risk of arrhythmias.

In conclusion, the combination of the patient's history of ischemic dilated cardiomyopathy, reduced LVEF, high Pro-BNP levels, non-sustained VT, and impaired renal function likely contributed to the patient's outcome of sudden cardiac death."
291,291,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, I can infer that the patient had a high risk of sudden cardiac death due to his complex medical history and current clinical status. The patient has ischemic dilated cardiomyopathy, which is a known cause of sudden cardiac death. The left ventricular ejection fraction (LVEF) of 25% indicates severe systolic dysfunction, which further increases the risk of sudden cardiac death.

The patient's history of myocardial infarction and dyslipemia also contribute to the development of coronary artery disease, which is a common cause of ischemic dilated cardiomyopathy. The elevated total cholesterol and LDL levels in the blood further support this diagnosis.

The patient's medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitor, is aimed at managing heart failure and reducing the risk of sudden cardiac death. However, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystole on the ECG indicates ongoing arrhythmogenic activity, which increases the risk of sudden cardiac death.

The elevated Pro-BNP level of 2542 ng/L also suggests that the patient has significant heart failure, which is a known risk factor for sudden cardiac death. Additionally, the patient's low hemoglobin level and elevated urea level may indicate anemia and renal dysfunction, respectively, which can further contribute to the risk of sudden cardiac death.

In summary, the combination of ischemic dilated cardiomyopathy, severe systolic dysfunction, coronary artery disease, ongoing arrhythmogenic activity, and significant heart failure makes the patient highly susceptible to sudden cardiac death."
292,292,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of his underlying medical conditions and the results of his diagnostic tests. 

1. Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged due to a heart attack or coronary artery disease. This condition can lead to reduced cardiac function, making the heart more susceptible to arrhythmias and sudden cardiac death.

2. Reduced LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 25%, which is significantly below the normal range of 55-70%. This indicates that the patient's heart is not pumping efficiently, which can lead to decreased cardiac output and increased risk of arrhythmias.

3. Non-Sustained Ventricular Tachycardia (NSVT): The patient's ECG shows NSVT, which is a condition where the heart beats at a rate of 100-240 beats per minute for 30 seconds or less. While NSVT is often a benign condition, it can be a precursor to sustained ventricular tachycardia, which can lead to sudden cardiac death.

4. High Pro-BNP (Brain Natriuretic Peptide): The patient's Pro-BNP level is 2542.0 ng/L, which is significantly elevated. Elevated Pro-BNP levels are associated with heart failure and increased risk of sudden cardiac death.

5. Medications: While the patient is on beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, these medications may not be sufficient to control the patient's underlying conditions, particularly the non-sustained ventricular tachycardia.

6. Electrolyte Imbalance: The patient's potassium level is 4 mEq/L, which is slightly low. Electrolyte imbalances can contribute to arrhythmias and sudden cardiac death.

7. Poor Control of Diabetes: The patient's glucose level is 9 mmol/L, which is above the target range for diabetes management. Uncontrolled diabetes can lead to cardiac complications, including sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to the combination of his underlying medical conditions, reduced cardiac function, and the presence of non-sustained ventricular tachycardia."
293,293,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death is likely due to a combination of several factors related to his underlying heart condition and other comorbidities.

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or coronary artery disease. This condition can lead to reduced cardiac function, making the heart more susceptible to arrhythmias and sudden cardiac death.

2.  Low LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 25%, which is significantly below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, making it difficult for the heart to meet the body's oxygen demands, leading to increased risk of sudden cardiac death.

3.  Pro-BNP (N-terminal pro-b-type natriuretic peptide) level: The patient's Pro-BNP level is elevated at 2542.0 ng/L, which is indicative of heart failure. Elevated Pro-BNP levels are associated with increased risk of sudden cardiac death.

4.  Ventricular arrhythmias: The ECG shows non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can lead to sudden cardiac death.

5.  Electrolyte imbalance: The patient's potassium level is slightly low at 4 mEq/L, which can increase the risk of arrhythmias and sudden cardiac death.

6.  Medication non-adherence or inadequate management: The patient is on multiple medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors. However, the patient's condition may not be adequately managed, contributing to the risk of sudden cardiac death.

7.  Comorbidities: The patient has diabetes, dyslipemia, and a history of myocardial infarction, which can further increase the risk of cardiovascular events and sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of his underlying heart condition, low LVEF, elevated Pro-BNP levels, ventricular arrhythmias, electrolyte imbalance, and inadequate management of his condition."
294,294,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying heart condition and laboratory results. 

Firstly, the patient has ischemic dilated cardiomyopathy, a condition characterized by reduced left ventricular function, which is reflected in the low left ventricular ejection fraction (LVEF) of 25%. This indicates a significant impairment of the heart's ability to pump blood effectively, making the patient prone to cardiac arrhythmias and sudden cardiac death.

The patient's elevated Pro-BNP (brain natriuretic peptide) level of 2542.0 ng/L is a marker of heart failure and increased ventricular wall stress, further indicating the severity of the patient's heart condition.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests a high risk of life-threatening arrhythmias. The combination of NSVT and a low LVEF increases the risk of sudden cardiac death.

Additionally, the patient's diabetes and dyslipemia contribute to the development and progression of atherosclerosis, which can lead to ischemic heart disease and further compromise cardiac function.

The patient's medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitor, is aimed at managing heart failure and reducing the risk of arrhythmias. However, the patient's underlying condition and laboratory results suggest that these medications may not be sufficient to prevent sudden cardiac death.

The patient's low T3 and T4 levels, as well as a slightly elevated TSH, may indicate hypothyroidism, which can also contribute to heart failure and arrhythmias.

In conclusion, the patient's outcome of sudden cardiac death can be attributed to a combination of their underlying ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, NSVT, polymorphic ventricular extrasystoles, and other contributing factors such as diabetes, dyslipemia, and potential hypothyroidism."
295,295,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors evident from the provided data. 

1. Severe Left Ventricular Dysfunction: The patient has an LVEF of 25%, indicating severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death. Ischemic dilated cardiomyopathy, as mentioned in the patient's past medical history, likely contributed to this condition.

2. High Pro-BNP Levels: A Pro-BNP level of 2542.0 ng/L is significantly elevated, indicating severe heart failure. Elevated Pro-BNP levels are associated with increased risk of adverse cardiac events, including sudden cardiac death.

3. Presence of Non-Sustained Ventricular Tachycardia (NSVT): The ECG impression shows non-sustained ventricular tachycardia, which is a known predictor of sudden cardiac death. NSVT is a marker of electrical instability in the heart and can increase the risk of life-threatening arrhythmias.

4. Previous Myocardial Infarction and Ischemic Dilated Cardiomyopathy: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. These conditions can lead to scarring and electrical instability in the heart, making it more susceptible to life-threatening arrhythmias.

5. Medication Non-Optimization: Although the patient is on several medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, there might be a need for further optimization or adjustment of these medications to better manage the patient's heart failure and arrhythmias. For example, beta blockers are crucial in reducing the risk of sudden cardiac death in patients with heart failure, but the optimal dosage and titration might not be achieved.

6. Suboptimal Lipid Profile: The patient's total cholesterol and LDL levels are not optimally managed, which may contribute to ongoing atherosclerotic disease and increase the risk of cardiac events.

7. Electrolyte Imbalance: Although not significantly abnormal, the patient's potassium level is slightly low at 4 mEq/L. Electrolyte imbalances can contribute to arrhythmias and cardiac instability.

Given these factors, the patient's outcome of sudden cardiac death is not unexpected. It highlights the need for close monitoring, optimization of medications, and aggressive management of heart failure and arrhythmias to reduce the risk of future cardiac events."
296,296,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in the patient's medical history and current condition. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which significantly reduces the heart's pumping efficiency, leading to decreased left ventricular ejection fraction (LVEF) of 25.0%. This is a strong indicator of heart failure and a significant risk factor for sudden cardiac death.

Additionally, the patient has a high level of B-type natriuretic peptide (BNP), with a value of 2542.0 ng/L, which is significantly elevated. BNP is a marker of heart failure and is used to assess the severity of heart failure. High levels of BNP are associated with increased risk of sudden cardiac death.

The patient's ECG results show non-sustained ventricular tachycardia (VT), which is a type of abnormal heart rhythm that can be a precursor to sustained VT and potentially life-threatening arrhythmias. The presence of polymorphic ventricular extrasystoles further increases the risk of arrhythmia and sudden cardiac death.

Furthermore, the patient's history of myocardial infarction (heart attack) and diabetes mellitus also contribute to the risk of sudden cardiac death. Diabetes mellitus can lead to cardiac autonomic neuropathy, which can disrupt the heart's normal rhythm and increase the risk of arrhythmias.

Lastly, the patient's low HDL cholesterol level (1.09 mmol/L) and high LDL cholesterol level (2.04 mmol/L) indicate poor lipid profile, which can exacerbate atherosclerosis and increase the risk of myocardial infarction and sudden cardiac death.

In summary, the combination of ischemic dilated cardiomyopathy, high BNP levels, non-sustained VT, polymorphic ventricular extrasystoles, history of myocardial infarction, and poor lipid profile all contribute to the patient's outcome of sudden cardiac death."
297,297,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided data. 

1. Ischemic dilated cardiomyopathy (IDC): The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. IDC is a condition where the heart's left ventricle is enlarged and weakened due to coronary artery disease, leading to reduced cardiac function.

2. Low LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is severely reduced at 25%, indicating poor cardiac function. A low LVEF is a strong predictor of sudden cardiac death in patients with heart failure.

3. High Pro-BNP levels: The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is elevated at 2542.0 ng/L. Elevated Pro-BNP levels are associated with increased risk of sudden cardiac death in patients with heart failure.

4. History of non-sustained ventricular tachycardia (NSVT): The presence of NSVT is a known risk factor for sudden cardiac death. NSVT is a type of abnormal heart rhythm that can increase the risk of sudden cardiac arrest.

5. Ventricular extrasystoles: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of electrical instability in the heart and may contribute to the risk of sudden cardiac death.

6. Poor glycemic control: The patient's glucose level is elevated at 9 mmol/L, indicating poor glycemic control. Diabetes mellitus is a known risk factor for sudden cardiac death, and poor glycemic control can further exacerbate cardiac dysfunction.

7. Medication regimen: Although the patient is on beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, which are standard medications for heart failure and ischemic cardiomyopathy, the combination and dosages may not be sufficient to adequately manage the patient's condition, contributing to the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of his underlying ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, history of NSVT, ventricular extrasystoles, poor glycemic control, and potentially inadequate medication management."
298,298,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient is a 70-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25%, indicating severe systolic heart failure. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG further increases the risk of sudden cardiac death.

The elevated Pro-BNP (brain natriuretic peptide) level of 2542 ng/L is indicative of heart failure and suggests that the patient's heart is under strain. The patient's low hemoglobin level (139 g/L) may indicate anemia, which can contribute to fatigue and decreased exercise tolerance, further exacerbating heart failure symptoms.

The patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. However, the presence of NSVT and a reduced LVEF suggests that the patient may not be adequately responding to these medications.

The patient's blood work shows elevated creatinine levels (118.0 mol/L), which may indicate kidney dysfunction, a common comorbidity in patients with heart failure. The patient's glucose level is also elevated (9 mmol/L), which may contribute to the progression of heart failure.

Given the patient's complex medical history, reduced LVEF, NSVT, and elevated Pro-BNP level, the patient is at high risk for sudden cardiac death. The patient's underlying heart failure and kidney dysfunction may have contributed to a fatal arrhythmia, leading to sudden cardiac death."
299,299,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided data. 

1. Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death due to the underlying structural and functional abnormalities of the heart. The low left ventricular ejection fraction (LVEF) of 25% further supports this, indicating poor heart function.

2. Low LVEF and High Pro-BNP: The low LVEF of 25% indicates severe systolic dysfunction, which is a significant predictor of adverse outcomes, including sudden cardiac death. The elevated Pro-BNP (brain natriuretic peptide) level of 2542 ng/L also suggests heart failure with reduced ejection fraction, further supporting the risk of sudden cardiac death.

3. History of Myocardial Infarction: The patient's history of myocardial infarction (heart attack) contributes to the development of ischemic dilated cardiomyopathy and increases the risk of sudden cardiac death.

4. Electrocardiogram (ECG) Findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates abnormal heart rhythms, which can lead to sudden cardiac death. Non-sustained ventricular tachycardia is particularly concerning as it can degenerate into sustained ventricular tachycardia or ventricular fibrillation, both of which are life-threatening.

5. Medications: The patient is on beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are commonly used in heart failure and arrhythmia management. However, despite these medications, the patient's condition remains severe, indicating that the treatment may not be adequately addressing the underlying issues.

6. Other Factors: The patient's age (70 years), gender (male), and the presence of diabetes and dyslipidemia further increase the risk of cardiovascular events, including sudden cardiac death.

In summary, the combination of ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP, history of myocardial infarction, abnormal ECG findings, and other risk factors likely contributed to the patient's outcome of sudden cardiac death."
300,300,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, myocardial infarction, diabetes, and dyslipemia, the patient is at high risk for adverse cardiac events. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 15%, indicating significant heart failure.

The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, are typical for managing heart failure and ischemic cardiomyopathy. The presence of a high pro-BNP level (593 ng/L) further supports the diagnosis of heart failure, as elevated BNP levels are associated with increased ventricular wall stress and fluid overload.

The patient's blood pressure is within a relatively normal range (110/60 mmHg), which may be attributed to the effect of beta blockers and loop diuretics. However, the patient's lipid profile (Total Cholesterol: 4.29 mmol/L, LDL: 2.38 mmol/L) indicates that the statin therapy is effective in managing dyslipemia.

The patient's glucose level (8.4 mmol/L) is elevated, suggesting uncontrolled diabetes, which may contribute to the progression of cardiovascular disease. However, the patient's hemoglobin A1c level is not provided, which would be essential in assessing the adequacy of glucose control.

The patient's kidney function, as indicated by creatinine levels (71.0 mmol/L), is within the normal range. However, the patient's urea level (6.16 mg/dL) is slightly elevated, which may indicate mild renal impairment.

The patient's ECG shows evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and possible paroxysmal supraventricular tachyarrhythmia and bradycardia, which are consistent with the patient's history of ischemic cardiomyopathy and heart failure.

Considering the patient's complex medical history and current condition, the patient's survival outcome is likely due to the comprehensive management of their heart failure and ischemic cardiomyopathy, as well as the ongoing medical therapy and monitoring. The patient's relatively stable vital signs, normal kidney function, and controlled lipid profile further support this outcome."
301,301,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 60-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, has a complex medical condition that required careful management. Despite the presence of a severely reduced left ventricular ejection fraction (LVEF) of 15%, the patient was able to survive, likely due to the combination of her current medications and a relatively low level of troponin (0.01 ng/mL), indicating minimal ongoing myocardial damage.

The use of beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor suggests that the patient's heart failure was being adequately managed, which contributed to her survival. The presence of a normal hemoglobin level (135 g/L) and a relatively low creatinine level (71.0 umol/L) also indicate that the patient's kidney function was well-preserved.

The patient's blood pressure of 110/60 mmHg is within a relatively normal range, which may be due to the effects of her medications. The low level of total cholesterol (4.29 mmol/L) and LDL (2.38 mmol/L) suggests that the patient's lipid profile was being effectively managed with statins.

The elevated level of pro-BNP (593.0 ng/L) is consistent with heart failure, but the patient's survival suggests that this level was not indicative of severe heart failure exacerbation. The patient's TSH level (2.84 mIU/L) is within the normal range, indicating that her thyroid function was not contributing to her cardiac condition.

The presence of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia on the ECG may have contributed to the patient's risk of cardiac arrhythmias, but the fact that she survived suggests that these arrhythmias were not life-threatening.

In summary, the combination of the patient's current medications, relatively low level of troponin, preserved kidney function, and effective management of her lipid profile contributed to her survival, despite her complex medical condition."
302,302,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, a 60-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, is a high-risk patient with a reduced left ventricular ejection fraction (LVEF) of 15%. Despite her history, the patient is currently a survivor. Several factors contribute to this outcome:

1.  Optimal Medical Management: The patient is on a multidrug regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors. These medications are crucial in managing heart failure symptoms, reducing morbidity, and mortality in patients with heart failure.

2.  Controlled Blood Pressure: The patient's blood pressure is within a normal range (110/60 mmHg), which is beneficial for heart health. Hypertension is a significant risk factor for cardiovascular disease, and well-managed blood pressure can reduce the strain on the heart.

3.  Low Troponin Levels: A troponin level of 0.01 ng/mL is within the normal range, indicating that there is no ongoing myocardial infarction or cardiac damage.

4.  Pro-BNP Levels: Although the patient has a high Pro-BNP level (593.0 ng/L), which is indicative of heart failure, the level is not extremely high, suggesting that the patient's heart failure is not severe.

5.  Hemoglobin and Urea Levels: The patient's hemoglobin level is within the normal range, and urea levels are not significantly elevated, indicating that the kidneys are functioning adequately.

6.  ECG Findings: While the patient has ventricular extrasystoles, non-sustained ventricular tachycardia, and an unknown paroxysmal supraventricular tachyarrhythmia, these are not life-threatening conditions in this context.

Considering these factors, the patient's survival can be attributed to the effectiveness of her medical management, controlled blood pressure, and the absence of ongoing cardiac damage."
303,303,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and NYHA Class II, it is expected that the patient has a compromised cardiac function. The patient's LVEF (Left Ventricular Ejection Fraction) of 15% indicates severe systolic dysfunction, which is a significant predictor of poor outcomes in heart failure patients.

The patient's laboratory results show elevated Pro-BNP (brain natriuretic peptide) levels at 593.0 ng/L, which is indicative of heart failure. The patient's total cholesterol and LDL levels are high, which may contribute to the progression of the patient's heart condition. However, the patient is on statins, which should help manage these levels.

The patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitor, which are standard treatments for heart failure and ischemic cardiomyopathy. These medications are likely helping to manage the patient's symptoms and slow the progression of the disease.

The ECG findings of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles indicate arrhythmias, which are common in patients with heart failure. However, the presence of these arrhythmias does not necessarily indicate a poor prognosis.

The patient's overall outcome of survival is likely due to the comprehensive management of their heart failure and ischemic cardiomyopathy, including the use of evidence-based medications and close monitoring. The patient's age, sex, and weight are also factors that contribute to their survival. The patient's weight of 74 kg is within a relatively normal range for their height, which may also contribute to their survival.

However, the patient's low LVEF and high Pro-BNP levels indicate that they are still at risk for cardiac complications and should continue to be closely monitored."
304,304,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and current NYHA Class II classification, it is expected that the patient has significant cardiac dysfunction. The patient's left ventricular ejection fraction (LVEF) of 15% indicates severe left ventricular dysfunction, which is consistent with the diagnosis of heart failure with reduced ejection fraction (HFrEF).

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitor, are all appropriate for managing heart failure and reducing the risk of cardiovascular events. The presence of these medications suggests that the patient is receiving standard care for heart failure.

The patient's laboratory results show elevated levels of pro-BNP (593.0 ng/L), which is consistent with heart failure. The patient's creatinine level (71.0 mmol/L) is elevated, indicating impaired renal function, which is common in patients with heart failure. The patient's glucose level (8.4 mmol/L) is also elevated, which may be related to diabetes.

The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a common finding in patients with heart failure. The presence of NSVT is a marker of increased risk of sudden cardiac death, but the patient's overall survival outcome suggests that the risk of sudden cardiac death was mitigated by their treatment.

The patient's TSH level (2.84 mIU/L) is within the normal range, indicating that there is no evidence of thyroid dysfunction. The patient's troponin level (0.01 ng/mL) is normal, indicating that there is no acute myocardial infarction.

The patient's outcome of survival suggests that the patient's treatment plan was effective in managing their heart failure and reducing the risk of cardiovascular events. The patient's medications and laboratory results suggest that they are receiving appropriate care for their condition, and their ECG findings do not indicate any acute cardiac complications.

Overall, the patient's outcome of survival is likely due to the effectiveness of their treatment plan, including their medications and lifestyle modifications, which have helped to manage their heart failure and reduce the risk of cardiovascular events."
305,305,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 60-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. Despite her complex medical history and multiple comorbidities, the patient is a survivor, indicating that she has managed to overcome her cardiac condition. Several factors contribute to her favorable outcome:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and related conditions. This suggests that her healthcare team has effectively managed her symptoms and comorbidities.

2.  Monitoring and Treatment of Arrhythmias: The patient has been diagnosed with ventricular extrasystole, non-sustained ventricular tachycardia, and a non-sustained ventricular tachycardia with a cycle length > 10 seconds. Despite these arrhythmias, she has not experienced a sustained or life-threatening cardiac event, indicating effective management of these conditions.

3.  Blood Work: Her blood work shows slightly elevated creatinine levels (71.0 mmol/L), but her urea levels (6.16 mg/dL) are within a relatively normal range, indicating that her kidney function is not significantly impaired. Her electrolyte levels, including potassium (4.4 mEq/L) and sodium (140.0 mEq/L), are also within normal limits, which is crucial for maintaining cardiac function.

4.  Hemoglobin and Protein Levels: Her hemoglobin (135.0 g/L) and protein (65 g/L) levels are within normal ranges, indicating that she does not have significant anemia or malnutrition, which can exacerbate heart failure.

5.  Hormonal Balance: Her TSH (2.84 mIU/L) and T4 (13 ng/L) levels are within normal ranges, indicating that her thyroid function is well-managed.

6.  Low Pro-BNP Levels: Her pro-BNP (593.0 ng/L) levels, although slightly elevated, are not extremely high, indicating that her heart failure symptoms are not severe.

7.  LVEF: Her left ventricular ejection fraction (LVEF) of 15% is extremely low, indicating severe heart failure. However, her survival suggests that her healthcare team has effectively managed her symptoms and comorbidities to prevent further decline.

Considering these factors, the patient's survival can be attributed to effective management of her cardiac condition, optimal medication, and close monitoring of her comorbidities and arrhythmias."
306,306,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 60-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. She has been prescribed a comprehensive treatment regimen consisting of beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor.

The patient's laboratory results show elevated levels of troponin (0.01 ng/mL) indicating myocardial damage, but it is significantly lower than the typical range for an acute myocardial infarction. Her LVEF is severely reduced at 15%, which is consistent with her diagnosis of ischemic dilated cardiomyopathy.

The patient's blood pressure is within a relatively normal range (110/60 mmHg), and her potassium levels are slightly low (4.4 mEq/L), which may be related to the use of loop diuretics.

The patient's Pro-BNP level is elevated at 593.0 ng/L, indicating increased ventricular wall stress, which is consistent with her heart failure diagnosis.

The patient's ECG shows polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and an unknown paroxysmal supraventricular tachyarrhythmia. However, despite these arrhythmias, the patient is still alive, indicating that her treatment regimen is effective in managing her arrhythmias and preventing further complications.

The patient's overall clinical picture suggests that she has a severe but stable heart failure condition, with a reduced ejection fraction and evidence of myocardial damage. Her treatment regimen is likely aimed at managing her symptoms, reducing her risk of further cardiac events, and improving her quality of life.

Given the patient's treatment regimen and laboratory results, the most likely reason for her survival is the effectiveness of her medication, particularly the beta blockers, ACE inhibitor, and spironolactone, which are all known to improve outcomes in patients with heart failure and reduce the risk of sudden cardiac death. Additionally, the patient's relatively normal blood pressure and low potassium levels may also contribute to her survival."
307,307,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 60-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, which are all significant risk factors for heart failure. Her current NYHA Class II classification indicates that she experiences some limitations in physical activity but is still able to perform everyday tasks.

The patient's laboratory results show elevated Pro-BNP levels (593.0 ng/L), which is indicative of heart failure. Her left ventricular ejection fraction (LVEF) is severely reduced at 15.0%, further supporting the diagnosis of heart failure. Additionally, her Troponin level is within normal limits (0.01 ng/mL), indicating that she is not experiencing an acute myocardial infarction.

The patient's ECG shows non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, which are both associated with an increased risk of sudden cardiac death. However, the presence of beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors in her medication list suggests that she is receiving appropriate treatment for her heart failure and arrhythmias.

Considering the patient's overall clinical picture, including her reduced LVEF, elevated Pro-BNP levels, and the presence of arrhythmias, the most likely outcome is that she is experiencing heart failure with reduced ejection fraction (HFrEF). However, despite these factors, the patient's survival suggests that her treatment plan is effective in managing her condition, and she is likely receiving close monitoring and follow-up care to prevent further complications."
308,308,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor is likely due to a combination of factors. 

Firstly, the patient is currently on a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic dilated cardiomyopathy. These medications are likely helping to manage the patient's symptoms and slow the progression of the disease.

Secondly, the patient's blood pressure is within a relatively normal range (110/60 mmHg), which is beneficial for heart health. The patient's low blood pressure may be a result of the diuretic medications, which help to reduce fluid buildup in the body.

Thirdly, the patient's LVEF (Left Ventricular Ejection Fraction) is 15%, which is very low, indicating severe heart failure. However, the fact that the patient has survived despite this low LVEF suggests that the patient's body has adapted to the condition and is compensating in some way.

Fourthly, the patient's troponin level is 0.01 ng/mL, which is within a normal range, indicating that there is no ongoing myocardial infarction (heart attack) and that the patient's heart muscle is not being severely damaged.

Lastly, the patient's pro-BNP (B-type natriuretic peptide) level is 593.0 ng/L, which is elevated, indicating that the patient's heart is under strain and that there is fluid buildup in the body. However, the patient's overall clinical presentation and medication regimen are likely helping to manage this condition.

Overall, the patient's outcome as a survivor is likely due to a combination of effective medical management, low blood pressure, and the patient's body's ability to adapt to the severe heart failure."
309,309,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 60-year-old female with a history of ischemic dilated cardiomyopathy, myocardial infarction, diabetes, and dyslipemia, presented with a low left ventricular ejection fraction (LVEF) of 15%, indicating severe heart failure. Despite this, the patient survived. Several factors contributed to this outcome:

1.  Optimal Medication Regimen: The patient was on a comprehensive medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, which are all standard treatments for heart failure and ischemic cardiomyopathy. This multidrug approach likely helped manage the patient's symptoms and slow disease progression.

2.  Good Blood Pressure Control: The patient's blood pressure was well-controlled at 110/60 mmHg, which is within the normal range. Hypertension is a significant risk factor for heart failure, and controlling blood pressure can reduce the strain on the heart.

3.  Low Cholesterol Levels: The patient's total cholesterol level was 4.29 mmol/L, and LDL was 2.38 mmol/L, which is relatively low. This suggests that the patient's lipid-lowering therapy (statins) was effective in managing dyslipemia, reducing the risk of further cardiac events.

4.  Normal Renal Function: The patient's creatinine level was 71.0 mol/L, indicating normal renal function. Kidney disease is a common comorbidity in patients with heart failure, and preserved renal function may have contributed to the patient's better outcome.

5.  Low Pro-BNP Level: The patient's Pro-BNP level was 593.0 ng/L, which is elevated but not extremely high. B-type natriuretic peptide (BNP) is a biomarker for heart failure severity; a lower level suggests that the patient's heart failure symptoms were not extremely severe.

6.  Absence of Severe Electrocardiographic Abnormalities: Although the patient had ventricular extrasystoles and non-sustained ventricular tachycardia, these findings were not indicative of severe arrhythmias that would have increased the risk of sudden cardiac death.

7.  Normal Hemoglobin and Protein Levels: The patient's hemoglobin and protein levels were within normal ranges, indicating that she did not have significant anemia or malnutrition, which can worsen heart failure outcomes.

8.  TSH and T4 Levels within Normal Range: The patient's thyroid function was normal, which is essential for maintaining a healthy heart.

9.  Good Electrolyte Balance: The patient's potassium level was 4.4 mEq/L, which is within the normal range, indicating that her electrolyte balance was well-managed.

In summary, the patient's survival can be attributed to a combination of her well-managed medical conditions, optimal medication regimen, controlled blood pressure, low cholesterol levels, preserved renal function, and absence of severe electrocardiographic abnormalities."
310,310,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, it is not surprising that the patient survived. Here are some key factors that contributed to the patient's outcome:

1. Medications: The patient is on a regimen of medications that are beneficial for heart health, including beta blockers, statins, and an ACE inhibitor. Beta blockers help reduce the heart rate and blood pressure, while statins lower cholesterol levels, and ACE inhibitors help manage blood pressure and reduce strain on the heart.

2. LVEF (Left Ventricular Ejection Fraction): Although the patient's LVEF is only 45%, which indicates a reduced ejection fraction and potential heart failure, the patient's overall condition does not seem to be catastrophic. An LVEF of 45% is still within the range of moderate heart failure, and the patient is likely on medications to manage this condition.

3. Pro-BNP (B-type Natriuretic Peptide): Pro-BNP levels are elevated at 1860.0 ng/L, which is consistent with heart failure. However, the patient's survival suggests that the heart failure is not severe, and the elevated Pro-BNP levels may be a reflection of the patient's underlying condition rather than an immediate life-threatening issue.

4. ECG findings: While the patient has polymorphic ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia, which is a more severe condition that can be life-threatening. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is not typically a life-threatening condition and can often be managed with treatment.

5. Other factors: The patient's age, weight, and height are not particularly alarming, and the patient's blood pressure is within a relatively normal range. The patient's laboratory results, including the blood glucose and creatinine levels, are also within relatively normal ranges.

Considering these factors, it is likely that the patient's survival is due to a combination of the patient's current treatment regimen, the relatively moderate severity of their heart failure, and the absence of more severe cardiac arrhythmias or other life-threatening conditions."
311,311,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the patient's current management and treatment plan, the presence of certain biomarkers, and the absence of severe cardiac complications. 

Firstly, the patient is already on a comprehensive medication regimen, including diabetes medication, beta blockers, statins, and an ACE inhibitor, which are all crucial in managing his ischemic dilated cardiomyopathy, hypertension, and dyslipemia. These medications help to reduce the workload on the heart, lower blood pressure, and improve lipid profiles, thereby reducing the risk of further cardiac complications.

Secondly, the patient's laboratory results indicate that his troponin levels are within the normal range (0.01 ng/mL), suggesting that there is no ongoing myocardial infarction. Additionally, his pro-BNP levels are elevated at 1860.0 ng/L, which is a marker of heart failure. However, the patient's LVEF (left ventricular ejection fraction) is 45%, which is below the normal range but not critically low, indicating that the patient's heart is still functioning, albeit with reduced efficiency.

The patient's ECG results show polymorphic ventricular extrasystoles, which are common in patients with heart failure, but there is no evidence of sustained ventricular tachycardia or bradycardia, indicating that the patient's heart rhythm is relatively stable.

Lastly, the patient's age, weight, and height suggest that he is not severely malnourished or dehydrated, as indicated by his albumin and protein levels, which are within the normal range. His urea and creatinine levels are also within the normal range, suggesting that his kidney function is not severely impaired.

Taking all these factors into consideration, the patient's outcome of survival can be attributed to the effectiveness of his current treatment plan, the absence of severe cardiac complications, and the relatively stable heart rhythm."
312,312,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, which are all significant risk factors for cardiac complications. However, despite these comorbidities, the patient's blood pressure is well-controlled at 140/70 mmHg, and he is on a regimen of diabetes medication, beta blockers, statins, and ACE inhibitors, which are all appropriate for his conditions.

The patient's LVEF (left ventricular ejection fraction) is 45%, which is below the normal range of 55-70%, indicating that he has some degree of heart failure. However, his NYHA Class III classification indicates that he is experiencing symptoms of heart failure, such as shortness of breath and fatigue, but is still able to perform some physical activity.

The patient's laboratory results show elevated levels of creatinine (109.0 mmol/L), which may indicate some degree of kidney dysfunction, but his albumin and protein levels are within normal limits. His glucose level is slightly elevated at 6.9 mmol/L, but this is likely due to his diabetes.

The patient's troponin level is 0.01 ng/mL, which is within normal limits, indicating that he is not experiencing an acute myocardial infarction. His pro-BNP level is elevated at 1860.0 ng/L, which is consistent with heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. The presence of TPSV (paroxysmal supraventricular tachyarrhythmia) is also noted.

Considering these factors, the patient's outcome as a survivor is likely due to the following reasons:

1. Optimal medical management: The patient is on appropriate medications for his conditions, which has helped to control his symptoms and prevent further cardiac complications.
2. Mild symptoms: The patient's NYHA Class III classification indicates that he is experiencing some symptoms of heart failure, but is still able to perform some physical activity, which suggests that his condition is not severe.
3. No acute cardiac event: The patient's troponin level is within normal limits, indicating that he is not experiencing an acute myocardial infarction.
4. Mild kidney dysfunction: The patient's creatinine level is elevated, but his albumin and protein levels are within normal limits, indicating that his kidney function is not severely compromised.

Overall, the patient's outcome as a survivor is likely due to a combination of optimal medical management, mild symptoms, and the absence of an acute cardiac event."
313,313,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, survived the current episode, likely due to a combination of several factors.

The patient's left ventricular ejection fraction (LVEF) is 45%, indicating a moderately reduced cardiac function, which is consistent with his history of ischemic dilated cardiomyopathy. However, his blood pressure is well-controlled at 140/70 mmHg, and he is on beta blockers, which suggests that his heart rate and blood pressure are being managed effectively.

The patient's troponin level is within normal limits (0.01 ng/mL), indicating that there is no current acute myocardial infarction. His pro-BNP level is elevated at 1860.0 ng/L, which suggests that he has some degree of heart failure, but it is not severe.

The patient's ECG shows polymorphic ventricular extrasystoles, which are common in patients with cardiomyopathy, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

The patient's laboratory results show that his kidney function is slightly impaired, with a creatinine level of 109.0 umol/L, but his urea level is within normal limits. His liver function tests are also within normal limits, except for a slightly elevated gamma-glutamyl transferase (GGT) level, which may indicate some degree of liver dysfunction.

The patient's diabetes is well-controlled, with a hemoglobin A1c level not available, but his glucose level is 6.9 mmol/L, which is within the target range. His lipid profile shows a high total cholesterol level, but his LDL level is well-controlled with statins.

Overall, the patient's survival is likely due to a combination of his well-managed medical conditions, his current medications, and his relatively stable cardiac function."
314,314,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, has been prescribed a comprehensive medication regimen consisting of diabetes medication, beta blockers, statins, and an ACE inhibitor. His current medications are likely aimed at managing his heart failure symptoms, controlling his blood pressure, and reducing his cholesterol levels.

The patient's New York Heart Association (NYHA) Class III classification indicates that he experiences symptoms of heart failure with mild to moderate limitation in physical activity. His left ventricular ejection fraction (LVEF) of 45% is within the range for heart failure with reduced ejection fraction (HFrEF), indicating that his heart is not pumping efficiently.

The patient's elevated pro-BNP (brain natriuretic peptide) level of 1860 ng/L suggests that he is experiencing heart failure, and his creatinine level of 109.0 mol/L indicates mild kidney impairment, which is a common comorbidity in patients with heart failure.

The patient's ECG findings of polymorphic ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia (PSVT) suggest that he may be at risk for arrhythmias, which can be a complication of heart failure.

Given the patient's complex medical history and the presence of heart failure, the fact that he is a survivor suggests that his treatment plan is effective in managing his condition. His medications are likely helping to control his symptoms, slow the progression of his heart failure, and reduce his risk of complications.

It is also possible that the patient has undergone some form of treatment or intervention, such as cardiac resynchronization therapy (CRT) or an implantable cardioverter-defibrillator (ICD), which can help to improve his symptoms and reduce his risk of sudden cardiac death.

In summary, the patient's survival outcome is likely due to the effectiveness of his treatment plan, which includes medications and possibly other interventions, in managing his heart failure and reducing his risk of complications."
315,315,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's age and NYHA Class III classification indicate that they have a moderate to severe level of heart failure symptoms. Despite this, the patient survived, which can be attributed to several factors:

1.  Optimal Medications: The patient is on a comprehensive treatment plan, including diabetes medication, beta blockers, statins, and an ACE inhibitor. Beta blockers and ACE inhibitors are particularly effective in managing heart failure by reducing the heart's workload and improving its pumping efficiency.

2.  Controlled Blood Pressure: The patient's blood pressure is within a relatively normal range (140/70 mmHg), which is crucial for patients with heart failure. High blood pressure can exacerbate heart failure symptoms and increase the risk of cardiovascular events.

3.  LVEF of 45%: Although the patient's left ventricular ejection fraction (LVEF) is low (45%), indicating reduced heart function, it is not severely impaired. An LVEF of 45-50% is considered mildly to moderately reduced, and patients with LVEF in this range can still survive with proper treatment and lifestyle modifications.

4.  Stable Troponin Levels: The patient's troponin levels are within normal limits (0.01 ng/mL), indicating that there is no acute myocardial infarction or significant cardiac damage.

5.  Normal Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within normal ranges, which is essential for maintaining proper heart function and reducing the risk of arrhythmias.

6.  TSH and T4 Levels: The patient's thyroid function tests (TSH and T4) are within normal limits, which is crucial for maintaining cardiac function and overall health.

7.  Absence of Severe Comorbidities: The patient's creatinine levels (109.0 umol/L) are slightly elevated, indicating mild kidney dysfunction. However, this is not severe enough to impact the patient's survival.

Considering these factors, the patient's survival can be attributed to a combination of optimal medication management, controlled blood pressure, relatively preserved LVEF, stable troponin levels, and the absence of severe comorbidities."
316,316,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 73-year-old male, has a complex medical history that includes ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and a history of myocardial infarction. Despite these significant comorbidities, the patient is a survivor, which can be attributed to several factors:

1.  Optimal Medications: The patient is on a comprehensive treatment regimen that includes diabetes medication, beta blockers, statins, and an ACE inhibitor. Beta blockers are particularly beneficial for patients with heart failure and myocardial infarction, as they help reduce the workload on the heart and lower the risk of arrhythmias. Statins help manage dyslipemia and reduce the risk of further cardiovascular events.

2.  Proper Blood Pressure Control: The patient's blood pressure is within a relatively normal range (140/70 mmHg), which is crucial for patients with heart failure and peripheral vascular disease. Adequate blood pressure control helps reduce the strain on the heart and prevents further damage to the blood vessels.

3.  LVEF of 45%: Although the patient's left ventricular ejection fraction (LVEF) is lower than normal, indicating some degree of heart failure, it is not extremely low. An LVEF of 45% is still within the range where medical management can be effective in managing symptoms and slowing disease progression.

4.  Normal Troponin Levels: The patient's troponin level is within the normal range, indicating that there is no acute myocardial infarction at the time of the assessment.

5.  ECG Findings: Although the patient has ventricular extrasystoles, which can be a sign of underlying cardiac disease, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's cardiac rhythm is relatively stable.

6.  Other Laboratory Results: The patient's albumin, AST, ALT, and gamma-glutamil transpeptidase levels are within normal limits or only slightly elevated, indicating that the liver function is not severely compromised. The patient's potassium level is within the normal range, which is important for maintaining cardiac function.

7.  Pro-BNP Level: The patient's pro-BNP level is elevated, indicating some degree of heart failure, but it is not extremely high. This suggests that the patient's heart failure is not severe at this time.

8.  Hemoglobin Level: The patient's hemoglobin level is within the normal range, which is essential for maintaining adequate oxygen delivery to the tissues.

9.  TSH Level: The patient's TSH level is within the normal range, indicating that the thyroid function is not contributing to the patient's cardiac condition.

10. Comprehensive Management: The patient's overall management plan appears to be comprehensive, addressing multiple aspects of his complex medical condition.

Considering these factors, the patient's survival can be attributed to the effective management of his comorbidities, the use of appropriate medications, and the absence of acute cardiac events or severe cardiac dysfunction at the time of assessment."
317,317,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the management of his underlying conditions and the effectiveness of his current treatment regimen. 

Firstly, the patient has been on beta blockers, which are commonly used to manage heart failure and reduce the risk of cardiovascular events. The presence of beta blockers in his medication list suggests that he has been receiving appropriate treatment for his ischemic dilated cardiomyopathy, which is likely contributing to his reduced left ventricular ejection fraction (LVEF) of 45%. 

Additionally, the patient is on statins, which are known to reduce the risk of cardiovascular events and mortality in patients with heart disease. His total cholesterol level of 4.03 mmol/L is elevated, but it is not excessively high, and his HDL level of 1.14 mmol/L is low. The use of statins in conjunction with lifestyle modifications may be contributing to his survival.

The patient is also on an ACE inhibitor, which is a common treatment for heart failure and hypertension. ACE inhibitors have been shown to improve survival and reduce morbidity in patients with heart failure.

The patient's diabetes is well-controlled, with a glucose level of 6.9 mmol/L. Good glycemic control is essential for reducing the risk of cardiovascular complications in diabetic patients.

The patient's TSH level is within the normal range, indicating that his thyroid function is not contributing to his heart failure symptoms. His T3 and T4 levels are also within normal limits.

The patient's pro-BNP level of 1860.0 ng/L is elevated, which is consistent with heart failure. However, this is not uncommon in patients with heart failure, and the fact that he is on beta blockers and ACE inhibitors suggests that his symptoms are being managed.

The patient's LVEF of 45% indicates that he has significant left ventricular dysfunction, but it is not as low as some patients with heart failure. His hemoglobin level of 136 g/L is within the normal range, which suggests that he is not anemic.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that his heart rhythm is relatively stable, and he is not at high risk of sudden cardiac death.

In conclusion, the patient's outcome of survival can be attributed to the effective management of his underlying conditions, including his heart failure, diabetes, and hypertension, as well as the use of appropriate medications, such as beta blockers, statins, and ACE inhibitors."
318,318,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival in this case can be attributed to a combination of factors, including the patient's current medical management and the presence of certain indicators that suggest a relatively stable cardiac condition.

Firstly, the patient is already on optimal medical therapy for their conditions, including diabetes, hypertension, and ischemic dilated cardiomyopathy. They are taking medications such as beta blockers, statins, and an ACE inhibitor, which are standard treatments for these conditions. These medications help to manage symptoms, slow disease progression, and reduce the risk of complications.

Secondly, the patient's laboratory results, such as the low troponin level (0.01 ng/mL), suggest that there is no acute myocardial infarction. Additionally, the patient's LVEF (Left Ventricular Ejection Fraction) is 45%, which, although slightly below the normal range, indicates that the patient's heart is still pumping blood efficiently enough to maintain a stable condition.

Thirdly, the patient's ECG findings do not indicate any severe arrhythmias or other life-threatening conditions. The presence of polymorphic ventricular extrasystoles is a common finding in patients with ischemic heart disease, but it is not typically a cause for concern unless it is associated with other symptoms or signs of instability.

Lastly, the patient's age and NYHA class III suggest that they have a moderate level of heart failure symptoms, but they are still able to perform daily activities with some limitation. The patient's overall clinical presentation and laboratory results suggest that they are relatively stable and not in immediate danger of cardiac decompensation.

In summary, the patient's survival can be attributed to their optimal medical management, the absence of acute cardiac events, and the presence of indicators that suggest a relatively stable cardiac condition."
319,319,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, has been managed with a multidrug regimen including diabetes medication, beta blockers, statins, and an ACE inhibitor. 

The patient's New York Heart Association (NYHA) Class III classification indicates that he experiences symptoms of heart failure during ordinary physical activity, but is still able to perform daily activities. The patient's left ventricular ejection fraction (LVEF) of 45% indicates a reduced ejection fraction, which is consistent with his diagnosis of ischemic dilated cardiomyopathy.

The patient's blood pressure of 140/70 mmHg is within a relatively normal range, and his creatinine level of 109.0 mmol/L suggests mild renal impairment. The elevated pro-BNP level of 1860.0 ng/L indicates increased ventricular wall stress, which is consistent with his heart failure symptoms.

The patient's ECG findings, including polymorphic ventricular extrasystoles, are common in patients with heart failure and are not necessarily indicative of an adverse outcome. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's cardiac rhythm is relatively stable.

Given the patient's stable medical regimen, relatively controlled blood pressure, and lack of acute cardiac arrhythmias, it is not surprising that the patient has survived."
320,320,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 61-year-old male with a history of ischemic dilated cardiomyopathy, has a New York Heart Association (NYHA) Class II classification, indicating mild to moderate symptoms of heart failure. Despite this, the patient has survived, likely due to several factors.

Firstly, the patient's medications, including beta blockers, spironolactone, statins, and ACE inhibitors, are all appropriate for managing heart failure and hypertension, which may have contributed to his survival.

Secondly, the patient's ejection fraction (LVEF) is 35%, which is relatively low but not extremely low. This suggests that the patient's heart is still pumping blood effectively enough to meet the body's needs, allowing him to survive.

Thirdly, the patient's troponin levels are within normal limits, indicating that there is no ongoing myocardial infarction or significant cardiac damage.

Fourthly, the patient's pro-BNP levels are elevated at 709.0 ng/L, which is consistent with heart failure. However, this level is not extremely high, suggesting that the patient's heart failure is not severe.

Lastly, the patient's ECG does not show any signs of severe arrhythmias, such as ventricular tachycardia or bradycardia, which could have contributed to his survival.

In conclusion, the combination of appropriate medications, relatively preserved LVEF, absence of ongoing cardiac damage, and absence of severe arrhythmias likely contributed to the patient's survival."
321,321,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival is likely due to a combination of factors. 

Firstly, the patient's current medication regimen, including beta blockers, spironolactone, statins, and an ACE inhibitor, appears to be well-managed for their ischemic dilated cardiomyopathy, hypertension, and dyslipemia. These medications are commonly used to reduce the risk of cardiac complications and improve symptoms in patients with heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is below the normal range (50-70%), indicating reduced cardiac function. However, the patient's Pro-BNP (brain natriuretic peptide) level is 709.0 ng/L, which is elevated but not excessively high. Elevated Pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure, but in this case, the level is not extremely high, suggesting that the patient's condition is not in an acute decompensated state.

The patient's blood pressure is well-controlled at 124/55 mmHg, which is within a relatively normal range. This suggests that the patient's hypertension is under control, which is beneficial for reducing cardiac workload and strain.

Additionally, the patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no acute myocardial infarction.

The patient's albumin level is 43 g/L, which is slightly low, but not critically low. Low albumin levels can be associated with malnutrition and inflammation, but in this case, the patient's protein level is 66 g/L, which is within the normal range, suggesting that the patient is not malnourished.

The patient's creatinine level is 80.0 umol/L, which is slightly elevated, but not excessively high. This may indicate some degree of renal impairment, but it is not severe enough to suggest that the patient is in renal failure.

Overall, while the patient has a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, their current medication regimen and laboratory results suggest that their condition is relatively stable, and they are not in an acute decompensated state. Therefore, the patient's outcome of survival is likely due to the effective management of their condition and the absence of acute cardiac complications."
322,322,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to several factors based on the provided data. Firstly, the patient is on optimal medical therapy for heart failure, including beta blockers, spironolactone, statins, and an ACE inhibitor. These medications are known to improve survival and reduce morbidity in patients with heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is below the normal range (50-70%), indicating systolic dysfunction. However, the patient's ejection fraction is not severely low, and the patient is on appropriate medical therapy.

Additionally, the patient's blood pressure is well-controlled, with a systolic blood pressure of 124 mmHg, which is within the target range for patients with heart failure. The patient's potassium level is also within the normal range, which is essential for patients taking ACE inhibitors.

The patient's troponin level is within the normal range, indicating that there is no ongoing myocardial infarction or ischemia. The patient's TSH level is within the normal range, indicating that the patient does not have hyperthyroidism or hypothyroidism, which can exacerbate heart failure.

The patient's creatinine level is elevated, indicating some degree of renal impairment, but it is not severe. The patient's urea level is also elevated, which can be a reflection of the patient's decreased renal function. However, the patient's eGFR (estimated glomerular filtration rate) is not provided, which would be a more accurate indicator of renal function.

The patient's pro-BNP level is elevated, indicating some degree of heart failure, but it is not extremely high, which suggests that the patient's heart failure is not severely decompensated.

In conclusion, the patient's survival can be attributed to optimal medical therapy, well-controlled blood pressure, and a lack of severe cardiac or renal dysfunction."
323,323,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 61-year-old male with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) is 35%, which is below the normal range (50-70%), indicating a significant impairment of the heart's pumping ability. 

The patient's high Pro-BNP (brain natriuretic peptide) level of 709.0 ng/L is indicative of heart failure, as it is a marker of ventricular strain and increased wall stress. The patient's blood pressure is 124/55 mmHg, which is within a relatively normal range, but the low diastolic blood pressure may indicate orthostatic hypotension, a common issue in patients with heart failure.

The patient's lipid profile shows elevated total cholesterol (4.86 mmol/L) and low HDL (1.78 mmol/L), which are risk factors for atherosclerosis and ischemic heart disease. However, the LDL level is within a relatively normal range (2.61 mmol/L). The patient is on statins, which are likely being used to manage his dyslipemia.

The patient's liver function tests (ALT and AST) are within normal limits, indicating no significant liver damage. The patient's kidney function is also relatively preserved, with a creatinine level of 80.0 mmol/L (normal range: 44-133 mmol/L).

The patient's medication regimen includes beta blockers, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. Beta blockers help reduce the heart rate and workload, while spironolactone is used to reduce fluid retention and alleviate symptoms of heart failure. Statins help lower cholesterol levels, and ACE inhibitors help relax blood vessels and reduce blood pressure.

The ECG shows ventricular extrasystoles, which are common in patients with heart failure, but there is no evidence of sustained ventricular tachycardia or other arrhythmias.

Given the patient's history, medication regimen, and test results, it is likely that the patient's outcome is a survivor due to the following factors:

1.  The patient is on an appropriate medication regimen for heart failure and hypertension.
2.  The patient's kidney function is relatively preserved, which is a good prognostic indicator for patients with heart failure.
3.  The patient's liver function is within normal limits, which reduces the risk of liver-related complications.
4.  The patient's lipid profile is being managed with statins, which reduces the risk of atherosclerosis and ischemic heart disease.
5.  The patient's blood pressure is relatively well-controlled, which reduces the risk of cardiovascular complications.

Overall, the patient's outcome as a survivor is likely due to the combination of his medication regimen, relatively preserved kidney and liver function, and controlled blood pressure."
324,324,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 61-year-old male with a history of ischemic dilated cardiomyopathy, has survived despite having a low left ventricular ejection fraction (LVEF) of 35%. Several factors contribute to his survival:

1.  Optimal medical therapy: The patient is on a comprehensive treatment regimen consisting of beta blockers, spironolactone, statins, and an ACE inhibitor. Beta blockers help reduce the heart rate and contractility, while spironolactone and ACE inhibitors improve heart function and reduce fluid overload. Statins lower cholesterol levels, which is beneficial for patients with ischemic heart disease.

2.  Controlled blood pressure: The patient's blood pressure is well-managed at 124/55 mmHg, which is lower than the recommended target for patients with heart failure. This suggests that his blood pressure is under good control, reducing the strain on his heart.

3.  Normal troponin levels: A troponin level of 0.01 ng/mL indicates that the patient has not experienced a recent myocardial infarction, which is a significant risk factor for mortality in patients with heart failure.

4.  Low pro-BNP levels: A pro-BNP level of 709.0 ng/L is elevated, but not extremely high. BNP (B-type natriuretic peptide) is a hormone produced by the heart in response to increased ventricular wall tension. Elevated levels can indicate heart failure, but a value of 709.0 ng/L is not excessively high, suggesting that the patient's heart failure is not in an acute decompensated state.

5.  Lack of arrhythmias: The ECG findings do not indicate any significant arrhythmias, such as ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia, which could increase the risk of sudden cardiac death.

6.  Well-managed electrolytes: The patient's potassium level is within a normal range (4.2 mEq/L), which is essential for maintaining proper heart function.

7.  Good nutritional status: The patient's albumin level is 43 g/L, which is within the normal range, indicating that his nutritional status is well-managed.

8.  No significant liver or kidney dysfunction: The patient's liver enzymes (ALT and AST) and kidney function (creatinine) are within normal limits, suggesting that his liver and kidneys are functioning properly.

Overall, the patient's survival can be attributed to a combination of optimal medical therapy, controlled blood pressure, absence of recent myocardial infarction, and well-managed electrolytes, nutritional status, and organ function."
325,325,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and current LVEF of 35%, the patient is at high risk for adverse cardiac events. However, the patient's current medications, including beta blockers, spironolactone, statins, and an ACE inhibitor, are appropriate for managing heart failure and reducing the risk of further cardiac events. 

The patient's blood pressure is within a relatively normal range (124/55 mmHg), which is likely due to the effect of the ACE inhibitor and beta blockers. The low levels of troponin (0.01 ng/mL) suggest that there is no current acute myocardial infarction. 

The elevated Pro-BNP level (709.0 ng/L) is consistent with heart failure, but it is not extremely high, indicating that the patient's heart failure symptoms are being managed effectively. The patient's hemoglobin level is within the normal range, and the TSH level is within the normal range, indicating that there are no signs of hyperthyroidism or hypothyroidism contributing to the heart failure.

The patient's lipid profile shows high total cholesterol (4.86 mmol/L) and LDL (2.61 mmol/L), but this is being managed with statins. The patient's potassium level is within the normal range, which is essential for preventing arrhythmias.

The patient's ECG shows monomorphic ventricular extrasystoles, which is a common finding in patients with heart failure. However, there is no evidence of sustained or non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering the patient's history, current medications, and test results, it is reasonable to conclude that the patient's outcome is a survivor. The patient's heart failure symptoms are being managed effectively, and there are no signs of acute cardiac events or other life-threatening conditions."
326,326,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 61-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, has been prescribed a comprehensive treatment plan including beta blockers, spironolactone, statins, and an ACE inhibitor. This treatment regimen is aimed at managing his heart failure symptoms and reducing the risk of further cardiac events.

The patient's NYHA Class II classification indicates that he experiences some limitation in physical activity but is still able to perform everyday activities without severe symptoms. His blood pressure is well-controlled, which is crucial for managing his hypertension and reducing the strain on his heart.

The laboratory results indicate that the patient's liver function is within normal limits, with a slightly elevated ALT level, but this is not considered significant given his overall clinical context. His lipid profile shows a high total cholesterol level, but the patient is on statin therapy, which should help to manage this. His kidney function is also within normal limits.

The patient's LVEF (Left Ventricular Ejection Fraction) of 35% is below the normal range, indicating that he has reduced cardiac function. However, his Pro-BNP level is elevated at 709.0 ng/L, which suggests that he has some degree of heart failure. Despite this, his troponin level is within normal limits, indicating that he does not have acute myocardial infarction.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other significant arrhythmias. This suggests that his heart rhythm is generally stable.

Given the patient's comprehensive treatment plan, well-controlled blood pressure, and stable heart rhythm, it is not surprising that he has survived. His overall clinical condition, while not ideal, is being managed effectively, and he is able to perform everyday activities without severe symptoms."
327,327,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of being a survivor can be attributed to several factors based on the provided data. 

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) of 35% is below the normal range (50-70%), indicating that the patient has a reduced left ventricular function due to ischemic dilated cardiomyopathy. However, the patient is still alive, suggesting that the current management strategy, including beta blockers, spironolactone, statins, and an ACE inhibitor, is effective in managing the condition.

The patient's blood pressure of 124/55 mmHg is within the normal range, which is a good sign for cardiac health. The low diastolic blood pressure might be a concern, but it's not uncommon in patients with heart failure. 

The patient's troponin level of 0.01 ng/mL is within the normal range, indicating that there is no acute myocardial infarction. This, combined with the absence of ventricular tachycardia and non-sustained ventricular tachycardia, suggests that the patient's cardiac function is relatively stable.

The patient's pro-BNP level of 709.0 ng/L is elevated, indicating that the patient has some degree of cardiac stress. However, this level is not extremely high, and it's likely that the patient's current medication regimen is helping to manage the stress on the heart.

The patient's laboratory results, including the normal liver function tests (ALT, AST, GGT), normal kidney function (creatinine, urea), and normal electrolyte levels (potassium, sodium), suggest that there are no other significant underlying conditions that could have contributed to the patient's outcome.

The patient's TSH level of 3.49 mIU/L is within the normal range, indicating that there are no signs of hypothyroidism, which can sometimes contribute to cardiac dysfunction.

Overall, the patient's outcome of being a survivor can be attributed to the effective management of their ischemic dilated cardiomyopathy, the absence of acute myocardial infarction, and the relatively stable cardiac function as indicated by the ECG and laboratory results."
328,328,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 61-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. Despite having a reduced left ventricular ejection fraction (LVEF) of 35%, which is indicative of heart failure, the patient is on optimal medical therapy with beta blockers, spironolactone, statins, and an ACE inhibitor. The patient's blood pressure is well-controlled at 124/55 mmHg, and his lipid profile is being managed with statins.

The patient's troponin level is within normal limits (0.01 ng/mL), indicating that there is no acute myocardial infarction. The pro-BNP level is elevated at 709.0 ng/L, which is consistent with heart failure, but not excessively high, suggesting that the patient's condition is being managed.

The patient's liver function tests (ALT, AST, and GGT) are within normal limits, indicating that there is no evidence of liver dysfunction that could be contributing to the patient's heart failure. The patient's kidney function, as indicated by creatinine and urea levels, is also within normal limits.

The patient's hemoglobin level is slightly elevated at 130 g/L, which may be due to polycythemia secondary to chronic heart failure. However, this is not a contraindication to optimal medical therapy.

Given the patient's stable condition, optimal medical therapy, and lack of acute decompensation, the patient's outcome of survival is likely due to the effectiveness of his treatment plan and close monitoring. The patient's condition is being managed, and he is likely to continue to survive with continued medical therapy and lifestyle modifications."
329,329,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of being a survivor can be attributed to several factors based on the provided information.

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) of 35% indicates that the heart is still functioning, albeit at a reduced capacity, which is a crucial factor in determining the prognosis of a patient with ischemic dilated cardiomyopathy. The fact that the patient is on beta blockers, spironolactone, statins, and ACE inhibitors suggests that they are receiving appropriate medical management for their condition.

The patient's blood pressure is well-controlled, with a reading of 124/55 mmHg, which is within the target range for patients with heart failure. The patient's electrolyte levels, including potassium, sodium, and urea, are within normal limits, indicating that there are no significant electrolyte imbalances that could contribute to cardiac arrhythmias or other complications.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no ongoing myocardial infarction. The absence of ventricular tachycardia and other arrhythmias on the ECG also suggests that the patient is not experiencing any acute cardiac instability.

The patient's hemoglobin level is 130 g/L, which is within the normal range, indicating that there is no significant anemia contributing to reduced oxygen delivery to the tissues. The patient's albumin level is slightly low at 43 g/L, but this is not uncommon in patients with heart failure and may not necessarily be a contributing factor to their outcome.

The patient's total cholesterol level is elevated at 4.86 mmol/L, but they are on statins, which are likely helping to manage this. The patient's LDL level is also elevated at 2.61 mmol/L, but again, they are on statins, which should help to lower this.

The patient's Pro-BNP level is elevated at 709 ng/L, which is consistent with heart failure. However, the fact that the patient is on spironolactone and ACE inhibitors suggests that they are receiving appropriate treatment for heart failure.

Overall, the patient's outcome of being a survivor can be attributed to their appropriate medical management, controlled blood pressure, lack of acute cardiac instability, and absence of significant electrolyte imbalances."
330,330,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's age, gender, and past medical history of enolic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension, the patient is at a high risk for cardiovascular events. The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilator, suggest that they are being managed for heart failure and hypertension.

The patient's laboratory results show a low LVEF (40%) indicating left ventricular dysfunction, which is consistent with dilated cardiomyopathy. Elevated Pro-BNP levels (1083.0 ng/L) also indicate heart failure, and the patient's creatinine level (97.0 mmol/L) suggests mild kidney impairment, which is not uncommon in patients with heart failure.

The patient's lipid profile shows elevated total cholesterol (4.16 mmol/L) and LDL (2.38 mmol/L), which are risk factors for cardiovascular disease. However, the patient's HDL level (0.7 mmol/L) is low, which is a risk factor for cardiovascular disease.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that the patient's heart rhythm is not significantly abnormal, but the extrasystoles may be a sign of underlying cardiac disease.

Considering the patient's overall condition, the patient's survival is likely due to the following factors:

1.  The patient's medications, particularly the beta blockers and ACE inhibitors, which are effective in managing heart failure and reducing the risk of cardiovascular events.
2.  The patient's relatively low troponin level (0.03 ng/mL), which suggests that there is no acute myocardial infarction.
3.  The patient's normal hemoglobin level (151.0 g/L), which suggests that there is no significant anemia, which can contribute to heart failure.
4.  The patient's low TSH level (2.22 mIU/L), which suggests that there is no underlying thyroid dysfunction, which can contribute to heart failure.

Overall, the patient's survival is likely due to the combination of their medications, the absence of acute myocardial infarction, and the lack of underlying conditions that could contribute to heart failure."
331,331,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 55-year-old male with a history of enolic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension. His current medications include beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilator, which are all consistent with the management of heart failure and hypertension.

The patient's LVEF (left ventricular ejection fraction) is 40%, which is below the normal range (50-70%), indicating left ventricular dysfunction. The elevated Pro-BNP (brain natriuretic peptide) level of 1083.0 ng/L suggests that the patient has heart failure, which is consistent with his history of dilated cardiomyopathy.

The patient's blood pressure is elevated at 137/102 mmHg, which is consistent with his history of hypertension. His lipid profile shows elevated total cholesterol and LDL levels, which is consistent with his history of dyslipemia.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction.

Given the patient's history, medications, and test results, it is likely that the patient's heart failure and hypertension are well-managed, and he is able to survive with ongoing medical management. The patient's LVEF of 40% suggests that he has some degree of left ventricular dysfunction, but it is not severe enough to result in death. The patient's Pro-BNP level has likely decreased with treatment, indicating an improvement in heart failure symptoms.

Overall, the patient's survival outcome is likely due to the effectiveness of his current medical management, including his medications and lifestyle modifications, which have helped to control his heart failure and hypertension."
332,332,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's medical history and the provided data, the outcome of survival can be attributed to several factors:

1. Optimal Medication Management: The patient is on a combination of medications that are commonly used to manage heart failure, including beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilators. This comprehensive medication regimen likely helped to alleviate symptoms, slow disease progression, and improve quality of life.

2. Early Detection and Management of Cardiomyopathy: The patient has been diagnosed with enolic dilated cardiomyopathy, which is a chronic condition that can lead to heart failure. Early detection and management of cardiomyopathy through medications and lifestyle modifications likely helped to slow disease progression and prevent further complications.

3. Control of Hypertension: The patient's blood pressure is well-controlled, which is essential for preventing further strain on the heart. High blood pressure is a significant risk factor for heart failure, and controlling it can help slow disease progression.

4. Normal Electrolyte Levels: The patient's potassium and sodium levels are within normal ranges, which is essential for maintaining proper heart function. Electrolyte imbalances can lead to arrhythmias and other cardiac complications.

5. Lack of Severe Cardiac Arrhythmias: Although the ECG shows ventricular extrasystoles, there is no indication of sustained ventricular tachycardia or other severe arrhythmias, which can be life-threatening.

6. Normal Thyroid Function: The patient's TSH level is within the normal range, indicating that thyroid function is not contributing to the heart failure.

7. Low Pro-BNP Level: The patient's Pro-BNP level is elevated at 1083.0 ng/L, but it is not extremely high. Pro-BNP is a biomarker of heart failure, and elevated levels indicate increased ventricular stress. However, the patient's overall clinical presentation and response to treatment suggest that the heart failure is well-managed.

8. Reasonable LVEF: The patient's left ventricular ejection fraction (LVEF) is 40%, which is lower than the normal range but not extremely low. An LVEF of 40% indicates that the heart is pumping efficiently, but not optimally.

Overall, the combination of optimal medication management, early detection and management of cardiomyopathy, controlled hypertension, normal electrolyte levels, lack of severe cardiac arrhythmias, normal thyroid function, and reasonable LVEF all contributed to the patient's survival."
333,333,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 55-year-old male with a history of enolic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension. His current medications include beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilators. 

His laboratory results indicate elevated Pro-BNP levels (1083.0 ng/L), which is consistent with heart failure. His left ventricular ejection fraction (LVEF) is 40%, which is below the normal range, indicating reduced systolic function. The presence of ventricular extrasystoles on the ECG suggests some level of cardiac arrhythmia, but it is not life-threatening.

The patient's blood pressure is elevated (137/102 mmHg), which may be contributing to his cardiac disease. His lipid profile is abnormal, with a high total cholesterol level (4.16 mmol/L) and low HDL level (0.7 mmol/L), which increases his risk for cardiovascular events.

Despite these factors, the patient is currently a survivor, which suggests that his current treatment plan is effective in managing his symptoms and preventing further cardiac deterioration. The combination of beta blockers, digoxin, loop diuretics, and spironolactone is likely helping to control his heart rate, reduce fluid overload, and improve his cardiac function. The nitrovasodilators may also be contributing to vasodilation and reducing his blood pressure.

The patient's low T3 and normal T4 levels, along with a normal TSH level, suggest that his thyroid function is within a normal range, which is important to consider in the management of heart failure.

Overall, the patient's survival outcome is likely due to his ongoing medical treatment and management of his cardiac disease, which has helped to slow the progression of his heart failure and reduce his risk for adverse cardiac events."
334,334,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 55-year-old male with a history of enolic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension. He has a reduced left ventricular ejection fraction (LVEF) of 40%, indicating systolic heart failure. His NT-proBNP level is elevated at 1083 ng/L, which is a marker of heart failure severity and prognosis. 

Despite his multiple comorbidities and reduced LVEF, the patient is on a comprehensive treatment regimen including beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilator. This treatment is aimed at reducing symptoms, improving heart function, and managing his comorbidities.

The patient's ECG shows monomorphic ventricular extrasystoles, which is a common finding in patients with dilated cardiomyopathy. However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia suggests that his heart rhythm is relatively stable.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST) and lipid profile (total cholesterol and LDL), which may be related to his dyslipemia and peripheral vascular disease. However, his kidney function is relatively preserved, with a creatinine level of 97 umol/L.

Given the patient's comprehensive treatment regimen and the absence of any acute cardiac events or severe complications, it is reasonable to conclude that the patient is a survivor, indicating that he has survived the period of observation or treatment without any major adverse outcomes."
335,335,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 55-year-old male with a history of enolic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension. His current medications include beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilators. The patient's left ventricular ejection fraction (LVEF) is 40%, indicating a reduced left ventricular function.

Given the patient's medical history and current medications, it is likely that he has heart failure with reduced ejection fraction (HFrEF). The presence of ventricular extrasystoles on the ECG, although not uncommon in patients with heart failure, does not necessarily indicate a poor prognosis.

The patient's serum creatinine level is elevated at 97.0 mmol/L, indicating some degree of renal impairment. However, his glomerular filtration rate (GFR) is not provided, which would be a more accurate indicator of renal function.

The patient's blood pressure is elevated at 137/102 mmHg, which may be contributing to his heart failure. His lipid profile shows a high total cholesterol level (4.16 mmol/L) and low HDL level (0.7 mmol/L), which may be contributing to his peripheral vascular disease.

The patient's thyroid function tests (TSH and T4) are within normal limits, which suggests that hypothyroidism is unlikely to be contributing to his heart failure.

The patient's BNP level is elevated at 1083.0 ng/L, which is consistent with heart failure.

Given the patient's overall clinical picture, it is likely that he is receiving appropriate treatment for his heart failure, including beta blockers, ACE inhibitors or ARBs (although not specified), and diuretics. The patient's LVEF is stable at 40%, and he is not experiencing any acute decompensated heart failure episodes, which suggests that his treatment is effective in managing his symptoms.

Therefore, the patient's outcome of survival is likely due to the effective management of his heart failure, including his medications and lifestyle modifications, which have helped to stabilize his condition and prevent further progression of his disease."
336,336,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 55-year-old male with a history of enolic dilated cardiomyopathy, hypertension, dyslipemia, and peripheral vascular disease, was able to survive due to a combination of factors. 

Firstly, the patient's LVEF (left ventricular ejection fraction) was 40%, which indicates that his heart was still functioning, albeit at a reduced capacity. This suggests that the cardiomyopathy had not progressed to a point where it had severely compromised cardiac function.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilators, were likely contributing to his survival. These medications are commonly used to manage heart failure, hypertension, and cardiac arrhythmias, and their use suggests that the patient was receiving appropriate treatment for his conditions.

The patient's blood pressure, although elevated at 137/102 mmHg, was not severely hypertensive, which may have reduced the risk of cardiovascular complications. Additionally, the patient's total cholesterol level was within a relatively normal range, which may have also contributed to his survival.

The patient's low T3 and T4 levels, as well as his slightly elevated TSH level, suggest that his thyroid function was within a relatively normal range, which is important for cardiac function.

The patient's troponin level was within a normal range, indicating that he did not have acute myocardial infarction (heart attack) at the time of the measurement. However, his elevated Pro-BNP level (1083.0 ng/L) suggests that he had some degree of heart failure, which may have contributed to his reduced LVEF.

Overall, the patient's survival can be attributed to a combination of his relatively preserved cardiac function, appropriate medical treatment, and the absence of severe cardiovascular complications at the time of the assessment."
337,337,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 55-year-old male with a history of enolic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension. His current medications include beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilators. 

The patient's ejection fraction (LVEF) is 40%, indicating that his heart is functioning at a reduced level, which is consistent with dilated cardiomyopathy. The elevated pro-BNP level (1083.0 ng/L) further supports the presence of heart failure, as it is a marker of increased ventricular stretch and wall tension.

The patient's blood pressure is elevated at 137/102 mmHg, which may be contributing to his heart failure and peripheral vascular disease. His total cholesterol is elevated at 4.16 mmol/L, which is a risk factor for cardiovascular disease.

The patient's ECG shows monomorphic ventricular extrasystoles, which can be a benign finding in some cases but may also be a sign of underlying cardiac disease. However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia suggests that the patient's cardiac rhythm is generally stable.

Given the patient's complex medical history and the presence of heart failure, it is likely that the patient has been receiving aggressive treatment for his condition. The combination of beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilators suggests that the patient's treatment team is working to manage his heart failure, hypertension, and dyslipemia.

The patient's survival outcome is likely due to the effectiveness of his treatment regimen and close monitoring by his healthcare team. The patient's stable ECG findings and lack of acute cardiac events suggest that his cardiac function is being managed effectively. However, ongoing monitoring and adjustments to his treatment plan will be necessary to prevent further cardiac complications."
338,338,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the provided patient data, the patient's outcome of survival is likely due to a combination of factors, including the presence of a relatively low level of cardiac dysfunction despite a low left ventricular ejection fraction (LVEF) of 40%. The patient's LVEF is below the normal range (50-70%), indicating some degree of heart failure, but the patient is still able to survive, which may be attributed to the compensatory mechanisms of the body and the effectiveness of the current medication regimen.

The patient's Pro-BNP level of 1083.0 ng/L is elevated, which is often seen in patients with heart failure. However, the level is not extremely high, suggesting that the patient's condition is not as severe as it could be. Additionally, the patient's hemoglobin level is within the normal range, which indicates that the patient is not experiencing significant anemia, which can be a complication of heart failure.

The patient's medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilators, is comprehensive and aimed at managing heart failure symptoms, hypertension, and improving cardiac function. These medications may have contributed to the patient's survival by reducing symptoms, improving cardiac output, and slowing disease progression.

Furthermore, the patient's other medical conditions, such as enolic dilated cardiomyopathy, dyslipemia, and peripheral vascular disease, are being managed with medications and lifestyle modifications. The patient's blood pressure is well-controlled, which is essential in managing heart failure and reducing the risk of cardiovascular events.

In summary, the patient's survival is likely due to a combination of effective medical management, relatively mild cardiac dysfunction, and compensatory mechanisms of the body."
339,339,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the effectiveness of their current medication regimen and the relatively stable condition of their heart function. 

Firstly, the patient is on a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilators. These medications are commonly used to manage heart failure and hypertension, and their combination is likely contributing to the stabilization of the patient's cardiac function. Beta blockers, in particular, have been shown to improve survival and reduce morbidity in patients with heart failure.

The patient's left ventricular ejection fraction (LVEF) of 40% indicates that their heart function is compromised, but not severely so. An LVEF of 40% is still within the range of moderate heart failure, but it suggests that the patient's heart is still able to pump blood effectively enough to sustain life.

Additionally, the patient's blood pressure is well-controlled, with a reading of 137/102 mmHg, which is within a relatively normal range. This suggests that the patient's hypertension is under good control, which is essential for preventing further cardiac damage.

The patient's laboratory results also suggest that their liver function is relatively normal, with an albumin level of 46 g/L and a normal ALT and AST level. This is important because liver dysfunction can contribute to worsening heart failure.

The patient's electrolyte levels are also relatively well-controlled, with a potassium level of 4.4 mEq/L, which is within the normal range. Hypokalemia can contribute to cardiac arrhythmias and worsening heart failure.

The patient's troponin level is normal, indicating that there is no acute myocardial infarction. The absence of a significant elevation in troponin levels suggests that the patient's heart is not experiencing significant damage or stress.

Overall, the combination of the patient's medication regimen, relatively stable cardiac function, well-controlled blood pressure, and normal laboratory results all contribute to their outcome of survival."
340,340,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which are significant risk factors for heart failure and cardiac arrhythmias. The patient's LVEF (Left Ventricular Ejection Fraction) of 34% indicates a reduced left ventricular function, which is a common complication of ischemic cardiomyopathy.

The patient's NYHA Class II classification indicates that the patient experiences some limitation in physical activity due to heart disease, but is still able to perform light physical activity without discomfort. However, the presence of non-sustained ventricular tachycardia (NSVT) on the ECG suggests a higher risk of arrhythmic events.

The patient's laboratory results show elevated levels of Pro-BNP (brain natriuretic peptide), which is a marker of heart failure and cardiac stress. The elevated levels of creatinine (106.0 mmol/L) indicate impaired renal function, which can be a complication of heart failure and may require careful monitoring.

The patient's lipid profile shows a high total cholesterol level (4.73 mmol/L) and a low HDL (1.68 mmol/L), which may increase the risk of cardiovascular events. However, the patient is on statins, which may help to manage these lipid levels.

The patient's medication regimen includes angiotensin II receptor blockers, beta blockers, loop diuretics, spironolactone, statins, and nitrovasodilators, which are all standard treatments for heart failure and hypertension. The patient's blood pressure is well-controlled at 110/55 mmHg, which is a good sign.

Given the patient's complex medical history, laboratory results, and medication regimen, the patient's survival outcome is likely due to the following factors:

1.  Aggressive management of heart failure symptoms and arrhythmias with medications such as beta blockers and angiotensin II receptor blockers.
2.  Control of blood pressure with loop diuretics and spironolactone, which may help to reduce cardiac workload and improve cardiac function.
3.  Management of lipid levels with statins, which may help to reduce the risk of cardiovascular events.
4.  Monitoring and management of renal function with careful monitoring of creatinine levels.
5.  Regular follow-up and adjustment of medications as needed to ensure optimal management of the patient's heart failure and arrhythmias.

Overall, the patient's survival outcome is likely due to a combination of aggressive medical management, careful monitoring, and regular follow-up, which has helped to manage the patient's heart failure and reduce the risk of cardiac arrhythmias."
341,341,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a compromised cardiac function. His left ventricular ejection fraction (LVEF) of 34% is significantly below the normal range (50-70%), indicating a reduced cardiac output and increased risk of heart failure.

The patient's laboratory results show elevated Pro-BNP levels (1107 ng/L), which is a marker of heart failure and cardiac stress. His creatinine level of 106.0 mmol/L is also elevated, indicating impaired renal function, which is common in patients with heart failure.

The patient's medication regimen, including angiotensin II receptor blockers, beta blockers, loop diuretics, spironolactone, statins, and nitrovasodilators, is consistent with the management of heart failure and hypertension.

The ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia suggest underlying cardiac electrical instability, which is a risk factor for sudden cardiac death. However, the patient's overall clinical picture and treatment plan suggest that the cardiac condition is being managed.

Considering the patient's age, comorbidities, and treatment plan, the most likely reason for the patient's survival is the effective management of his heart failure and cardiac conditions, along with the use of medications that help to reduce the risk of sudden cardiac death and improve cardiac function."
342,342,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors based on the provided data and medical history. 

Firstly, the patient's current medications, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator, are all consistent with standard treatment for ischemic dilated cardiomyopathy and heart failure, suggesting that the patient is receiving appropriate management for their condition. The use of beta blockers and ACE inhibitors (or ARBs) are known to improve survival and reduce morbidity in patients with heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) of 34% is within the range of heart failure with reduced ejection fraction (HFrEF), which is consistent with the patient's diagnosis of ischemic dilated cardiomyopathy. However, despite this, the patient's LVEF is not extremely low, which may indicate some degree of preserved cardiac function.

The patient's creatinine level of 106.0 umol/L suggests some degree of renal impairment, which is not uncommon in patients with heart failure. However, this is not severe enough to significantly impact the patient's overall prognosis.

The patient's Pro-BNP (brain natriuretic peptide) level of 1107.0 ng/L is elevated, which is consistent with heart failure. However, the level is not extremely high, which may indicate some degree of compensation.

The patient's TSH (thyroid-stimulating hormone) level of 2.55 mIU/L is within the normal range, which suggests that thyroid dysfunction is not contributing to the patient's symptoms.

The patient's ECG findings of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles are concerning, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias suggests that the patient is not at high risk of sudden cardiac death.

In summary, the combination of appropriate medical management, a relatively preserved LVEF, and the absence of severe renal impairment or other life-threatening complications likely contributed to the patient's outcome as a survivor."
343,343,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors:

1. Optimal medical management: The patient is on a comprehensive regimen of medications, including an Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and a Nitrovasodilator. These medications are crucial in managing heart failure and reducing the risk of complications.

2. Stable blood pressure: The patient's blood pressure is well-controlled, with a reading of 110/55 mmHg, which is within the target range for someone with heart failure. This suggests that the patient's blood pressure is not placing excessive strain on the heart.

3. LVEF (Left Ventricular Ejection Fraction) of 34%: Although the LVEF is low, indicating reduced heart function, it is not as low as some other cases. This suggests that the patient's heart is still able to pump blood effectively to some extent.

4. Low levels of BNP (B-type Natriuretic Peptide): A BNP level of 1107 ng/L is elevated but not extremely high, indicating that the patient's heart is not under extreme stress. Elevated BNP levels are associated with heart failure, but a lower level like this suggests that the patient's heart is not in a state of acute decompensation.

5. Absence of severe electrolyte imbalances: The patient's potassium and sodium levels are within normal ranges, which is essential for maintaining proper heart function.

6. Controlled glucose levels: The patient's glucose level of 5.4 mmol/L is within the normal range, which is beneficial for heart health.

7. No signs of severe liver dysfunction: The patient's liver enzymes (ALT and AST) are within normal ranges, indicating that the liver is functioning properly, which is essential for metabolizing medications and maintaining overall health.

8. Absence of severe kidney dysfunction: The patient's creatinine level of 106.0 umol/L is elevated, indicating some degree of kidney impairment, but it is not severe. The patient's urea level is also within a relatively normal range.

9. No history of severe arrhythmias: Although the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these are not severe arrhythmias, and the patient is not experiencing any symptoms of arrhythmia-related complications.

Considering these factors, the patient's survival outcome is likely due to the combination of optimal medical management, stable blood pressure, relatively preserved LVEF, and controlled levels of biomarkers and electrolytes."
344,344,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates significant cardiovascular disease. The patient's LVEF (Left Ventricular Ejection Fraction) is 34%, which is below the normal range (50-70%), indicating reduced heart function.

The patient's NYHA Class II classification suggests that he experiences some limitations in physical activity but is still able to perform everyday activities without significant discomfort.

The patient's laboratory results show elevated levels of Pro-BNP (Brain Natriuretic Peptide), which is a biomarker for heart failure and indicates increased ventricular wall stress. The elevated levels of Pro-BNP (1107 ng/L) suggest that the patient has heart failure with reduced ejection fraction (HFrEF).

The patient's lipid profile shows a high total cholesterol level (4.73 mmol/L) and low HDL (1.68 mmol/L), which are risk factors for atherosclerotic cardiovascular disease.

The patient's medication regimen, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator, suggests that the patient is receiving appropriate treatment for heart failure and cardiovascular disease.

The ECG results show polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, which are common in patients with heart failure and ischemic cardiomyopathy.

Considering the patient's overall clinical presentation, laboratory results, and medication regimen, the patient's outcome as a survivor is likely due to the following factors:

1. Appropriate medical treatment: The patient is receiving evidence-based medications for heart failure and cardiovascular disease, which has helped to manage symptoms and slow disease progression.
2. Close monitoring and follow-up: Regular monitoring of the patient's condition has allowed for timely adjustments to the medication regimen and interventions to prevent complications.
3. Patient's overall health status: Despite the patient's advanced age and significant cardiovascular disease, his NYHA Class II classification suggests that he is still relatively stable and able to manage his condition with medical treatment.

However, it is essential to continue monitoring the patient's condition closely and adjust the treatment plan as needed to prevent further complications and improve quality of life."
345,345,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy and myocardial infarction, it is not surprising that they have a reduced left ventricular ejection fraction (LVEF) of 34.0%, indicating a decreased ability of the heart to pump blood efficiently. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG suggests that the patient is at risk for cardiac arrhythmias, which is a common complication in patients with heart failure and reduced ejection fraction.

The patient's laboratory results show elevated levels of pro-BNP (brain natriuretic peptide), which is a marker of heart failure and cardiac stress. The high levels of pro-BNP (1107.0 ng/L) suggest that the patient's heart is under significant stress and is likely experiencing some degree of heart failure.

The patient's medications, including angiotensin II receptor blockers, beta blockers, loop diuretics, spironolactone, statins, and nitrovasodilators, are all consistent with the management of heart failure and are aimed at reducing symptoms, slowing disease progression, and improving survival.

The patient's weight of 90 kg and height of 163 cm result in a body mass index (BMI) of approximately 29.3, which falls into the overweight category. Obesity is a risk factor for heart failure, and the patient's weight may be contributing to their symptoms.

The patient's blood pressure of 110/55 mmHg is within the normal range, which is a positive sign. However, the patient's low HDL cholesterol (1.68 mmol/L) and high LDL cholesterol (2.4 mmol/L) may be contributing to their cardiovascular risk.

In conclusion, the patient's survival is likely due to the combination of their ongoing medical treatment, which is aimed at managing their heart failure and reducing their cardiovascular risk factors. The patient's relatively low blood pressure and the presence of medications that are known to improve survival in heart failure patients also contributed to their survival."
346,346,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which is a significant risk factor for cardiac mortality. However, the patient is currently on a comprehensive treatment regimen, including angiotensin II receptor blockers, beta blockers, loop diuretics, spironolactone, statins, and nitrovasodilators, which are standard treatments for heart failure and ischemic cardiomyopathy.

The patient's left ventricular ejection fraction (LVEF) of 34% indicates reduced cardiac function, which is consistent with dilated cardiomyopathy. However, the patient's New York Heart Association (NYHA) class II classification suggests that the patient has mild to moderate symptoms of heart failure, which may indicate some degree of compensation and adaptation to the underlying cardiac dysfunction.

The patient's laboratory results show elevated levels of pro-BNP (1107 ng/L), which is a biomarker of cardiac stress and strain. However, the patient's creatinine level (106.0 mol/L) is within the normal range, indicating that renal function is preserved. The patient's hemoglobin level (137 g/L) is also within the normal range, which is a positive sign.

The patient's ECG shows evidence of ventricular extrasystoles and non-sustained ventricular tachycardia, which may indicate underlying cardiac electrical instability. However, the absence of sustained ventricular tachycardia or bradycardia suggests that the patient's cardiac rhythm is generally stable.

Considering these factors, the patient's outcome of survival is likely due to the combination of effective medical therapy, preserved renal function, and the patient's relatively mild symptoms of heart failure (NYHA class II). The patient's treatment regimen is likely helping to manage the underlying cardiac dysfunction and prevent further cardiac complications."
347,347,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a compromised cardiac function. His left ventricular ejection fraction (LVEF) of 34% is significantly below the normal range (50-70%), indicating severe systolic heart failure. 

The patient's low albumin level (39 g/L) and high creatinine level (106.0 mol/L) suggest renal impairment, which is common in patients with heart failure. The elevated pro-BNP (brain natriuretic peptide) level of 1107.0 ng/L is indicative of increased ventricular wall stress, consistent with heart failure.

The patient's lipid profile shows a high total cholesterol level (4.73 mmol/L) and low HDL (1.68 mmol/L), which are risk factors for atherosclerosis and further cardiovascular disease. His LDL level of 2.4 mmol/L is within a relatively safe range, but still a concern given his overall cardiovascular risk.

The patient's blood pressure is within a relatively safe range (110/55 mmHg), but it's essential to note that the diastolic pressure is low, which may indicate vasodilation or decreased peripheral resistance. The patient's potassium level (4.1 mEq/L) is within a relatively safe range.

The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a common finding in patients with heart failure and may indicate a risk of sudden cardiac death. However, the absence of sustained ventricular tachycardia or other life-threatening arrhythmias is a positive sign.

Given the patient's history, lab results, and ECG findings, it is likely that the patient has a high risk of cardiac events, but the combination of medications (Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator) and the patient's relatively stable vital signs suggest that the patient is being managed appropriately for heart failure. The patient's survival can be attributed to the effective management of his heart failure symptoms and the prevention of further cardiac events through medication and lifestyle modifications.

However, the patient's survival outcome can be improved with close monitoring of his condition, adjustments to his medication regimen as needed, and regular follow-up appointments with his healthcare provider to ensure that his heart failure is being effectively managed."
348,348,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors:

1. Optimal Medical Management: The patient is on a comprehensive treatment regimen, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator. These medications are commonly used to manage heart failure, hypertension, and ischemic dilated cardiomyopathy, indicating that the patient is receiving appropriate care for their condition.

2. Stable Blood Pressure: The patient's blood pressure is within a relatively stable range (110/55 mmHg), which is crucial for preventing further cardiac strain and reducing the risk of cardiovascular events.

3. Normal Electrolytes: The patient's potassium levels (4.1 mEq/L) are within the normal range, which is essential for maintaining cardiac function and preventing arrhythmias.

4. Low Pro-BNP Levels: A Pro-BNP level of 1107 ng/L is elevated, but not extremely high, indicating that the patient's heart is not experiencing extreme stress or strain, which is a good prognostic sign.

5. No Recent Myocardial Infarction: The patient's history of myocardial infarction is not recent, suggesting that the heart has had time to recover and adapt to the damage.

6. LVEF of 34%: Although the patient's left ventricular ejection fraction (LVEF) is low (34%), it is not extremely low, which suggests that the heart is still functioning, albeit with some impairment.

7. Absence of Severe Anemia: The patient's hemoglobin level is within a normal range (137 g/L), which is essential for maintaining adequate oxygen delivery to the tissues and preventing further cardiac strain.

8. No Severe Kidney Dysfunction: The patient's creatinine level (106.0 mol/L) is slightly elevated, but not severely so, indicating that the kidneys are still functioning relatively well.

Considering these factors, the patient's outcome of survival is likely due to the combination of optimal medical management, stable blood pressure, normal electrolytes, low Pro-BNP levels, no recent myocardial infarction, a relatively stable LVEF, absence of severe anemia, and no severe kidney dysfunction."
349,349,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 73-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has a complex clinical presentation. Despite having a low left ventricular ejection fraction (LVEF) of 34%, which indicates significant left ventricular dysfunction, the patient's overall condition suggests that they are stable and able to survive.

Several factors contribute to this outcome:

1.  Optimal medical management: The patient is on a comprehensive medication regimen, including an angiotensin II receptor blocker, beta blockers, loop diuretics, spironolactone, statins, and nitrovasodilators. This treatment plan is aimed at managing heart failure symptoms, reducing blood pressure, and improving cardiac function.
2.  Low BNP levels: The patient's B-type natriuretic peptide (BNP) level of 1107 ng/L is elevated, indicating some degree of heart failure. However, the level is not extremely high, suggesting that the patient's condition is not in acute decompensation.
3.  Stable blood pressure: The patient's blood pressure of 110/55 mmHg is within a relatively normal range, indicating that the patient's cardiovascular system is not under extreme stress.
4.  Electrocardiogram (ECG) findings: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these findings are not indicative of an acute cardiac emergency. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia also suggests that the patient's cardiac rhythm is relatively stable.
5.  Normal hemoglobin and albumin levels: The patient's hemoglobin level of 137 g/L and albumin level of 39 g/L are within normal ranges, indicating that the patient is not experiencing significant anemia or malnutrition, which could contribute to cardiac decompensation.
6.  Low T3 and normal T4 levels: The patient's thyroid function tests are within normal limits, which suggests that hypothyroidism is not contributing to their cardiac condition.
7.  No signs of acute kidney injury: The patient's creatinine level of 106 mol/L is slightly elevated, but not significantly so, indicating that the patient's renal function is not severely compromised.

Considering these factors, the patient's ability to survive is likely due to a combination of optimal medical management, relatively stable cardiac function, and the absence of acute cardiac emergencies."
350,350,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's age of 30, gender as female, and NYHA Class II classification, which indicates mild symptoms of heart failure, the patient's overall condition is relatively stable. The patient's blood pressure is within the normal range, and there are no signs of acute coronary syndrome or severe cardiac dysfunction.

The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge. However, the patient's left ventricular ejection fraction (LVEF) is 50%, which is within the normal range for a young adult. This suggests that the cardiomyopathy may not be severe, and the patient is likely in a compensated state.

The patient's laboratory results show no significant abnormalities in liver enzymes (ALT, AST, GGT), renal function (creatinine, urea), or electrolytes (potassium, sodium). The patient's lipid profile shows high total cholesterol and LDL levels, which may be a concern for long-term cardiovascular risk. However, the patient's HDL level is relatively high, which is a protective factor against cardiovascular disease.

The patient's thyroid function tests (T3, T4, TSH) are within the normal range, indicating no evidence of hypothyroidism or hyperthyroidism.

The patient's pro-BNP level is 89 ng/L, which is slightly elevated but not significantly high. Pro-BNP is a marker of heart failure, and a level of 89 ng/L is often seen in patients with mild to moderate heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats that can be seen in patients with cardiomyopathy. However, there is no evidence of ventricular tachycardia, bradycardia, or paroxysmal supraventricular tachyarrhythmia.

Considering the patient's relatively stable condition, mild symptoms, and lack of severe cardiac dysfunction, the patient's outcome of survival is likely due to the following factors:

1. Early detection and treatment: The patient is already on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure. This suggests that the patient has been receiving appropriate medical care for their condition.
2. Compensated heart failure: The patient's LVEF is within the normal range, indicating that the heart is functioning relatively well, and the patient is in a compensated state.
3. Lack of severe cardiac dysfunction: There is no evidence of severe cardiac dysfunction, such as high creatinine levels, low ejection fraction, or severe arrhythmias.
4. Good lipid profile: The patient's high HDL level may be protective against cardiovascular disease, which could contribute to their survival.

Overall, the patient's outcome of survival is likely due to a combination of early detection and treatment, compensated heart failure, lack of severe cardiac dysfunction, and a relatively good lipid profile."
351,351,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 30-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced heart function. Despite this, the patient's ejection fraction (LVEF) is 50%, which is within the mildly reduced range. This suggests that the patient's heart function is still relatively preserved.

The patient is on a treatment regimen that includes beta blockers, loop diuretics, and an ACE inhibitor, which are all standard medications for managing heart failure and cardiomyopathy. The patient's blood pressure is within a normal range (110/70 mmHg), which is a good indicator of controlled hypertension.

The patient's laboratory results show a slightly elevated creatinine level (71.0 mol/L), which may indicate mild kidney impairment, but this is not uncommon in patients with heart failure. The patient's liver function tests (ALT and AST) are within normal limits, and her glucose and lipid profiles are also within normal limits.

The patient's TSH level is within the normal range (0.44 mIU/L), which suggests that her thyroid function is normal. Her troponin level is slightly elevated (0.03 ng/mL), but this is not indicative of acute myocardial infarction, and the patient's ECG does not show any signs of acute coronary syndrome.

The patient's ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with cardiomyopathy. However, the absence of sustained ventricular tachycardia or other serious arrhythmias suggests that the patient's heart rhythm is relatively stable.

Overall, the patient's stable medical regimen, controlled blood pressure, and preserved LVEF suggest that she is being effectively managed for her cardiomyopathy. The patient's relatively young age and absence of other significant comorbidities also contribute to her favorable prognosis. Therefore, the patient's outcome is likely to be a survivor."
352,352,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 30-year-old female with a history of idiopathic dilated cardiomyopathy, has a relatively favorable outcome, which can be attributed to several factors. 

1. Medications: The patient is on a standard treatment regimen for heart failure, including beta blockers, loop diuretics, and an ACE inhibitor. Beta blockers help reduce the heart rate and contractility, while loop diuretics aid in reducing fluid overload. ACE inhibitors improve cardiac function by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.

2. LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 50%, which is within the range of mildly reduced ejection fraction. Although not optimal, it suggests that the patient's heart is still pumping blood efficiently enough to meet the body's needs, contributing to the favorable outcome.

3. Blood Pressure: The patient's blood pressure is within the normal range (110/70 mmHg), indicating good blood pressure control, which is essential for heart health.

4. Electrocardiogram (ECG) findings: The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient is not experiencing severe arrhythmias, which can be a life-threatening complication of heart failure.

5. Serum biomarkers: The patient's troponin level is within normal limits (0.03 ng/mL), indicating minimal myocardial damage. The pro-BNP (brain natriuretic peptide) level is also relatively low (89.0 ng/L), suggesting that the patient is not experiencing significant cardiac stress or strain.

6. Other laboratory values: The patient's albumin, creatinine, and urea levels are within normal limits, indicating that the kidneys are functioning adequately, and there is no evidence of significant liver dysfunction (normal AST, ALT, and GGT levels).

Considering these factors, the patient's favorable outcome can be attributed to the effectiveness of her treatment regimen, the relatively preserved cardiac function, and the absence of severe complications."
353,353,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 30-year-old female with a history of idiopathic dilated cardiomyopathy, has a relatively favorable outcome. Several factors contribute to this outcome:

1.  Current Medications: The patient is on a combination of beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and dilated cardiomyopathy. These medications help manage symptoms, reduce mortality, and improve quality of life.

2.  Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 50%, which is within the range of moderate heart failure. While not normal, it's not as low as some patients with severe heart failure. An LVEF of 50% indicates that the heart is still pumping enough blood to meet the body's needs.

3.  Blood Pressure: The patient's blood pressure is within a relatively normal range (110/70 mmHg), which is beneficial for heart health.

4.  Laboratory Results: The patient's liver enzymes (ALT and AST) are within normal limits, indicating no significant liver dysfunction. The total cholesterol level is slightly elevated, but the LDL is relatively high, which may require further management. The patient's potassium level is within normal limits, which is crucial for heart function.

5.  Pro-BNP: The Pro-BNP level is 89.0 ng/L, which is within the normal range. Elevated Pro-BNP levels are often associated with heart failure.

6.  ECG Results: The patient does not have any signs of sustained or non-sustained ventricular tachycardia, which are indicators of more severe cardiac issues.

Considering these factors, the patient's current medications, relatively stable LVEF, normal blood pressure, and lack of severe laboratory abnormalities, contribute to a favorable outcome."
354,354,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 30-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition characterized by the enlargement of the heart, leading to reduced heart function. Despite this, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 50%, indicating that the heart is still pumping blood effectively to some extent. 

The patient's laboratory results show normal liver function tests (ALT, AST, and GGT), normal kidney function (creatinine and urea), and normal electrolyte levels (potassium and sodium). The patient's glucose level is within the normal range, and her hemoglobin is slightly elevated, which may be due to the use of diuretics.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which are risk factors for cardiovascular disease. However, the patient's HDL level is also elevated, which may help counteract some of the negative effects of high LDL.

The patient's thyroid function tests (TSH, T3, and T4) are within the normal range, indicating that thyroid dysfunction is unlikely to be contributing to her cardiac condition.

The patient's BNP level is elevated at 89.0 ng/L, which suggests that the patient's heart is under strain and may be experiencing some degree of heart failure. However, the patient's symptoms and overall clinical picture do not suggest severe heart failure, and the patient is able to tolerate her medications without significant adverse effects.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats originating from the ventricles. However, this finding is not uncommon in patients with dilated cardiomyopathy and is not necessarily indicative of severe cardiac disease.

Given the patient's relatively preserved LVEF, normal laboratory results, and ability to tolerate her medications, the patient's outcome of survival is likely due to the effectiveness of her current treatment regimen, including beta blockers, loop diuretics, and an ACE inhibitor. These medications are standard treatments for dilated cardiomyopathy and help to manage symptoms, slow disease progression, and improve outcomes in patients with this condition."
355,355,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 30-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. Despite this, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 50%, indicating that the heart is still pumping blood effectively, albeit not at its optimal level.

The patient's blood pressure is within a relatively normal range (110/70 mmHg), and her laboratory results show no significant abnormalities in liver enzymes (ALT, AST, GGT) or kidney function (Creatinine, Urea). Her glucose level is slightly elevated (4.6 mmol/L), but this is not significantly abnormal.

The patient's lipid profile shows elevated total cholesterol (6.65 mmol/L) and LDL cholesterol (4.99 mmol/L), which may contribute to her cardiac condition. However, her HDL cholesterol is within a relatively normal range (1.34 mmol/L).

The patient's thyroid function tests (TSH, T3, T4) are within normal limits, indicating no thyroid dysfunction. Her troponin level is slightly elevated (0.03 ng/mL), but this is not significantly abnormal and may be a result of the patient's underlying cardiac condition.

The patient is on a regimen of beta blockers, loop diuretics, and ACE inhibitors, which are standard medications for managing heart failure and dilated cardiomyopathy.

Given these factors, the patient's outcome of survival can be attributed to several factors:

1.  The patient's relatively preserved LVEF of 50% indicates that her heart is still functioning adequately, allowing her to survive.
2.  The absence of significant abnormalities in liver and kidney function suggests that her organs are not being severely affected by her cardiac condition.
3.  The patient's medications are likely helping to manage her symptoms and slow the progression of her disease.
4.  Her overall blood pressure and glucose levels are relatively well-controlled, which may also be contributing to her survival.

In summary, the patient's outcome of survival can be attributed to a combination of her relatively preserved cardiac function, well-controlled blood pressure and glucose levels, and effective management of her medications."
356,356,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including their current treatment regimen and the presence of a relatively preserved left ventricular ejection fraction (LVEF) of 50%. The patient's LVEF is significantly higher than what is typically observed in patients with idiopathic dilated cardiomyopathy, which often has an LVEF of <40%. This suggests that the patient's heart function is relatively preserved, allowing them to tolerate their condition and respond well to treatment.

The patient is on a comprehensive treatment regimen that includes beta blockers, loop diuretics, and an ACE inhibitor, which are all standard therapies for managing heart failure and reducing symptoms. These medications are likely contributing to the patient's stable condition and improved survival.

Additionally, the patient's laboratory values, such as the low troponin level (0.03 ng/mL) and normal creatinine level (71.0 mol/L), suggest that there is no significant cardiac damage or kidney dysfunction, which are common complications in patients with dilated cardiomyopathy. The patient's slightly elevated Pro-BNP level (89.0 ng/L) may indicate some degree of heart failure, but it is not excessively high, which suggests that the patient's condition is being well-managed.

The patient's overall clinical presentation and laboratory values suggest that they are receiving effective treatment and are likely to continue to survive with proper management of their condition."
357,357,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 30-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition characterized by a weakened heart muscle leading to decreased left ventricular ejection fraction (LVEF). The patient's LVEF is 50%, indicating a moderate degree of heart failure.

The patient's current medications, including beta blockers, loop diuretics, and ACE inhibitors, are standard treatments for heart failure and idiopathic dilated cardiomyopathy. Beta blockers help slow the heart rate and reduce the heart's workload, while loop diuretics help remove excess fluid from the body, and ACE inhibitors help reduce blood pressure and alleviate strain on the heart.

The patient's laboratory results show a normal albumin level, indicating no significant liver dysfunction, and a slightly elevated creatinine level, which may indicate some degree of renal impairment. However, the creatinine level is not significantly elevated, and the patient's urea level is within normal limits.

The patient's lipid profile shows a total cholesterol level of 6.65 mmol/L, which is above the normal range, and an LDL level of 4.99 mmol/L, which is also above the normal range. However, the patient's HDL level is within the normal range, which is a good sign.

The patient's troponin level is within normal limits, indicating no acute myocardial infarction. The TSH level is within the normal range, indicating no thyroid dysfunction.

The patient's Pro-BNP level is 89.0 ng/L, which is within the normal range, indicating no significant cardiac stress or strain.

The patient's ECG shows polymorphic ventricular extrasystoles, which are a common finding in patients with idiopathic dilated cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Based on the patient's medical history, laboratory results, and ECG findings, it is likely that the patient's idiopathic dilated cardiomyopathy is being managed effectively with current medications, and the patient is at a low risk of cardiac complications. Therefore, the patient outcome is survivor."
358,358,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 30-year-old female with a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood efficiently. Despite this, the patient is classified as NYHA Class II, indicating that she experiences some limitations in physical activity but is still able to perform everyday activities.

The patient's current medications, including beta blockers, loop diuretics, and an ACE inhibitor, are aimed at reducing the workload on the heart, managing fluid buildup, and improving cardiac function. The fact that the patient is on these medications and has a relatively preserved LVEF (left ventricular ejection fraction) of 50% suggests that her condition is being managed effectively.

The patient's blood work and lab results show no significant abnormalities that would indicate acute cardiac damage or severe cardiac dysfunction. The Troponin level is within normal limits, and the Pro-BNP level is not excessively elevated, which suggests that the patient is not experiencing acute heart failure.

The ECG results do show polymorphic ventricular extrasystoles, which can be a common finding in patients with cardiomyopathy. However, the absence of other concerning arrhythmias such as ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is generally stable.

Considering these factors, the patient's outcome as a survivor is likely due to the effective management of her idiopathic dilated cardiomyopathy with medications and close monitoring. The patient's preserved LVEF and lack of significant laboratory abnormalities suggest that her heart function is stable, and she is not experiencing acute cardiac decompensation."
359,359,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 30-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood efficiently. Despite the presence of this chronic condition, the patient has been on a treatment regimen consisting of beta blockers, loop diuretics, and an ACE inhibitor. 

The patient's left ventricular ejection fraction (LVEF) is 50%, which is within the mildly reduced range (45-55%) but not severely reduced (<45%). The presence of polymorphic ventricular extrasystoles on the ECG is a common finding in patients with cardiomyopathy, but it does not necessarily indicate a poor prognosis. 

The patient's blood work shows relatively normal electrolyte levels, a slightly elevated creatinine level, but within normal limits, and a mildly elevated total cholesterol level. The pro-BNP level is within the normal range, which suggests that the patient's heart is not experiencing significant stress or strain.

The patient's thyroid function tests (TSH, T3, and T4) are within the normal range, which suggests that thyroid dysfunction is not contributing to the patient's cardiac condition. The troponin level is within the normal range, indicating that there is no acute myocardial injury.

Considering the patient's age, the mildly reduced LVEF, and the presence of idiopathic dilated cardiomyopathy, the patient's outcome as a survivor is likely due to the effectiveness of the current treatment regimen and the absence of any acute cardiac events or complications. The patient's overall clinical condition appears to be stable, and the prognosis is guarded but not poor."
360,360,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors:

1. Optimal Medication Management: The patient is on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure and idiopathic dilated cardiomyopathy. These medications help reduce fluid overload, decrease blood pressure, and improve cardiac function.

2. Low TSH Level: The patient's TSH (thyroid-stimulating hormone) level is within the normal range, indicating that hypothyroidism, which can exacerbate heart failure, is unlikely to be a contributing factor.

3. Normal Glucose Level: The patient's glucose level is within the normal range, which reduces the risk of diabetic cardiomyopathy.

4. Low Troponin Level: The patient's troponin level is low, indicating minimal myocardial injury, which suggests that the heart is not experiencing significant damage.

5. Low T3 Level: The patient's T3 level is low, which is often seen in heart failure and may indicate a compensatory mechanism to reduce cardiac workload.

6. Non-Sustained Ventricular Tachycardia: Although the patient has non-sustained ventricular tachycardia, it is not sustained, indicating that the heart is not experiencing a life-threatening arrhythmia.

7. High LVEF: The patient's left ventricular ejection fraction (LVEF) is 35%, which is relatively high considering the patient's age and NYHA class II. This suggests that the patient's heart is still functioning relatively well.

8. Good Renal Function: The patient's creatinine level is within the normal range, indicating that the kidneys are functioning well, which is essential for removing waste products and excess fluids from the body.

9. No History of Cardiac Arrest or Sudden Cardiac Death: The patient has not experienced any cardiac arrest or sudden cardiac death, which suggests that the heart is still functioning relatively well.

10. Good Nutritional Status: The patient's albumin and protein levels are within the normal range, indicating good nutritional status, which is essential for cardiac function and overall health.

Considering these factors, the patient's outcome of survival is likely due to the combination of optimal medication management, good renal function, low TSH and troponin levels, and a relatively high LVEF, among other factors."
361,361,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the patient's current management and treatment plan. 

Firstly, the patient is already on loop diuretics, which are effective in reducing fluid overload and alleviating symptoms of heart failure. The patient's albumin level of 44 g/L suggests mild hypoalbuminemia, which may be related to the patient's heart failure. The presence of a low serum albumin level may indicate a degree of malnutrition, but it does not directly impact the patient's survival.

The patient's blood pressure is within a relatively normal range, with a systolic pressure of 150 mmHg. This is slightly elevated, but not excessively high, which may be due to the use of loop diuretics. The diastolic pressure of 60 mmHg is low, which may indicate decreased cardiac output. However, this is not uncommon in patients with heart failure.

The patient's creatinine level of 94.0 mmol/L is within a relatively normal range, indicating that renal function is preserved. The patient's potassium level of 4.62 mEq/L is also within a normal range.

The patient's LVEF of 35% is significantly reduced, indicating severe left ventricular dysfunction. However, the patient is on an ACE inhibitor, which is a standard treatment for heart failure and can help improve LVEF. The presence of non-sustained ventricular tachycardia may be a concern, but it is not an independent predictor of mortality.

The patient's TSH level of 1.35 mIU/L is within a normal range, indicating that the patient's thyroid function is normal. The patient's T3 and T4 levels are also within normal ranges.

The patient's troponin level of 0.5 ng/mL is slightly elevated, indicating some degree of cardiac damage, but it is not excessively high.

The patient's Pro-BNP level of 200 ng/L is elevated, indicating that the patient has some degree of heart failure. However, the patient's overall clinical presentation and laboratory results suggest that the heart failure is not severe.

In summary, the patient's outcome of survival can be attributed to the effective management of heart failure with loop diuretics and ACE inhibitors, as well as the patient's preserved renal function and normal thyroid function. The patient's LVEF is severely reduced, but the patient's overall clinical presentation and laboratory results suggest that the heart failure is not severe."
362,362,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome as a survivor can be attributed to several factors, despite his history of idiopathic dilated cardiomyopathy and significant left ventricular dysfunction (LVEF 35.0%). The patient's current medication regimen, including loop diuretics and an ACE inhibitor, is likely contributing to his survival. Loop diuretics help manage fluid overload and reduce symptoms of heart failure, while ACE inhibitors are known to improve survival and reduce morbidity in patients with heart failure.

The patient's blood pressure reading of 150/60 mmHg may be indicative of orthostatic hypotension, which is not uncommon in patients with heart failure. However, this does not appear to have negatively impacted his outcome.

The patient's laboratory results show a relatively stable kidney function (Creatinine 94.0 mmol/L), which is a good prognostic indicator. His albumin levels are also within a relatively normal range, suggesting that he is not experiencing significant malnutrition or liver dysfunction.

The patient's low T3 and T4 levels may indicate a euthyroid state, which is not typically associated with poor outcomes in heart failure patients.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias may have contributed to his survival.

The patient's hemoglobin level of 146.0 g/L is slightly below the normal range, but it is not low enough to suggest anemia as a contributing factor to his survival.

In summary, the combination of the patient's current medication regimen, relatively stable kidney function, and lack of severe laboratory abnormalities likely contributed to his survival."
363,363,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors:

1.  Prompt Medical Intervention: The patient's idiopathic dilated cardiomyopathy, indicated by a left ventricular ejection fraction (LVEF) of 35%, suggests a severe heart condition. However, the patient is on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure. These medications likely helped manage the patient's condition and improved symptoms.

2.  Stable Blood Pressure: The patient's blood pressure of 150/60 mmHg is within a relatively stable range. This suggests that the patient's blood pressure is being managed effectively, reducing the strain on the heart.

3.  Reasonable Electrolyte Levels: The patient's potassium level of 4.62 mEq/L is within a relatively stable range. This is crucial for heart function, as abnormal potassium levels can lead to arrhythmias and other cardiac complications.

4.  Minimal Signs of Organ Damage: The patient's creatinine level of 94.0 mol/L is slightly elevated, indicating some kidney strain, but not severe enough to suggest acute kidney injury. The patient's urea level of 5.3 mg/dL is also within a relatively stable range, indicating that the kidneys are functioning adequately.

5.  Normal TSH and T4 Levels: The patient's thyroid function tests are within normal limits, which is essential for heart health, as thyroid disorders can exacerbate heart conditions.

6.  Low Troponin Levels: The patient's troponin level of 0.5 ng/mL is within a relatively normal range, indicating minimal myocardial damage.

7.  Pro-BNP Levels: The patient's pro-BNP level of 200.0 ng/L is elevated, indicating heart failure, but not to a level that suggests severe heart failure or acute decompensation.

8.  Absence of Severe Arrhythmias: Although the patient has non-sustained ventricular tachycardia, there is no evidence of sustained or life-threatening arrhythmias, which is a positive sign.

Considering these factors, the patient's outcome as a survivor is likely due to a combination of effective medical management, stable vital signs, and minimal signs of organ damage. However, close monitoring and continued treatment are essential to prevent further complications."
364,364,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors. Firstly, the patient has been prescribed loop diuretics and an ACE inhibitor, which are standard treatments for heart failure and idiopathic dilated cardiomyopathy. The use of these medications suggests that the patient has been receiving appropriate medical management for their condition.

The patient's LVEF (Left Ventricular Ejection Fraction) of 35% indicates that they have significant left ventricular dysfunction, but it is not the lowest possible value, which suggests that there is some degree of preserved cardiac function. This may also indicate that the patient's heart is still able to compensate to some extent, contributing to their survival.

The patient's Pro-BNP level of 200.0 ng/L is elevated, indicating increased ventricular stress and potential heart failure, but it is not excessively high, which may suggest that the patient's condition is being managed.

The absence of severe electrolyte imbalances, such as hypokalemia or hyperkalemia, which can be a risk factor for arrhythmias and cardiac arrest, is also a positive factor in the patient's survival.

Additionally, the patient's TSH level of 1.35 mIU/L is within the normal range, which suggests that the patient's thyroid function is not contributing to their cardiac condition.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG may be a concern, but it is not a predictor of poor outcome in this case, as the patient is being managed with medications and is otherwise stable.

Overall, the combination of appropriate medical management, preserved cardiac function, and lack of severe electrolyte imbalances likely contributed to the patient's survival."
365,365,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival is attributed to the combination of the patient's current medical management and the relatively stable clinical condition at the time of evaluation. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition characterized by the enlargement and weakening of the heart muscle, leading to reduced left ventricular ejection fraction (LVEF) of 35%. 

Despite the low LVEF, the patient is on optimal medical therapy with loop diuretics and an ACE inhibitor, which are commonly used to manage heart failure and reduce symptoms. The patient's blood pressure is within a relatively normal range (150/60 mmHg), and the blood urea level is within a safe range (5.3 mg/dL), indicating that the patient's renal function is not significantly compromised.

The patient's electrolyte levels, including potassium (4.62 mEq/L) and sodium (140.0 mEq/L), are within normal limits, which is crucial for maintaining proper cardiac function. The patient's glucose level (5.3 mmol/L) is also within a relatively normal range, which suggests that the patient does not have diabetes mellitus, a condition that can exacerbate heart failure.

The patient's troponin level (0.5 ng/mL) is within a normal range, indicating that there is no evidence of acute myocardial infarction. The patient's TSH level (1.35 mIU/L) is within a normal range, indicating that the patient's thyroid function is normal.

The patient's LVEF of 35% is a significant concern, but the patient's overall clinical condition is relatively stable, and the patient is on optimal medical therapy. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a concern, but it is a common finding in patients with heart failure and does not necessarily indicate a poor prognosis.

In conclusion, the patient's survival outcome is likely due to the combination of optimal medical therapy, relatively stable clinical condition, and the absence of acute complications such as acute myocardial infarction or severe electrolyte imbalances."
366,366,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 66-year-old male with a history of idiopathic dilated cardiomyopathy, has a relatively favorable outcome despite his underlying condition. The patient's LVEF (Left Ventricular Ejection Fraction) of 35% indicates that his heart is not pumping efficiently, which is a common feature of dilated cardiomyopathy. However, the patient is on appropriate medications, including loop diuretics and an ACE inhibitor, which are standard treatments for heart failure.

The patient's Pro-BNP (B-type natriuretic peptide) level of 200 ng/L is elevated, indicating increased ventricular stress and potential heart failure, but not excessively high, suggesting that the patient's condition is not deteriorating rapidly. The patient's troponin level of 0.5 ng/mL is within the normal range, indicating minimal myocardial damage.

The patient's ECG shows non-sustained ventricular tachycardia (VT), which is a common arrhythmia in patients with heart failure. However, the patient does not have a history of sustained VT or other severe arrhythmias.

The patient's laboratory results show a relatively well-managed metabolic profile, with normal electrolyte levels, normal liver function tests, and a slightly elevated creatinine level, which may be related to his heart failure.

The patient's TSH level of 1.35 mIU/L is within the normal range, indicating that his thyroid function is not contributing to his cardiac condition. The patient's T3 and T4 levels are also within normal limits.

Overall, the patient's outcome is likely due to the effectiveness of his current treatment regimen, including loop diuretics and an ACE inhibitor, which are helping to manage his heart failure symptoms and prevent further deterioration. Additionally, the patient's relatively stable laboratory results and lack of severe arrhythmias suggest that his condition is being well-managed."
367,367,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 66-year-old male with a history of idiopathic dilated cardiomyopathy, has survived despite his advanced heart condition. Several factors contribute to this outcome:

1.  Optimal medication management: The patient is on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure. These medications have helped manage his symptoms and slow the progression of his condition.
2.  Low levels of troponin: The patient's troponin level of 0.5 ng/mL is within the normal range, indicating minimal cardiac muscle damage. Elevated troponin levels are often associated with heart attacks and increased mortality risk.
3.  Normal TSH and T4 levels: The patient's thyroid function is within normal limits, which is essential for maintaining cardiac health. Hypothyroidism can exacerbate heart failure, and hyperthyroidism can increase cardiac workload.
4.  Low Pro-BNP levels: Although the patient's Pro-BNP level is elevated at 200 ng/L, it is not excessively high, indicating that his heart is not under extreme stress. Elevated Pro-BNP levels are associated with heart failure and increased mortality risk.
5.  Slightly low potassium levels: The patient's potassium level of 4.62 mEq/L is slightly below the normal range. Low potassium levels can increase the risk of arrhythmias and cardiac arrest, but the patient has not experienced any bradycardia or other cardiac complications.
6.  LVEF of 35%: Although the patient's left ventricular ejection fraction (LVEF) is low at 35%, it is not the lowest possible value. The patient's heart is still pumping some blood, and his symptoms have not progressed to the point of severe heart failure.
7.  No evidence of significant liver dysfunction: The patient's liver enzymes (ALT, AST, and GGT) are within normal limits, indicating that his liver is functioning properly and not contributing to his heart condition.
8.  Controlled blood pressure: The patient's blood pressure is within a relatively normal range, which is essential for managing heart failure.

Considering these factors, the patient's survival is likely due to the effectiveness of his medication regimen, the absence of significant cardiac muscle damage, and the presence of normal thyroid function, among other factors. However, the patient's condition is still critical, and close monitoring and follow-up appointments with his cardiologist are essential to prevent further complications and manage his heart failure."
368,368,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 66-year-old male with a history of idiopathic dilated cardiomyopathy, has a relatively favorable outcome despite having a low left ventricular ejection fraction (LVEF) of 35%. This suggests that the patient's heart is still functioning to some extent, albeit inefficiently.

Several factors contribute to this outcome:

1. Optimal medical management: The patient is on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure and idiopathic dilated cardiomyopathy. These medications help manage symptoms, reduce fluid overload, and improve cardiac function.
2. Low troponin levels: The patient's troponin level is 0.5 ng/mL, which is within the normal range. Elevated troponin levels often indicate myocardial injury or infarction, but in this case, it suggests that the patient's heart is not experiencing significant acute damage.
3. Normal TSH and T4 levels: The patient's thyroid function is within normal limits, which is essential for maintaining cardiac function and metabolism.
4. Slightly elevated Pro-BNP levels: While the patient's Pro-BNP level is elevated at 200 ng/L, it is not excessively high, indicating that the patient's heart is not under extreme stress or failing catastrophically.
5. Absence of severe arrhythmias: The patient does not have sustained ventricular tachycardia or other severe arrhythmias, which could indicate a more critical cardiac condition.
6. Well-controlled blood pressure: The patient's blood pressure is within a relatively normal range (150/60 mmHg), which is essential for maintaining cardiac function and reducing the risk of complications.
7. No signs of acute kidney injury: The patient's creatinine and urea levels are within normal limits, indicating that the kidneys are functioning adequately, which is crucial for maintaining cardiac function and overall health.

Considering these factors, the patient's outcome as a survivor is likely due to the combination of optimal medical management, relatively low troponin levels, normal thyroid function, and absence of severe arrhythmias or acute kidney injury."
369,369,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor, which can be attributed to several factors observed in the provided data.

1.  Stable NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating that the patient has some limitations in physical activity but is still able to perform daily tasks without symptoms. This suggests that the patient's heart failure is not severe, and they are likely receiving effective treatment.

2.  Medications: The patient is taking loop diuretics and an ACE inhibitor, which are standard treatments for heart failure and idiopathic dilated cardiomyopathy. These medications help reduce fluid buildup in the body, lower blood pressure, and improve heart function.

3.  LVEF of 35%: Although the left ventricular ejection fraction (LVEF) is low, indicating reduced heart function, the patient is still alive, which suggests that the heart is still pumping some blood effectively. This may be due to the effectiveness of their current treatment regimen.

4.  Pro-BNP level: The Pro-BNP level is elevated at 200.0 ng/L, which is consistent with heart failure. However, the patient's survival suggests that their heart is still adapting to the condition, and their medications are helping to manage the symptoms.

5.  ECG findings: While the ECG shows non-sustained ventricular tachycardia, this is a common finding in patients with heart failure and idiopathic dilated cardiomyopathy. The absence of sustained ventricular tachycardia or other severe arrhythmias is a positive sign.

6.  Hemoglobin level: The patient's hemoglobin level is within the normal range, which suggests that their kidneys are functioning relatively well, and they are not experiencing significant anemia.

7.  Glucose and lipid profiles: The patient's glucose and lipid profiles are within relatively normal ranges, which suggests that they are not experiencing significant metabolic derangements that could exacerbate their heart condition.

8.  TSH level: The patient's thyroid-stimulating hormone (TSH) level is within the normal range, which suggests that their thyroid function is not contributing to their heart condition.

Considering these factors, the patient's outcome as a survivor is likely due to the effectiveness of their current treatment regimen, stable NYHA class, and relatively well-managed heart failure symptoms."
370,370,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

Given the patient's advanced age of 80, the patient's survival is a positive outcome, considering the high risk factors associated with this age group. The patient's New York Heart Association (NYHA) Class III indicates that the patient experiences symptoms of heart failure with ordinary physical activity, but is still able to perform daily activities. 

The patient's blood pressure is elevated at 150/65 mmHg, but it is not excessively high, which might be managed with the current medication regimen. The presence of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension are significant risk factors for cardiovascular disease, but the patient's left ventricular ejection fraction (LVEF) of 70% is relatively well-preserved, indicating that the patient's heart is still functioning adequately.

The patient's laboratory results show elevated creatinine levels (118.0 mmol/L), indicating some degree of kidney impairment, but the patient's medication regimen includes loop diuretics, which are commonly used to manage fluid overload in heart failure patients. The patient's electrolyte levels are relatively stable, with a potassium level of 4.4 mEq/L, which is within the normal range.

The patient's TSH level is within the normal range, indicating that the patient's thyroid function is normal, which is an important factor in heart function and overall health. The patient's Pro-BNP level is elevated at 195.0 ng/L, which is a marker of heart failure, but the patient's LVEF is still relatively well-preserved, suggesting that the patient's heart is adapting to the increased workload.

The patient's ECG shows a ventricular extrasystole, which is a common finding in patients with heart disease, but there is no indication of sustained ventricular tachycardia or other life-threatening arrhythmias. The presence of sinus node dysfunction is also a common finding in elderly patients and is not necessarily a cause for concern.

Considering the patient's overall clinical picture, the patient's survival is likely due to the effective management of their heart failure symptoms with medication, the preservation of their LVEF, and the absence of any life-threatening arrhythmias."
371,371,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient is an 80-year-old female with a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these comorbidities, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 70%, which is a good prognostic indicator. The patient's medications, including angiotensin II receptor blockers, beta blockers, loop diuretics, statins, and nitrovasodilators, are appropriate for managing heart failure and comorbid conditions.

The patient's electrocardiogram (ECG) shows a few notable findings, including ventricular extrasystoles and sinus node dysfunction, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. The presence of TPSV (paroxysmal supraventricular tachyarrhythmia) is also noted, but this is not uncommon in patients with heart failure.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST) and gamma-glutamil transpeptidase, which may be related to her diabetes or dyslipemia. The patient's kidney function, as indicated by creatinine levels, is mildly impaired, which is consistent with her age and comorbidities.

Given the patient's overall clinical picture, the most likely reason for her outcome as a survivor is the effectiveness of her current treatment regimen and her relatively preserved cardiac function. The patient's age and comorbidities do increase her risk for adverse outcomes, but her current medications and preserved LVEF suggest that she is well-managed and able to tolerate her conditions."
372,372,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient, an 80-year-old female, has a complex medical history that includes valvular cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite her advanced age and multiple comorbidities, the patient has a left ventricular ejection fraction (LVEF) of 70%, indicating preserved cardiac function. 

The patient's blood pressure is elevated at 150/65 mmHg, which may be a concern for her hypertension. However, her current medications, including an angiotensin II receptor blocker, beta blockers, and a nitrovasodilator, are likely helping to manage her blood pressure and cardiac function.

The patient's laboratory results show evidence of mild renal impairment (elevated creatinine), which may be related to her diabetes and hypertension. Her lipid profile is abnormal, with high total cholesterol and low HDL levels, but her LDL levels are relatively well-controlled with statin therapy.

The patient's thyroid function tests are within normal limits, with a TSH of 1.05 mIU/L and normal T3 and T4 levels. Her liver function tests are also normal, with mildly elevated GGT levels that may be related to her alcohol consumption or other liver pathology.

The ECG findings are notable for ventricular extrasystoles and sinus node dysfunction, which may be related to her valvular cardiomyopathy and advanced age. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's overall clinical picture, her survival can be attributed to the following factors:

1.  Effective management of her hypertension and cardiac function with medications.
2.  Preserved cardiac function, as indicated by her LVEF of 70%.
3.  Mild renal impairment, which may be managed with further medical therapy.
4.  Normal thyroid function, which is essential for maintaining cardiac function and overall health.
5.  Normal liver function, which is crucial for metabolizing her medications and managing her lipid profile.

In conclusion, the patient's survival can be attributed to a combination of effective medical therapy, preserved cardiac function, and normal thyroid and liver function."
373,373,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient, an 80-year-old female with a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension, has been prescribed a comprehensive treatment regimen that includes medications for diabetes, hypertension, and heart failure. The patient's left ventricular ejection fraction (LVEF) is within a relatively normal range at 70%, indicating that the heart is pumping blood efficiently.

The patient's blood pressure is elevated at 150/65 mmHg, which is likely being managed with the angiotensin II receptor blocker and beta blockers. The use of loop diuretics is also consistent with the treatment of heart failure, as it helps to reduce fluid overload and alleviate symptoms.

The patient's laboratory results show a slightly elevated creatinine level (118.0 mmol/L), which may indicate some degree of renal impairment. However, this is not unexpected given the patient's age and the presence of diabetes and hypertension. The patient's glucose level is well-controlled at 4.8 mmol/L, which is within the target range for diabetes management.

The patient's TSH level is within the normal range (1.05 mIU/L), indicating that the thyroid function is normal. The low T3 level (0.0327 pg/dL) may be related to the patient's age or the use of certain medications, such as beta blockers.

The patient's ECG shows a ventricular extrasystole, which is a common finding in patients with heart disease. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia is reassuring. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) and sinus node dysfunction is consistent with the patient's age and underlying heart disease.

Overall, the patient's treatment regimen and laboratory results suggest that the patient is receiving appropriate care for their heart failure and other comorbidities. The patient's survival outcome is likely due to the comprehensive management of their heart disease and other medical conditions, as well as the absence of any acute complications or severe organ dysfunction."
374,374,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors based on the provided data.

1.  Stable LVEF of 70%: The patient's left ventricular ejection fraction (LVEF) is within a relatively normal range, indicating that the heart is pumping efficiently, which is a good prognostic sign.
2.  Controlled Blood Pressure: The patient's blood pressure is within a relatively controlled range, with a systolic pressure of 150 mmHg, which is not excessively high considering her age and comorbidities. Controlled blood pressure reduces the strain on the heart.
3.  Current Medications: The patient is on a comprehensive regimen of medications that address her conditions, including diabetes medication, angiotensin II receptor blockers, beta blockers, loop diuretics, statins, and nitrovasodilators. These medications are likely contributing to her controlled blood pressure and improved heart function.
4.  No Indication of Severe Cardiac Arrhythmias: The ECG shows a monomorphic ventricular extrasystole, but there is no indication of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia, which are concerning signs that could lead to cardiac arrest or other serious complications.
5.  Mild Kidney Function Impairment: The patient's creatinine level is slightly elevated at 118.0 mmol/L, indicating mild kidney function impairment. However, this is not severe enough to significantly impact her cardiac function or overall survival.
6.  Normal Thyroid Function: The patient's TSH, T3, and T4 levels are within normal ranges, indicating that her thyroid function is not contributing to her cardiac condition.
7.  No Severe Anemia: The patient's hemoglobin level is 114.0 g/L, which is within a relatively normal range, indicating that she does not have severe anemia, which could exacerbate cardiac function.

Considering these factors, the patient's outcome as a survivor is likely due to the combination of her stable cardiac function, controlled blood pressure, comprehensive medication regimen, and the absence of severe cardiac arrhythmias or other complications."
375,375,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient is an 80-year-old female with a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these comorbidities, she has a relatively preserved left ventricular ejection fraction (LVEF) of 70%. This suggests that her heart function is still relatively well-preserved, which is a positive prognostic indicator.

The patient's blood pressure is elevated at 150/65 mmHg, which is consistent with her history of hypertension. However, her use of angiotensin II receptor blocker and beta blockers suggests that her blood pressure is being well-managed.

The patient's laboratory results show mild elevations in creatinine and urea, which may indicate some degree of renal impairment. However, her eGFR is not provided, so it is difficult to assess the severity of this impairment.

The patient's glucose level is slightly elevated at 4.8 mmol/L, which is consistent with her history of diabetes. Her use of diabetes medication is likely helping to manage this condition.

The patient's lipid profile shows a high total cholesterol level of 4.91 mmol/L, with a high LDL of 2.53 mmol/L. Her use of statins is likely helping to manage this condition.

The patient's TSH level is within the normal range, suggesting that her thyroid function is well-managed. Her T3 and T4 levels are also within the normal range, which is consistent with her thyroid function.

The patient's ECG shows a sinus node dysfunction, which may be contributing to her bradycardia. However, this is not necessarily a negative prognostic indicator, as many patients with sinus node dysfunction can still lead active and healthy lives.

The patient's ventricular extrasystoles are monomorphic, which is a relatively benign finding. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia are also positive prognostic indicators.

Overall, while the patient has several comorbidities, her relatively preserved LVEF, well-managed blood pressure, and absence of severe cardiac arrhythmias suggest that she is likely to survive with proper management of her conditions."
376,376,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient is an 80-year-old female with a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension. She is on a comprehensive medication regimen including diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, statins, and nitrovasodilators. 

Despite her complex medical history and multiple comorbidities, the patient's left ventricular ejection fraction (LVEF) is 70%, indicating preserved cardiac function. The patient's blood pressure is 150/65 mmHg, which is within a relatively controlled range considering her hypertension diagnosis. 

The patient's laboratory results show elevated creatinine levels (118.0 mmol/L), which may indicate some degree of renal impairment. However, her albumin levels are within a relatively normal range (39 g/L). Her glucose levels are well-controlled (4.8 mmol/L) with her diabetes medication, and her lipid profile shows a high total cholesterol level (4.91 mmol/L) but a relatively low LDL level (2.53 mmol/L) due to statin therapy.

The patient's ECG shows a ventricular extrasystole and a sinus node dysfunction, but no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. The presence of paroxysmal supraventricular tachycardia (PSVT) is noted, but it is not life-threatening.

Considering the patient's age, comorbidities, and comprehensive medication regimen, it is not surprising that she has survived her current condition. The combination of preserved cardiac function, well-controlled blood pressure and glucose levels, and effective management of her comorbidities likely contributed to her survival."
377,377,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: The patient, an 80-year-old female with a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex medical profile. Despite these comorbidities, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 70%, which is within the normal range. This suggests that the patient's heart function is relatively well-preserved, which is a positive prognostic factor.

The patient's medications, including angiotensin II receptor blockers, beta blockers, loop diuretics, statins, and nitrovasodilators, are appropriate for managing her conditions, including hypertension, heart failure, and dyslipidemia. The presence of diabetes medication also indicates that the patient's blood sugar levels are being managed.

The ECG findings, while showing some arrhythmias, such as ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia, do not suggest any acute or severe cardiac issues. The absence of sustained ventricular tachycardia and the presence of sinus node dysfunction are also noted.

The patient's laboratory results show some abnormalities, such as elevated creatinine levels, which may indicate mild renal impairment, and elevated glucose levels, which are being managed with diabetes medication. However, the albumin levels are within the normal range, and the liver function tests (ALT and AST) are normal.

Considering the patient's age, comorbidities, and the overall assessment of her cardiac function and laboratory results, it is likely that the patient's survival is due to the following factors:

1. Appropriate medical management of her conditions, including heart failure, hypertension, and diabetes.
2. Preserved left ventricular function, as indicated by a normal LVEF.
3. The absence of severe cardiac arrhythmias or acute cardiac events.
4. The presence of a relatively well-managed renal function, despite elevated creatinine levels.

Therefore, the patient's outcome of survival is likely due to a combination of these factors, which have contributed to her ability to tolerate her comorbidities and manage her cardiac condition effectively."
378,378,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient, an 80-year-old female, has a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension, which are all significant risk factors for cardiovascular disease. However, the patient's left ventricular ejection fraction (LVEF) is within the normal range (70%), indicating that the heart is functioning relatively well.

The patient's blood pressure is elevated (150/65 mmHg), which may be contributing to the progression of the patient's valvular cardiomyopathy. However, the patient is on angiotensin II receptor blocker, beta blockers, and loop diuretics, which are all medications that can help control blood pressure and alleviate symptoms of heart failure.

The patient's laboratory results show elevated creatinine levels (118.0 mmol/L), which indicates impaired kidney function. However, the patient's urea levels are not significantly elevated, suggesting that the kidneys are still functioning to some extent.

The patient's thyroid function tests (T3, T4, and TSH) are within the normal range, which suggests that the patient's thyroid function is not contributing to the patient's cardiac symptoms.

The patient's electrocardiogram (ECG) shows ventricular extrasystole, which is a common finding in patients with valvular cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering the patient's age, comorbidities, and the fact that the patient is on appropriate medications, the patient's outcome as a survivor is likely due to the following factors:

1. Adequate medical management: The patient is on a comprehensive treatment plan that includes medications for diabetes, hypertension, and heart failure, which may have contributed to the patient's survival.
2. Normal LVEF: The patient's LVEF is within the normal range, indicating that the heart is functioning relatively well.
3. No evidence of severe cardiac dysfunction: The patient's ECG does not show any evidence of severe cardiac dysfunction, such as sustained ventricular tachycardia or bradycardia.

Overall, the patient's outcome as a survivor is likely due to a combination of adequate medical management, normal LVEF, and the absence of severe cardiac dysfunction."
379,379,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient, an 80-year-old female with a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension, had a complex set of risk factors that contributed to her overall cardiovascular health. Despite these factors, she was able to survive, likely due to a combination of her current treatment regimen and her relatively preserved left ventricular ejection fraction (LVEF) of 70%.

The patient's use of medications such as angiotensin II receptor blockers, beta blockers, loop diuretics, statins, and nitrovasodilators likely helped to manage her conditions and mitigate potential complications. The presence of diabetes medication also suggests that her glucose levels were being closely monitored and managed.

The ECG findings of ventricular extrasystoles, sinus node dysfunction, and paroxysmal supraventricular tachyarrhythmia (TPSV) indicate some degree of cardiac electrical instability, but the absence of sustained ventricular tachycardia or other more severe arrhythmias suggests that her heart was able to compensate for these issues.

Additionally, the patient's laboratory results show relatively well-controlled blood glucose and lipid levels, as well as a normal potassium level, which are all positive indicators of her overall health.

The elevated Pro-BNP level of 195.0 ng/L may indicate some degree of heart failure, but the patient's LVEF of 70% suggests that her heart function is still relatively preserved. The presence of albuminuria (albumin 39 g/L) may also indicate some degree of kidney damage, but this is not uncommon in patients with heart failure.

Overall, while the patient has a complex set of risk factors and cardiac issues, her ability to survive suggests that her current treatment regimen and her relatively preserved cardiac function have helped to mitigate potential complications."
380,380,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient outcome of survival can be attributed to several factors based on the provided data. 

Firstly, the patient's left ventricular ejection fraction (LVEF) of 53% is relatively preserved, indicating that the patient's heart is still functioning adequately, despite a history of enolic dilated cardiomyopathy. This suggests that the patient's cardiac function has not significantly deteriorated, which is a positive prognostic indicator.

Secondly, the patient's medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, is well-tailored to manage heart failure symptoms and prevent further cardiac deterioration. These medications are known to improve survival and reduce hospitalizations in patients with heart failure.

Thirdly, the patient's laboratory results, such as the normal troponin level (0.01 ng/mL) and hemoglobin level (160 g/L), indicate that there is no acute cardiac damage or anemia, which are both favorable factors for survival.

Lastly, the patient's electrocardiogram (ECG) shows non-sustained ventricular tachycardia, which is a common finding in patients with heart failure, but the presence of ventricular extrasystoles is relatively benign. The absence of sustained ventricular tachycardia or other life-threatening arrhythmias is a positive sign.

Considering these factors, the patient's survival can be attributed to the effective management of their heart failure symptoms, preserved cardiac function, and the absence of acute cardiac damage or other life-threatening conditions."
381,381,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of being a survivor can be attributed to several factors based on the provided data and information. 

Firstly, the patient's left ventricular ejection fraction (LVEF) is 53%, which is within the normal range (50-70%). This indicates that the patient's heart is still pumping blood effectively, and the patient is not in a state of severe heart failure. The LVEF is a crucial indicator of the heart's pumping efficiency, and a value of 53% suggests that the patient's heart is still functioning relatively well.

Secondly, the patient's pro-BNP (B-type natriuretic peptide) level is 320 ng/L, which is elevated but not extremely high. Elevated pro-BNP levels are often associated with heart failure, but the patient's LVEF and other clinical parameters do not indicate severe heart failure. This suggests that the patient's heart is adapting to the stress of the dilated cardiomyopathy, and the elevated pro-BNP level may be a sign of mild to moderate heart failure.

Thirdly, the patient's medication regimen is comprehensive and appropriate for a patient with dilated cardiomyopathy. The use of beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors is a standard approach for managing heart failure and reducing the risk of arrhythmias. This suggests that the patient is receiving optimal medical care, which has contributed to their survival.

Lastly, the patient's troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels are associated with myocardial infarction or cardiac damage, but the patient's low troponin level suggests that they have not experienced a recent myocardial infarction.

Considering these factors, the patient's outcome of being a survivor can be attributed to the effective management of their dilated cardiomyopathy, the maintenance of a relatively high LVEF, and the absence of severe heart failure or recent cardiac damage."
382,382,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors from the provided data.

1.  Optimal Medication Regimen: The patient is on a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. This combination is typically used to manage heart failure symptoms, control blood pressure, and reduce the risk of cardiac arrhythmias. The use of beta blockers, in particular, has been shown to improve survival in patients with heart failure by reducing the heart rate and the force of contraction, thereby reducing the oxygen demand of the heart.

2.  Moderate Heart Failure: The patient's LVEF (Left Ventricular Ejection Fraction) is 53%, which indicates moderate heart failure. While this is not normal (normal LVEF is typically >55%), it is not as severe as heart failure with an LVEF <30-40%. The patient's NYHA Class II classification also indicates that the patient experiences some symptoms of heart failure, but they are manageable with medication and lifestyle changes.

3.  Low Troponin Levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels are indicative of myocardial damage, and low levels suggest that the patient has not experienced a recent myocardial infarction (heart attack).

4.  Normal Electrolytes: The patient's potassium level is 4.2 mEq/L, which is within the normal range. Electrolyte imbalances, particularly hypokalemia (low potassium), can contribute to cardiac arrhythmias and increase the risk of cardiac arrest.

5.  Low Creatinine Levels: The patient's creatinine level is 88.0 umol/L, which is within the normal range. Elevated creatinine levels can indicate kidney dysfunction, which can worsen heart failure and increase the risk of mortality.

6.  Normal Thyroid Function: The patient's TSH (thyroid-stimulating hormone) level is 4.19 mIU/L, which is within the normal range. Thyroid dysfunction can contribute to heart failure and cardiac arrhythmias.

7.  Absence of Recent Cardiac Arrest or Sudden Cardiac Death: The patient's ECG findings indicate non-sustained ventricular tachycardia, but there is no indication of a recent cardiac arrest or sudden cardiac death.

Considering these factors, the patient's outcome as a survivor can be attributed to the optimal management of their heart failure symptoms, the absence of recent myocardial damage, normal electrolytes, and normal thyroid function, as well as the absence of recent cardiac arrest or sudden cardiac death."
383,383,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 58-year-old male with a history of enolic dilated cardiomyopathy, has been treated with a multidrug regimen including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. The patient's current medication regimen is likely aimed at managing symptoms of heart failure, reducing morbidity and mortality, and controlling arrhythmias.

The patient's LVEF (Left Ventricular Ejection Fraction) of 53% indicates a mildly reduced ejection fraction, which is consistent with dilated cardiomyopathy. The patient's Pro-BNP (B-type natriuretic peptide) level of 320 ng/L is elevated, which is indicative of heart failure with reduced ejection fraction (HFrEF).

The patient's ECG findings of monomorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia and bradycardia are consistent with the patient's underlying cardiac disease.

The patient's laboratory results show a slightly elevated creatinine level (88.0 umol/L), which may indicate mild renal impairment, a common comorbidity in patients with heart failure. The patient's total cholesterol and LDL levels are elevated, which may contribute to the progression of cardiac disease.

Given the patient's treatment regimen and the management of his cardiac disease, it is likely that the patient's outcome of survival is due to the effectiveness of his medication regimen and the close monitoring and management of his cardiac disease. The patient's LVEF, despite being mildly reduced, is stable, and the patient is able to tolerate his medication regimen without significant adverse effects. The patient's ECG findings and laboratory results indicate that his cardiac disease is being well-managed, and he is at a lower risk of adverse cardiac events."
384,384,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors in the provided medical data. 

1. Effective Medication Management: The patient is on a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are standard treatments for heart failure and arrhythmias, and their use suggests that the patient's condition has been well-managed.

2. Stable LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 53%, which is within the range of a mildly reduced ejection fraction. Although it is lower than the normal range (60-70%), it indicates that the patient's heart is still functioning relatively well, allowing for adequate blood circulation and oxygen delivery to vital organs.

3. Normal Blood Pressure: The patient's blood pressure of 110/60 mmHg is within the normal range, indicating that the heart is not experiencing excessive workload due to high blood pressure.

4. Low Troponin Levels: The patient's troponin level of 0.01 ng/mL is within the normal range, indicating that there is no significant cardiac muscle damage.

5. Normal Hemoglobin and Protein Levels: The patient's hemoglobin and protein levels are within the normal range, indicating that there is no significant anemia or malnutrition, which could exacerbate heart failure.

6. Normal Electrolyte Levels: The patient's potassium level of 4.2 mEq/L is within the normal range, indicating that there are no significant electrolyte imbalances that could contribute to arrhythmias.

7. TSH Level: The patient's TSH level of 4.19 mIU/L is within the normal range, indicating that there are no signs of hypothyroidism, which can contribute to heart failure.

8. Pro-BNP Level: The patient's Pro-BNP level of 320.0 ng/L is elevated, but within the range seen in heart failure patients. However, it is not excessively high, suggesting that the patient's heart failure is well-managed.

Considering these factors, the patient's outcome as a survivor can be attributed to effective management of their heart failure and arrhythmias, stable cardiac function, and absence of significant electrolyte imbalances or other underlying conditions that could contribute to poor outcomes."
385,385,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 58-year-old male with a history of enolic dilated cardiomyopathy, which indicates a weakened heart muscle leading to a reduced left ventricular ejection fraction (LVEF) of 53%. This condition can lead to heart failure symptoms, which are classified under New York Heart Association (NYHA) Class II, indicating mild to moderate symptoms with moderate limitation in physical activity.

The patient's laboratory results show elevated levels of Creatinine (88.0 mmol/L), indicating impaired kidney function, and high levels of Pro-BNP (320.0 ng/L), which is a biomarker for heart failure. The patient is on medications such as Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor, which are commonly used to manage heart failure and dilated cardiomyopathy.

The ECG results show non-sustained ventricular tachycardia and ventricular extrasystole, which are abnormal heart rhythms that can be associated with heart failure and cardiomyopathy. However, the patient's Troponin levels are within normal limits, indicating that there is no acute myocardial infarction.

Considering the patient's age, medical history, and laboratory results, the patient's survival outcome can be attributed to the following factors:

1.  The patient is on appropriate medication for heart failure and dilated cardiomyopathy, which has likely helped to manage the condition and prevent further deterioration.
2.  The patient's LVEF of 53% is not severely low, indicating that the heart muscle is still functioning to some extent.
3.  The patient's kidney function is impaired, but not severely, as indicated by the Creatinine levels.
4.  The patient's Pro-BNP levels are elevated, but not extremely high, indicating that the heart failure is not in an advanced stage.

In conclusion, the patient's survival outcome is likely due to the effective management of his heart failure and dilated cardiomyopathy with medication, relatively preserved LVEF, and not severely impaired kidney function."
386,386,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 58-year-old male with a history of enolic dilated cardiomyopathy, a condition where the heart's left ventricle is enlarged and not pumping efficiently. Despite this, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 53%, indicating that the heart is still functioning to some extent.

The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, suggest that they are receiving standard treatment for heart failure and arrhythmias. The use of beta blockers and ACE inhibitors aims to reduce the heart rate and workload, while digoxin helps regulate heart rhythm. Loop diuretics and spironolactone are used to reduce fluid buildup and alleviate symptoms.

The patient's laboratory results show slightly elevated liver enzymes (AST and ALT), which may indicate some degree of liver stress, but not severe enough to cause significant concern. The patient's lipid profile is slightly abnormal, with high total cholesterol and LDL levels, which may be contributing to the progression of heart disease.

The patient's creatinine level is elevated at 88.0 umol/L, indicating some degree of kidney impairment, which is not uncommon in patients with heart failure.

The patient's TSH level is within the normal range, and the T3 and T4 levels are also within normal limits, indicating that the patient does not have hypothyroidism.

The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with heart failure and cardiomyopathy. The presence of monomorphic ventricular extrasystoles may also be a sign of underlying heart disease.

Given the patient's overall condition, it is likely that the patient's outcome of survival is due to the combination of the following factors:

1.  Effective medical management with standard medications for heart failure and arrhythmias.
2.  A relatively preserved LVEF, indicating that the heart is still functioning to some extent.
3.  The patient's overall stable condition, with no acute decompensation or severe symptoms.
4.  The patient's age and sex, which are generally favorable for survival in patients with heart failure.

However, it is essential to continue monitoring the patient's condition and adjust their treatment plan as needed to prevent further complications and improve their quality of life."
387,387,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 58-year-old male with a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, reducing the heart's ability to pump blood effectively. Despite this, the patient has a relatively well-controlled condition, as indicated by a left ventricular ejection fraction (LVEF) of 53%, which is higher than the typical threshold for heart failure.

The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, are standard treatments for heart failure and are likely contributing to the patient's stable condition. The patient's blood pressure is within a relatively normal range (110/60 mmHg), and there is no indication of significant electrolyte imbalances or renal dysfunction.

The patient's troponin level is low (0.01 ng/mL), indicating minimal cardiac damage. The pro-BNP level is elevated (320.0 ng/L), but this is not uncommon in patients with heart failure and is likely related to the patient's underlying condition.

The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with heart failure. However, the patient is still able to tolerate these arrhythmias without significant symptoms or complications.

The patient's overall clinical picture suggests that they are a survivor due to the following factors:

1. Well-controlled heart failure symptoms (NYHA Class II)
2. Stable LVEF
3. Appropriate medications for heart failure
4. Minimal cardiac damage (low troponin level)
5. No significant electrolyte imbalances or renal dysfunction
6. Ability to tolerate arrhythmias without symptoms or complications

Overall, the patient's clinical status and treatment plan are likely contributing to their survival, and they are being closely monitored and managed by their healthcare team."
388,388,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to several factors based on the provided data and medical history. 

1. Current Medications: The patient is on a comprehensive regimen of medications, including Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor. These medications are commonly used to manage heart failure symptoms, control blood pressure, and prevent arrhythmias, which may have contributed to the patient's survival.

2. LVEF (Left Ventricular Ejection Fraction) of 53%: Although the patient's LVEF is lower than the normal range (60-70%), it is still relatively high, indicating that the left ventricle is still pumping blood effectively, which is a good prognostic sign.

3. Pro-BNP (Brain Natriuretic Peptide) of 320 ng/L: The Pro-BNP level is elevated, which is consistent with heart failure, but not excessively high. Elevated Pro-BNP levels can indicate increased ventricular wall stress, but the patient's survival suggests that the levels are manageable with current treatment.

4. ECG Findings: The presence of monomorphic ventricular extrasystoles and non-sustained ventricular tachycardia may indicate underlying cardiac arrhythmias, but the patient's survival suggests that these are being managed effectively with the current medication regimen.

5. Blood Pressure and Hemodynamics: The patient's blood pressure is within a relatively normal range (110/60 mmHg), which is consistent with controlled hypertension. The hemoglobin level is within the normal range, indicating adequate oxygen delivery to tissues.

6. Liver Function Tests (ALT, AST, GGT): The patient's liver function tests are within the normal range, which suggests that there is no significant liver dysfunction contributing to the patient's overall condition.

7. Kidney Function (Creatinine, Urea): The patient's kidney function is within the normal range, which is essential for the excretion of waste products and electrolytes.

8. Hormonal Imbalance (T3, T4, TSH): The patient's thyroid function is within the normal range, which is essential for overall metabolic balance and cardiac function.

In summary, the patient's survival can be attributed to a combination of effective medical management, relatively preserved cardiac function, and absence of significant comorbidities or organ dysfunction."
389,389,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 58-year-old male with a history of enolic dilated cardiomyopathy, has a relatively favorable outcome despite his condition. Several factors contribute to this outcome:

1.  Effective Medical Management: The patient is on a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are standard treatments for heart failure and dilated cardiomyopathy, and their use likely helped to manage the patient's condition.

2.  Preserved LVEF: Although the patient's left ventricular ejection fraction (LVEF) is 53%, which is below the normal range, it is not severely decreased. This suggests that the patient's heart is still pumping blood efficiently enough to support his bodily needs.

3.  Mild Hypertension: The patient's blood pressure is within a relatively normal range (110/60 mmHg), which is a good sign for heart health. Hypertension is a major risk factor for heart disease, so this patient's blood pressure is not contributing to his condition.

4.  Normal Hemoglobin and Potassium Levels: The patient's hemoglobin level is within the normal range, indicating that his red blood cell count is adequate. His potassium level is also normal, which is important for heart function.

5.  Low Troponin Level: The patient's troponin level is low (0.01 ng/mL), indicating that there is no evidence of acute myocardial infarction (heart attack) and that his heart muscle is not experiencing significant damage.

6.  Normal TSH Level: The patient's thyroid-stimulating hormone (TSH) level is within the normal range, indicating that his thyroid function is normal. Hypothyroidism can contribute to heart failure, so this is a positive finding.

7.  ECG Findings: While the patient has some ECG abnormalities, including ventricular extrasystoles and non-sustained ventricular tachycardia, these are relatively common in patients with heart failure and are not necessarily indicative of a poor prognosis.

Considering these factors, the patient's outcome of survival is likely due to a combination of effective medical management, preserved LVEF, mild hypertension, and the absence of acute cardiac damage or other complicating factors."
390,390,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is likely a survivor due to a combination of factors. 

1. Age and comorbidities: Although the patient is 83 years old, which is considered elderly and increases the risk of mortality, her survival is not unexpected given her current treatment and medical history.

2. Medications: The patient is on a comprehensive regimen of medications, including Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, and Nitrovasodilator, which are commonly used in the management of heart failure and hypertension. These medications are likely contributing to her survival.

3. ECG findings: While the patient has ventricular extrasystole and non-sustained ventricular tachycardia, these are relatively common findings in patients with heart failure and are not necessarily indicative of an acute life-threatening condition.

4. Laboratory values: The patient's LVEF (Left Ventricular Ejection Fraction) is 50%, which is within the normal range, indicating that her heart is functioning adequately. Her blood pressure is well-controlled, and her kidney function, as indicated by creatinine levels, is also within a relatively normal range.

5. Pro-BNP levels: The patient's Pro-BNP level is elevated at 1094.0 ng/L, which is often seen in patients with heart failure. However, the fact that she is still alive and not showing signs of acute decompensation suggests that her treatment is effective.

6. Hemoglobin and electrolytes: Her hemoglobin level is within a normal range, and her potassium level is slightly low but not critically low, which may be a result of her treatment with diuretics.

7. TSH and T3/T4 levels: Her thyroid function is within a normal range, which is important for cardiac function and overall well-being.

In summary, the combination of the patient's age, comorbidities, medications, ECG findings, laboratory values, and Pro-BNP levels all contribute to her survival."
391,391,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors, despite their advanced age and multiple comorbidities. 

1.  Optimal Medication Management: The patient is on a comprehensive regimen of medications, including a loop diuretic, spironolactone, ACE inhibitor, and nitrovasodilator, which are commonly used to manage heart failure and hypertension. This combination of medications likely contributed to the patient's improved cardiac function and reduced symptoms.

2.  Good Blood Pressure Control: The patient's blood pressure is well-controlled at 140/70 mmHg, which is significantly lower than the typical hypertensive levels seen in patients with hypertensive cardiomyopathy. This suggests that the patient's blood pressure management has been effective in reducing cardiac workload and strain.

3.  Low Pro-BNP Levels: The patient's pro-BNP level is 1094.0 ng/L, which is elevated but not extremely high. Elevated pro-BNP levels are associated with increased risk of heart failure and mortality, but levels above 4000 ng/L are typically associated with more severe heart failure. The patient's relatively lower pro-BNP level suggests that their heart failure is not as severe as initially thought.

4.  Preserved LVEF: The patient's left ventricular ejection fraction (LVEF) is 50%, which is within the normal range. A preserved LVEF suggests that the patient's heart is still pumping effectively, which is a positive prognostic indicator.

5.  Stable Electrocardiogram: The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, but no other significant abnormalities. The absence of sustained ventricular tachycardia or other arrhythmias suggests that the patient's cardiac rhythm is relatively stable.

6.  Good Renal Function: The patient's creatinine level is 118.0 mol/L, which is slightly elevated but not indicative of severe kidney disease. The patient's urea level is also within normal limits. Good renal function is essential for the excretion of medications and waste products, which can impact cardiac function.

7.  Hemoglobin and Potassium Levels: The patient's hemoglobin level is 130 g/L, which is within the normal range. The patient's potassium level is 4.49 mEq/L, which is also within the normal range. Adequate hemoglobin and potassium levels are essential for maintaining cardiac function and preventing arrhythmias.

8.  Low T3 and T4 Levels: The patient's T3 and T4 levels are within normal limits, which suggests that the patient's thyroid function is not contributing to their cardiac symptoms.

In summary, the patient's survival can be attributed to a combination of optimal medication management, good blood pressure control, low pro-BNP levels, preserved LVEF, stable ECG, good renal function, and normal hemoglobin and potassium levels."
392,392,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is an 83-year-old female with a history of hypertensive cardiomyopathy, hypertension, and myocardial infarction, indicating a high risk for heart failure and arrhythmias. Despite this, she has been managed with a multidrug regimen consisting of digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, which is consistent with standard treatment for heart failure with reduced ejection fraction (HFrEF).

The patient's LVEF of 50% indicates a reduced left ventricular function, which is consistent with her history of myocardial infarction and hypertensive cardiomyopathy. Her elevated Pro-BNP level (1094 ng/L) further supports the diagnosis of heart failure.

The patient's blood pressure is within a relatively normal range (140/70 mmHg), which is a good indicator of controlled hypertension. Her potassium level (4.49 mEq/L) is also within the normal range, which is essential for cardiac function.

The absence of significant abnormalities in liver enzymes (ALT, AST, and GGT) suggests that the patient's liver function is relatively preserved, which is crucial for the metabolism of her medications.

The patient's glucose level (6.6 mmol/L) is within the normal range, which is essential for cardiac function and overall health. Her lipid profile (Total Cholesterol: 6.7 mmol/L, HDL: 0.88 mmol/L, and LDL: 2.77 mmol/L) is relatively well-controlled, which is beneficial for cardiovascular health.

The absence of significant abnormalities in electrolytes (sodium, potassium, and urea) suggests that the patient's kidney function is relatively preserved, which is essential for maintaining cardiac function.

The patient's TSH level (0.51 mIU/L) is within the normal range, indicating that her thyroid function is well-controlled, which is essential for cardiac function.

The patient's troponin level (0.4 ng/mL) is slightly elevated, which may indicate minor myocardial damage, but it is not significantly high enough to suggest acute coronary syndrome.

The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG indicates that the patient has some cardiac arrhythmias, but the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that these arrhythmias are not severe.

Overall, the patient's combination of medications, controlled blood pressure, relatively preserved liver and kidney function, well-controlled glucose and lipid profile, and normal thyroid function, along with her multidrug regimen, likely contributed to her survival outcome."
393,393,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor, which can be attributed to a combination of factors related to her medical history, current medications, and laboratory results. 

Firstly, the patient's age (83) and NYHA Class III indicate that she has a significant cardiac condition, but her survival is not entirely unexpected given her age and the presence of hypertensive cardiomyopathy and myocardial infarction. The patient's LVEF (50%) suggests that her left ventricular function is mildly reduced, which is consistent with her past medical history.

The patient's blood pressure (140/70 mmHg) is well-controlled, which is a positive factor for her survival. Her current medications, including digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, are commonly used to manage heart failure and hypertension. These medications are likely contributing to her stable condition.

The laboratory results show that her troponin level (0.4 ng/mL) is slightly elevated, indicating some cardiac damage, but not to a level that would suggest acute myocardial infarction. Her creatinine level (118.0 umol/L) is elevated, indicating some degree of renal impairment, which is common in patients with heart failure. However, her urea level (11.3 mg/dL) is within a relatively normal range.

The patient's pro-BNP level (1094.0 ng/L) is elevated, which is consistent with heart failure, but not excessively high, indicating that her condition is being managed.

The ECG results show ventricular extrasystole and non-sustained ventricular tachycardia, which are common findings in patients with heart failure. However, the absence of sustained ventricular tachycardia, bradycardia, and paroxysmal supraventricular tachyarrhythmia suggests that her arrhythmias are well-controlled.

Overall, the patient's survival can be attributed to her stable medical condition, well-controlled blood pressure, and effective management of her heart failure and hypertension with her current medications."
394,394,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's profile, the outcome of survival can be attributed to a combination of several factors. 

1.  Effective management of hypertension: The patient has been prescribed ACE Inhibitors, which are known to reduce mortality and morbidity in patients with heart failure and hypertension. The blood pressure of 140/70 mmHg indicates that the patient's blood pressure is being well-controlled.

2.  Use of Loop Diuretics and Spironolactone: These medications are commonly used to manage fluid overload and reduce mortality in patients with heart failure. Their use suggests that the patient's fluid status is being effectively managed.

3.  Digoxin therapy: Digoxin is often used to control ventricular rate in patients with atrial fibrillation or heart failure. Although the ECG does not indicate atrial fibrillation, the patient's use of Digoxin may be beneficial in controlling ventricular rate and improving symptoms.

4.  Nitrovasodilator therapy: This medication is used to reduce afterload and improve cardiac output. Its use in this patient suggests that the patient's cardiac function is being supported.

5.  High LVEF: Although the patient's LVEF is 50%, which is considered mildly reduced, it is not severely impaired. This suggests that the patient's cardiac function is still relatively preserved.

6.  Low Pro-BNP levels: BNP levels are often used as a marker of heart failure severity. A low Pro-BNP level (1094 ng/L) suggests that the patient's heart failure symptoms are not severe.

7.  Absence of severe electrolyte imbalances: The patient's potassium and sodium levels are within normal limits, which is important for cardiac function.

8.  Normal glucose and lipid profiles: The patient's glucose and lipid profiles are relatively well-controlled, which reduces the risk of cardiovascular events.

9.  No evidence of severe cardiac arrhythmias: The patient's ECG does show some arrhythmias, but they are non-sustained, and there is no evidence of severe cardiac arrhythmias that would suggest a high risk of sudden cardiac death.

Overall, the patient's survival can be attributed to a combination of effective medical management, relatively preserved cardiac function, and the absence of severe cardiac arrhythmias or electrolyte imbalances."
395,395,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, an 83-year-old female with a history of hypertensive cardiomyopathy, myocardial infarction, and hypertension, has been managed with a combination of medications including digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator. The patient's left ventricular ejection fraction (LVEF) is 50%, indicating a moderate reduction in cardiac function.

The patient's ECG results show monomorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are indicative of arrhythmias that may be related to her underlying cardiac disease. However, the absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia suggests that the arrhythmias are not severe or life-threatening.

The patient's laboratory results show elevated creatinine levels (118.0 mmol/L), which may indicate impaired renal function. However, the patient's blood urea level is within a relatively normal range (11.3 mg/dL), suggesting that the renal impairment is not severe. The patient's pro-BNP level is elevated (1094.0 ng/L), which is often associated with heart failure and cardiac dysfunction.

Considering the patient's age, underlying cardiac disease, and medication regimen, it is likely that the patient's outcome as a survivor is due to the following factors:

1. Effective management of cardiac disease: The patient is on a combination of medications that are commonly used to manage heart failure and hypertension, which may have contributed to her survival.
2. Mild cardiac dysfunction: The patient's LVEF of 50% indicates that her cardiac function is not severely impaired, which may have contributed to her ability to survive.
3. Absence of severe arrhythmias: The absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia suggests that the patient's arrhythmias are not life-threatening.
4. Relative stability of renal function: The patient's creatinine and urea levels are not severely elevated, suggesting that her renal function is relatively preserved.

Overall, the patient's outcome as a survivor is likely due to a combination of effective management of her cardiac disease, mild cardiac dysfunction, absence of severe arrhythmias, and relatively preserved renal function."
396,396,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's age (83) and NYHA Class III, indicating severe heart failure symptoms, the patient's survival can be attributed to the following factors:

1.  The patient is on appropriate medications, including ACE Inhibitor, which is beneficial for heart failure and hypertension management. 
2.  The patient's LVEF (Left Ventricular Ejection Fraction) is 50%, which is within the normal range (50-70%). This suggests that the patient's heart function is not severely impaired, allowing for adequate blood circulation and oxygen delivery to vital organs.
3.  The patient's blood pressure is within a relatively normal range (140/70 mmHg), indicating that the heart is able to maintain adequate blood pressure.
4.  The patient's Troponin level is 0.4 ng/mL, which is within normal limits, indicating that there is no acute myocardial infarction.
5.  The patient's Pro-BNP level is 1094.0 ng/L, which is elevated but not extremely high. Elevated Pro-BNP levels can indicate heart failure, but in this case, it may be a chronic elevation due to the patient's heart failure history.
6.  The patient's TSH level is 0.51 mIU/L, which is within the normal range, indicating that thyroid function is not contributing to the patient's heart failure symptoms.
7.  The patient's T3 and T4 levels are also within normal limits, which suggests that there is no evidence of hypothyroidism or hyperthyroidism contributing to the patient's symptoms.
8.  The patient's potassium level is 4.49 mEq/L, which is within the normal range, indicating that there is no electrolyte imbalance contributing to the patient's heart rhythm abnormalities.
9.  The patient's LVEF, blood pressure, and medication regimen suggest that the patient's heart failure is being managed effectively, allowing for the patient to survive.

However, the patient's age and past medical history of myocardial infarction, hypertensive cardiomyopathy, and hypertension indicate that the patient is at high risk for future cardiac events. Close monitoring and continued management of the patient's heart failure and hypertension will be crucial to prevent further complications."
397,397,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is an 83-year-old female with a history of hypertensive cardiomyopathy, hypertension, and myocardial infarction, presenting with a New York Heart Association (NYHA) Class III classification, indicating moderate to severe symptoms of heart failure. The patient's left ventricular ejection fraction (LVEF) is 50%, which falls within the range of mildly reduced ejection fraction, indicating some impairment in heart function.

The patient's laboratory results show elevated levels of creatinine (118.0 mmol/L), which may indicate impaired kidney function, possibly due to chronic heart failure or other underlying conditions. The elevated pro-BNP (1094.0 ng/L) level suggests increased ventricular stress and potential heart failure. 

The patient's lipid profile shows a total cholesterol level of 6.7 mmol/L, which is elevated, and an LDL level of 2.77 mmol/L, which is also elevated, indicating a potential risk for atherosclerotic cardiovascular disease. However, the patient's HDL level is relatively low at 0.88 mmol/L, which may further contribute to the risk of cardiovascular disease.

The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, indicating potential arrhythmic activity, but no sustained ventricular tachycardia or other significant arrhythmias.

Considering the patient's age, comorbidities, and the medications she is taking (Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, and Nitrovasodilator), it is likely that the patient is being managed for heart failure and hypertension. The presence of mildly reduced LVEF and elevated pro-BNP levels suggests that the patient is at risk for adverse cardiovascular events.

Given the patient's age and the fact that she is being managed for heart failure and hypertension, the most likely reason for her survival is that she is receiving appropriate medical management for her condition, including medications that help to manage her symptoms, slow disease progression, and reduce the risk of adverse cardiovascular events. The patient's survival is also likely due to the fact that she does not have any acute cardiovascular events such as myocardial infarction or stroke, and her laboratory results do not indicate any severe acute kidney injury or other life-threatening conditions."
398,398,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, an 83-year-old female, has been diagnosed with Hypertensive cardiomyopathy and has a history of Hypertension and Myocardial Infarction. Despite her advanced age and history of cardiovascular disease, she has managed to survive. Several factors contributed to her survival:

1. Medications: She is on a comprehensive regimen of Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, and Nitrovasodilator, which are all aimed at managing her heart failure and hypertension. These medications likely helped to control her symptoms and prevent further cardiac deterioration.

2. LVEF of 50%: Although her Left Ventricular Ejection Fraction (LVEF) is slightly below the normal range, it is still relatively well-preserved, indicating that her heart is still pumping adequately. This suggests that her cardiac function is not severely compromised.

3. Pro-BNP levels: Her Pro-BNP levels are elevated at 1094.0 ng/L, which is indicative of heart failure. However, this level is not extremely high, suggesting that her heart failure is not severe.

4. ECG findings: While she has ventricular extrasystoles and non-sustained ventricular tachycardia, these are not indicative of life-threatening arrhythmias. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia also suggests that her heart rate regulation is relatively stable.

5. Laboratory values: Her blood work, including electrolytes, liver enzymes, and kidney function, is relatively well-preserved. Her hemoglobin level is slightly elevated, which may be a result of anemia of chronic disease.

6. Age and comorbidities: While her advanced age and history of cardiovascular disease increase her risk of mortality, her overall survival suggests that she has a robust compensatory mechanism and/or effective management of her comorbidities.

In summary, the patient's survival can be attributed to a combination of her comprehensive medication regimen, relatively preserved cardiac function, and well-managed comorbidities, despite her advanced age and history of cardiovascular disease."
399,399,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's age (83) and NYHA Class III, indicating moderate to severe heart failure, the patient's outcome of survival is likely due to the comprehensive management of her cardiovascular disease. The patient's current medications, including Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, and Nitrovasodilator, are standard treatments for heart failure and hypertension. The use of these medications has likely helped to manage her symptoms, improve cardiac function, and reduce the risk of complications.

The patient's LVEF (Left Ventricular Ejection Fraction) of 50% indicates that her heart is still functioning relatively well, considering her age and medical history. This suggests that the patient's heart is able to pump blood effectively, which is a positive indicator for survival.

The patient's blood pressure of 140/70 mmHg is within a relatively normal range, which is also a positive indicator for survival. The low levels of Troponin (0.4 ng/mL) and Pro-BNP (1094.0 ng/L) suggest that there is no acute myocardial infarction or severe cardiac dysfunction at the time of assessment.

Additionally, the patient's laboratory results show relatively normal levels of electrolytes, liver enzymes, and kidney function, which suggests that her organs are functioning relatively well. The patient's hemoglobin level of 130 g/L is slightly above the normal range, indicating that her anemia is not severe.

The patient's low TSH level of 0.51 mIU/L suggests that her thyroid function is within a normal range, which is also a positive indicator for survival.

While the patient has a history of myocardial infarction, the fact that she has survived to the age of 83 suggests that she has a robust cardiovascular system that has been able to withstand the effects of the infarction. Overall, the combination of her comprehensive medical treatment, relatively normal laboratory results, and preserved cardiac function have likely contributed to her survival."
400,400,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

The patient, a 66-year-old female with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, presented with a complex set of laboratory and clinical findings. Despite her severe heart failure symptoms (NYHA Class III), she was able to survive. Several factors contributed to her survival:

1. Optimal medical management: The patient was on a multi-drug regimen, including diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure and hypertension. These medications likely helped to control her symptoms, slow disease progression, and improve her prognosis.

2. LVEF of 56%: Although the patient's left ventricular ejection fraction (LVEF) was slightly below the normal range (50-70%), it was still relatively preserved, indicating that her heart was still functioning adequately to meet her body's needs.

3. Mildly elevated troponin: The patient's troponin level was only 0.01 ng/mL, which is within the normal range, indicating that she did not experience significant myocardial damage.

4. No evidence of severe electrolyte imbalances: Her potassium level was within the normal range (4.1 mEq/L), which is essential for maintaining proper cardiac function.

5. Reasonable blood pressure control: Although her blood pressure was slightly elevated (150/90 mmHg), it was not severely elevated, which may have contributed to her survival.

6. No signs of severe kidney dysfunction: Her creatinine level (106.0 mol/L) and urea level (8.99 mg/dL) were elevated but not severely abnormal, indicating that her kidney function was still relatively preserved.

7. No acute coronary syndrome: The absence of troponin elevation and the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggest that she did not experience an acute coronary event.

8. No signs of thyroid dysfunction: Her TSH level was elevated (49.17 mIU/L), but her T4 level was within the normal range, indicating that she did not have overt hypothyroidism, which could have contributed to her cardiac symptoms.

In summary, the combination of optimal medical management, preserved LVEF, mildly elevated troponin, reasonable blood pressure control, and no signs of severe kidney dysfunction or acute coronary syndrome contributed to the patient's survival."
401,401,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

The patient is a 66-year-old female with a complex medical history, including hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. Her current medications include diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that her condition is being managed for heart failure and hypertension.

The patient's LVEF (Left Ventricular Ejection Fraction) is 56%, which is within the normal range (50-70%). This suggests that the patient's heart function is relatively preserved despite her history of cardiomyopathy.

The patient's blood pressure is elevated at 150/90 mmHg, which is consistent with her history of hypertension. However, it is well-controlled on her current medication regimen.

The patient's electrolyte panel shows a slightly low potassium level (4.1 mEq/L), which may be contributing to her arrhythmias.

The patient's liver function tests (ALT, AST, GGT) are mildly elevated, suggesting some degree of liver dysfunction, which may be contributing to her condition.

The patient's glucose level is elevated at 12.1 mmol/L, indicating poorly controlled diabetes.

The patient's thyroid function tests (TSH, T3, T4) show a high TSH level (49.17 mIU/L), which suggests hypothyroidism. This is a new finding and may be contributing to her symptoms.

The patient's ECG shows a second-degree AV block (type II), which is a conduction abnormality that may be contributing to her symptoms.

Despite these factors, the patient is listed as a survivor, suggesting that her condition is stable and manageable with her current treatment regimen. The presence of a polymorphic ventricular extrasystole on her ECG may indicate a risk of arrhythmias, but it is not necessarily a life-threatening finding in this context.

Overall, the patient's outcome is likely due to the fact that her heart function is relatively preserved, her blood pressure is well-controlled, and she is receiving appropriate treatment for her underlying conditions."
402,402,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: The patient is a 66-year-old female with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, presenting with a New York Heart Association (NYHA) Class III functional capacity. Despite the presence of multiple comorbidities and laboratory abnormalities, including elevated creatinine, glucose, and liver enzymes, the patient's left ventricular ejection fraction (LVEF) is 56%, indicating preserved systolic function.

The patient's medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are consistent with the management of heart failure and hypertension. The presence of a second-degree atrioventricular block (type II) is noted on the ECG, which may be a consequence of the patient's hypertensive cardiomyopathy.

The patient's biomarkers, including troponin and Pro-BNP, are within normal limits, suggesting that there is no acute myocardial infarction or significant cardiac strain. The patient's hemoglobin level is slightly low, which may be related to anemia or chronic disease.

The patient's TSH level is elevated, which may indicate hypothyroidism, but the T3 and T4 levels are within normal limits, making this less likely.

The patient's outcome as a survivor can be attributed to the following factors:

1.  Effective management of hypertension and heart failure with medications.
2.  Preserved LVEF, indicating that the patient's cardiac function is relatively well-preserved.
3.  Absence of acute myocardial infarction or significant cardiac strain.
4.  Presence of a stable and controlled comorbidities, such as diabetes and dyslipemia.
5.  Appropriate medical therapy and monitoring, which has likely contributed to the patient's survival.

However, the patient's prognosis remains guarded due to the presence of multiple comorbidities and the risk of further cardiac events. Close monitoring and continued medical therapy are necessary to prevent progression of the patient's condition."
403,403,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

Given the patient's medical history, the patient is a 66-year-old female with a history of Hypertensive cardiomyopathy, diabetes, dyslipidemia, and hypertension. The patient's NYHA Class III classification indicates that she experiences symptoms of heart failure with mild to moderate limitation in physical activity.

The patient's blood pressure is elevated at 150/90 mmHg, which is concerning for uncontrolled hypertension. The elevated creatinine level of 106.0 mmol/L suggests impaired renal function, likely due to chronic kidney disease secondary to hypertension and diabetes. The patient's glucose level of 12.1 mmol/L indicates poor glycemic control, which can exacerbate cardiovascular disease.

The patient's lipid profile shows elevated total cholesterol (6.05 mmol/L) and LDL (3.7 mmol/L), which increases the risk of atherosclerotic cardiovascular disease. The low HDL level of 1.14 mmol/L further contributes to this risk.

The patient's liver function tests (ALT and AST) are within normal limits, but the gamma-glutamyl transferase (GGT) level of 160 IU/L is elevated, suggesting possible liver damage or bile duct obstruction.

The patient's thyroid function tests (TSH and T4) are abnormal, with a high TSH level of 49.17 mIU/L and a low T4 level of 13 ng/L, indicating primary hypothyroidism. This condition can contribute to cardiovascular disease, including heart failure and atherosclerosis.

The patient's LVEF (left ventricular ejection fraction) is 56%, which is below the normal range, indicating left ventricular dysfunction.

The patient's medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are standard treatments for heart failure and hypertension. However, the presence of ventricular extrasystoles and second-degree AV block (type II) on the ECG suggests that the patient may require further management to prevent cardiac arrhythmias.

Considering the patient's complex medical history, the presence of heart failure, and the abnormal laboratory results, the patient's survival outcome is likely due to the following factors:

1.  Aggressive management of heart failure with optimal medical therapy, including beta blockers, loop diuretics, and ACE inhibitors.
2.  Close monitoring and management of blood pressure, glucose, and lipid levels to prevent further cardiovascular complications.
3.  Treatment of hypothyroidism to prevent further cardiovascular damage.
4.  Avoidance of cardiac arrhythmias through careful management of cardiac medications and monitoring of ECG results.
5.  Presence of a supportive medical team and regular follow-up appointments to adjust treatment plans as needed.

The patient's survival outcome is likely a result of a combination of these factors, which have helped to manage and stabilize her cardiovascular disease."
404,404,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to several factors. 

1. Current Medications: The patient is on a comprehensive treatment regimen that includes diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications are crucial in managing the patient's hypertension, diabetes, and heart failure. Beta blockers help reduce the heart rate and blood pressure, while loop diuretics and spironolactone aid in fluid management and electrolyte balance. The ACE inhibitor helps to reduce blood pressure and alleviate strain on the heart.

2. Blood Pressure Management: Although the patient's blood pressure is slightly elevated at 150/90 mmHg, it is not significantly high enough to cause immediate concern. The blood pressure is being managed with the current medications, which is likely contributing to the patient's survival.

3. LVEF (Left Ventricular Ejection Fraction) of 56%: The patient's LVEF is within the moderate range, indicating that the heart is still pumping blood effectively. This is a good sign, as an LVEF below 40% is typically associated with severe heart failure. The patient's LVEF of 56% suggests that the heart is still functioning adequately, contributing to their survival.

4. Low Troponin Levels: The patient's troponin levels are within normal limits, indicating that there is no acute myocardial infarction (heart attack) or significant cardiac damage.

5. ECG Results: Although the patient has polymorphic ventricular extrasystoles, there is no indication of sustained ventricular tachycardia, which is a significant risk factor for cardiac mortality. The presence of second-degree AV block type II is a concern, but it is not immediately life-threatening.

6. Pro-BNP Levels: The patient's Pro-BNP levels are elevated at 104.0 ng/L, which is a marker of heart failure. However, the levels are not extremely high, indicating that the heart failure is not severe.

7. Other Factors: The patient's age, gender, weight, and height are not particularly concerning. The patient's laboratory results, including electrolyte levels and liver function tests, are relatively normal.

Considering these factors, the patient's survival can be attributed to the effective management of their hypertension, diabetes, and heart failure with medication, as well as the relatively mild nature of their cardiac condition."
405,405,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: The patient is a 66-year-old female with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. Her current medical condition, as reflected in her NYHA Class III, indicates that she has severe symptoms of heart failure, such as shortness of breath and fatigue, that limit her physical activity.

The patient's laboratory results show elevated levels of creatinine (106.0 mmol/L) and urea (8.99 mg/dL), indicating impaired renal function. The presence of diabetes and hypertension likely contributes to this renal impairment.

The patient's lipid profile shows high levels of total cholesterol (6.05 mmol/L) and LDL (3.7 mmol/L), which is a risk factor for cardiovascular disease. The patient's TSH level is elevated at 49.17 mIU/L, which may indicate hypothyroidism, a condition that can contribute to heart failure.

The patient's LVEF is 56%, indicating a reduced left ventricular ejection fraction, which is a sign of heart failure. However, this value is not severely low, and the patient is still classified as a survivor.

The ECG shows second-degree atrioventricular block (AVB) type II, which is a type of heart block that can be a risk factor for heart failure and sudden cardiac death. However, the patient does not have ventricular tachycardia, and the presence of polymorphic ventricular extrasystoles is not a significant concern.

Considering the patient's overall condition, the presence of heart failure, impaired renal function, and other comorbidities, the patient's outcome as a survivor is likely due to the following factors:

1. Optimal medical management: The patient is on a combination of medications, including diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all aimed at managing her heart failure and other comorbidities.
2. Presence of mild heart failure: The patient's LVEF is not severely low, which may indicate that the heart failure is not as severe as in other patients with similar conditions.
3. Absence of severe arrhythmias: The absence of ventricular tachycardia and other severe arrhythmias reduces the risk of sudden cardiac death.
4. Presence of supportive treatment: The patient's healthcare team is likely providing supportive care, including monitoring and adjusting her medications as needed, to manage her condition and prevent complications.

Overall, the patient's outcome as a survivor is likely due to a combination of optimal medical management, mild heart failure, absence of severe arrhythmias, and supportive treatment."
406,406,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

This patient is a 66-year-old female with a history of Hypertensive cardiomyopathy, diabetes, dyslipidemia, and hypertension, presenting with a New York Heart Association (NYHA) Class III, indicating moderate to severe heart failure symptoms. 

Her laboratory results show evidence of cardiac strain and potential liver dysfunction, as indicated by elevated Creatinine levels (106.0 mmol/L) and Gamma-glutamil transpeptidase (160 IU/L). The patient's blood pressure is elevated at 150/90 mmHg, which is a contributing factor to her hypertensive cardiomyopathy. Her glucose level is elevated at 12.1 mmol/L, indicating poor glycemic control, which can exacerbate cardiac conditions.

The patient's LVEF (Left Ventricular Ejection Fraction) is 56.0%, indicating mildly reduced cardiac function. The presence of ventricular extrasystoles and elevated Pro-BNP (104.0 ng/L) levels suggest cardiac strain and potential heart failure.

The patient is on a regimen of diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which is a comprehensive treatment plan for managing her conditions.

Despite these factors, the patient is classified as a survivor, indicating that she has been able to manage her conditions and prevent further cardiac complications. The presence of second-degree AV block (type II) on the ECG may indicate some cardiac conduction abnormalities, but it does not appear to have significantly impacted her outcome.

The patient's TSH level is elevated at 49.17 mIU/L, which may indicate hypothyroidism, but it is not directly related to her cardiac outcome. The low T3 level (0.02 pg/dL) and normal T4 level (13 ng/L) support this diagnosis.

Overall, the patient's survival is likely due to the comprehensive management of her conditions, including her diabetes, hypertension, and cardiac issues, as well as her adherence to her medication regimen and lifestyle modifications."
407,407,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

The patient is a 66-year-old female with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. Her New York Heart Association (NYHA) class is III, indicating moderate to severe heart failure symptoms. 

The patient's blood pressure is elevated at 150/90 mmHg, which is consistent with her history of hypertension. Her total cholesterol level is elevated at 6.05 mmol/L, and her low-density lipoprotein (LDL) level is 3.7 mmol/L, indicating dyslipemia. Her glucose level is elevated at 12.1 mmol/L, consistent with her diabetes diagnosis. 

Her liver enzymes, including ALT and AST, are within normal limits. However, her gamma-glutamil transpeptidase (GGT) is elevated at 160 IU/L, suggesting some degree of liver dysfunction. Her kidney function, as indicated by creatinine and urea levels, is impaired, with a creatinine level of 106.0 mol/L and urea level of 8.99 mg/dL. 

Her thyroid function tests show an elevated TSH level of 49.17 mIU/L, indicating hypothyroidism. Her troponin level is within normal limits, and her left ventricular ejection fraction (LVEF) is 56.0%, which is mildly reduced.

The ECG shows a second-degree atrioventricular (AV) block, type II, which is a significant finding. However, the presence of polymorphic ventricular extrasystoles is also noted, which can be a sign of underlying cardiac disease.

Considering the patient's complex medical history, impaired kidney function, and the presence of a second-degree AV block, the patient's survival can be attributed to the following factors:

1.  The patient is on appropriate medical therapy for her conditions, including diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor.
2.  The patient's LVEF is mildly reduced, but not severely compromised, which suggests that her heart function is still relatively preserved.
3.  The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction.
4.  The patient's kidney function, although impaired, is not severely compromised, which suggests that her renal function is still relatively preserved.
5.  The patient's overall clinical condition is stable, and she is not experiencing acute decompensation of her heart failure.

Overall, the patient's survival can be attributed to the combination of her ongoing medical therapy, relatively preserved heart function, and stable kidney function."
408,408,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: The patient's outcome of survival is likely due to a combination of factors, including the patient's current treatment regimen and the presence of certain biomarkers that indicate a relatively stable cardiac condition.

The patient has been prescribed medications that are commonly used to manage heart failure and hypertension, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications have been shown to improve survival and reduce morbidity in patients with heart failure and hypertension. The patient's LVEF (left ventricular ejection fraction) of 56% is within the normal range, indicating that the heart is still pumping blood efficiently.

The patient's Pro-BNP (brain natriuretic peptide) level of 104 ng/L is within the normal range, which suggests that the heart is not under excessive strain. Additionally, the patient's Troponin level of 0.01 ng/mL is within the normal range, indicating that there is no acute myocardial infarction.

The patient's TSH (thyroid-stimulating hormone) level of 49.17 mIU/L is elevated, which may be a contributing factor to the patient's cardiac condition. However, the patient's T4 level of 13 ng/L is within the normal range, indicating that the thyroid hormone levels are not significantly abnormal.

The patient's ECG shows a second-degree AV block, which is a common finding in patients with heart failure and hypertension. However, this is not a life-threatening condition and is not typically a predictor of mortality.

Overall, the patient's current treatment regimen and the presence of certain biomarkers that indicate a relatively stable cardiac condition suggest that the patient is likely to survive. However, the patient's underlying conditions, including hypertension, diabetes, and dyslipidemia, require ongoing management to prevent further cardiac complications."
409,409,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: The patient's outcome is a survivor, which can be attributed to several factors based on the provided data. 

1.  Effective Medication Management: The patient is on a comprehensive treatment regimen, including diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. This combination of medications is likely contributing to the stabilization of the patient's condition, particularly in controlling the symptoms of heart failure and hypertension.

2.  Monitoring and Management of Hypertension: The patient's blood pressure, although elevated at 150/90 mmHg, is not extremely high. The patient's hypertension is being managed with medications, which is crucial in preventing further cardiac damage.

3.  Control of Blood Glucose Levels: The patient's glucose level is 12.1 mmol/L, which is slightly elevated but not critically high. Good control of diabetes is essential for preventing complications and is likely contributing to the patient's survival.

4.  Assessment of Cardiac Function: The patient's left ventricular ejection fraction (LVEF) is 56.0%, indicating that the heart is still pumping efficiently, albeit not at its optimal level. This suggests that the patient's heart is still functioning to some extent, which is a positive sign.

5.  ECG Findings: Although the ECG shows ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. The presence of second-degree AV block type II is a significant finding, but it is not necessarily a contraindication for survival, especially if it is being monitored and managed appropriately.

6.  Lab Values: The patient's liver function tests (ALT and AST) are within normal limits, which suggests that there is no significant liver damage, which could have contributed to the patient's outcome.

7.  Patient's Age and Gender: The patient is a 66-year-old female, which, in itself, does not necessarily predict a poor outcome. Age is a risk factor for many conditions, but it is not a definitive predictor of survival.

Considering these factors, the patient's survival can be attributed to the effective management of her medical conditions, monitoring and control of her blood pressure and glucose levels, and the absence of any severe cardiac complications."
410,410,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 71-year-old female with a history of hypertensive cardiomyopathy, has shown a favorable outcome despite the presence of several risk factors. 

The patient's LVEF (Left Ventricular Ejection Fraction) of 62% indicates that the heart is pumping blood efficiently, which is a good sign. The absence of sustained ventricular tachycardia and bradycardia on the ECG also suggests that the patient's heart rhythm is relatively stable.

The patient's Pro-BNP (Brain Natriuretic Peptide) level of 433 ng/L is elevated, which is often associated with heart failure, but in this case, it may be related to the patient's hypertensive cardiomyopathy. The patient's blood pressure is well-controlled at 140/70 mmHg, which is within a relatively normal range.

The patient's medication regimen, including spironolactone and an ACE inhibitor, is appropriate for managing heart failure and hypertension. The absence of significant liver enzyme elevation (ALT 22.0 IU/L, AST 21.0 IU/L) suggests that the patient's liver function is relatively preserved.

The patient's total cholesterol level of 5.12 mmol/L is slightly elevated, but the HDL (good cholesterol) level of 1.29 mmol/L is within a relatively normal range. The LDL (bad cholesterol) level of 3.1 mmol/L is also within a relatively normal range.

The patient's urea level of 8.49 mg/dL is slightly elevated, which may indicate mild kidney dysfunction, but it is not severe enough to impact the patient's overall outcome.

The patient's hemoglobin level of 123 g/L is within a relatively normal range, and the TSH (Thyroid-Stimulating Hormone) level of 1.95 mIU/L is within a relatively normal range, indicating that the patient's thyroid function is well-controlled.

Overall, the patient's stable heart function, controlled blood pressure, and appropriate medication regimen have contributed to a favorable outcome."
411,411,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 71-year-old female with a history of hypertensive cardiomyopathy, has a relatively favorable outcome despite her condition. Several factors contribute to this outcome:

1.  NYHA Class II: The patient's New York Heart Association (NYHA) functional classification indicates that she experiences some limitation in physical activity but is still able to perform ordinary physical activity without symptoms. This suggests that her heart condition is not severely impacting her daily life.

2.  Medications: The patient is on Spironolactone and an ACE Inhibitor, which are commonly used to manage heart failure and hypertension. These medications likely play a crucial role in managing her condition and preventing further deterioration.

3.  LVEF of 62%: Although the left ventricular ejection fraction (LVEF) is below the normal range (typically > 55-60%), it is not severely decreased, indicating that the patient's heart is still pumping effectively enough to meet her body's needs.

4.  Pro-BNP levels: The brain natriuretic peptide (BNP) level of 433 ng/L is elevated but not extremely high. Elevated BNP levels are associated with heart failure, but in this case, the level is not as high as it could be, suggesting that the patient's heart is not under extreme stress.

5.  ECG findings: The patient has ventricular extrasystoles, which are common in people with heart conditions. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

6.  Laboratory results: The patient's kidney function (Creatinine 123.0 mol/L) is slightly elevated, but not severely impaired. Her liver enzymes (ALT and AST) are within normal limits, indicating that her liver function is not significantly compromised.

Considering these factors, the patient's outcome can be attributed to a combination of effective medication management, relatively well-preserved cardiac function, and the absence of severe complications."
412,412,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 71-year-old female with a history of hypertensive cardiomyopathy, which is a condition where high blood pressure damages the heart muscle, leading to reduced heart function. Despite this, her left ventricular ejection fraction (LVEF) is 62%, indicating that her heart is still functioning relatively well.

The patient's blood pressure is within a relatively normal range (140/70 mmHg), and her medications, including spironolactone and an ACE inhibitor, are aimed at managing her hypertension and heart failure symptoms.

The elevated pro-BNP (brain natriuretic peptide) level of 433 ng/L suggests that the patient's heart is experiencing some degree of strain, but this is not an uncommon finding in patients with heart failure.

The patient's liver function tests (ALT and AST) are within normal limits, indicating that her liver is functioning properly. Her total cholesterol and LDL levels are elevated, but her HDL level is low, which is a risk factor for cardiovascular disease.

The patient's creatinine level is elevated (123.0 mmol/L), indicating some degree of kidney impairment. However, her urea level is within a relatively normal range (8.49 mg/dL), suggesting that her kidneys are still functioning to some extent.

The patient's TSH and T4 levels are within normal limits, indicating that her thyroid function is normal.

The ECG findings show polymorphic ventricular extrasystoles, which are abnormal heartbeats that can be a sign of underlying cardiac disease. However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia suggests that the patient's heart is not experiencing severe arrhythmias.

Overall, the patient's outcome as a survivor suggests that her heart disease is being managed effectively with her current medications and lifestyle, and she is not experiencing any acute cardiac events or severe complications."
413,413,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 71-year-old female with a history of hypertensive cardiomyopathy, has a complex set of laboratory results and ECG findings. Despite her age and underlying heart condition, she has a relatively preserved left ventricular ejection fraction (LVEF) of 62%, which suggests that her heart is still functioning adequately.

The patient's blood pressure is within a relatively normal range, and her kidney function, as indicated by creatinine levels, is mildly elevated but not severely impaired. Her liver function tests (ALT, AST, and GGT) are within normal limits, suggesting that her liver is functioning well.

The patient's lipid profile shows a high total cholesterol level, but her HDL cholesterol is low, which is a risk factor for cardiovascular disease. However, her LDL cholesterol is relatively low, which may be due to her current medication regimen.

The patient's TSH level is within the normal range, indicating that her thyroid function is not contributing to her cardiovascular condition. Her T4 level is also within the normal range, which is consistent with her TSH level.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a common finding in patients with hypertensive cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia or non-sustained ventricular tachycardia, which suggests that her heart rhythm is relatively stable.

The patient's pro-BNP level is elevated, which is consistent with her heart failure diagnosis. However, her medication regimen, which includes spironolactone and an ACE inhibitor, is likely contributing to her survival.

Given the patient's relatively preserved LVEF, stable blood pressure, and absence of severe organ dysfunction, it is not surprising that she has survived. Her medication regimen and close monitoring of her condition have likely contributed to her survival.

REASONING FOR SURVIVOR OUTCOME: The patient's relatively preserved LVEF, stable blood pressure, and absence of severe organ dysfunction, combined with her medication regimen and close monitoring, have contributed to her survival."
414,414,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 71-year-old female with a history of hypertensive cardiomyopathy, has been diagnosed with several cardiac and non-cardiac conditions. Despite the presence of these conditions, the patient's overall prognosis appears to be relatively favorable, as indicated by the patient outcome of survivor.

The patient's LVEF (Left Ventricular Ejection Fraction) is 62%, which is within the normal range (>55%), suggesting that the patient's heart function is not significantly compromised. The patient's blood pressure is also well-controlled, at 140/70 mmHg, and they are on appropriate medications, including an ACE inhibitor and spironolactone, which are commonly used to treat heart failure and hypertension.

The patient's biomarkers, such as creatinine and urea, are within normal limits, indicating that their renal function is preserved. The patient's hemoglobin and potassium levels are also within normal limits, which suggests that their anemia and electrolyte balance are well-managed.

The patient's TSH (thyroid-stimulating hormone) level is within the normal range, indicating that their thyroid function is not significantly abnormal. The patient's T4 (thyroxine) level is also within the normal range, further supporting this conclusion.

The patient's ECG shows a polymorphic ventricular extrasystole, but no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. The presence of a paroxysmal supraventricular tachyarrhythmia (PSVT) is also noted, but this is typically a relatively benign condition that can be managed with medication.

The patient's albumin level is slightly low, which may indicate mild liver dysfunction, but the AST and ALT levels are within normal limits, which suggests that the liver damage is not severe. The patient's total cholesterol and LDL levels are elevated, but these can be managed with lifestyle modifications and medication.

Overall, the patient's combination of medications, relatively preserved cardiac function, and normal biomarkers suggest that they are at low risk for adverse cardiac events and are likely to survive with proper management of their conditions."
415,415,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 71-year-old female with a history of hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and weakened due to high blood pressure. The patient's current medications, Spironolactone and ACE Inhibitor, are appropriate for managing heart failure and hypertension. 

The patient's ejection fraction (LVEF) is 62%, which is within the normal range (50-70%). This indicates that the patient's heart is pumping blood efficiently, and the patient is not in heart failure. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also suggests that the patient is not at high risk of cardiac arrhythmias.

The patient's laboratory results show slightly elevated creatinine levels (123.0 mmol/L), which may indicate mild kidney impairment. However, the urea levels are within the normal range (8.49 mg/dL), suggesting that the kidneys are still functioning adequately.

The patient's blood pressure is well-controlled at 140/70 mmHg, which is within the target range for patients with hypertension. The patient's lipid profile is also relatively well-controlled, with a total cholesterol of 5.12 mmol/L and an LDL of 3.1 mmol/L.

The patient's TSH level is within the normal range (1.95 mIU/L), indicating that the thyroid function is normal. The patient's T4 level is also within the normal range (15 ng/L).

The patient's Pro-BNP level is elevated at 433.0 ng/L, which may indicate some degree of cardiac stress or strain. However, this is not uncommon in patients with a history of heart disease, and the patient's overall clinical picture suggests that the elevation is likely not indicative of a life-threatening condition.

Overall, the patient's clinical and laboratory results suggest that they are being managed appropriately for their hypertensive cardiomyopathy and hypertension. The patient's current medications and lifestyle are likely contributing to their stable condition, and they are at low risk of cardiac complications. Therefore, the patient outcome is a survivor."
416,416,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 71-year-old female with a history of hypertensive cardiomyopathy, has been treated with spironolactone and an ACE inhibitor. Despite her medical history and the presence of a reduced LVEF (62%), the patient has survived, which can be attributed to several factors.

Firstly, the patient's LVEF is still within the moderate range, indicating that the heart is still pumping efficiently to some extent. Although it is below the normal range, an LVEF of 62% is not considered severely reduced, which may indicate that the patient's heart is still compensating for the cardiomyopathy.

Secondly, the patient's blood pressure is well-controlled, with a reading of 140/70 mmHg. This is within the normal range and suggests that the patient's blood pressure is not contributing to further strain on the heart.

Thirdly, the patient's creatinine level is elevated at 123.0 mmol/L, indicating some degree of kidney dysfunction. However, this is not uncommon in patients with hypertensive cardiomyopathy, and the patient's urea level is within the normal range, suggesting that the kidney dysfunction is not severe.

Fourthly, the patient's TSH level is within the normal range, indicating that the patient's thyroid function is not contributing to her cardiac condition.

Lastly, the patient's Pro-BNP level is elevated at 433.0 ng/L, which is consistent with heart failure. However, the patient's survival suggests that the Pro-BNP level is not indicative of severe heart failure, and the patient's overall cardiac function is being maintained.

In conclusion, the patient's survival can be attributed to a combination of factors, including a moderate LVEF, well-controlled blood pressure, kidney function that is not severely impaired, normal thyroid function, and an elevated Pro-BNP level that is not indicative of severe heart failure. The patient's treatment with spironolactone and an ACE inhibitor is also likely contributing to her survival."
417,417,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 71-year-old female with a history of hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and stiff due to high blood pressure. Her current medications, Spironolactone and ACE Inhibitor, are appropriate for managing heart failure and hypertension. 

The patient's laboratory results show elevated Pro-BNP (433.0 ng/L), which is a biomarker for heart failure. However, her LVEF (Left Ventricular Ejection Fraction) is 62%, indicating that the heart is still pumping blood effectively, albeit not at a normal level. 

Her other laboratory results are mostly within normal limits, with the exception of slightly elevated Creatinine (123.0 mmol/L), which may indicate mild kidney impairment. However, her Urea level is within normal limits, which suggests that her kidney function is not severely compromised.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles. While this can be a concern, the absence of sustained ventricular tachycardia or other more severe arrhythmias suggests that the patient's heart rhythm is not severely disrupted.

Given her age, medical history, and laboratory results, the patient's outcome of survival is likely due to the fact that her heart failure is being managed with appropriate medications, and her kidney function is not severely impaired. The presence of polymorphic ventricular extrasystoles is a concern, but it does not appear to be causing significant harm at this time."
418,418,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 71-year-old female with a history of hypertensive cardiomyopathy, which is a condition where high blood pressure damages the heart muscle, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) is 62%, which indicates a mildly reduced heart function, but still within a relatively preserved range.

The patient's blood pressure is well-controlled at 140/70 mmHg, and she is on spironolactone and an ACE inhibitor, which are appropriate medications for managing heart failure and hypertension.

The patient's biomarkers, such as troponin and creatinine, are within normal limits, indicating no acute myocardial infarction or significant kidney damage. The patient's liver function tests (ALT, AST, and GGT) are also within normal limits, indicating no liver damage.

The patient's lipid profile shows a total cholesterol level of 5.12 mmol/L, which is slightly elevated, but her HDL (good cholesterol) level is 1.29 mmol/L, which is within a healthy range. The LDL (bad cholesterol) level is 3.1 mmol/L, which is slightly elevated, but not significantly high.

The patient's potassium level is slightly low at 4.2 mEq/L, which may be a side effect of the ACE inhibitor medication.

The patient's pro-BNP level is elevated at 433 ng/L, which is consistent with heart failure, but not extremely high.

The patient's T4 and TSH levels are within normal limits, indicating no thyroid dysfunction.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a benign finding, and a paroxysmal supraventricular tachycardia (PSVT), which is a type of abnormal heart rhythm. However, there is no indication of sustained ventricular tachycardia or bradycardia.

Overall, the patient's condition appears to be well-managed, and her medications are appropriate for her condition. The patient's LVEF is mildly reduced, but not severely impaired, and her biomarkers are within normal limits. Therefore, the patient's outcome is a survivor, indicating that she is stable and not at high risk of immediate cardiac complications."
419,419,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors based on the provided data. 

1.  Effective Medication Management: The patient is on Spironolactone and an ACE Inhibitor, which are both commonly used to manage heart failure and hypertension. These medications likely contributed to the stabilization of the patient's condition.

2.  Reasonable LVEF: The patient's left ventricular ejection fraction (LVEF) is 62%, which is within the normal range (50-70%). This indicates that the patient's heart is pumping blood effectively, which is crucial for survival.

3.  Mildly Elevated Creatinine: The patient's creatinine level is 123.0 mmol/L, which is slightly elevated but not significantly high. This suggests that the patient's kidneys are functioning relatively well, which is essential for eliminating waste products, including medications.

4.  Normal Blood Pressure: The patient's blood pressure is 140/70 mmHg, which is within the normal range. This is a positive sign, as high blood pressure can exacerbate heart conditions.

5.  Absence of Severe Arrhythmias: The ECG impression indicates the absence of sustained ventricular tachycardia and bradycardia, which are serious heart rhythm disorders that can lead to cardiac arrest.

6.  Reasonable Electrolyte Levels: The patient's potassium level is 4.2 mEq/L, which is within the normal range. Abnormal electrolyte levels can lead to cardiac arrhythmias and other complications.

7.  Normal Glucose and Hemoglobin Levels: The patient's glucose and hemoglobin levels are within normal limits, which suggests that the patient's diabetes and anemia are under control.

8.  Low Pro-BNP Level: The patient's pro-BNP level is 433.0 ng/L, which is elevated but not extremely high. Pro-BNP is a marker of heart failure, and a low level indicates that the patient's heart failure symptoms are not severe.

9.  Absence of Severe Liver Enzyme Elevation: The patient's liver enzyme levels (ALT and AST) are within normal limits, which suggests that the patient's liver function is relatively preserved.

Considering these factors, the patient's outcome as a survivor can be attributed to effective medication management, reasonable LVEF, mildly elevated creatinine, normal blood pressure, absence of severe arrhythmias, reasonable electrolyte levels, normal glucose and hemoglobin levels, low pro-BNP level, and absence of severe liver enzyme elevation."
420,420,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the current management of her idiopathic dilated cardiomyopathy and the presence of a relatively preserved renal function, as indicated by a creatinine level of 71.0 mol/L. 

The patient's LVEF (Left Ventricular Ejection Fraction) of 26% suggests that she has severe left ventricular dysfunction, which is consistent with her NYHA Class III classification. However, her current medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, are all appropriate for managing heart failure and may be contributing to her survival.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction. However, the liver enzymes are not significantly elevated, and her albumin level is within the normal range, which suggests that her liver function is not severely compromised.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which are a risk factor for cardiovascular disease. However, her HDL level is low, which may be a protective factor.

The patient's thyroid function tests (TSH and T4) are within the normal range, which suggests that her thyroid function is not contributing to her cardiac dysfunction.

The patient's Pro-BNP level is elevated, which is consistent with heart failure. However, the level is not extremely high, which may indicate that the patient is being effectively managed with her current medications.

Overall, the patient's outcome of survival can be attributed to the effective management of her idiopathic dilated cardiomyopathy, relatively preserved renal function, and the presence of a multidisciplinary treatment plan that includes medications, lifestyle modifications, and monitoring."
421,421,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's extensive medical history and current condition, the patient's outcome of survival can be attributed to several factors:

1.  Optimal Medication Regimen: The patient is on a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are commonly used to manage heart failure symptoms, regulate heart rhythm, and improve cardiac function. The combination of these medications has likely helped to stabilize the patient's condition and improve their cardiac function.

2.  Monitoring and Management of Heart Failure: The patient has idiopathic dilated cardiomyopathy, which can lead to heart failure. The patient's NYHA Class III classification indicates that they experience symptoms of heart failure with moderate limitation in physical activity. However, the patient's survival can be attributed to close monitoring and management of their heart failure symptoms, which has likely prevented further deterioration.

3.  Low Levels of Potassium: The patient's potassium level (4.7 mEq/L) is within the normal range, which is essential for cardiac function. Low potassium levels can lead to arrhythmias and cardiac arrest, but in this case, the patient's potassium levels are within the normal range, reducing the risk of cardiac complications.

4.  Normal Thyroid Function: The patient's thyroid function tests (TSH, T3, and T4) are within the normal range, which is crucial for maintaining cardiac function. Hypothyroidism can exacerbate heart failure symptoms and reduce the effectiveness of heart failure medications.

5.  Monitoring of Liver Function: The patient's liver function tests (ALT and AST) are elevated, indicating some liver dysfunction. However, the patient's liver function is being monitored, and the elevated liver enzymes are likely being managed through medication adjustments or other interventions.

6.  No Evidence of Cardiac Arrest or Sudden Cardiac Death: The ECG results do not indicate any life-threatening arrhythmias, such as ventricular tachycardia or bradycardia, which could have led to cardiac arrest.

7.  Patient's Age and Gender: The patient is 61 years old, which is a relatively advanced age for survival with idiopathic dilated cardiomyopathy. The patient's female gender may also contribute to her survival, as women tend to have a better prognosis than men with heart failure.

Considering these factors, the patient's outcome of survival is likely due to the combination of optimal medication management, close monitoring and management of heart failure symptoms, and the absence of life-threatening cardiac complications."
422,422,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival in this case can be attributed to a combination of factors, including the patient's current treatment regimen and her underlying medical conditions. 

The patient has been prescribed a comprehensive medication regimen consisting of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and cardiomyopathy. Beta blockers help reduce the heart rate and contractility, while digoxin and spironolactone are used to improve heart function and reduce fluid overload. Loop diuretics help manage fluid retention, and ACE inhibitors are used to reduce blood pressure and alleviate strain on the heart.

The patient's LVEF (left ventricular ejection fraction) is 26%, which is significantly reduced but still within the range that can be managed with medical therapy. The patient's Pro-BNP (brain natriuretic peptide) level is elevated at 27,434 ng/L, indicating increased ventricular stress and potential fluid overload. However, this is not an uncommon finding in patients with heart failure and is likely being managed with the diuretic therapy.

The patient's blood pressure is within a relatively normal range, and her potassium level is slightly low, which may be a result of the diuretic therapy. The liver enzymes (ALT and AST) are mildly elevated, which may be a result of the cardiomyopathy or the spironolactone therapy. The patient's glucose level is elevated, which may be related to the heart failure itself or other underlying conditions.

The patient's ECG shows polymorphic ventricular extrasystoles, which are common in patients with heart failure and cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's overall clinical presentation and treatment regimen, it is likely that her survival is due to the effective management of her heart failure and cardiomyopathy with a comprehensive medication regimen and close monitoring of her condition."
423,423,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 61-year-old female with a history of idiopathic dilated cardiomyopathy, has been managed with a multi-drug regimen including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. The patient's current medication regimen is aimed at reducing the heart rate, improving cardiac contractility, and managing fluid overload.

The patient's laboratory results indicate that her LVEF (left ventricular ejection fraction) is severely impaired at 26%, which is a hallmark of dilated cardiomyopathy. However, her pro-BNP (brain natriuretic peptide) level is elevated at 27434 ng/L, which is indicative of heart failure and suggests that the current treatment regimen is effective in managing symptoms.

The patient's ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with dilated cardiomyopathy. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's arrhythmias are well-controlled.

Given the patient's current medication regimen and laboratory results, it is likely that the patient is experiencing a stable phase of heart failure, and the treatment plan is effective in managing her symptoms and improving her quality of life. The patient's outcome as a survivor suggests that she has been able to manage her condition effectively and is not experiencing any acute complications."
424,424,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 61-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced heart function. Her left ventricular ejection fraction (LVEF) of 26% is significantly reduced, indicating poor heart function.

The patient's NYHA Class III classification indicates that she experiences symptoms of heart failure, such as shortness of breath and fatigue, even at rest or with minimal exertion. However, her blood pressure is within a relatively normal range, which is a positive sign.

The patient is on a combination of medications, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which are standard treatments for heart failure and idiopathic dilated cardiomyopathy. Beta blockers help slow the heart rate and reduce the workload on the heart, while digoxin helps regulate heart rhythm. Loop diuretics help reduce fluid buildup in the body, and spironolactone helps counteract the effects of aldosterone, a hormone that can exacerbate heart failure. ACE inhibitors help relax blood vessels and reduce blood pressure.

The patient's laboratory results show elevated levels of liver enzymes (ALT and AST), which can indicate liver damage or inflammation. However, these levels are not extremely high, and the patient's TSH and T4 levels are within normal ranges, suggesting that her thyroid function is normal.

The patient's glucose level is slightly elevated, which may be a concern for diabetes or insulin resistance, but it is not extremely high. Her lipid profile shows high total cholesterol and LDL levels, which can contribute to atherosclerosis and cardiovascular disease.

The patient's potassium level is slightly low, which can be a concern for cardiac arrhythmias, but her sodium level is within a normal range. Her creatinine level is slightly elevated, which can indicate kidney impairment, but her urea level is within a normal range.

The patient's Pro-BNP level is extremely high, which is a marker of heart failure and can indicate that the patient is experiencing fluid overload or cardiac dysfunction.

Given the patient's complex medical history and laboratory results, it is surprising that she is a survivor. However, the combination of her medications, which are tailored to her specific condition, and her relatively normal blood pressure, may have contributed to her survival. Additionally, her lack of other comorbidities, such as diabetes or kidney disease, may have also played a role in her survival."
425,425,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history and current condition, I would attribute the patient's outcome as a survivor to a combination of factors, including:

1. Optimal Medication Regimen: The patient is on a comprehensive medication regimen consisting of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. This combination is standard for managing heart failure and idiopathic dilated cardiomyopathy, which likely contributed to the patient's improved survival.

2. Stable Blood Pressure: The patient's blood pressure is within a relatively normal range (120/80 mmHg), which is essential for maintaining cardiac function and reducing the risk of further cardiac complications.

3. Monitoring and Management of Cardiac Function: The patient's LVEF (Left Ventricular Ejection Fraction) of 26% indicates a severely impaired cardiac function. However, the fact that the patient has been able to survive suggests that their cardiac function has been stabilized and managed effectively.

4. Absence of Sustained Ventricular Tachycardia: The absence of sustained ventricular tachycardia on the ECG suggests that the patient's cardiac rhythm has not significantly deteriorated, which is a good prognostic sign.

5. Biochemical Parameters: Although the patient has elevated levels of liver enzymes (ALT and AST), total cholesterol, and GGT, these are not indicative of acute decompensation or severe cardiac damage. The patient's albumin and protein levels are also within a relatively normal range, suggesting that they are not experiencing significant malnutrition or liver dysfunction.

6. Hemodynamic Stability: The patient's hemoglobin and potassium levels are within normal limits, indicating that they are not experiencing significant anemia or electrolyte imbalances that could compromise cardiac function.

7. TSH and Thyroid Function: The patient's thyroid function is within a normal range, which is essential for maintaining cardiac function and metabolism.

In summary, the combination of the patient's optimal medication regimen, stable blood pressure, effective management of cardiac function, absence of sustained ventricular tachycardia, and stable biochemical parameters likely contributed to their survival."
426,426,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 61-year-old female with a history of idiopathic dilated cardiomyopathy, has a poor left ventricular ejection fraction (LVEF) of 26%, indicating severe heart failure. The patient's NYHA Class III classification further supports this, indicating that she experiences symptoms of heart failure with moderate limitations in physical activity.

The patient's lab results show elevated liver enzymes (ALT and AST), indicating liver dysfunction, which may be secondary to heart failure or another underlying condition. Her total cholesterol and LDL levels are high, which is a risk factor for cardiovascular disease. Her low HDL level also contributes to this risk.

The patient's kidney function, as indicated by the creatinine level, is within normal limits, which is a positive sign. Her blood glucose level is elevated, which may be a risk factor for cardiovascular disease.

The patient's thyroid function tests (T3, T4, and TSH) are within normal limits, indicating that her thyroid function is not contributing to her heart failure.

The patient's Pro-BNP level is elevated, which is consistent with heart failure. Her protein level is within normal limits, which suggests that she does not have significant proteinuria.

The patient is on a comprehensive medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which are common in patients with heart failure. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's comprehensive treatment regimen and the absence of life-threatening arrhythmias, it is likely that she has been managed effectively and has survived with heart failure."
427,427,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome as a survivor can be attributed to several factors in her clinical presentation and treatment regimen. 

Firstly, the patient's left ventricular ejection fraction (LVEF) of 26% indicates severe systolic dysfunction, characteristic of her idiopathic dilated cardiomyopathy. However, despite this, she is still alive, suggesting that her condition is being effectively managed.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor, are standard treatments for heart failure with reduced ejection fraction (HFrEF). These medications have been shown to improve symptoms, reduce morbidity, and improve survival in patients with HFrEF. The fact that she is on these medications likely contributed to her survival.

The patient's laboratory results also provide some insight into her condition. Her elevated creatinine level of 71.0 mol/L indicates some degree of renal impairment, which is common in patients with advanced heart failure. However, her urea level of 7.82 mg/dL is within a relatively normal range, suggesting that her renal function is not severely compromised.

The patient's low T3 level (0.05 pg/dL) and normal T4 level (20 ng/L) suggest that she does not have overt hypothyroidism, which can sometimes be associated with heart failure. Her TSH level of 1.25 mIU/L is also within the normal range, indicating that her thyroid function is not significantly abnormal.

The patient's Pro-BNP level of 27434.0 ng/L is elevated, which is consistent with her diagnosis of heart failure. However, the fact that she is still alive suggests that her condition is being effectively managed.

In summary, the patient's survival can be attributed to a combination of her effective medication regimen, relatively preserved renal function, and absence of other complicating factors such as overt hypothyroidism."
428,428,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 61-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition characterized by the enlargement of the heart's chambers, reducing the heart's ability to pump blood efficiently. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 26%, indicating a significant reduction in cardiac function.

The patient's laboratory results show elevated levels of troponin (indirectly indicated by the elevated Pro-BNP of 27434.0 ng/L), which is a biomarker of cardiac damage. Additionally, the patient has elevated liver enzymes (ALT and AST) and a slightly elevated total cholesterol level, which may be indicative of dyslipemia. The patient's glucose level is also slightly elevated, which could be a sign of insulin resistance or diabetes.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats originating from the ventricles. However, there is no indication of sustained ventricular tachycardia or other serious arrhythmias.

Given the patient's severe cardiac dysfunction and the presence of polymorphic ventricular extrasystoles, it is likely that the patient's prognosis is guarded. However, the patient is still alive, which suggests that the current treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, is helping to manage the patient's symptoms and slow the progression of the disease.

The patient's NYHA class III classification indicates that she has severe symptoms of heart failure, such as shortness of breath and fatigue, but is still able to perform everyday activities. The fact that the patient is a survivor suggests that the treatment is helping to alleviate some of these symptoms, allowing her to maintain a relatively stable condition.

In summary, the patient's survival is likely due to the effectiveness of the current treatment regimen and the absence of any acute cardiac events such as heart failure exacerbation or arrhythmias."
429,429,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 61-year-old female with a history of idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle that leads to a decrease in the heart's ability to pump blood effectively. Her left ventricular ejection fraction (LVEF) is severely reduced at 26%, indicating poor heart function. Despite these complications, the patient has been prescribed a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver dysfunction or damage, possibly related to her dyslipemia and hypertension. Her total cholesterol level is high (6.67 mmol/L), and her LDL cholesterol is particularly high at 4.27 mmol/L, contributing to her risk of cardiovascular disease. Her low HDL cholesterol (1.03 mmol/L) further increases this risk.

Her blood glucose level is elevated at 11.7 mmol/L, suggesting insulin resistance or type 2 diabetes, which can exacerbate heart failure. Her kidney function is impaired, as indicated by a creatinine level of 71.0 mol/L and a urea level of 7.82 mg/dL.

The patient's thyroid function tests (TSH, T3, and T4) are within normal limits, ruling out hypothyroidism as a contributing factor to her heart failure.

The patient's high Pro-BNP level (27434.0 ng/L) is indicative of severe heart failure, as BNP is a hormone released by the heart in response to increased ventricular wall stress. Her low albumin level (39 g/L) may be a result of nephrotic syndrome, a complication of heart failure.

Given the patient's severe heart failure, elevated liver enzymes, high cholesterol, and impaired kidney function, it is remarkable that she is a survivor. This may be attributed to her comprehensive medication regimen, which includes medications that help manage heart failure symptoms, reduce fluid overload, and improve cardiac function. Additionally, her relatively normal blood pressure (120/80 mmHg) may also contribute to her survival, as hypertension can exacerbate heart failure.

In conclusion, the patient's survival is likely due to a combination of her comprehensive treatment plan, relatively controlled blood pressure, and the absence of other life-threatening conditions that could have contributed to her mortality."
430,430,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 69-year-old male, has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to decreased heart function. His current LVEF (Left Ventricular Ejection Fraction) of 40% indicates that his heart is functioning at a reduced capacity.

The patient's medications, including Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, suggest that he is being managed for heart failure and possibly arrhythmias. The presence of Amiodarone and Beta Blockers indicates that the patient has a history of arrhythmias, but the ECG impression does not show any current arrhythmias.

The patient's Pro-BNP (Brain Natriuretic Peptide) level of 458.0 ng/L is elevated, which is a marker of heart failure. However, his other biomarkers, such as Troponin (0.01 ng/mL) and Creatinine (104.0 umol/L), are within normal limits, indicating that there is no acute myocardial infarction or significant kidney dysfunction.

The patient's hemoglobin level (132.0 g/L) is within normal limits, which suggests that there is no significant anemia contributing to his heart failure. His TSH level (1.88 mIU/L) is within the normal range, indicating that there is no hypothyroidism contributing to his heart failure.

Considering the patient's overall clinical presentation and laboratory results, it appears that he has well-managed heart failure, and the medications are likely effective in controlling his symptoms and preventing further cardiac complications. The fact that the patient is a survivor suggests that he has not experienced any significant cardiac events, such as a myocardial infarction or sudden cardiac death, in the recent past.

Therefore, the patient's outcome of survival is likely due to the effective management of his heart failure and arrhythmias, as well as the absence of any acute cardiac events."
431,431,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's age of 69 and male gender places him in a high-risk category for cardiovascular events. His past medical history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension indicates a history of cardiac issues, which may have led to his current reduced left ventricular ejection fraction (LVEF) of 40%. 

The patient's blood pressure is within a relatively normal range (110/80 mmHg), which suggests that his hypertension is well-controlled with medication. His albumin and protein levels are within normal limits, indicating no significant renal impairment at this time. However, his elevated creatinine level (104.0 mol/L) may indicate some degree of renal impairment, which could be a concern in the context of his heart failure.

The patient's lipid profile shows a high total cholesterol level (4.45 mmol/L) and low HDL level (1.03 mmol/L), which are risk factors for cardiovascular disease. His LDL level (2.72 mmol/L) is within a relatively safe range, and his triglycerides are not provided, but his statin therapy is likely aimed at reducing his total cholesterol and LDL levels.

The patient's TSH level (1.88 mIU/L) is within the normal range, indicating no apparent thyroid dysfunction. His T3 and T4 levels are also within normal limits, ruling out hypothyroidism as a contributing factor to his heart failure.

The patient's LVEF of 40% indicates a reduced ejection fraction, which is a hallmark of heart failure with reduced ejection fraction (HFrEF). His BNP level of 458.0 ng/L is elevated, which is consistent with heart failure, and his troponin level is within normal limits, indicating no acute myocardial infarction.

Given the patient's complex medical history, medications, and laboratory results, it is likely that he is being treated for heart failure with reduced ejection fraction (HFrEF). His medications, including amiodarone, angiotensin II receptor blockers, beta blockers, loop diuretics, and statins, are consistent with standard therapy for HFrEF.

The patient's ECG results show no signs of ventricular extrasystoles, ventricular tachycardia, or non-sustained ventricular tachycardia, which suggests that he does not have an acute arrhythmia that would require urgent intervention.

Considering the patient's overall clinical picture, his age, and the presence of heart failure, it is reasonable to assume that the patient is a survivor of heart failure, with a focus on long-term management and optimization of his current treatment regimen to improve his quality of life and reduce the risk of future cardiovascular events."
432,432,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's medical history and current laboratory results, the patient's outcome as a survivor can be attributed to a combination of several factors:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, which are all relevant to managing the patient's idiopathic dilated cardiomyopathy, hypertension, and dyslipemia. These medications likely helped to stabilize the patient's cardiac function and reduce the risk of adverse outcomes.

2.  Moderate NYHA Class II: The patient's New York Heart Association (NYHA) class of II indicates that the patient has some limitations in physical activity but is still able to carry out light physical activity without discomfort. This suggests that the patient's heart condition is not severe enough to prevent them from living a relatively normal life, contributing to their survival.

3.  LVEF of 40%: Although the patient's left ventricular ejection fraction (LVEF) is slightly below the normal range, it is not significantly low. An LVEF of 40% is still within the range of mildly impaired cardiac function, which may not be severe enough to lead to an adverse outcome.

4.  Stable Blood Pressure: The patient's blood pressure is within a relatively normal range (110/80 mmHg), which is likely indicative of effective management of their hypertension.

5.  Normal Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within normal limits, indicating that there are no significant electrolyte imbalances that could contribute to cardiac arrhythmias or other cardiac complications.

6.  Normal TSH and T4 Levels: The patient's thyroid function is within normal limits, which is important for cardiac health, as thyroid dysfunction can impact cardiac function.

7.  Low Pro-BNP: The patient's brain natriuretic peptide (BNP) level is within a relatively low range, which is indicative of a relatively low level of cardiac stress and a lower risk of adverse cardiac events.

Considering these factors, the patient's survival can be attributed to the effectiveness of their medication regimen, their relatively mild cardiac impairment, and the absence of significant electrolyte imbalances or other factors that could contribute to cardiac complications."
433,433,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 69-year-old male with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension, has been managed with a multi-drug regimen including Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins. The patient's left ventricular ejection fraction (LVEF) is 40%, indicating a reduced cardiac function.

Despite the presence of reduced LVEF, the patient's blood pressure is well-controlled at 110/80 mmHg, which is within a normal range. The patient's laboratory results show a mildly elevated creatinine level (104.0 umol/L), which may indicate some degree of renal impairment. However, the patient's electrolyte levels, including potassium and sodium, are within normal limits.

The patient's Pro-BNP level is elevated at 458.0 ng/L, which is consistent with heart failure. However, the patient's Troponin level is normal, indicating that there is no acute myocardial infarction.

The patient's medication regimen is appropriate for managing heart failure and arrhythmias, and the ECG results do not indicate any acute arrhythmias. The patient's NYHA Class II classification suggests that the patient has mild symptoms of heart failure, which is consistent with the patient's ability to survive.

Based on the patient's overall clinical presentation, laboratory results, and medication regimen, it is likely that the patient's survival is due to effective management of their heart failure and arrhythmias, as well as a lack of acute cardiac events or complications. The patient's age and comorbidities also contribute to their risk of mortality, but the patient's survival suggests that the current treatment plan is effective in managing their condition."
434,434,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome is a survivor due to a combination of factors, including the patient's current medical treatment plan and the presence of certain biomarkers. 

Firstly, the patient is being treated with Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, which are all medications commonly used to manage heart failure and related conditions. These medications are likely contributing to the patient's survival by controlling symptoms, reducing the workload on the heart, and preventing complications.

The patient's LVEF (Left Ventricular Ejection Fraction) of 40% is below the normal range (50-70%), indicating some degree of heart failure. However, the patient's Pro-BNP (Brain Natriuretic Peptide) level of 458 ng/L is not extremely elevated, suggesting that the patient's heart failure is not severe. 

Additionally, the patient's Troponin level of 0.01 ng/mL is within the normal range, indicating that there is no acute myocardial infarction (heart attack) occurring. 

The patient's TSH (Thyroid-Stimulating Hormone) level of 1.88 mIU/L is within the normal range, which is important as thyroid disorders can contribute to heart failure.

The patient's ECG impression shows no signs of ventricular tachycardia, ventricular extrasystole, or bradycardia, which are all conditions that could potentially be life-threatening.

Overall, the combination of the patient's treatment plan, the presence of some biomarkers within the normal range, and the absence of life-threatening ECG findings suggest that the patient is likely a survivor."
435,435,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's medical history, laboratory results, and current medications, it is likely that the patient's outcome is a survivor due to a combination of factors. 

Firstly, the patient has been diagnosed with idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, reducing its ability to pump blood effectively. However, the patient's left ventricular ejection fraction (LVEF) is 40%, which indicates that the heart is still pumping a significant amount of blood. 

The patient is on a comprehensive treatment regimen that includes amiodarone, an anti-arrhythmic medication, an angiotensin II receptor blocker, a beta blocker, a loop diuretic, and statins, which are all aimed at managing the patient's heart condition and reducing the risk of arrhythmias and heart failure. The patient's blood pressure is well-controlled at 110/80 mmHg, and the creatinine level is within a relatively normal range, indicating that the kidneys are functioning adequately.

The patient's laboratory results also indicate that the liver enzymes (ALT and AST) are within normal limits, and the total cholesterol and LDL levels are well-managed. The patient's glucose level is slightly elevated, but not to a level that would indicate diabetes. The patient's thyroid function tests (T3 and T4) are also within normal limits.

The elevated Pro-BNP (brain natriuretic peptide) level of 458.0 ng/L suggests that the patient has some degree of heart failure, but the level is not extremely high, which may indicate that the patient's condition is being managed effectively.

The ECG results do not show any significant arrhythmias, which suggests that the patient's heart rhythm is stable.

Considering these factors, it is likely that the patient's outcome is a survivor due to the comprehensive treatment regimen, well-managed blood pressure, and stable laboratory results. However, it is essential to continue monitoring the patient's condition closely to ensure that the heart failure is being adequately managed and to adjust the treatment plan as needed."
436,436,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's medical history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function, the patient's left ventricular ejection fraction (LVEF) of 40% indicates a moderate to severe reduction in heart function. 

The patient's medication regimen, including Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, suggests that the patient is being managed for heart failure and possibly arrhythmias. The presence of Beta Blockers and Angiotensin II Receptor Blocker indicates that the patient's condition is being treated with evidence-based therapies to improve survival and reduce morbidity in heart failure patients.

The patient's laboratory results show elevated levels of Pro-BNP (brain natriuretic peptide), which is a biomarker associated with heart failure and increased risk of adverse outcomes. However, the patient's Troponin level is within normal limits, indicating that there is no acute myocardial infarction.

The patient's ECG shows no signs of ventricular tachycardia or ventricular extrasystoles, which suggests that the patient is not experiencing acute arrhythmias that could compromise cardiac function.

Considering the patient's age (69), NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, the patient's survival is likely due to the effective management of their heart failure with evidence-based medications and close monitoring. The patient's overall clinical presentation and laboratory results suggest that they are being managed appropriately for their condition, which contributed to their survival."
437,437,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 69-year-old male with a history of idiopathic dilated cardiomyopathy, has been managed with a combination of medications including Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins. His current LVEF (Left Ventricular Ejection Fraction) of 40% suggests that he has a reduced ejection fraction, which is a common complication of dilated cardiomyopathy. However, despite this, the patient's blood pressure is well-controlled at 110/80 mmHg, and his cardiac biomarkers, including Troponin and Pro-BNP, are within a relatively stable range.

The patient's renal function, as indicated by his Creatinine level of 104.0 mol/L, is mildly impaired, which is consistent with his history of dyslipemia and hypertension. His lipid profile shows a total cholesterol level of 4.45 mmol/L, which is slightly elevated, but his HDL and LDL levels are within a relatively healthy range.

The patient's liver function tests, including ALT and AST, are within normal limits, and his TSH level is within a normal range, indicating that his thyroid function is well-managed. His T3 and T4 levels are also within a normal range, indicating that his thyroid hormone levels are well-controlled.

Given the patient's stable cardiac biomarkers, controlled blood pressure, and well-managed thyroid function, it is likely that the patient's outcome is a survivor due to the following reasons:

1. Optimal medication regimen: The patient is on a combination of medications that are effective in managing his dilated cardiomyopathy, including Amiodarone, which is often used to treat arrhythmias, and Beta Blockers, which are effective in reducing the workload on the heart.
2. Good blood pressure control: The patient's blood pressure is well-controlled, which is essential in managing heart failure and reducing the risk of cardiovascular events.
3. Stable cardiac biomarkers: The patient's Troponin and Pro-BNP levels are within a relatively stable range, indicating that his cardiac function is stable and not deteriorating.
4. Well-managed thyroid function: The patient's TSH, T3, and T4 levels are within a normal range, indicating that his thyroid function is well-managed, which is essential in managing heart failure.

Overall, the patient's outcome as a survivor is likely due to a combination of his optimal medication regimen, good blood pressure control, stable cardiac biomarkers, and well-managed thyroid function."
438,438,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors:

1. Optimal medication regimen: The patient is on a comprehensive medication regimen, including Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins. These medications are commonly used to manage heart failure, hypertension, and dyslipidemia, which are all relevant to the patient's conditions.

2. Moderate NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates that they experience some limitation of physical activity but are still able to carry on normal everyday activities without symptoms. This classification suggests that the patient's heart condition is manageable, and they are not in an advanced stage of heart failure.

3. LVEF of 40%: Although the patient's left ventricular ejection fraction (LVEF) is low at 40%, it is not severely impaired. An LVEF of 40-50% is often associated with mild to moderate heart failure. This suggests that the patient's heart is still functioning adequately to some extent.

4. Normal Troponin levels: The patient's troponin levels are within normal limits, indicating that there is no acute myocardial infarction or significant cardiac damage.

5. Normal TSH and T4 levels: The patient's thyroid function is within normal limits, which is essential for maintaining a healthy heart function.

6. No significant electrolyte imbalance: The patient's potassium and sodium levels are within normal limits, which is crucial for maintaining cardiac function.

7. Stable blood pressure: The patient's blood pressure is within a relatively normal range, which is beneficial for heart health.

8. Regular monitoring and follow-up: The fact that the patient is under medical care and receiving regular monitoring and follow-up suggests that their condition is being managed effectively.

Considering these factors, the patient's outcome of survival is likely due to a combination of optimal medical management, relatively mild symptoms, and stable cardiac function."
439,439,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 69-year-old male with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension. His current medications include Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, which indicate that he has been receiving appropriate treatment for his cardiovascular conditions.

The patient's left ventricular ejection fraction (LVEF) is 40%, which falls within the range of heart failure with reduced ejection fraction (HFrEF). However, his New York Heart Association (NYHA) functional class is II, indicating that he has some symptoms of heart failure but is still able to perform most daily activities.

His blood pressure is within a relatively normal range, and his lipid profile shows high total cholesterol and low HDL levels, which are consistent with his history of dyslipemia. His liver enzymes (ALT and AST) are within normal limits, and his kidney function is slightly impaired, as indicated by elevated creatinine levels.

The patient's thyroid function is within normal limits, with a TSH level of 1.88 mIU/L, and his troponin level is low, indicating no acute myocardial infarction. His B-type natriuretic peptide (BNP) level is elevated, which is consistent with heart failure.

The patient's ECG shows no signs of ventricular tachycardia or ventricular extrasystoles, and his heart rate is not significantly abnormal.

Given the patient's overall clinical picture, it appears that he is being effectively managed for his heart failure and other cardiovascular conditions. His medications are appropriate for his condition, and his symptoms are well-controlled. Therefore, the patient's outcome is likely a survivor, indicating that he is living with his condition and managing it effectively with his current treatment regimen."
440,440,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the provided patient data, the patient's outcome as a survivor can be attributed to a combination of factors. 

Firstly, the patient is being actively managed for their conditions, with a comprehensive medication regimen that includes diabetes medication, beta blockers, loop diuretics, statins, and an ACE inhibitor. This suggests that the patient is receiving appropriate treatment for their hypertension, diabetes, and dyslipemia, which are all contributing factors to their cardiomyopathy.

The patient's LVEF (Left Ventricular Ejection Fraction) of 45% indicates that while the patient has some degree of left ventricular dysfunction, it is not severe. This is likely due to the patient's current treatment regimen and the fact that the patient is not experiencing symptoms of heart failure (NYHA Class II).

The patient's blood pressure is well-controlled at 160/85 mmHg, which is relatively low for someone with hypertension. This suggests that the patient's blood pressure is being effectively managed, which is crucial in preventing further cardiac damage.

Additionally, the patient's Troponin level of 0.2 ng/mL is within the normal range, indicating that there is no significant cardiac muscle damage. The patient's Pro-BNP level of 918.0 ng/L is elevated, but not excessively high, which suggests that the patient is not experiencing severe heart failure.

The patient's ECG results show a monomorphic ventricular extrasystole, but no sustained ventricular tachycardia or other arrhythmias. This suggests that the patient's cardiac rhythm is relatively stable.

While the patient has a history of hypertensive cardiomyopathy, diabetes, and dyslipemia, their current treatment regimen and the fact that they are a survivor suggest that they are being effectively managed for these conditions.

In conclusion, the patient's outcome as a survivor can be attributed to their comprehensive treatment regimen, well-controlled blood pressure, and relatively stable cardiac function."
441,441,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's age, gender, and past medical history, it is not surprising that they have a reduced left ventricular ejection fraction (LVEF) of 45%. The patient's history of hypertensive cardiomyopathy, diabetes, and dyslipemia are all risk factors for heart failure and reduced LVEF. The elevated blood pressure of 160/85 mmHg is also concerning, as it can further exacerbate cardiac disease.

The patient's laboratory results also support the presence of cardiac disease. The elevated Pro-BNP level (918.0 ng/L) is a marker of heart failure, and the troponin level of 0.2 ng/mL is slightly elevated, indicating some degree of cardiac damage. The patient's creatinine level of 123.0 umol/L is also elevated, which may indicate impaired kidney function, possibly due to chronic heart failure.

Despite these concerning factors, the patient is on a comprehensive treatment regimen, including diabetes medication, beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all aimed at managing their cardiac and metabolic conditions.

The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient does not have a life-threatening arrhythmia at this time. The presence of monomorphic ventricular extrasystoles is a common finding in patients with cardiomyopathy, but it is not typically a cause for concern unless it is accompanied by other symptoms or signs of cardiac instability.

Given the patient's overall clinical picture and treatment regimen, it is reasonable to conclude that they are a survivor, indicating that they are stable and not currently experiencing a life-threatening cardiac event."
442,442,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 75-year-old male with a history of Hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. His blood pressure is elevated at 160/85 mmHg, and his left ventricular ejection fraction (LVEF) is 45%, indicating reduced cardiac function. However, despite these risk factors, the patient's overall condition and treatment plan seem to be well-managed.

The patient is on a combination of medications including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are commonly used to manage hypertension, heart failure, and dyslipemia. His blood glucose levels are also well-controlled with diabetes medication.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common and often benign, especially in the context of this patient's age and medical history. There is no evidence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

The patient's creatinine level is elevated at 123.0 mol/L, which may indicate some degree of renal impairment. However, this is not uncommon in patients with hypertension and diabetes, and his urea level is only slightly elevated at 8.3 mg/dL.

The patient's Pro-BNP level is elevated at 918.0 ng/L, which is consistent with heart failure, but his overall clinical picture and treatment plan suggest that his condition is being managed.

Given the patient's age, medical history, and treatment plan, it is likely that the patient's outcome as a survivor is due to the following factors:

1. Timely and effective management of his hypertension, heart failure, and diabetes.
2. Use of evidence-based medications to manage his conditions.
3. Regular monitoring and follow-up care, which allowed for early detection and management of any potential complications.
4. The patient's relatively low risk profile, considering his age and medical history.

Overall, the patient's outcome as a survivor suggests that his treatment plan and management of his conditions were effective in preventing adverse outcomes and improving his quality of life."
443,443,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome of survival can be attributed to a combination of factors. Firstly, the patient is on a comprehensive treatment regimen that includes diabetes medication, beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all aimed at managing the patient's underlying conditions of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. The use of beta blockers, in particular, is beneficial in reducing the risk of arrhythmias and improving survival in patients with heart failure.

The patient's LVEF (left ventricular ejection fraction) is 45%, which is below the normal range of 55-70%, indicating some degree of left ventricular dysfunction. However, it is not severely impaired, and the patient's symptoms are classified as NYHA Class II, indicating mild to moderate symptoms with moderate limitation in physical activity.

The patient's blood pressure is well-controlled at 160/85 mmHg, which is lower than the target of 140/90 mmHg for most adults. The patient's creatinine level is elevated at 123.0 mol/L, but it is not significantly high, and the patient is not showing signs of acute kidney injury. The pro-BNP level is elevated at 918.0 ng/L, indicating some degree of heart failure, but it is not excessively high.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart failure and are not typically associated with poor prognosis. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also suggests that the patient is not at high risk for life-threatening arrhythmias.

Overall, while the patient has significant underlying cardiovascular disease, the comprehensive treatment regimen and the patient's relatively stable clinical status have contributed to their survival."
444,444,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's profile, several factors contributed to the positive outcome. 

Firstly, the patient is on a comprehensive medication regimen, including diabetes medication, beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all appropriate for managing hypertension, diabetes, and dyslipidemia. This polypharmacological approach likely helped control the patient's blood pressure and lipid profiles, reducing the strain on the heart.

The patient's LVEF (Left Ventricular Ejection Fraction) of 45% indicates a reduced ejection fraction, which is a hallmark of heart failure. However, the fact that the patient is classified as NYHA Class II suggests that the heart failure is not severe, and the patient is still able to perform moderate physical activity without symptoms. This classification, along with the patient's age and the fact that they are on appropriate medications, may have contributed to their ability to survive.

The patient's laboratory results, including normal albumin and potassium levels, suggest that they do not have significant liver or kidney dysfunction, which can be a contraindication to certain treatments. The slightly elevated creatinine level may indicate some degree of kidney impairment, but it is not severe enough to have a significant impact on the patient's survival.

The patient's blood pressure of 160/85 mmHg is elevated, but it is not extremely high, and their medication regimen likely helps to control it. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have any acute cardiac arrhythmias that could have contributed to their outcome.

Finally, the patient's TSH level of 1.16 mIU/L is within the normal range, indicating that their thyroid function is not a contributing factor to their cardiac condition.

In summary, the combination of the patient's comprehensive medication regimen, their NYHA Class II classification, and the absence of severe laboratory abnormalities or acute cardiac arrhythmias likely contributed to their positive outcome."
445,445,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 75-year-old male with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, presented with a range of laboratory results and an ECG impression. The patient's heart function, as indicated by the left ventricular ejection fraction (LVEF) of 45%, is slightly below the normal range (50-70%), suggesting some degree of left ventricular dysfunction. However, the patient's current medications, including beta blockers, loop diuretics, statins, and an ACE inhibitor, are appropriate for managing hypertension and heart failure symptoms.

The elevated Pro-BNP level (918.0 ng/L) suggests that the patient may have some degree of heart failure, but the level is not excessively high, indicating that the patient's heart failure symptoms are not severe. The patient's creatinine level of 123.0 mol/L suggests some degree of kidney impairment, but it is not severe enough to cause significant hemodynamic instability.

The patient's ECG impression shows monomorphic ventricular extrasystoles, which are common in patients with cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering the patient's age, comorbidities, and laboratory results, the patient's survival outcome is likely due to the following factors:

1.  The patient is receiving appropriate medications for managing hypertension, heart failure, and dyslipemia, which are contributing to his overall cardiovascular health.
2.  The patient's LVEF is not severely compromised, indicating that the left ventricle is still able to pump blood effectively.
3.  The patient's kidney function, although impaired, is not severely compromised, and the patient is not experiencing significant hemodynamic instability.
4.  The patient's Pro-BNP level is not excessively high, indicating that the patient's heart failure symptoms are not severe.

In conclusion, the patient's survival outcome is likely due to a combination of the patient's age, comorbidities, and the effectiveness of his current medications, as well as the relatively mild nature of his heart failure symptoms and kidney impairment."
446,446,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to a combination of factors. 

Firstly, the patient's current medications, including beta blockers, ACE inhibitors, and statins, are likely contributing to the stabilization of their cardiovascular condition. Beta blockers help regulate heart rate and reduce the workload on the heart, while ACE inhibitors help lower blood pressure and reduce strain on the heart. Statins also help lower cholesterol levels, which can reduce the risk of further cardiac complications.

Secondly, the patient's LVEF (Left Ventricular Ejection Fraction) of 45% indicates that the heart is still pumping blood effectively, albeit at a reduced capacity. This suggests that the patient's heart is still able to maintain some level of function, which is essential for survival.

Thirdly, the patient's Pro-BNP (B-type natriuretic peptide) level of 918 ng/L is elevated, indicating increased ventricular wall stress, but it is not at a critically high level that would suggest imminent cardiac failure. This suggests that the patient's heart is still able to adapt to the increased stress, which is a positive sign.

Lastly, the patient's age and comorbidities, including hypertension, diabetes, and dyslipidemia, are significant risk factors for cardiovascular disease. However, the patient's current medications and the fact that they have not experienced a cardiac event in the past (e.g., myocardial infarction, heart failure) suggest that they have been able to manage their condition effectively.

In conclusion, the patient's outcome of survival is likely due to the combination of their current medications, the heart's residual pumping function, and their ability to manage their comorbidities."
447,447,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 75-year-old male with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, presented with a complex set of laboratory values and ECG findings. Despite the presence of several risk factors for adverse cardiac outcomes, including reduced left ventricular ejection fraction (LVEF) at 45%, the patient's overall clinical picture suggests a favorable outcome.

Several factors contributed to the patient's survival:

1.  Effective medical management: The patient is on a comprehensive treatment regimen that includes diabetes medication, beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all evidence-based therapies for managing hypertension, diabetes, and heart failure. These medications likely helped mitigate the progression of his cardiomyopathy and controlled his blood pressure.

2.  Reasonable blood pressure control: Although the patient's blood pressure is elevated at 160/85 mmHg, it is not extremely high, and his medication regimen is likely helping to manage it.

3.  Low troponin levels: The patient's troponin level is 0.2 ng/mL, which is within the normal range. Elevated troponin levels are often associated with cardiac damage or ischemia, but in this case, the patient's troponin level suggests minimal cardiac injury.

4.  Normal hemoglobin and urea levels: The patient's hemoglobin level is 136.0 g/L, which is within the normal range, indicating adequate oxygen delivery to tissues. His urea level is also normal at 8.3 mg/dL, suggesting that his kidneys are functioning adequately.

5.  Normal TSH and T3/T4 levels: The patient's thyroid function is within the normal range, which is essential for overall cardiac health.

6.  Absence of significant arrhythmias: The ECG findings do not indicate any sustained or non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia, which are all potential indicators of cardiac instability.

Considering these factors, the patient's survival is likely due to a combination of effective medical management, controlled blood pressure, minimal cardiac injury, and the absence of significant arrhythmias."
448,448,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor is likely due to a combination of factors, including the presence of a well-managed medical regimen and the absence of severe cardiac complications. 

The patient has been taking a comprehensive set of medications for their conditions, including diabetes medication, beta blockers, loop diuretics, statins, and an ACE inhibitor, which suggests that they are receiving appropriate treatment for their hypertension, diabetes, and dyslipidemia. This suggests that the patient's cardiomyopathy and hypertension are being managed, which may have contributed to their survival.

The patient's LVEF (Left Ventricular Ejection Fraction) is 45%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, the patient's LVEF is not severely impaired, and they are not in heart failure (NYHA Class II), which suggests that their heart function is still relatively preserved.

Additionally, the patient's troponin level is within normal limits, indicating that they do not have significant acute coronary syndrome. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also suggests that the patient does not have severe arrhythmia.

The patient's pro-BNP level is elevated at 918.0 ng/L, which is indicative of heart failure, but the patient's symptoms and physical examination are not suggestive of severe heart failure, and the patient is not in NYHA Class IV.

Overall, the patient's outcome as a survivor is likely due to a combination of effective medical management, relatively preserved left ventricular function, and the absence of severe cardiac complications."
449,449,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, the outcome of survival can be attributed to several factors:

1.  Current Medications: The patient is on a comprehensive regimen of medications, including ACE inhibitors, beta-blockers, loop diuretics, and statins. These medications are crucial in managing hypertension, heart failure, and dyslipidemia, which are all contributing factors to the patient's cardiomyopathy. The ACE inhibitor and beta-blockers are particularly beneficial in reducing the strain on the heart and improving cardiac function.

2.  Control of Blood Pressure: The patient's blood pressure is relatively well-controlled at 160/85 mmHg, which is lower than the systolic blood pressure typically seen in patients with hypertensive cardiomyopathy. This controlled blood pressure reduces the strain on the heart and minimizes the risk of further cardiac damage.

3.  Blood Glucose Control: The patient's blood glucose level is 13.2 mmol/L, which is within the target range for diabetes management. Good blood glucose control is essential in preventing complications associated with diabetes, such as cardiovascular disease and nephropathy.

4.  LVEF: The patient's left ventricular ejection fraction (LVEF) is 45%, which indicates some degree of heart failure. However, it is not severely compromised, and the patient is likely benefiting from the medications and lifestyle modifications that have helped to stabilize the condition.

5.  ECG Findings: The absence of sustained ventricular tachycardia and other significant arrhythmias on the ECG suggests that the patient's heart rhythm is relatively stable, which is a positive indicator of their cardiac health.

6.  Pro-BNP Levels: The patient's pro-BNP level is 918.0 ng/L, which is elevated but not excessively high. Elevated pro-BNP levels are associated with heart failure, but the patient's overall clinical picture and other test results suggest that the condition is being managed effectively.

7.  Other Lab Results: The patient's albumin and protein levels are within normal limits, indicating that renal function is relatively preserved. The patient's potassium and sodium levels are also within normal limits, which is essential for maintaining proper cardiac function.

Considering these factors, the patient's survival can be attributed to the effective management of their underlying conditions, good blood pressure control, and adherence to their medication regimen."
